

8EHQ-0503-15343

May 23, 2003

RECEIVED  
OPPT NCIC

03 MAY 27 AM 10:56

MA# 266985



**By Hand Delivery**

Document Processing Center (7407)  
Office of Pollution, Prevention and Toxics  
U.S. Environmental Protection Agency  
1200 Pennsylvania Avenue, N. W.  
Washington, DC 20460  
Attention: Section 8(e) Coordinator

**COMPANY SANITIZED**

Re: TSCA Section 8(e) Submissions

Dear Sir/Madam:

3M Company ("3M") requests that EPA place the attached studies in the TSCA Section 8(e) docket. We have included an index for these studies identifying the study title, test substance and CAS number. A CBI version of this index and the studies also is being submitted today pursuant to EPA procedures.


3M has concluded that data in these studies may not be, strictly speaking, "corroborative" of previously reported or published information as defined in EPA's reporting guidance or otherwise potentially may warrant 8(e) submission based on EPA's reporting guidance.

3M appreciates EPA's attention to this matter. Please contact the undersigned if you have any questions or require further information regarding this submission.

Very truly yours,

*Dr. Katherine E. Reed (974)*

Dr. Katherine E. Reed, Ph.D  
Executive Director  
3M Environmental Technology  
And Safety Services  
(651) 778-4331  
kereed@mmm.com



2003 JUN 23 AM 9:23

RECEIVED  
OPPT NCIC

**SUBMISSION BY 3M COMPANY ON MAY 23, 2003**

Study Title	Test Substance	CAS Number
1. Exploratory 28-Day Oral Toxicity Study with T-7250, T-7251, T-7252, T-7253, T-7254, and T-7255 by Daily Gavage in the Rat Followed by a 14/28-Day Recovery Period (NOTOX Project 264656)	Separate studies for each chemical: [CBI removed]; Hexanesulfonamide, 1,1,2,2,3,3,4,4,5,5,6,6,6 - Tridecafluoro-n-(2-Hydroxyethyl)-N-Methyl - 100%; 1-Butanesulfonamide, 1,1,2,2,3,3,4,4,4-Nonafluoro-N-(2-Hydroxyethyl)-N-Methyl - 100%	[CBI removed]; 68555-75-9; 34454-97-2
2. Exploratory 28-Day Oral Toxicity Study with T-7125, T-7126, T-7127, T-7128, and T-7129 by Daily Gavage in the Rat Followed by a 14/28-Day Recovery Period (NOTOX Project 256679)	Cyclohexanesulfonic acid, decafluoro(pentafluoromethyl)-, potassium salt (CAS No. 67584-42-3) - 66-70%; Cyclohexanesulfonic acid, decafluoro(trifluoromethyl)-, potassium salt (CAS No. 68156-07-0) - 18-22%; Cyclohexanesulfonic acid, nonafluorobis(trifluoromethyl)-, potassium salt (CAS No. 68156-01-4) - 9-13%; Cyclohexanesulfonic acid, undecafluoro-, potassium salt (CAS No. 3107-18-4) - 1-3%	67584-42-3; 68156-07-0; 68156-01-4; 3107-18-4
3. Subchronic 90-Day Oral Toxicity with T-6524 by Daily Gavage in the Rat Followed by a 28-Day Recovery Period	65% Sulfonamides, C4-8-alkane, perfluoro, N-(3-(dimethyloxidoamino)propyl), potassium CAS#179005-06-2; 20% Amine oxide C8F17SO2NH(->O)CH2CH2CH2N(CH3)2; 15% C3-C7 K-salts of amine oxides CNF2N+1SO2N-)(+K)(->O)CH2CH2CH2N(CH3)2	179005-06-2
4. A Study for Effects on Embryofoetal Development of the Rat (Inhalation Administration)	[CBI removed]	[CBI removed]
5. Evaluation of the Ability of T-5870 to Induce Chromosome Aberrations in Cultured Peripheral Human Lymphocytes (with Independent Repeat)	2-ethoxy ethyl acrylate	106-74-1
6. Chromosomal Aberration Test of T-6695 Using Cultured Mammalian Cells	[CBI removed]	[CBI removed]
7. Acute Oral Toxicity Study in Rats (Exp. No. 920584) (Test Article: Intermedio 1249)	2-methyl-2-butanone-(4-sulfonamidophenyl)-hydrazone; Molecular Formula: C11H17N3O2S	Unknown
8. Acute Oral Toxicity Study in Rats (Exp. No. 930321) (Test Article: 501149)	3H-pyrazol-3-One, 2-(4-aminophenyl), 4-dihydro-5-(1-pyrrolidinyl)	30707-77-8
9. Skin Corrosivity Study of T-5799 in Rabbits (DOT/UN Regulations)	1-Octanesulfonyl Fluoride - 87.5%, Other Alkyl Sulfonyl Fluorides and Acidic Impurities - 11%, Water - 5.4%, Octanesulfonyl Chloride - 1.4%	40630-63-5; Unknown; 7732-18-5; 7795-95-1
10. Skin Corrosivity Study of T-5800 in Rabbits (DOT/UN Regulations)	1-Octanesulfonyl Fluoride - 87.5%, Other Alkyl Sulfonyl Fluorides and Acidic Impurities - 11%, Water - 5.4%, Octanesulfonyl Chloride - 1.4%.	40630-63-5; Unknown; 7732-18-5; 7795-95-1
11. Primary Dermal Irritation/Corrosion Study of T-5635 in Rabbits (OECD Guidelines)	[CBI removed]	[CBI removed]
12. Primary Dermal Irritation/Corrosion Study of T-5897 in Rabbits (OECD Guidelines)	Isophthaloylbis (2-methylarziridine) - 97%, Toluene - 2%, Xylene - 0.5%.	7652-64-4; 108-88-3; 1330-20-7
13. Skin Corrosivity Study of T-7030.1 in Rabbits (with Protocol TP4206 attached)	[CBI removed]	[CBI removed]
14. Dermal Sensitization Study of T-5474 in Guinea Pigs - Maximization Test (EPA Guidelines)	Water (CAS No. 7732-18-5) - 68.4%; Dodecylbenzenesulfonic Acid (CAS No. 27176-87-0) - 17.5%; Polymethacrylate (CAS No. 25087-26-7) - 11.76%; Sodium Hydroxide (CAS No. 1310-73-2) - 2.3%; Unknown - 0.040%	7732-18-5; 27176-87-0; 25087-26-7; 1310-73-2

**SUBMISSION BY 3M COMPANY ON MAY 23, 2003**

Study Title	Test Substance	CAS Number
15. Dermal Sensitization Study of T-5894 in Guinea Pigs - Maximization Test (EC Guidelines) (with Protocol TP6164E attached)	[CBI removed]	[CBI removed]
16. Dermal Sensitization Study of T-6006 in Guinea Pigs - Closed Patch Technique (EPA Guidelines)	Dimethyltetradecylamine Oxide - 55%, Oleamidopropyldimethylamine - 18%, 1-Methoxy -2-Propanol - 5%, Citronellol - 5%, Polyethylene Glycol - < 3%, Alpha - (Carboxymethyl) - Omega - (Dodecyloxy) Poly (Oxyethylene) Sodium Salt - ~3%, Trialkyl Amine Oxide - 2%, Isopropyl Alcohol - 2%, Fragrance Sozio SZ 5467 - 2%, Water - 1%, Acetic Acid - 1%, Miscellaneous ingredients at less than 1%	3332-27-2; 109-28-4; 107-98-2; 106-22-9; 25322-68-3; 33939-64-9; 7128-91-8; 67-63-0; Unknown; 7732-18-5; 64-19-7
17. Dermal Sensitization Study of T-7280 in Guinea Pigs - Closed Patch Technique (with Protocol TP2008 attached)	[CBI removed]	[CBI removed]
18. Acute Oral Toxicity Study of T-6735 in Rats (OECD Guidelines) (with Protocol TP2069 attached)	4,6-dibromo-2-isopropyl phenol	Unknown
19. Acute Toxicity to Daphnia Magna	[CBI removed]	[CBI removed]
20. Evaluation of the Mutagenic Activity of T-5870 in an In Vitro Mammalian Cell Gene Mutation Test with L5178Y Mouse Lymphoma Cells (with Independent Repeat)	2-ethoxy ethyl acrylate	106-74-1
21. Acute Eye Irritation Study in New Zealand White Rabbits (Exp. No. 920364) (Test Article: 586442-50055)	HP=Benzothiazolium (9CI); SB=3-ethyl-2-((3-(3-ethyl-2(3H)-benzothiazolylidene)-1-propenyl)-5,5-dimethyl-2-cyclohexen-1-ylidene)methyl)-6-methoxy-5-methyl-; NM=Iodide; Molecular Formula: C32H37N2OS2.I	87699-86-3
22. Acute Eye Irritation Study in New Zealand White Rabbits (Exp. No. 940151) (Test Article: 580066)	Thiazolium, 3-ethyl-2-[3-(3-ethyl-2-thiazolidinylidene)-1-propenyl]-4,5-dihydro-, iodide; Molecular Formula: C13H21N2S2.I	3065-71-2
23. Acute Eye Irritation Study in New Zealand White Rabbits (Exp. No. 930529) (Test Article: 1268)	3-ethoxy-carbonyl-methyl-4-etoxy-methylidene-rhodanine; Molecular Formula: C10H13NO4S2	Unknown
24. Acute Eye Irritation Study in New Zealand White Rabbits (Exp. No. 920582) (Test Article: 1248)	C6H10CIN3O2S	Unknown
25. One Generation Reproduction Study of PFOS - Mevalonic Acid/Cholesterol Challenge and NOEL Investigation in Rats	Perfluorooctane Sulfonic Acid Potassium Salt	2795-39-3
26. Augmented acute (4-hour) inhalation toxicity study with T-6905 in rats	2% solids of fluorochemical fatty acid ester in water	306974-63-0

# **REPORT**

**EXPLORATORY 28-DAY ORAL TOXICITY STUDY  
WITH  
T-7250, T-7251, T-7152, T-7253, T-7254, and T-7255  
BY DAILY GAVAGE  
IN THE RAT  
FOLLOWED BY A 14/28-DAY RECOVERY PERIOD**

**NOTOX Project 264656  
NOTOX Substances 91872, 91881, 91899, 91908, 91917, 91926  
3M Test No. T-7250, T-7251, T-7252, T-7253, T-7254, T-7255**

REPORT APPROVAL


---

Study Director  
Ir. S.C.M. de Hoog



Date: 17 March 2000

Management  
Drs. W.J.A.M. Frieling



Date: 21 March, 2000

Ir. J.C.M. van der Hoeven  
Managing Director

**CONTENTS**

REPORT APPROVAL .....	2
SUMMARY.....	5
PREFACE.....	8
STUDY PLAN .....	9
MATERIALS AND METHODS.....	10
TEST SUBSTANCES.....	10
TEST SUBSTANCE FORMULATION.....	11
PURPOSE AND RATIONALE.....	11
GUIDELINES.....	12
ARCHIVING .....	12
TEST SYSTEM .....	12
ALLOCATION .....	12
ANIMAL HUSBANDRY .....	13
TREATMENT .....	14
RECOVERY .....	14
OBSERVATIONS.....	14
CLINICAL LABORATORY INVESTIGATIONS .....	15
HAEMATOLOGY.....	15
CLINICAL BIOCHEMISTRY .....	16
URINALYSIS .....	17
PATHOLOGY.....	18
NECROPSY.....	18
ORGAN WEIGHTS.....	18
LIVER SAMPLING.....	19
HISTOTECHNOLOGY .....	19
HISTOPATHOLOGY .....	19
STATISTICAL ANALYSIS.....	20
RESULTS .....	21
OBSERVATIONS.....	21
MORTALITY .....	21
CLINICAL SIGNS .....	21
BODY WEIGHT .....	21
FOOD CONSUMPTION .....	22
HAEMATOLOGY.....	22
CLINICAL BIOCHEMISTRY .....	23
MACROSCOPIC EXAMINATION .....	24
ORGAN WEIGHTS.....	25
DISCUSSION AND CONCLUSION.....	25
FIGURES.....	27
Body Weights .....	29
Body Weight Gain .....	30
Food Consumption.....	32
Relative Food Consumption.....	34
	36

**CONTENTS (Continued)**

TABLES – SUMMARY DATA .....	38
Clinical Signs .....	39
Body Weights .....	63
Body Weight Gain .....	67
Food Consumption .....	71
Relative Food Consumption .....	75
Haematology .....	79
Clinical Biochemistry .....	91
Macroscopic Findings .....	103
Organ Weights-Organ/Body Weight Ratios .....	105
Historical Data Haematology/Clinical Biochemistry .....	117
TABLES – INDIVIDUAL DATA .....	121
Mortality .....	122
Clinical Signs .....	134
Body Weights .....	167
Body Weight Gain .....	179
Food Consumption .....	191
Relative Food Consumption .....	193
Key to Missing Values Haematology / Clinical Biochemistry .....	195
Incidence of Haemolytic Serum Samples .....	196
Haematology .....	197
Clinical Biochemistry .....	230
Macroscopic Findings .....	263
Organ Weights-Organ/Body Weight Ratios .....	290
APPENDIX 1 Pathology Report .....	1-166
LAST PAGE OF REPORT .....	475

## SUMMARY

---

An exploratory oral rat toxicity study with T-7250, T-7251, T-7252, T-7253, T-7254 and T-7255 administered by daily gavage for 28 days followed by a 14/28-day recovery period was conducted.

Dose levels for this study were provided by the sponsor and were selected to be 0 (Vehicle Control), 15 (T-7254, T-7255; males only) and 30 mg/kg body weight/day (T-7250, T-7251, T-7252, T-7253).

The study was based on the following guidelines:

- EEC Directive 96/54/EEC, B.7 Repeated Dose (28 days) Toxicity (oral), 1996.
- OECD 407, Repeated Dose 28-day Oral Toxicity Study in Rodents, 1995.

The test substances, formulated in 1% aqueous carboxymethyl cellulose, were administered daily for at least 28 days by oral gavage to SPF-bred Sprague Dawley rats. One vehicle control group and 6 treated groups were tested. Five groups consisted of 8 males and 8 females and two groups consisted of 8 males only. An extra 3 animals per sex per group were allowed 14 days of recovery and another 3 animals per sex per group were allowed 28 days of recovery.

Based on severely reduced body weights and significant clinical signs, dosing of Group 7 animals (T-7255) was stopped on day 11.

The following parameters were evaluated: clinical signs twice daily (during treatment) or once daily (during recovery); body weight twice weekly; food consumption weekly; clinical pathology after 4 weeks and at the end of both recovery periods; gross pathology at termination; organ weights and histopathology on a selection of tissues.

## RESULTS

### T-7250 (30 mg/kg/day):

1. Hunched posture was incidentally noted during recovery (♀).
2. Slight increase in severity of haemopoiesis - primarily erythropoiesis - of the spleen (♂), but decreasing during recovery compared to the grades after 4 weeks of treatment.
3. Haemolytic serum samples noted after treatment (♂/♀) and recovery (♂).

### T-7251 (30 mg/kg/day):

1. One female died accidentally after blood sampling at the end of the treatment period.
2. Increased incidence of haemolytic serum samples noted after treatment (♂); haemoglobin values and red blood cell count were decreased after treatment (♀).
3. Total cholesterol (♂) and total bilirubin (♀) were decreased after treatment. After 2 weeks recovery, triglyceride and glucose values were increased (♀).
4. Liver:body weight (♂/♀) and kidney:body weight ratios (♂) were increased after treatment.
5. Midzonal/centrilobular hypertrophy in the liver after treatment (♂).

### T-7252 (30 mg/kg/day):

1. Relative food consumption was decreased during week 2 of treatment (♀).
2. Increased incidence of haemolytic serum samples noted after treatment (♂).
3. Slight increase in the severity of haemopoiesis - primarily erythropoiesis - of the spleen after treatment and during recovery (♂).



T-7253 (30 mg/kg/day):

1. One female died accidentally after blood sampling at the end of the treatment period
2. Increased incidence of haemolytic serum samples noted after treatment (♂).
3. Haemoglobin values (♀), red blood cell count (♀) and partial thromboplastin time (♂) were decreased after treatment.
4. Total bilirubin (♀), chloride (♀), creatinine (♀) and total cholesterol values (♂) were decreased; creatinine, urea, albumin, albumin/globulin ratio and inorganic phosphate were increased (♂) after treatment. After 2 weeks recovery, total bilirubin (♀), inorganic phosphate (♀) and chloride values (♂) were decreased; glucose values were increased (♀). After 4 weeks recovery, chloride values were decreased (♀).
5. Accentuated lobular pattern of the liver noted after treatment (♀).
6. Liver and kidney weights (♂), spleen:body weight (♀), liver:body weight (♂/♀) and kidney:body weight ratios (♂/♀) were increased after treatment.
7. Midzonal/centrilobular hypertrophy and focal coagulative necrosis in the liver (♂) after treatment.

T-7254 (15 mg/kg/day; males only):

1. Piloerection and hunched posture noted incidentally during the last week of treatment and/or beginning of recovery.
2. Body weight was decreased during the second half of the treatment period.
3. Relative food consumption was increased from week 2 of treatment up to the first half of the recovery phase.
4. Increased incidence of haemolytic serum samples noted after treatment.
5. Haemoglobin and haematocrit values were decreased and red cell distribution width was increased. After 2 weeks recovery, haemoglobin and mean corpuscular haemoglobin values were decreased and red cell distribution width was increased. After 4 weeks recovery, haemoglobin values and partial thromboplastin time were decreased.
6. Glucose, urea, albumin, albumin/globulin ratio, alkaline phosphatase and inorganic phosphate values were increased and globulin values were decreased after treatment. After 2 weeks recovery, alkaline phosphatase values were increased, and total protein and chloride values were decreased. After 4 weeks recovery, urea values were increased and inorganic phosphate levels were decreased.
7. Enlarged, dark brown discoloured livers with an accentuated lobular pattern noted after treatment.
8. Autopsy body weight was decreased and liver weights, liver:body weight and kidney:body weight ratios were increased. Autopsy body weight was decreased after 2 weeks recovery; liver:body weight ratios were increased after 2 and 4 weeks recovery.
9. Slight increase in severity of haemopoiesis - primarily erythropoiesis - of the spleen after treatment and recovery; midzonal/centrilobular hypertrophy and focal coagulative necrosis in the liver after treatment; hypertrophy remaining present after 2 weeks recovery.

T-7255 (15 mg/kg/day; males only):

1. All animals were killed *in extremis* between days 10 and 14 of the treatment period.
2. Hunched posture, piloerection, emaciation, uncoordinated movements and/or a pale appearance were noted prior to death.
3. Body weight was decreased during treatment.
4. Food consumption was decreased during treatment.
5. Pale livers and an accentuated lobular pattern of the liver were noted. Additional findings included reduced size of prostate, seminal vesicles, spleen, epididymides and/or thymus. Incidental findings included a pale pancreas, an irregular surface of the liver, haemorrhage of the stomach, an enlarged liver, red brown foci and/or thickening of the glandular mucosa of the stomach, thickened limiting ridge of the stomach, alopecia and dark red discolouration of the duodenum and thymus.
6. Secondary microscopic effects related to the lack of growth, including hepatocellular atrophy in the liver, reduced zymogen in the pancreas and atrophy of the prostate and seminal vesicles. Focal coagulative necrosis of the liver was noted in some animals.

From the results presented in this report it can be concluded that T-7255 (15 mg/kg/day) was the compound with the most severe effects. T-7253 (30 mg/kg/day), T-7254 (15 mg/kg/day) and to a lesser degree T-7251 (30 mg/kg/day), induced less severe effects which consisted of effects on the liver, haemolytic effects, and changes in a range of clinical pathology parameters. In addition, T-7254 also showed a slightly increased severity of splenic haemopoiesis. T-7252 (15 mg/kg/day) induced some haemolytic effects after treatment, a slightly increased severity of splenic haemopoiesis and a decreased relative food consumption in females during treatment. Apart from a slightly increased severity of splenic haemopoiesis in males, T-7250 did not result in evident systemic toxicity and organ dysfunction at macroscopic or microscopic level and was considered to be the least toxic compound.

**PREFACE**

---

Sponsor	3M Corporate Toxicology 3M Center, Bldg 220-2E-02 St. Paul, MN 55144-1000 USA
Study Monitor	Marvin T. Case, DVM, PhD 3M Corporate Toxicology 3M Center, Bldg 220-2E-02 St. Paul MN 55144-1000 Telephone (651)- 733-5180 Fax (651)- 733-1773
Invoice Contact	Barbara Nelson 3M Procurement Operations 3M Center, Bldg 224-1N-04 St. Paul, MN 55144-1000 Telephone (651)- 733-0766 Fax (651)- 733-1799
Testing Facility	NOTOX B.V. Hambakenwetering 3 5231 DD 's-Hertogenbosch The Netherlands
Test site: histotechnology	Propath UK Ltd. Willow Court, Netherwood Road Hereford, HR2 6JU England
histopathology	Propath GmbH, Oberemattstrasse 52A, CH 4133 Pratteln, Switzerland
Study Director Histotechnology Histopathology	Ir. S.C.M. de Hoog (NOTOX) I.J. Stiff (Principal Investigator, Propath UK Ltd.) Dr. J. Th. Wilson (Principal Investigator, Propath GmbH)

## STUDY PLAN

---

### Start of Treatment

24 August 1999 (males)  
26 August 1999 (females)

### Start Recovery

22 September 1999 (males)  
24 September 1999 (females)

### Blood sampling

21 September 1999 (Main groups, males)  
22 September 1999 (Main and Recovery groups 1 and 2, males)  
23 September 1999 (Main groups, females)  
24 September 1999 (Main and Recovery groups 1 and 2, females)  
06 October 1999 (Recovery groups 1, males)  
08 October 1999 (Recovery groups 1, females)  
20 October 1999 (Recovery groups 2, males)  
22 October 1999 (Recovery groups 2, females)

### Urine collection

predose : 18-19 August 1999 (Recovery groups 1 and 2, males and females)  
day 8 : 30-31 August 1999 (Recovery groups 1 and 2, males)  
day 8 : 01-02 September 1999 (Recovery groups 1 and 2, females)  
day 15 : 06-07 September 1999 (Recovery groups 1 and 2, males)  
day 15 : 08-09 September 1999 (Recovery groups 1 and 2, females)  
end of treatment : 21-22 September 1999 (Recovery groups 1 and 2, males)  
end of treatment : 23-24 September 1999 (Recovery groups 1 and 2, females)  
end of recovery : 05-06 October 1999 (Recovery groups 1, males)  
end of recovery : 07-08 October 1999 (Recovery groups 1, females)  
end of recovery : 19-20 October 1999 (Recovery groups 2, males)  
end of recovery : 21-22 October 1999 (Recovery groups 2, females)

### Necropsy

21 September 1999 (Main groups, males)  
22 September 1999 (Main groups, males)  
23 September 1999 (Main groups, females)  
24 September 1999 (Main groups, females)  
06 October 1999 (Recovery groups 1, males)  
08 October 1999 (Recovery groups 1, females)  
20 October 1999 (Recovery groups 2, males)  
22 October 1999 (Recovery groups 2, females)

**MATERIALS AND METHODS**

---

**TEST SUBSTANCES**

The sponsor is responsible for the completeness of all test substance data.

**NOTOX SUBSTANCE 91872**

Identification	T-7250
Description	White powder
Batch	Not indicated
Purity	100%
Test substance storage	At room temperature in the dark
Stability under storage conditions	Not indicated
Expiry date	21 June 2000 (allocated by NOTOX, 1 year after receipt of the test substance)

**NOTOX SUBSTANCE 91881**

Identification	T-7251
Description	White powder
Batch	Not indicated
Purity	100%
Test substance storage	At room temperature in the dark
Stability under storage conditions	Not indicated
Expiry date	21 June 2000 (allocated by NOTOX, 1 year after receipt of the test substance)

**NOTOX SUBSTANCE 91899**

Identification	T-7252
Description	White powder
Batch	Not indicated
Purity	100%
Test substance storage	At room temperature in the dark
Stability under storage conditions	Not indicated
Expiry date	21 June 2000 (allocated by NOTOX, 1 year after receipt of the test substance)

**NOTOX SUBSTANCE 91908**

Identification	T-7253
Description	White powder
Batch	Not indicated
Purity	100%
Test substance storage	At room temperature in the dark
Stability under storage conditions	Not indicated
Expiry date	21 June 2000 (allocated by NOTOX, 1 year after receipt of the test substance)

**NOTOX SUBSTANCE 91917**

Identification	T-7254
Description	White powder
Batch	Not indicated
Purity	100%
Test substance storage	At room temperature in the dark
Stability under storage conditions	Not indicated
Expiry date	21 June 2000 (allocated by NOTOX, 1 year after receipt of the test substance)

**NOTOX SUBSTANCE 91926**

Identification	T-7255
Description	White powder
Batch	Not indicated
Purity	100%
Test substance storage	At room temperature in the dark
Stability under storage conditions	Not indicated
Expiry date	21 June 2000 (allocated by NOTOX, 1 year after receipt of the test substance)

Vehicle	1% aqueous carboxymethyl cellulose
Rationale for vehicle	Based on information provided by the sponsor
Stability in vehicle	Stability over 4 hours will be determined by the sponsor

**TEST SUBSTANCE FORMULATION**

Method	Formulations (w/w) were prepared daily within 4 hours prior to dosing.
--------	------------------------------------------------------------------------

Storage conditions	At ambient temperature
--------------------	------------------------

No chemical analysis of dose preparations was performed.

**PURPOSE AND RATIONALE**

The nature and purpose of this exploratory study was to determine and compare the relative oral toxicity in rats following oral (gastric gavage) doses administered daily over 28 days and identify developmental compounds of lesser toxicity for commercial development.

This study should provide part of a rational basis for toxicological risk assessment in man. The oral route was selected as it is a possible route of human exposure during manufacture, handling or use of the test substance.

## GUIDELINES

---

The protocol was reviewed and agreed by the Article 14-functionary and the Ethical Committee of NOTOX as required by the Dutch Act on Animal Experimentation.

The study procedures described in this report were based on the following guidelines:

1) EC Directive 96/54/EEC, Annex IV.D, replacing EEC Directive 67/548/EEC, Part B : Methods for the Determination of Toxicity and other Health Effects; B.7: "Repeated Dose (28 days) Toxicity (oral)". Official Journal of the European Communities No. L248, September 1996.

2) OECD Guideline for Testing of Chemicals, Guideline 407: "Repeated Dose 28-day Oral Toxicity Study in Rodents", Paris Cedex, 27 July 1995.

The protocol, study procedures and the report were not inspected by the NOTOX Quality Assurance Unit.

## ARCHIVING

---

NOTOX B.V., will archive the following data for at least 10 years: protocol, raw data, report and all specimens.

No data will be withdrawn without the sponsor's written consent.

## TEST SYSTEM

---

Test System	Sprague Dawley rat CrI:CD BR (outbred, SPF-Quality) Recognised by international guidelines as the recommended test system (e.g. EPA, FDA, OECD, EEC). Females were nulliparous and non-pregnant. Source : Charles River Deutschland, Sulzfeld, Germany
Age at Start of Treatment	Approximately 6 weeks.
Number of animals	98 males, 70 females
Randomisation	At least 5 days before study start, by computer-generated random algorithm according to body weight, with all animals within $\pm 20\%$ of the sex mean. A health inspection was performed prior to commencement of treatment to ensure that the animals were in a good state of health.
Identification	Earmark and tattoo

## ALLOCATION

Group Identification	Test Substance	Number of Animals		Animal Numbers	
		Males	Females	Males	Females
1 Main group	Vehicle control	8	8	1-8	113-120
1 Recovery group 1	Vehicle control	3	3	9-11	121-123
1 Recovery group 2	Vehicle control	3	3	13-15	125-127
2 Main group	T-7250	8	8	17-24	129-136
2 Recovery group 1	T-7250	3	3	25-27	137-139
2 Recovery group 2	T-7250	3	3	29-31	141-143
3 Main group	T-7251	8	8	33-40	145-152
3 Recovery group 1	T-7251	3	3	41-43	153-155
3 Recovery group 2	T-7251	3	3	45-47	157-159
4 Main group	T-7252	8	8	49-56	161-168
4 Recovery group 1	T-7252	3	3	57-59	169-171
4 Recovery group 2	T-7252	3	3	61-63	173-175
5 Main group	T-7253	8	8	65-72	177-184
5 Recovery group 1	T-7253	3	3	73-75	185-187
5 Recovery group 2	T-7253	3	3	77-79	189-191
6 Main group	T-7254	8	---	81-88	---
6 Recovery group 1	T-7254	3	---	89-91	---
6 Recovery group 2	T-7254	3	---	93-95	---
7 Main group	T-7255	8	---	97-104	---
7 Recovery group 1	T-7255	3	---	105-107	---
7 Recovery group 2	T-7255	3	---	109-111	---

Test substances T-7250 (substance 91872), T-7251 (substance 91881), T-7252 (substance 91899), T-7253 (substance 91908) were tested at a dose level of 30 mg/kg body weight/day and T-7254 (substance 91917) and T-7255 (substance 91926) were tested at a dose level of 15 mg/kg body weight/day.



**ANIMAL HUSBANDRY**

---

**Conditions**

Air-conditioned room with approximately 15 air changes per hour and the environment controlled with optimal conditions considered as being a temperature of 21°C and a relative humidity of 50%. Lighting was 12 hours artificial fluorescent light and 12 hours dark per day. Deviations from these optimal conditions occurred, but were considered not to have affected study integrity.

**Accommodation**

Group housing of 3-4 animals per sex per cage in stainless steel suspended cages with wire mesh floors. Acclimatisation period was at least 5 days before start of treatment under laboratory conditions.

**Diet**

Free access to standard pelleted laboratory animal diet (from Carfil Quality BVBA, Oud-Turnhout, Belgium). Each batch is analysed for nutrients and contaminants are analysed on a regular basis. Results are examined and archived.

**Water**

Free access to tap-water. Certificates of analysis (performed quarterly) were examined and archived.

**TREATMENT**

---

Method	Oral gavage, using a stainless steel stomach tube. Formulations were placed on a magnetic stirrer during dosing.
Frequency	Once daily for at least 28 days, approximately the same time each day, 7 days per week. Main group animals were dosed up to the day prior to necropsy. Based on severely reduced body weights and severe clinical signs, dosing of Group 7 animals (T-7255) was stopped from day 11 onwards.
Dose volume	5 ml/kg body weight. Actual dose volumes were calculated weekly according to the latest body weight.
Dose level	Group 1: 0 mg/kg b.w./day (Vehicle Control) Group 2: 30 mg/kg b.w./day (T-7250) Group 3: 30 mg/kg b.w./day (T-7251) Group 4: 30 mg/kg b.w./day (T-7252) Group 5: 30 mg/kg b.w./day (T-7253) Group 6: 15 mg/kg b.w./day (T-7254; males only) Group 7: 15 mg/kg b.w./day (T-7255; males only)

**RECOVERY**

---

Duration	Recovery group 1: at least 14 days Recovery group 2: at least 28 days
----------	--------------------------------------------------------------------------

OBSERVATIONS

Mortality / Viability	Twice daily.
Clinical signs	<p>During the treatment period detailed clinical observations were made twice daily in all animals: once immediately after dosing and once approximately 4 hours after dosing. During the recovery period only one observation per day was performed. The time of onset, degree and duration were recorded.</p> <p>All symptoms were recorded and graded according to fixed scales:  Maximum grade 4: grading slight (1) to very severe (4).  Maximum grade 3: grading slight (1) to severe (3).  Maximum grade 1: presence is scored (1).</p>
Body weights	<p>Treatment period : on days 1, 5, 8, 12, 15, 19, 22, 25 and 28.  Recovery period : on days 1, 5, 8, 12, 15, 19, 22, 25 and 28.  Additional body weight measurements were performed for male number 102 on day 9, and for all Group 7 animals on day 10 and 14 of the treatment period. These measurements were necessary to monitor the health status and did not affect study integrity. The data are mentioned in the raw data but are not reported.</p>
Food consumption	Weekly.
Water consumption	Subjective appraisal was maintained during the study, but no quantitative investigation introduced as no effect was suspected.

CLINICAL LABORATORY INVESTIGATIONS (MAIN AND RECOVERY GROUP ANIMALS)

Blood samples were collected under light ether anaesthesia, between 7.30 and 9.30 a.m. immediately prior to *post mortem* examination for Main and Recovery group animals, and for Recovery group animals also at the end of the treatment period. The animals were fasted overnight (with a maximum of 20 hours) before blood sampling, but water was provided. Blood samples were drawn from the retro-orbital sinus of all Main and Recovery rats/sex/group and collected into tubes prepared with EDTA for haematological parameters (0.5 ml), with citrate for clotting tests (1.0 ml) and untreated tubes for clinical biochemistry parameters (>2.0 ml).

## HAEMATOLOGY

The following haematology parameters were determined from blood prepared with EDTA as an anti-coagulant, using the instruments listed:

Parameter/Abbreviation	Unit	Instrumentation
Erythrocyte count/RBC	T/l	Sysmex K-1000
Haemoglobin/HB	mmol/l	Sysmex K-1000
Haematocrit/HCT	l/l	Sysmex K-1000
Mean corpuscular volume/MCV	fl	Sysmex K-1000
Mean corpuscular haemoglobin/MCH	fmol	Sysmex K-1000
Mean corpuscular haemoglobin concentration/MCHC	mmol/l	Sysmex K-1000
Platelet count	G/l	Sysmex K-1000
Red cell distribution width/RDW	%	Sysmex K-1000
Total leucocyte count/WBC	G/l	Sysmex K-1000
Differential leucocyte count/SEG (Neutrophils), EO (Eosinophils), BASO (Basophils), LYMPH (Lymphocytes), MONO (Monocytes)	1(rel)	Manual (Microscope)

The following haematology parameters were determined from blood prepared with citrate as an anti-coagulant, using the instruments listed:

Parameter/Abbreviation	Unit	Instrumentation
Prothrombin time/PT	sec	Sysmex CA-5000
Partial thromboplastin time/PTT	sec	Sysmex CA-5000

## CLINICAL BIOCHEMISTRY

The following clinical biochemistry parameters were determined from serum samples using the instruments listed:

Parameter/Abbreviation	Unit	Instrumentation
Alanine aminotransferase/ ALAT/GPT	µkat/l	ELAN analyser (Eppendorf)
Aspartate aminotransferase/ ASAT/GOT	µkat/l	ELAN analyser (Eppendorf)
Bilirubin, total/ BILI T.	µmol/l	ELAN analyser (Eppendorf)
Cholesterol, total/ CHOLEST. T.	mmol/l	ELAN analyser (Eppendorf)
Triglycerides/TRIGL.	mmol/l	ELAN analyser (Eppendorf)
Creatinine	µmol/l	ELAN analyser (Eppendorf)
Glucose	mmol/l	ELAN analyser (Eppendorf)
Urea	mmol/l	ELAN analyser (Eppendorf)
Protein, total/ PROTEIN T.	g/l	ELAN analyser (Eppendorf)
Protein, albumin/ ALBUMIN	g/l	ELAN analyser (Eppendorf)
Protein, globulin/ GLOBULIN	g/l	Calculation [PROTEIN T.- ALBUMIN]
Albumin Globulin ratio A/G RATIO	1	Calculation [ALBUMIN/GLOBULIN]
Alkaline phosphatase/ ALP	µkat/l	ELAN analyser (Eppendorf)
Sodium	mmol/l	EFIX 5055 Flame Photometer Eppendorf
Potassium	mmol/l	EFIX 5055 Flame Photometer Eppendorf
Chloride	mmol/l	ELAN analyser (Eppendorf)
Calcium	mmol/l	EFIX 5055 Flame Photometer Eppendorf
Phosphorus/ INORG. PHOSPH	mmol/l	ELAN analyser (Eppendorf)

Prostate gland  
Rectum  
Salivary glands - mandibular  
Sciatic nerve  
Seminal vesicles  
Spinal cord -cervical, midthoracic, lumbar  
Spleen  
Sternum with bone marrow  
Stomach  
Testes  
Thymus  
Thyroid including parathyroid  
Trachea  
Urinary bladder  
Uterus  
All gross lesions

#### ORGAN WEIGHTS

The following organ weights and terminal body weight were recorded from the surviving animals on the scheduled day of necropsy:

Adrenal glands  
Brain  
Heart  
Kidneys  
Liver  
Ovaries  
Spleen  
Testes

Both absolute and relative (% body weight) organ weight data are included in the study report.

Inadvertently, no terminal body weight was determined from animal 139.

#### LIVER SAMPLING

From all animals surviving until the scheduled necropsy at least 1 gram of the left lateral liver lobe was frozen in isopentane/N<sub>2</sub>. Liver samples were stored at -20°C at NOTOX until further analysis.

#### HISTOTECHNOLOGY

All organ and tissue samples, as defined under histopathology (following), were processed, embedded and cut at a thickness of 2-4 micrometers and stained with haematoxylin and eosin.

## HISTOPATHOLOGY

The following slides were examined by a pathologist:

- all underlined organs and tissues (see under Necropsy) collected at the scheduled sacrifice from all Main group animals of all dose groups
- all underlined organs and tissues (see under Necropsy) from all animals of all dose groups which died spontaneously or were terminated *in extremis*
- all gross lesions of all animals (all dose groups)

Based on treatment-related morphological changes in the liver of Groups 3, 4, 5 and 6 and the spleen of Groups 2, 4 and 6, the histological examination was extended to the livers and spleens of the recovery allocations 1 and 2.

All abnormalities were described and included in the report.

## STATISTICAL ANALYSIS

---

The following statistical methods were used to analyse the data:

Univariate one-way analysis of variance was used to assess the significance of intergroup differences.

If the variables could be assumed to follow a normal distribution, the Dunnett-test (many-to-one t-test) based on a pooled variance estimate was applied for the comparison of the treated groups and the control groups for each sex.

The Steel-test (many-to-one rank test) was applied instead of the Dunnett-test when the data could not be assumed to follow a normal distribution.

The Fisher-Exact test was applied to frequency data.

All tests were two-sided and in all cases  $p < 0.05$  was accepted as the lowest level of significance.

Group means were calculated for continuous data and medians were calculated for discrete data (scores) in the summary tables.

Test statistics were calculated on the basis of exact values for means and pooled variances. Individual values, means and standard deviations may have been rounded off before printing. Therefore, two groups may display the same printed means for a given parameter, yet display different test statistics values.

References:

- C.W. Dunnett  
A Multiple Comparison Procedure for Comparing Several Treatments with a Control, J. Amer. Stat. Assoc. 50, 1096-1121 (1955).
- R.G. Miller  
Simultaneous Statistical Inference, Springer Verlag, New York (1981).
- R.A. Fisher  
Statistical Methods for Research Workers, Oliver and Boyd, Edinburgh (1950).

## RESULTS

### OBSERVATIONS

#### MORTALITY

---

##### T-7255

All animals were killed *in extremis* on day 10 (animal no. 102), day 11 (animal no. 98, 107 and 111) or day 14 (remaining animals) of treatment. Various clinical signs were noted in these animals prior to death and included a hunched posture, piloerection, emaciation, uncoordinated movements and/or a pale appearance.

One T-7251 treated female (Recovery group 3; animal no. 153) and one T-7253 treated female (Main group 5; animal no. 181) died accidentally after blood sampling at the end of the treatment period.

No mortality occurred among animals receiving T-7250, T-7252 and T-7254.

#### CLINICAL SIGNS

---

##### T-7250

A hunched posture was incidentally noted in two females during the first week of the recovery phase.

##### T-7254

Piloerection was observed in one animal during the last week of treatment and had resolved within the first week of recovery. A hunched posture was noted in two animals on some days during the first week of recovery.

Red staining of the fur occurred in all groups but was particularly evident in Group 3 (T-7251; females), Group 5 (T-7253; females) and Group 6 (T-7254). This symptom mainly occurred in the second half of the treatment period and gradually disappeared during recovery. This finding might be a stress-related phenomenon occurring secondary to the treatment procedure, but was considered to be of no toxicological relevance.

Other findings such as alopecia, scabs, wounds, salivation and eye abnormalities were noted among the treated and/or control animals. These findings were considered to be of no toxicological significance as incidences remained within the range of biological variation for rats of this age and strain or could be attributed to the blood sampling procedure.

## BODY WEIGHT

---

### T-7254

Body weight and body weight gain of males were decreased when compared to control values during the second half of the treatment period. During recovery, body weights returned to values comparable to control values.

### T-7255

Body weight and body weight gain of males were decreased during the treatment period.

Other slight non-significant changes in body weight (gain) in the T-7252 group occurring during the recovery phase were considered to be of no toxicological relevance, as these findings were not evident during the treatment phase and did not attain statistical significance.

Body weights and body weight gain of animals receiving T-7250, T-7251 and T-7253 remained in the same range as controls over the treatment and recovery period.

## FOOD CONSUMPTION

---

### T-7252

Relative food consumption (i.e. after correction for body weight) was decreased in females during week 2 of the treatment period.

### T-7254

Relative food consumption was increased from week 2 of the treatment phase onwards up to the first half of the recovery phase, attaining statistical significance in most cases.

### T-7255

Absolute and relative food consumption were decreased during the treatment period.

Absolute and relative food consumption of animals receiving T-7250, T-7251 and T-7253 remained in the same range as controls over the treatment and recovery periods.



## CLINICAL LABORATORY INVESTIGATIONS

All Group 7 animals (T-7255) were killed *in extremis* between days 10 and 14 of the treatment period. Therefore, no clinical pathology data are available for this group.

## HAEMATOLOGY

---

### T-7251

After 4 weeks, haemoglobin values and red blood cell count were decreased in females. After 2 and 4 weeks recovery, these findings were not apparent anymore.

### T-7253

After 4 weeks, haemoglobin values (♀), red blood cell count (♀) and partial thromboplastin time (♂) were decreased.

After 2 and 4 weeks recovery, these findings were not apparent anymore.

### T-7254

After 4 weeks, haemoglobin and haematocrit values were decreased and red cell distribution width was increased in males.

After 2 weeks recovery, haemoglobin values remained decreased and red cell distribution width remained increased. Additionally, mean corpuscular haemoglobin values were decreased.

After 4 weeks recovery, haemoglobin values were still decreased. In addition, partial thromboplastin time was decreased.

An increase of relative numbers of neutrophilic granulocytes was found in males dosed with T-7252 and T-7254 after 4 weeks of treatment. However, similar findings in the opposite sex were absent for the T-7252 group and most of these values remained within the range of historical data found for rats of this age and strain. Therefore, the toxicological significance of this finding is doubted.

The decreased mean corpuscular haemoglobin concentration noted in females of the T-7250 group after 4 weeks recovery, and the increased prothrombin time in males of the T-7251 group after 2 weeks recovery were considered to be due to slightly high or low control values respectively. As all values remained within the range of historical data found for rats of this age and strain and similar findings during treatment were absent, these findings were considered toxicologically irrelevant.

CLINICAL BIOCHEMISTRY

---

T-7250

After 4 weeks, haemolytic serum samples were noted in 4/14 males and 3/14 females.  
After 2 weeks recovery, haemolytic serum samples were noted in all males.  
After 4 weeks recovery, haemolytic serum samples were still noted in 1/3 males.

T-7251

After 4 weeks, total cholesterol (♂) and total bilirubin (♀) were decreased. The decreased aspartate aminotransferase activity found in females did not have toxicological relevance since the opposite effect would be expected in case of organ toxicity. Haemolytic serum samples were noted in 8/14 males and 2/14 females.  
After 2 weeks recovery, triglyceride and glucose values were increased in females. Haemolytic serum samples were noted in 1/3 males.  
After 4 weeks recovery, all values had returned to control range values.

T-7252

After 4 weeks, no statistically significant differences were found when compared to the control group. Haemolytic serum samples were noted in 8/14 males and 4/14 females.  
After 2 weeks recovery, albumin (♂) and glucose values (♀) were increased, and chloride (♂) and inorganic phosphate (♂) were decreased. Haemolytic serum samples were noted in 1/3 females.  
After 4 weeks recovery, haemolytic serum samples were noted in 1/3 males.

T-7253

After 4 weeks, total cholesterol was decreased, while creatinine, urea, albumin, albumin/globulin ratio and inorganic phosphate were increased in males. Total bilirubin, creatinine and chloride values were decreased in females. Haemolytic serum samples were noted in 10/14 males and 1/14 females.  
After 2 weeks recovery, total bilirubin values remained decreased in females, while chloride values were decreased in males. In addition, glucose values were increased and inorganic phosphate values were decreased in females. Haemolytic serum samples were noted in 1/3 females.  
After 4 weeks recovery, chloride values were decreased in females.

T-7254

After 4 weeks, glucose, urea, albumin, albumin/globulin ratio, alkaline phosphatase and inorganic phosphate values were increased, and globulin values were decreased. Haemolytic serum samples were noted in 12/14 males.  
After 2 weeks, alkaline phosphatase values remained increased, while total protein and chloride values were decreased.  
After 4 weeks, urea values were increased and inorganic phosphate levels were decreased.

Other changes noted in T-7254 treated animals included decreased adrenal weights and increased testes and brain:body weight ratios after 4 weeks of treatment and/or after 2 weeks recovery. These changes were likely to reflect low body weights at autopsy.

Statistically significant changes noted after 2 or 4 weeks recovery in animals treated with T-7250 or T-7252 were considered to have no toxicological relevance as similar findings were absent in the opposite sex and did not occur during treatment.

#### MICROSCOPIC EXAMINATION (see Appendix 1)

---

Primary treatment related microscopic findings were noted as follows.

##### T-7250

After 4 weeks, a slight increase in the severity of haemopoiesis – primarily erythropoiesis – in the spleen was noted in males.

After 2 and 4 weeks recovery, the severity of the splenic haemopoiesis was lower compared to the grades after 4 weeks of treatment.

##### T-7251

After 4 weeks, minimal to slight midzonal/centrilobular hypertrophy in the liver was seen in all males.

After 2 and 4 weeks recovery, this effect was not observed anymore.

##### T-7252

After 4 weeks, a slight increase in the severity of haemopoiesis – primarily erythropoiesis – in the spleen was noted in males.

After 2 and 4 weeks recovery, severity grades of haemopoiesis remained at levels similar to those at end of treatment.

##### T-7253

After 4 weeks, minimal to slight midzonal/centrilobular hypertrophy in the liver was seen in 7/8 males, in 2 cases accompanied by focal coagulative necrosis.

After 2 and 4 weeks recovery, these effects were not observed anymore.

##### T-7254

After 4 weeks, a slight increase in the severity of haemopoiesis – primarily erythropoiesis – in the spleen was noted in males. In addition, slight to moderate midzonal/centrilobular hypertrophy in the liver was seen in all males, in 5 cases accompanied by focal coagulative necrosis.

After 2 weeks recovery, minimal midzonal/centrilobular hypertrophy was seen in 1/3 males.

After 2 and 4 weeks recovery, severity grades of haemopoiesis remained at levels similar to those at end of treatment.

##### T-7255

A range of findings were recorded in various organs which can be considered as secondary effects related to the lack of growth in these animals. These included hepatocellular atrophy in the liver, reduced zymogen in the pancreas and atrophy of the prostate and seminal vesicles. In addition, focal coagulative necrosis of the liver was noted in 4/14 animals.

The remainder of the microscopic findings recorded at all necropsies, were within the range of background pathology encountered in Sprague Dawley rats of this age and strain and occurred at similar incidences and severity in both control and treated rats.

## DISCUSSION AND CONCLUSION

Following daily oral administrations of T-7250, T-7251, T-7252, T-7253, T-7254 and T-7255 to male and/or female Sprague Dawley rats for at least 28 days, treatment-related changes were most pronounced in males treated with T-7255. These animals were sacrificed moribund between days 10 and 14 of treatment. Before termination severe body weight loss and reduced food consumption, in addition to severe clinical signs such as hunched posture and uncoordinated movements were observed. Macroscopic observation particularly revealed pale livers which in most cases showed an accentuated lobular pattern. At microscopic level, there were secondary effects - primarily atrophy - or indications of reduced function, in a range of organs. Focal coagulative necrosis of the liver was noted in some animals.

Among the surviving groups the primary morphologic alteration took the form of hepatocellular hypertrophy after 4 weeks of treatment, noted in males only from the T-7251, T-7253 and T-7254 groups. Animals treated with T-7254 were affected to the greatest degree. Complete reversal of this finding had occurred in all the affected groups by the end of the 28 day recovery period. The T-7253 and T-7254 groups also showed some cases of hepatic focal coagulative necrosis after treatment.

In addition, liver weights were increased in these dose groups, particularly in the T-7254 group. In this group all males showed an enlarged and dark brown discoloured liver. These findings had disappeared during recovery.

Clinical pathology measurements supporting hepatocellular hypertrophy or indicating liver damage were increased albumin values in the T-7253 and T-7254 groups, strongly increased alkaline phosphatase values and decreased globulin values in the T-7254 group. In males of the T-7251 and T-7253 groups reduced total cholesterol values were found. The liver is involved in the synthesis and metabolism of cholesterol and globulin.

Evidence suggesting haemolytic properties of compounds T-7253 and T-7254 consisted of an increased incidence of haemolytic serum samples when compared to control incidences. To a lesser degree this also occurred for T-7251 and T-7252 treated males. This effect was not apparent at the end of the recovery periods. In the T-7254 group further evidence indicative of haemolytic anaemia took the form of decreased haemoglobin and haematocrit values and an increased red cell distribution width. Haemoglobin values remained low throughout the recovery period.

In the T-7253 and T-7254 groups albumin values were increased after treatment. However, total bilirubin values were not increased in any of these dose groups. At microscopic level, a slightly increased severity of haemopoiesis (erythroid) in the spleen occurred in the T-7250, T-7252 and T-7254 group males at the end of treatment. In the T-7250 group, the severity of this finding was decreased following the recovery periods but remained slightly increased in the T-7252 and 7254 groups. Red blood cell formation in the spleen can be expected in response to an increased demand.

Increased kidney weights were found in animals dosed with T-7251, T-7253 or T-7254. In males dosed with T-7253 or T-7254 this was combined with increased inorganic phosphate and urea values after treatment, and decreased chloride values after 2 weeks recovery. In the T-7253 group creatinine levels were also increased. However, in females of this dose group creatinine values were decreased and at microscopic level no clear indications pointing to renal failure or damage were noted in any of the dose groups.

In T-7254 treated males body weight and body weight gain were decreased during the second half of the treatment period and the first half of the recovery period, which reflects their reduced health condition. Relative food consumption was increased during treatment and the first half of the recovery period.

Clinical signs were not overtly present in the surviving dose groups, and mainly consisted of hunched posture noted in some animals of the T-7250 and T-7254 groups during week 1 of

recovery. Piloerection was observed in one animal of the T-7254 dose group during the last week of treatment, which resolved during recovery.

No microscopic correlates were found for the changes in clinical biochemistry parameters and the decreased spleen size observed in the T-7252 group after 2 weeks recovery. As similar findings were absent during treatment, the toxicological relevance of these findings is doubted.


From the results presented in this report it can be concluded that T-7255 (15 mg/kg/day) was the compound with the most severe effects. T-7253 (30 mg/kg/day), T-7254 (15 mg/kg/day) and to a lesser degree T-7251 (30 mg/kg/day), induced less severe effects which consisted of effects on the liver, haemolytic effects, and changes in a range of clinical pathology parameters. In addition, T-7254 also showed a slightly increased severity of splenic haemopoiesis. T-7252 (15 mg/kg/day) induced some haemolytic effects after treatment, a slightly increased severity of splenic haemopoiesis and a decreased relative food consumption in females during treatment. Apart from a slightly increased severity of splenic haemopoiesis in males, T-7250 did not result in evident systemic toxicity and organ dysfunction at macroscopic or microscopic level and was considered to be the least toxic compound.

30


*Hyper-eosinophilia 7 July 2000*

## FIGURES

# BODY WEIGHTS MALES




# BODY WEIGHTS FEMALES







# BODY WEIGHT GAIN MALES




# FOOD CONSUMPTION MALES




# FOOD CONSUMPTION FEMALES



# RELATIVE FOOD CONSUMPTION MALES



# RELATIVE FOOD CONSUMPTION FEMALES



**TABLES - SUMMARY DATA**

**CLINICAL SIGNS (SUMMARY)**  
**MALES**  
**GROUP 1 (VEHICLE CONTROL)**

	TREATMENT
WEEKS:	1.....2.....3.....4.....5.
DAYS:	1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.
SIGN (MAX.GRADE)	TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABAB

---

NO CLINICAL SIGNS NOTED

**CLINICAL SIGNS, DAILY (SUMMARY)**  
**MALES**  
**GROUP 1 (VEHICLE CONTROL)**

SIGN (MAX.GRADE)	RECOVERY
LOCATION	WEEKS: 1.....2.....3.....4.....5.

---

NO CLINICAL SIGNS NOTED



**CLINICAL SIGNS (SUMMARY)**  
**MALES**  
**GROUP 2 (T-7250)**

SIGN (MAX.GRADE)	TREATMENT																		
	WEEKS: 1.	2.	3.	4.	5.	DAYS: 1.	2.	3.	4.	5.	6.	7.	1.	2.	3.	4.	5.	6.	7.
SKIN / FUR / PLUMAGE	-----																		
RED STAINING (3)																			
(HEAD)	G:	.....																	
	%:	.....																	
RED STAINING (3)																			
(NECK)	G:	.....11.....																	
	%:	.....11.....																	

---

G: Median value of the highest individual grades  
 %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%, ..., A = more than 95%)  
 Time after treatment (H.Mi) A: 0.00 B: 4.00

**CLINICAL SIGNS, DAILY (SUMMARY)**  
**MALES**  
**GROUP 2 (T-7250)**

SIGN (MAX.GRADE)	RECOVERY
LOCATION	WEEKS: 1.....2.....3.....4.....5.

---

SKIN / FUR / PLUMAGE

-----	
RED STAINING (3)	G: ...111111111.....
(HEAD)	%: ...222555555.....

---

G: Median value of the highest individual daily grades  
 %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%, ..., A = more than 95%)

**CLINICAL SIGNS (SUMMARY)**  
**MALES**  
**GROUP 3 (T-7251)**

	TREATMENT
WEEKS:	1.....2.....3.....4.....5.
DAYS:	1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.
SIGN (MAX.GRADE)	TIME: ABABABABABABABABABABABABABABABABABABABABABABABAB

SKIN / FUR / PLUMAGE  
-----

SWELLING (3)	G: .....
(PERIORBITAL REGION RIGHT)	%: .....

ALOPECIA (3)	G: .....	111111..
(CHEEK LEFT)	%: .....	111111..

ALOPECIA (3)	G: .....	111111..
(CHEEK RIGHT)	%: .....	111111..

ALOPECIA (3)	G: .....	1111111111111111..
(NECK)	%: .....	1111111111111111..

VARIOUS  
-----

EYE RIGHT, INJURED (1)	G: .....
	%: .....

DARK (3)	G: .....
(EYE RIGHT)	%: .....

G: Median value of the highest individual grades  
 %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%,..., A = more than 95%)  
 Time after treatment (H.Mi) A: 0.00 B: 4.00

**CLINICAL SIGNS, DAILY (SUMMARY)**  
**MALES**  
**GROUP 3 (T-7251)**

SIGN (MAX.GRADE)	RECOVERY
LOCATION	WEEKS: 1.....2.....3.....4.....5.

---

SKIN / FUR / PLUMAGE

-----  
SWELLING (3) G: 11.....  
(PERIORBITAL REGION RIGHT) %: 12.....

VARIOUS

-----  
EYE RIGHT, INJURED (1) G: 11111111...11.....  
%: 12222222...22.....

DULL (3) G: .....11111.....  
(EYE RIGHT) %: .....22222.....

DARK (3) G: 11.....  
(EYE RIGHT) %: 12.....

---

G: Median value of the highest individual daily grades  
%: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%, ..., A = more than 95%)

**CLINICAL SIGNS (SUMMARY)**  
**MALES**  
**GROUP 4 (T-7252)**

	TREATMENT
WEEKS:	1.....2.....3.....4.....5.
DAYS:	1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.
SIGN (MAX.GRADE)	TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB

---

SKIN / FUR / PLUMAGE  
-----

ALOPECIA (3) (NECK)	G: .....11111111111111111111111111111111..
	%: .....11111111111111111111111111111111..
SCABS (3) (NECK)	G: .....22222222222222222222222222221111..
	%: .....11111111111111111111111111111111..

---

G: Median value of the highest individual grades  
 %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%, ..., A = more than 95%)  
 Time after treatment (H.Mi) A: 0.00 B: 4.00

**CLINICAL SIGNS, DAILY (SUMMARY)**  
**MALES**  
**GROUP 4 (T-7252)**

SIGN (MAX.GRADE)	RECOVERY
LOCATION	WEEKS: 1.....2.....3.....4.....5.

---

NO CLINICAL SIGNS NOTED

CLINICAL SIGNS (SUMMARY)  
MALES  
GROUP 5 (T-7253)

	TREATMENT
WEEKS: 1.....2.....3.....4.....5.	
DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.	
SIGN (MAX.GRADE)	TIME: ABABABABABABABABABABABABABABABABABABABABABABAB

SKIN / FUR / PLUMAGE

SCABS (3) (NECK)	G: .....111111111111111222211111111111
	%: .....11111111111111111111111111111111
RED STAINING (3) (EYE RIGHT)	G: .....11.....
	%: .....11.....
RED STAINING (3) (NECK)	G: .....111111111111111111111111111111
	%: .....1111111111111111111112222222222

G: Median value of the highest individual grades  
 %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%, ..., A = more than 95%)  
 Time after treatment (H.Mi) A: 0.00 B: 4.00

**CLINICAL SIGNS, DAILY (SUMMARY)**  
**MALES**  
**GROUP 5 (T-7253)**

SIGN (MAX.GRADE) RECOVERY  
LOCATION WEEKS: 1.....2.....3.....4.....5.

SKIN / FUR / PLUMAGE

SCABS (3)	G: 11111111111111111111.....
(NECK)	%: 1222222222222222.....
WOUND (3)	G: .....111.....
(NECK)	%: .....222.....
RED STAINING (3)	G: 111.....
(NECK)	%: 232.....

---

G: Median value of the highest individual daily grades  
 %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%,..., A = more than 95%)





**CLINICAL SIGNS, DAILY (SUMMARY)**  
**MALES**  
**GROUP 6 (T-7254)**

SIGN (MAX.GRADE)	RECOVERY
LOCATION	WEEKS: 1.....2.....3.....4.....5.

---

POSTURE

HUNCHED POSTURE (1)	G: ...111.....
	%: ...332.....

SKIN / FUR / PLUMAGE

PILOERECTOR (1)	G: 1111.....
	%: 1222.....

RED STAINING (3) (BACK)	G: 11111111.....
	%: 23555555.....

RED STAINING (3) (NECK)	G: 111111111111.....
	%: 35555555555523.....

RED STAINING (3) (FLANK RIGHT)	G: .....1111.....
	%: .....2222.....

---

G: Median value of the highest individual daily grades  
%: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%, ..., A = more than 95%)

**CLINICAL SIGNS (SUMMARY)**  
**MALES**  
**GROUP 7 (T-7255)**

**TREATMENT**  
WEEKS: 1.....2.....3.....4.....5.  
DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.  
TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABAB

---

POSTURE

-----  
HUNCHED POSTURE (1)           G: .....1111111111..  
                                                                                 %: .....AAAAA988AAAA..

GAIT / MOTILITY

-----  
UNCOORDINATED MOVEMENTS (3)   G: .....111111..  
                                                                                 %: .....222223..

SKIN / FUR / PLUMAGE

-----  
PALE (3)                        G: .....111111..  
                                                                                 %: .....136899A..

PILOERECTION (1)           G: .....1111111111..  
                                                                                 %: .....111468AAAA..

ALOPECIA (3)  
(HEAD)                        G: .....2222221222..  
                                                                                 %: .....1111111111..

ALOPECIA (3)  
(NECK)                        G: .....2222222222222222..  
                                                                                 %: .....1111111111111111..

ALOPECIA (3)  
(ABDOMEN)                    G: .....22222111111111..  
                                                                                 %: .....111111111111..

ALOPECIA (3)  
(FLANK RIGHT)               G: .....1111111111..  
                                                                                 %: .....1111111111..

RED STAINING (3)  
(HEAD)                        G: .....1111111111..  
                                                                                 %: .....1111111222..

RED STAINING (3)  
(GENERAL)                    G: .....1111111111..  
                                                                                 %: .....2222227..

RED STAINING (3)  
(SNOUT)                       G: .....11..11..  
                                                                                 %: .....11..11..

RED STAINING (3)  
(BACK)                        G: .....1.....  
                                                                                 %: .....1.....

RED STAINING (3)  
(NECK)                        G: .....111111....11..  
                                                                                 %: .....111111....22...

VARIOUS

-----  
EMACIATED (1)                G: .....1111111111..  
                                                                                 %: .....669878AAAA..

G: Median value of the highest individual grades  
%: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%, ..., A = more than 95%)  
Time after treatment (H.Mi)   A: 0.00    B: 4.00

**CLINICAL SIGNS, DAILY (SUMMARY)**  
**MALES**  
**GROUP 7 (T-7255)**

SIGN (MAX.GRADE)	RECOVERY
LOCATION	WEEKS: 1.....2.....3.....4.....5.

---

NO CLINICAL SIGNS NOTED



**CLINICAL SIGNS, DAILY (SUMMARY)**  
**FEMALES**  
**GROUP 1 (VEHICLE CONTROL)**

SIGN (MAX.GRADE)	RECOVERY
LOCATION	WEEKS: 1.....2.....3.....4.....5.

---

SKIN / FUR / PLUMAGE  
-----

SWELLING (3)	G: .111.....
(PERIORBITAL REGION RIGHT)	%: .222.....

ALOPECIA (3)	G: 111111.....
(ABDOMEN)	%: 122222.....

VARIOUS  
-----

BULGING EYE (1)	G: 111.....
(EYE RIGHT)	%: 122.....

---

G: Median value of the highest individual daily grades  
%: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%, ..., A = more than 95%)



**CLINICAL SIGNS, DAILY (SUMMARY)  
FEMALES  
GROUP 2 (T-7250)**

SIGN (MAX.GRADE) LOCATION	RECOVERY				
	WEEKS: 1.....	2.....	3.....	4.....	5.....
<b>POSTURE</b>					
-----					
HUNCHED POSTURE (1)	G: .11.....				
	%: .33.....				
<b>SKIN / FUR / PLUMAGE</b>					
-----					
SWELLING (3) (PERIORBITAL REGION RIGHT)	G: .111.....				
	%: .222.....				
RED STAINING (3) (HEAD)	G: 111111111.....				
	%: 122222333.....				
RED STAINING (3) (NECK)	G: 1111111...1111.....				
	%: 2332222...2222.....				
<b>VARIOUS</b>					
-----					
BULGING EYE (1) (EYE RIGHT)	G: 111.....				
	%: 122.....				

G: Median value of the highest individual daily grades  
%: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%, ..., A = more than 95%)





**CLINICAL SIGNS, DAILY (SUMMARY)**  
**FEMALES**  
**GROUP 3 (T-7251)**

SIGN (MAX.GRADE)	RECOVERY
LOCATION	WEEKS: 1.....2.....3.....4.....5.

---

SKIN / FUR / PLUMAGE

ALOPECIA (3) (HEAD)	G: 1111111..... %: 1222222.....
RED STAINING (3) (HEAD)	G: 1111111111111111111..... %: 188888888888884777333.....
RED STAINING (3) (NECK)	G: 1111111111111111..... %: 366688888888884773.....

---

G: Median value of the highest individual daily grades  
 %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%, ..., A = more than 95%)

**CLINICAL SIGNS (SUMMARY)  
FEMALES  
GROUP 4 (T-7252)**

SIGN (MAX.GRADE)	TREATMENT				
	WEEKS: 1	2	3	4	5
	DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.				
	TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB				
<hr/>					
SKIN / FUR / PLUMAGE -----					
ALOPECIA (3) (NECK)	G: .....				111111111111111
	%: .....				111111111111111
ALOPECIA (3) (FLANK LEFT)	G: .....	11111111111111111111111111111111111111111111111111			111111111111111
	%: .....	11111111111111111111111111111111111111111111111111			111111111111111
ALOPECIA (3) (FLANK RIGHT)	G: ..	11111111111111111111111111111111111111111111111111			111111111111111
	%: ..	11111111111111111111111111111111111111111111111111			111111111111111
ALOPECIA (3) (SHOULDER RIGHT)	G: .....				111111
	%: .....				111111
SCABS (3) (NECK)	G: .....				111111111111111111111111
	%: .....				111111111111111111111111
RED STAINING (3) (HEAD)	G: .....	1111	111111111111111	111111111111111111111111111111111111111111111111	111111111111111
	%: .....	1111	111111111111111	111111111111111111111111111111111111111111111111	111111111111111
RED STAINING (3) (NECK)	G: .....	11111111111111111111111111111111111111111111111111			111111111111111
	%: .....	1111111111111111111111111222222222222222222222222222222111111			111111111111111
SECRETION / EXCRETION -----					
SALIVATION (3)	G: .....				11
	%: .....				11

G: Median value of the highest individual grades  
 %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%, ..., A = more than 95%)  
 Time after treatment (H.Mi) A: 0.00 B: 4.00

**CLINICAL SIGNS, DAILY (SUMMARY)**  
**FEMALES**  
**GROUP 4 (T-7252)**

SIGN (MAX.GRADE)	RECOVERY
LOCATION	WEEKS: 1.....2.....3.....4.....5.

---

SKIN / FUR / PLUMAGE

-----	
ALOPECIA (3)	
(NECK)	G: .....1111111.....
	%: .....222222.....
ALOPECIA (3)	
(SHOULDER RIGHT)	G: 1111111.....
	%: 122222.....

---

G: Median value of the highest individual daily grades  
 %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%, ..., A = more than 95%)



**CLINICAL SIGNS, DAILY (SUMMARY)**  
**FEMALES**  
**GROUP 5 (T-7253)**

SIGN (MAX.GRADE) LOCATION	RECOVERY WEEKS: 1.....2.....3.....4.....5.
------------------------------	-----------------------------------------------

---

SKIN / FUR / PLUMAGE

-----	
ALOPECIA (3) (FLANK LEFT)	G: 11111111111111111111111111111111 %: 122222222222222222222233333333333333
RED STAINING (3) (HEAD)	G: 1111111111111111..... %: 133333333333333.....
RED STAINING (3) (NECK)	G: 1111111111111111..... %: 355555533333333.....

---

G: Median value of the highest individual daily grades  
%: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%, ..., A = more than 95%)

BODY WEIGHTS (GRAM) SUMMARY  
MALES

TREATMENT		GROUP 1 VEHICLE CONTROL	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254	GROUP 7 T-7255
DAY 1	MEAN	223	220	215	228	222	216	222
WEEK 1	ST.DEV.	9.0	9.1	13.3	9.5	10.8	11.0	12.2
	N	14	14	14	14	14	14	14
DAY 5	MEAN	250	251	243	256	250	240	231 **
WEEK 1	ST.DEV.	9.7	9.6	15.7	13.1	11.6	15.9	9.7
	N	14	14	14	14	14	14	14
DAY 8	MEAN	268	267	257	274	261	251	208 **
WEEK 2	ST.DEV.	15.1	14.5	21.0	19.4	25.0	26.8	13.8
	N	14	14	14	14	14	14	14
DAY 12	MEAN	297	300	288	305	295	275 *	162 **
WEEK 2	ST.DEV.	13.9	16.6	21.0	21.0	18.7	26.3	12.8
	N	14	14	14	14	14	14	10
DAY 15	MEAN	312	311	298	321	311	284	---
WEEK 3	ST.DEV.	22.8	27.3	26.8	28.7	28.1	37.4	---
	N	14	14	14	14	14	14	0
DAY 19	MEAN	337	338	325	348	334	298 **	---
WEEK 3	ST.DEV.	20.5	26.4	27.3	26.4	24.9	36.4	---
	N	14	14	14	14	14	14	0
DAY 22	MEAN	356	354	341	363	351	308 **	---
WEEK 4	ST.DEV.	21.9	30.4	31.2	25.6	25.4	39.4	---
	N	14	14	14	14	14	14	0
DAY 25	MEAN	368	371	351	376	361	313 **	---
WEEK 4	ST.DEV.	22.3	29.1	31.9	28.2	28.2	42.9	---
	N	14	14	14	14	14	14	0
DAY 28	MEAN	377	378	361	387	369	314 **	---
WEEK 4	ST.DEV.	24.0	31.1	33.6	30.2	28.6	47.0	---
	N	14	14	14	14	14	14	0

\* / \*\* : Dunnett-Test based on pooled variance significant at 5% (\*) or 1% (\*\*) level

**BODY WEIGHTS (GRAM) SUMMARY  
MALES**

RECOVERY		GROUP 1 VEHICLE CONTROL	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254	GROUP 7 T-7255
DAY 1	MEAN	349	339	332	355	334	262 **	---
WEEK 1	ST.DEV.	30.3	15.7	27.2	31.8	31.5	39.3	---
	N	6	6	6	6	6	6	0
DAY 5	MEAN	386	376	365	398	376	298 **	---
WEEK 1	ST.DEV.	36.2	19.3	33.1	43.0	38.1	42.9	---
	N	6	6	6	6	6	6	0
DAY 8	MEAN	403	391	380	419	394	317 **	---
WEEK 2	ST.DEV.	39.9	21.1	38.8	47.8	43.1	41.6	---
	N	6	6	6	6	6	6	0
DAY 12	MEAN	413	402	391	430	408	327 **	---
WEEK 2	ST.DEV.	44.0	21.9	40.7	54.8	45.7	41.1	---
	N	6	6	6	6	6	6	0
DAY 15	MEAN	413	405	392	427	414	330 **	---
WEEK 3	ST.DEV.	42.2	22.0	37.4	51.6	48.4	42.3	---
	N	6	6	6	6	6	6	0
DAY 19	MEAN	405	419	388	486	432	373	---
WEEK 3	ST.DEV.	28.6	29.6	12.5	50.6	38.0	54.6	---
	N	3	3	3	3	3	3	0
DAY 22	MEAN	415	424	404	503	443	386	---
WEEK 4	ST.DEV.	34.4	29.0	16.6	53.1	37.0	57.8	---
	N	3	3	3	3	3	3	0
DAY 25	MEAN	421	433	406	504	446	383	---
WEEK 4	ST.DEV.	36.5	29.0	15.6	54.4	39.6	60.1	---
	N	3	3	3	3	3	3	0
DAY 28	MEAN	419	434	405	505	451	391	---
WEEK 4	ST.DEV.	36.2	31.3	19.4	54.6	47.3	59.5	---
	N	3	3	3	3	3	3	0

\* / \*\* : Dunnett-Test based on pooled variance significant at 5% (\*) or 1% (\*\*) level



BODY WEIGHTS (GRAM) SUMMARY  
FEMALES

TREATMENT		GROUP 1 VEHICLE CONTROL	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
DAY 1	MEAN	182	182	184	186	180
WEEK 1	ST.DEV.	9.7	10.4	10.0	12.7	8.6
	N	14	14	14	14	14
DAY 5	MEAN	191	192	193	197	189
WEEK 1	ST.DEV.	8.7	10.5	10.4	15.8	9.0
	N	14	14	14	14	14
DAY 8	MEAN	196	197	200	201	196
WEEK 2	ST.DEV.	12.2	11.1	12.4	15.5	9.0
	N	14	14	14	14	14
DAY 12	MEAN	215	216	220	221	212
WEEK 2	ST.DEV.	12.7	11.9	13.5	20.0	12.5
	N	14	14	14	14	14
DAY 15	MEAN	213	215	214	217	209
WEEK 3	ST.DEV.	16.4	20.1	16.1	21.1	10.5
	N	14	14	14	14	14
DAY 19	MEAN	231	232	233	235	227
WEEK 3	ST.DEV.	13.4	15.1	16.7	24.8	15.0
	N	14	14	14	14	14
DAY 22	MEAN	241	244	239	247	236
WEEK 4	ST.DEV.	15.7	20.1	19.2	27.5	14.7
	N	14	14	14		14
DAY 25	MEAN	248	248	249	251	240
WEEK 4	ST.DEV.	16.1	20.7	19.1	27.3	15.9
	N	14	14	14	14	14
DAY 28	MEAN	251	251	254	256	244
WEEK 4	ST.DEV.	16.6	21.5	19.4	27.9	17.3
	N	14	14	14	14	14

\* / \*\* : Dunnett-Test based on pooled variance significant at 5% (\*) or 1% (\*\*) level

**BODY WEIGHTS (GRAM) SUMMARY  
FEMALES**

RECOVERY		GROUP 1 VEHICLE CONTROL	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
DAY 1	MEAN	232	228	241	247	231
WEEK 1	ST.DEV.	11.6	16.1	15.3	28.1	17.9
	N	6	6	5	6	6
DAY 5	MEAN	261	255	272	281	262
WEEK 1	ST.DEV.	18.2	19.0	13.2	32.0	20.0
	N	6	6	5	6	6
DAY 8	MEAN	268	259	277	285	269
WEEK 2	ST.DEV.	18.4	18.6	16.2	34.5	21.6
	N	6	6	5	6	6
DAY 12	MEAN	272	263	283	291	274
WEEK 2	ST.DEV.	18.2	16.8	17.7	36.0	22.5
	N	6	6	5	6	6
DAY 15	MEAN	270	264	284	292	274
WEEK 3	ST.DEV.	16.1	14.1	18.7	36.5	21.6
	N	6	6	5	6	6
DAY 19	MEAN	273	274	287	306	284
WEEK 3	ST.DEV.	25.0	18.6	17.3	46.8	37.3
	N	3	3	3	3	3
DAY 22	MEAN	272	280	287	310	282
WEEK 4	ST.DEV.	20.6	14.7	16.5	54.6	34.9
	N	3	3	3	3	3
DAY 25	MEAN	276	280	290	317	287
WEEK 4	ST.DEV.	24.0	16.5	15.5	57.5	32.7
	N	3	3	3	3	3
DAY 28	MEAN	278	277	293	317	290
WEEK 4	ST.DEV.	23.6	18.0	21.8	57.0	31.3
	N	3	3	3	3	3

\* / \*\* : Dunnett-Test based on pooled variance significant at 5% (\*) or 1% (\*\*) level

**BODY WEIGHT GAIN (%) SUMMARY  
MALES**

TREATMENT		GROUP 1 VEHICLE CONTROL	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254	GROUP 7 T-7255
DAY 1	MEAN	0	0	0	0	0	0	0
WEEK 1	ST.DEV.	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	N	14	14	14	14	14	14	14
DAY 5	MEAN	12	14	13	13	13	11	4 **
WEEK 1	ST.DEV.	1.4	1.8	2.1	2.9	2.0	2.9	3.1
	N	14	14	14	14	14	14	14
DAY 8	MEAN	20	21	20	20	17	16	-6 **
WEEK 2	ST.DEV.	2.9	3.1	3.3	4.6	7.8	8.0	4.4
	N	14	14	14	14	14	14	14
DAY 12	MEAN	33	36	34	34	33	27 *	-27 **
WEEK 2	ST.DEV.	4.0	2.9	4.4	5.7	4.8	7.5	3.8
	N	14	14	14	14	14	14	10
DAY 15	MEAN	40	41	39	41	40	31 *	---
WEEK 3	ST.DEV.	6.1	8.0	4.8	8.7	8.1	12.7	---
	N	14	14	14	14	14	14	0
DAY 19	MEAN	51	53	51	53	51	38 **	---
WEEK 3	ST.DEV.	6.3	7.1	6.0	7.5	7.6	12.8	---
	N	14	14	14	14	14	14	0
DAY 22	MEAN	60	61	59	59	58	42 **	---
WEEK 4	ST.DEV.	7.4	8.5	6.9	6.6	8.4	14.2	---
	N	14	14	14	14	14	14	0
DAY 25	MEAN	65	68	63	65	63	45 **	---
WEEK 4	ST.DEV.	7.8	8.0	7.7	7.9	10.0	15.7	---
	N	14	14	14	14	14	14	0
DAY 28	MEAN	69	72	68	70	66	45 **	---
WEEK 4	ST.DEV.	8.8	8.9	8.4	8.5	9.9	17.8	---
	N	14	14	14	14	14	14	0

\* / \*\* : Dunnett-Test based on pooled variance significant at 5% (\*) or 1% (\*\*) level

BODY WEIGHT GAIN (%) SUMMARY  
MALES

RECOVERY		GROUP 1 VEHICLE CONTROL	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254	GROUP 7 T-7255
DAY 1	MEAN	61	56	59	58	56	25 **	---
WEEK 1	ST.DEV.	7.9	4.5	7.3	9.4	9.8	16.7	---
	N	6	6	6	6	6	6	0
DAY 5	MEAN	78	74	75	77	76	42 **	---
WEEK 1	ST.DEV.	10.0	7.3	9.3	14.1	12.3	18.4	---
	N	6	6	6	6	6	6	0
DAY 8	MEAN	87	81	82	86	84	52 **	---
WEEK 2	ST.DEV.	11.4	7.0	10.9	16.5	14.3	17.6	---
	N	6	6	6	6	6	6	0
DAY 12	MEAN	91	86	87	91	91	56 **	---
WEEK 2	ST.DEV.	13.1	8.8	12.3	19.5	15.2	17.6	---
	N	6	6	6	6	6	6	0
DAY 15	MEAN	91	87	87	90	94	58 **	---
WEEK 3	ST.DEV.	12.3	9.1	11.5	17.8	16.5	17.5	---
	N	6	6	6	6	6	6	0
DAY 19	MEAN	89	93	92	110	99	74	---
WEEK 3	ST.DEV.	10.1	14.9	12.9	20.8	14.3	26.0	---
	N	3	3	3	3	3	3	0
DAY 22	MEAN	93	95	100	118	104	80	---
WEEK 4	ST.DEV.	12.6	15.7	14.9	21.9	13.8	27.1	---
	N	3	3	3	3	3	3	0
DAY 25	MEAN	96	100	101	118	106	79	---
WEEK 4	ST.DEV.	13.7	15.7	15.7	22.4	15.0	28.3	---
	N	3	3	3	3	3	3	0
DAY 28	MEAN	95	100	100	119	108	82	---
WEEK 4	ST.DEV.	13.5	17.6	16.9	22.2	18.5	28.2	---
	N	3	3	3	3	3	3	0

\* / \*\* : Dunnett-Test based on pooled variance significant at 5% (\*) or 1% (\*\*) level

**BODY WEIGHT GAIN (%) SUMMARY  
FEMALES**

TREATMENT		GROUP 1 VEHICLE CONTROL	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
DAY 1	MEAN	0	0	0	0	0
WEEK 1	ST.DEV.	0.0	0.0	0.0	0.0	0.0
	N	14	14	14	14	14
DAY 5	MEAN	5	5	5	6	5
WEEK 1	ST.DEV.	2.3	1.6	1.7	2.3	1.4
	N	14	14	14	14	14
DAY 8	MEAN	8	8	9	8	9
WEEK 2	ST.DEV.	4.4	2.9	2.8	4.3	2.6
	N	14	14	14	14	14
DAY 12	MEAN	18	19	20	19	18
WEEK 2	ST.DEV.	3.4	3.3	3.2	4.2	2.9
	N	14	14	14	14	14
DAY 15	MEAN	17	18	16	17	16
WEEK 3	ST.DEV.	8.0	8.0	6.2	7.0	7.4
	N	14	14	14	14	14
DAY 19	MEAN	27	27	27	26	26
WEEK 3	ST.DEV.	4.7	5.0	4.3	6.0	5.1
	N	14	14	14	14	14
DAY 22	MEAN	32	33	30	33	31
WEEK 4	ST.DEV.	6.2	5.8	5.6	7.3	5.4
	N	14	14	14	14	14
DAY 25	MEAN	36	36	36	35	33
WEEK 4	ST.DEV.	5.6	5.8	5.0	6.9	4.8
	N	14	14	14	14	14
DAY 28	MEAN	38	38	38	37	35
WEEK 4	ST.DEV.	5.7	7.0	5.1	6.9	5.7
	N	14	14	14	14	14

\* / \*\* : Dunnett-Test based on pooled variance significant at 5% (\*) or 1% (\*\*) level

**BODY WEIGHT GAIN (%) SUMMARY  
FEMALES**

RECOVERY		GROUP 1 VEHICLE CONTROL	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
DAY 1	MEAN	26	26	28	30	23
WEEK 1	ST.DEV.	6.5	4.6	3.6	7.0	6.2
	N	6	6	5	6	6
DAY 5	MEAN	42	41	44	48	40
WEEK 1	ST.DEV.	7.8	6.7	4.7	8.2	7.1
	N	6	6	5	6	6
DAY 8	MEAN	46	44	47	49	43
WEEK 2	ST.DEV.	6.5	7.1	3.3	9.7	7.7
	N	6	6	5	6	6
DAY 12	MEAN	49	46	50	53	46
WEEK 2	ST.DEV.	7.8	5.8	5.2	9.9	8.2
	N	6	6	5	6	6
DAY 15	MEAN	48	46	51	53	46
WEEK 3	ST.DEV.	7.6	5.4	5.9	9.9	7.6
	N	6	6	5	6	6
DAY 19	MEAN	54	49	57	62	52
WEEK 3	ST.DEV.	5.6	1.8	6.2	12.4	13.5
	N	3	3	3	3	3
DAY 22	MEAN	54	52	57	64	51
WEEK 4	ST.DEV.	3.7	2.2	7.0	15.7	12.4
	N	3	3	3	3	3
DAY 25	MEAN	56	52	58	67	54
WEEK 4	ST.DEV.	8.1	2.3	6.6	17.7	10.7
	N	3	3	3	3	3
DAY 28	MEAN	57	51	60	67	55
WEEK 4	ST.DEV.	6.9	4.5	7.4	16.6	10.0
	N	3	3	3	3	3

\* / \*\* : Dunnett-Test based on pooled variance significant at 5% (\*) or 1% (\*\*) level

**FOOD CONSUMPTION (G/ANIMAL/DAY) SUMMARY  
MALES**

TREATMENT		GROUP 1 VEHICLE CONTROL	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254	GROUP 7 T-7255
DAYS 1-8	MEAN	27	28	27	29	27	27	21 **
WEEKS 1/2	ST.DEV.	0.6	1.5	1.6	1.4	3.2	3.7	1.4
	N (CAGE)	4	4	4	4	4	4	4
DAYS 8-15	MEAN	30	31	30	32	31	30	4 **
WEEKS 2/3	ST.DEV.	0.5	1.7	1.4	2.1	1.4	3.1	1.1
	N (CAGE)	4	4	4	4	4	4	4
DAYS 15-22	MEAN	30	32	30	31	30	30	---
WEEKS 3/4	ST.DEV.	2.1	1.7	2.2	0.8	0.7	2.0	---
	N (CAGE)	4	4	4	4	4	4	0
DAYS 22-28	MEAN	31	33	32	33	31	30	---
WEEK 4	ST.DEV.	2.1	2.1	2.6	2.5	1.2	2.5	---
	N (CAGE)	4	4	4	4	4	4	0
MEAN OF MEANS OVER TREATMENT MEAN		30	31	30	31	30	29	13

\* / \*\* : Dunnett-Test based on pooled variance significant at 5% (\*) or 1% (\*\*) level

**FOOD CONSUMPTION (G/ANIMAL/DAY) SUMMARY  
MALES**

RECOVERY		GROUP 1 VEHICLE CONTROL	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254	GROUP 7 T-7255
DAYS 1-8	MEAN	34	35	33	37	34	31	---
WEEKS 1/2	ST.DEV.	3.1	1.9	1.1	3.7	2.7	2.0	---
	N (CAGE)	2	2	2	2	2	2	0
DAYS 8-15	MEAN	33	35	33	34	35	29	---
WEEKS 2/3	ST.DEV.	2.3	1.5	1.1	3.0	2.1	1.8	---
	N (CAGE)	2	2	2	2	2	2	0
DAYS 15-22	MEAN	30	33	31	37	32	30	---
WEEKS 3/4	ST.DEV.	---	---	---	---	---	---	---
	N (CAGE)	1	1	1	1	1	1	0
DAYS 22-28	MEAN	32	35	32	38	34	31	---
WEEK 4	ST.DEV.	---	---	---	---	---	---	---
	N (CAGE)	1	1	1	1	1	1	0
MEAN OF MEANS OVER RECOVERY	MEAN	32	35	32	36	34	30	---

\* / \*\* : Dunnett-Test based on pooled variance significant at 5% (\*) or 1% (\*\*) level



**FOOD CONSUMPTION (G/ANIMAL/DAY) SUMMARY  
FEMALES**

TREATMENT		GROUP 1 VEHICLE CONTROL	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
DAYS 1-8	MEAN	20	21	21	21	21
WEEKS 1/2	ST.DEV.	1.2	0.4	0.4	1.4	0.3
	N (CAGE)	4	4	4	4	4
DAYS 8-15	MEAN	21	21	21	21	21
WEEKS 2/3	ST.DEV.	0.8	0.8	0.8	1.1	0.7
	N (CAGE)	4	4	4	4	4
DAYS 15-22	MEAN	24	24	24	24	24
WEEKS 3/4	ST.DEV.	2.3	2.1	2.8	2.6	2.3
	N (CAGE)	4	4	4	4	4
DAYS 22-28	MEAN	25	25	25	25	24
WEEK 4	ST.DEV.	2.0	1.5	2.5	2.1	1.8
	N (CAGE)	4	4	4	4	4
MEAN OF MEANS OVER TREATMENT MEAN		23	23	23	23	22

\* / \*\* : Dunnett-Test based on pooled variance significant at 5% (\*) or 1% (\*\*) level

**FOOD CONSUMPTION (G/ANIMAL/DAY) SUMMARY  
FEMALES**

RECOVERY		GROUP 1 VEHICLE CONTROL	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
DAYS 1-8	MEAN	28	27	28	29	29
WEEKS 1/2	ST. DEV.	2.1	0.5	0.8	1.9	0.1
	N (CAGE)	2	2	2	2	2
DAYS 8-15	MEAN	26	25	28	28	26
WEEKS 2/3	ST. DEV.	2.2	0.9	1.0	0.7	0.4
	N (CAGE)	2	2	2	2	2
DAYS 15-22	MEAN	23	24	25	25	25
WEEKS 3/4	ST. DEV.	---	---	---	---	---
	N (CAGE)	1	1	1	1	1
DAYS 22-28	MEAN	25	27	28	27	28
WEEK 4	ST. DEV.	---	---	---	---	---
	N (CAGE)	1	1	1	1	1
MEAN OF MEANS OVER RECOVERY	MEAN	26	26	27	27	27

\* / \*\* : Dunnett-Test based on pooled variance significant at 5% (\*) or 1% (\*\*) level

RELATIVE FOOD CONSUMPTION SUMMARY  
(G/KG BODY WEIGHT/DAY)  
MALES

TREATMENT			GROUP 1 VEHICLE CONTROL	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254	GROUP 7 T-7255
DAYS	1-8	MEAN	109	113	112	113	109	111	93 **
WEEKS	1/2	ST.DEV.	1.1	4.6	3.6	1.7	10.3	9.5	4.3
		N (CAGE)	4	4	4	4	4	4	4
DAYS	8-15	MEAN	102	105	104	104	105	112 *	22 **
WEEKS	2/3	ST.DEV.	4.1	2.7	4.2	3.3	1.8	6.0	6.9
		N (CAGE)	4	4	4	4	4	4	4
DAYS	15-22	MEAN	89	95	93	89	90	103	---
WEEKS	3/4	ST.DEV.	8.3	5.1	7.8	5.7	5.1	8.8	---
		N (CAGE)	4	4	4	4	4	4	0
DAYS	22-28	MEAN	84	90	90	88	86	97 *	---
WEEK	4	ST.DEV.	6.3	6.6	8.0	6.5	5.0	4.0	---
		N (CAGE)	4	4	4	4	4	4	0
MEAN OF MEANS OVER TREATMENT MEAN			96	101	100	98	98	106	58

\* / \*\* : Dunnett-Test based on pooled variance significant at 5% (\*) or 1% (\*\*) level

**RELATIVE FOOD CONSUMPTION SUMMARY  
(G/KG BODY WEIGHT/DAY)  
MALES**

RECOVERY			GROUP 1 VEHICLE CONTROL	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254	GROUP 7 T-7255
DAYS	1-8	MEAN	89	94	90	92	92	104	---
WEEKS	1/2	ST.DEV.	4.6	4.5	2.3	0.5	8.1	7.8	---
		N (CAGE)	2	2	2	2	2	2	0
DAYS	8-14	MEAN	80	87	86	80	86	90	---
WEEK	2	ST.DEV.	1.5	3.1	3.2	2.5	5.8	4.7	---
		N (CAGE)	2	2	2	2	2	2	0
DAYS	14-22	MEAN	73	78	80	76	74	80	---
WEEKS	2/4	ST.DEV.	---	---	---	---	---	---	---
		N (CAGE)	1	1	1	1	1	1	0
DAYS	22-28	MEAN	75	81	79	75	77	80	---
WEEK	4	ST.DEV.	---	---	---	---	---	---	---
		N (CAGE)	1	1	1	1	1	1	0
MEAN OF MEANS OVER RECOVERY MEAN			79	85	84	81	82	89	---

\*/\*\*: Dunnett-Test based on pooled variance significant at 5% (\*) or 1% (\*\*) level

RELATIVE FOOD CONSUMPTION SUMMARY  
(G/KG BODY WEIGHT/DAY)  
FEMALES

TREATMENT		GROUP 1 VEHICLE CONTROL	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
DAYS 1-8	MEAN	107	109	108	106	109
WEEKS 1/2	ST.DEV.	4.8	1.1	1.6	6.2	4.1
	N (CAGE)	4	4	4	4	4
DAYS 8-15	MEAN	97	98	94	93 *	96
WEEKS 2/3	ST.DEV.	1.4	1.4	1.8	3.3	2.1
	N (CAGE)	4	4	4	4	4
DAYS 15-22	MEAN	103	105	103	103	105
WEEKS 3/4	ST.DEV.	8.9	9.8	11.0	6.4	5.9
	N (CAGE)	4	4	4	4	4
DAYS 22-28	MEAN	100	101	100	98	101
WEEK 4	ST.DEV.	5.3	6.5	7.7	5.5	3.9
	N (CAGE)	4	4	4	4	4
MEAN OF MEANS OVER TREATMENT MEAN		102	103	101	100	103

\*/\*\*: Dunnett-Test based on pooled variance significant at 5% (\*) or 1% (\*\*) level

**RELATIVE FOOD CONSUMPTION SUMMARY  
(G/KG BODY WEIGHT/DAY)  
FEMALES**

RECOVERY			GROUP 1 VEHICLE CONTROL	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
DAYS	1-8	MEAN	107	105	104	103	109
WEEKS	1/2	ST.DEV.	3.7	1.4	7.5	6.8	2.3
		N (CAGE)	2	2	2	2	2
DAYS	8-14	MEAN	94	96	98	95	96
WEEK	2	ST.DEV.	4.7	3.8	3.2	3.5	0.0
		N (CAGE)	2	2	2	2	2
DAYS	14-22	MEAN	85	88	87	83	89
WEEKS	2/4	ST.DEV.	---	---	---	---	---
		N (CAGE)	1	1	1	1	1
DAYS	22-28	MEAN	92	95	97	86	97
WEEK	4	ST.DEV.	---	---	---	---	---
		N (CAGE)	1	1	1	1	1
MEAN OF MEANS OVER RECOVERY MEAN			94	96	97	92	98

\*/\*\*: Dunnett-Test based on pooled variance significant at 5% (\*) or 1% (\*\*) level

HAEMATOLOGY SUMMARY  
AFTER 4 WEEKS  
MALES

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254
HAEMATOLOGY PARAMETERS							
RBC T/l	MEAN	6.94	6.99	6.74	6.87	6.65	6.61
	ST.DEV.	0.37	0.39	0.13	0.27	0.38	0.42
	N	14	14	14	14	13	14
HB mmol/l	MEAN	9.5	9.4	9.1	9.3	9.1	8.7 **
	ST.DEV.	0.4	0.5	0.3	0.5	0.5	0.3
	N	14	14	14	14	13	14
HCT l/l	MEAN	0.406	0.404	0.392	0.400	0.394	0.379 **
	ST.DEV.	0.018	0.020	0.012	0.018	0.027	0.016
	N	14	14	14	14	13	14
MCV fl	MEAN	58.5	57.8	58.3	58.3	59.2	57.4
	ST.DEV.	2.1	1.4	1.9	2.2	2.0	3.2
	N	14	14	14	14	13	14
MCH fmol	MEAN	1.365	1.339	1.355	1.357	1.372	1.321
	ST.DEV.	0.045	0.039	0.041	0.048	0.038	0.072
	N	14	14	14	14	13	14
MCHC mmol/l	MEAN	23.3	23.2	23.3	23.3	23.2	23.0
	ST.DEV.	0.3	0.4	0.4	0.4	0.5	0.3
	N	14	14	14	14	13	14
RDW %	MEAN	12.0	12.4	12.0	12.5	12.3	12.8 **
	ST.DEV.	0.6	0.4	0.5	0.8	0.6	0.8
	N	14	14	14	14	13	14
PLATELETS G/l	MEAN	1196	1136	1099	1194	1128	1153
	ST.DEV.	154	134	129	107	176	182
	N	14	14	14	14	13	14
WBC G/l	MEAN	11.5	11.9	11.2	10.9	11.4	13.5
	ST.DEV.	2.3	2.5	2.4	2.3	2.9	3.4
	N	14	14	14	14	13	14
SEG. 1	MEAN	0.081	0.101	0.093	0.114 +	0.105	0.112 +
	ST.DEV.	0.020	0.035	0.032	0.038	0.033	0.033
	N	14	14	14	14	13	14
EO. 1	MEAN	0.006	0.009	0.004	0.005	0.005	0.005
	ST.DEV.	0.007	0.006	0.006	0.006	0.005	0.005
	N	14	14	14	14	13	14
BASO. 1	MEAN	0.000	0.000	0.000	0.000	0.000	0.000
	ST.DEV.	0.000	0.000	0.000	0.000	0.000	0.000
	N	14	14	14	14	13	14

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

**HAEMATOLOGY SUMMARY  
AFTER 4 WEEKS  
MALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254
HAEMATOLOGY PARAMETERS							
MONO. 1	MEAN	0.016	0.019	0.020	0.016	0.019	0.013
	ST.DEV.	0.009	0.007	0.006	0.010	0.010	0.005
	N	14	14	14	14	13	14
LYMPH. 1	MEAN	0.896	0.871	0.884	0.865	0.871	0.870
	ST.DEV.	0.023	0.034	0.033	0.038	0.037	0.029
	N	14	14	14	14	13	14
PT SEC	MEAN	12.3	12.2	12.1	12.1	12.2	12.1
	ST.DEV.	0.6	0.7	0.6	0.5	0.5	0.9
	N	14	14	14	14	13	14
PTT SEC	MEAN	17.1	17.6	17.4	17.8	15.3 **	17.6
	ST.DEV.	0.9	1.4	1.3	1.0	1.5	1.7
	N	14	13	14	14	13	14

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.



HAEMATOTOLOGY SUMMARY  
AFTER 4 WEEKS  
FEMALES

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
HAEMATOTOLOGY PARAMETERS						
RBC T/l	MEAN	6.62	6.67	6.29 *	6.39	6.26 **
	ST.DEV.	0.31	0.27	0.28	0.34	0.23
	N	14	14	14	14	14
HB mmol/l	MEAN	9.1	9.2	8.8 *	8.9	8.7 **
	ST.DEV.	0.4	0.4	0.4	0.4	0.2
	N	14	14	14	12	14
HCT l/l	MEAN	0.375	0.382	0.364	0.371	0.362
	ST.DEV.	0.016	0.016	0.015	0.017	0.009
	N	14	14	14	14	14
MCV fl	MEAN	56.7	57.2	57.9	58.1	57.9
	ST.DEV.	1.1	1.4	1.6	1.7	1.7
	N	14	14	14	14	14
MCH fmol	MEAN	1.382	1.379	1.399	1.401	1.391
	ST.DEV.	0.034	0.053	0.049	0.043	0.038
	N	14	14	14	14	14
MCHC mmol/l	MEAN	24.4	24.1	24.2	24.1	24.1
	ST.DEV.	0.4	0.7	0.4	0.3	0.3
	N	14	14	14	14	14
RDW %	MEAN	11.0	11.3	11.2	11.2	11.2
	ST.DEV.	0.3	0.5	0.5	0.4	0.3
	N	14	14	14	14	14
PLATELETS G/l	MEAN	1213	1140	1196	1220	1225
	ST.DEV.	60	125	120	108	98
	N	14	14	14	14	14
WBC G/l	MEAN	7.6	8.8	7.9	7.6	7.4
	ST.DEV.	2.1	1.9	1.5	2.0	2.2
	N	14	14	14	14	14
SEG. 1	MEAN	0.081	0.085	0.091	0.102	0.089
	ST.DEV.	0.035	0.038	0.041	0.043	0.036
	N	14	14	14	14	14
EO. 1	MEAN	0.007	0.005	0.010	0.008	0.008
	ST.DEV.	0.006	0.007	0.007	0.008	0.006
	N	14	14	14	14	14
BASO. 1	MEAN	0.000	0.000	0.000	0.000	0.000
	ST.DEV.	0.000	0.000	0.000	0.000	0.000
	N	14	14	14	14	14

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

**HAEMATOLOGY SUMMARY  
AFTER 2 WEEKS RECOVERY  
MALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254
HAEMATOLOGY PARAMETERS							
RBC T/1	MEAN	7.35	7.19	7.13	7.52	6.59	6.95
	ST.DEV.	0.46	0.13	0.08	0.25	0.27	0.51
	N	3	3	3	3	3	3
HB mmo1/1	MEAN	9.6	9.3	9.4	9.3	8.8	8.5 **
	ST.DEV.	0.6	0.0	0.2	0.3	0.4	0.3
	N	3	3	3	3	3	3
HCT 1/1	MEAN	0.409	0.389	0.391	0.391	0.366	0.376
	ST.DEV.	0.034	0.010	0.017	0.018	0.016	0.022
	N	3	3	3	3	3	3
MCV f1	MEAN	55.7	54.0	54.8	52.0	55.5	54.2
	ST.DEV.	1.2	1.5	2.9	1.1	1.5	2.8
	N	3	3	3	3	3	3
MCH fmo1	MEAN	1.310	1.293	1.313	1.236	1.340	1.222 *
	ST.DEV.	0.014	0.023	0.021	0.027	0.037	0.070
	N	3	3	3	3	3	3
MCHC mmo1/1	MEAN	23.6	23.9	24.0	23.8	24.1	22.5
	ST.DEV.	0.6	0.7	0.9	0.3	0.1	0.5
	N	3	3	3	3	3	3
RDW %	MEAN	13.7	13.7	13.1	14.1	14.5	17.1 **
	ST.DEV.	0.2	0.6	0.5	0.5	0.8	0.6
	N	3	3	3	3	3	3
PLATELETS G/1	MEAN	1132	1218	1036	1244	1287	1313
	ST.DEV.	168	28	176	117	268	222
	N	3	3	3	3	3	3
WBC G/1	MEAN	11.0	15.2	13.1	11.1	10.1	12.0
	ST.DEV.	1.2	3.3	2.5	1.0	1.9	2.2
	N	3	3	3	3	3	3
SEG. 1	MEAN	0.072	0.103	0.088	0.122	0.100	0.150
	ST.DEV.	0.015	0.036	0.015	0.030	0.035	0.030
	N	3	3	3	3	3	3
EO. 1	MEAN	0.007	0.012	0.003	0.017	0.005	0.005
	ST.DEV.	0.003	0.008	0.006	0.006	0.005	0.000
	N	3	3	3	3	3	3
BASO. 1	MEAN	0.000	0.000	0.000	0.000	0.000	0.000
	ST.DEV.	0.000	0.000	0.000	0.000	0.000	0.000
	N	3	3	3	3	3	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

**HAEMATOLOGY SUMMARY  
AFTER 2 WEEKS RECOVERY  
MALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254
HAEMATOLOGY PARAMETERS							
MONO.	MEAN	0.023	0.013	0.020	0.028	0.022	0.025
1	ST.DEV.	0.003	0.008	0.009	0.013	0.010	0.010
	N	3	3	3	3	3	3
LYMPH.	MEAN	0.898	0.872	0.888	0.833	0.873	0.820
1	ST.DEV.	0.018	0.033	0.018	0.018	0.038	0.040
	N	3	3	3	3	3	3
PT	MEAN	11.5	11.8	12.7 *	11.4	11.8	12.4
SEC	ST.DEV.	0.8	0.4	0.4	0.1	0.1	0.6
	N	3	3	3	3	3	3
PTT	MEAN	18.6	17.4	17.3	17.6	17.3	16.2
SEC	ST.DEV.	2.0	0.6	0.6	1.1	0.9	1.5
	N	2	3	3	3	3	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

**HAEMATOLOGY SUMMARY  
AFTER 2 WEEKS RECOVERY  
FEMALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
<b>HAEMATOLOGY PARAMETERS</b>						
RBC T/1	MEAN	6.53	6.70	6.02	6.61	6.26
	ST.DEV.	0.40	0.22	0.43	0.20	0.12
	N	3	3	2	3	3
HB mmo1/1	MEAN	9.2	9.4	8.9	9.3	9.0
	ST.DEV.	0.5	0.1	0.1	0.5	0.2
	N	3	3	2	3	3
HCT 1/1	MEAN	0.371	0.381	0.351	0.370	0.357
	ST.DEV.	0.023	0.010	0.007	0.015	0.004
	N	3	3	2	3	3
MCV fl	MEAN	56.8	56.9	58.5	55.9	57.1
	ST.DEV.	2.1	1.9	3.0	1.4	1.0
	N	3	3	2	3	3
MCH fmo1	MEAN	1.410	1.399	1.475	1.402	1.438
	ST.DEV.	0.042	0.038	0.094	0.029	0.047
	N	3	3	2	3	3
MCHC mmo1/1	MEAN	24.8	24.6	25.2	25.1	25.2
	ST.DEV.	0.2	0.4	0.3	0.5	0.4
	N	3	3	2	3	3
RDW %	MEAN	14.3	13.4	13.4	14.0	13.8
	ST.DEV.	0.5	0.6	0.8	0.8	0.6
	N	3	3	2	3	3
PLATELETS G/1	MEAN	1269	1131	1140	1206	1226
	ST.DEV.	81	117	37	19	77
	N	3	3	2	3	3
WBC G/1	MEAN	6.6	9.0	8.3	8.5	7.1
	ST.DEV.	0.8	0.7	0.1	3.9	0.3
	N	3	3	2	3	3
SEG. 1	MEAN	0.043	0.088	0.160	0.098	0.065
	ST.DEV.	0.014	0.043	0.078	0.006	0.023
	N	3	3	2	3	3
EO. 1	MEAN	0.003	0.007	0.008	0.010	0.012
	ST.DEV.	0.003	0.008	0.004	0.009	0.012
	N	3	3	2	3	3
BASO. 1	MEAN	0.000	0.000	0.000	0.000	0.000
	ST.DEV.	0.000	0.000	0.000	0.000	0.000
	N	3	3	2	3	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

**HAEMATOLOGY SUMMARY  
AFTER 2 WEEKS RECOVERY  
FEMALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
<b>HAEMATOLOGY PARAMETERS</b>						
MONO. 1	MEAN	0.022	0.018	0.020	0.008	0.015
	ST.DEV.	0.008	0.014	0.014	0.008	0.009
	N	3	3	2	3	3
LYMPH. 1	MEAN	0.932	0.887	0.813	0.883	0.908
	ST.DEV.	0.010	0.061	0.088	0.008	0.016
	N	3	3	2	3	3
PT SEC	MEAN	11.9	11.4	11.1	11.5	11.5
	ST.DEV.	0.2	0.7	0.1	0.5	0.7
	N	3	3	2	3	3
PTT SEC	MEAN	18.5	17.1	17.6	17.8	17.5
	ST.DEV.	0.2	0.3	2.3	1.2	0.9
	N	3	3	2	3	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

**HAEMATOLOGY SUMMARY  
AFTER 4 WEEKS RECOVERY  
MALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254
<b>HAEMATOLOGY PARAMETERS</b>							
RBC T/l	MEAN	7.75	7.68	7.42	7.37	7.33	7.50
	ST.DEV.	0.25	0.18	0.09	0.25	0.12	0.11
	N	3	3	3	3	3	3
HB mmo1/l	MEAN	9.8	9.6	9.3	9.1	9.2	9.1 *
	ST.DEV.	0.4	0.2	0.0	0.2	0.3	0.4
	N	3	3	3	3	3	3
HCT l/l	MEAN	0.414	0.403	0.391	0.384	0.394	0.391
	ST.DEV.	0.022	0.016	0.003	0.010	0.018	0.014
	N	3	3	3	3	3	3
MCV fl	MEAN	53.5	52.4	52.7	52.2	53.7	52.1
	ST.DEV.	2.2	1.7	1.0	3.0	1.6	1.6
	N	3	3	3	3	3	3
MCH fmo1	MEAN	1.265	1.246	1.254	1.241	1.259	1.209
	ST.DEV.	0.053	0.028	0.015	0.068	0.022	0.040
	N	3	3	3	3	3	3
MCHC mmo1/l	MEAN	23.7	23.8	23.8	23.8	23.4	23.2
	ST.DEV.	0.4	0.4	0.2	0.1	0.6	0.4
	N	3	3	3	3	3	3
RDW %	MEAN	13.4	14.2	13.4	13.6	13.0	15.1
	ST.DEV.	0.9	0.3	0.3	0.8	0.5	1.6
	N	3	3	3	3	3	3
PLATELETS G/l	MEAN	1189	1043	1167	1129	1076	1011
	ST.DEV.	191	50	59	105	176	98
	N	3	3	3	3	3	3
WBC G/l	MEAN	13.0	11.6	10.1	11.0	10.2	8.7
	ST.DEV.	1.3	3.4	1.4	1.7	0.5	1.7
	N	3	3	3	3	3	3
SEG. 1	MEAN	0.098	0.128	0.132	0.142	0.097	0.150
	ST.DEV.	0.033	0.015	0.010	0.013	0.026	0.013
	N	3	3	3	3	3	3
EO. 1	MEAN	0.005	0.015	0.007	0.010	0.005	0.017
	ST.DEV.	0.005	0.000	0.008	0.005	0.005	0.003
	N	3	3	3	3	3	3
BASO. 1	MEAN	0.000	0.000	0.000	0.000	0.000	0.000
	ST.DEV.	0.000	0.000	0.000	0.000	0.000	0.000
	N	3	3	3	3	3	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

**HAEMATOLOGY SUMMARY  
AFTER 4 WEEKS RECOVERY  
MALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254
HAEMATOLOGY PARAMETERS							
MONO. 1	MEAN	0.030	0.035	0.033	0.032	0.020	0.023
	ST.DEV.	0.009	0.015	0.012	0.008	0.005	0.008
	N	3	3	3	3	3	3
LYMPH. 1	MEAN	0.867	0.822	0.828	0.817	0.878	0.810
	ST.DEV.	0.043	0.025	0.015	0.013	0.028	0.023
	N	3	3	3	3	3	3
PT SEC	MEAN	11.7	11.6	11.9	11.2	11.5	11.5
	ST.DEV.	0.2	1.0	0.6	0.8	0.7	0.6
	N	3	3	3	3	3	3
PTT SEC	MEAN	17.1	17.1	17.4	15.9	15.5	14.4 **
	ST.DEV.	1.3	0.3	1.0	0.2	0.5	0.2
	N	3	3	3	3	3	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

**HAEMATOLOGY SUMMARY  
AFTER 4 WEEKS RECOVERY  
FEMALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
<b>HAEMATOLOGY PARAMETERS</b>						
RBC T/l	MEAN	6.95	7.01	6.54	6.66	6.97
	ST.DEV.	0.09	0.60	0.28	0.25	0.13
	N	3	3	3	3	3
HB mmo/l	MEAN	9.2	9.0	8.7	8.9	9.1
	ST.DEV.	0.1	0.4	0.2	0.2	0.2
	N	3	3	3	3	3
HCT l/l	MEAN	0.372	0.379	0.356	0.371	0.377
	ST.DEV.	0.003	0.019	0.014	0.013	0.006
	N	3	3	3	3	3
MCV fl	MEAN	53.5	54.1	54.5	55.7	55.5
	ST.DEV.	0.4	2.5	0.3	1.1	0.9
	N	3	3	3	3	3
MCH fmo/l	MEAN	1.323	1.283	1.326	1.342	1.346
	ST.DEV.	0.006	0.079	0.024	0.027	0.028
	N	3	3	3	3	3
MCHC mmo/l	MEAN	24.7	23.7 *	24.3	24.1	24.3
	ST.DEV.	0.1	0.4	0.4	0.5	0.2
	N	3	3	3	3	3
RDW %	MEAN	13.1	13.4	13.5	13.1	12.6
	ST.DEV.	0.4	0.3	0.8	1.0	0.4
	N	3	3	3	3	3
PLATELETS G/l	MEAN	1213	1116	1076	1044	1101
	ST.DEV.	59	80	109	202	50
	N	3	3	3	3	3
WBC G/l	MEAN	7.3	8.2	7.9	8.0	6.6
	ST.DEV.	1.4	2.1	1.2	2.6	2.5
	N	3	3	3	3	3
SEG. 1	MEAN	0.097	0.103	0.090	0.097	0.080
	ST.DEV.	0.033	0.039	0.039	0.028	0.023
	N	3	3	3	3	3
EO. 1	MEAN	0.000	0.010	0.017	0.015	0.005
	ST.DEV.	0.000	0.009	0.010	0.009	0.005
	N	3	3	3	3	3
BASO. 1	MEAN	0.000	0.000	0.000	0.000	0.000
	ST.DEV.	0.000	0.000	0.000	0.000	0.000
	N	3	3	3	3	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.



HAEMATOLOGY SUMMARY  
AFTER 4 WEEKS RECOVERY  
FEMALES

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
HAEMATOLOGY PARAMETERS						
MONO. 1	MEAN	0.015	0.023	0.012	0.018	0.015
	ST.DEV.	0.000	0.008	0.003	0.010	0.005
	N	3	3	3	3	3
LYMPH. 1	MEAN	0.888	0.863	0.882	0.870	0.900
	ST.DEV.	0.033	0.043	0.042	0.030	0.028
	N	3	3	3	3	3
PT SEC	MEAN	11.6	11.2	11.0	11.3	11.0
	ST.DEV.	0.3	0.2	0.3	0.2	0.7
	N	3	3	3	2	3
PTT SEC	MEAN	16.5	16.5	19.6	16.0	16.3
	ST.DEV.	1.1	0.6	5.8	0.3	1.7
	N	3	3	3	2	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

CLINICAL BIOCHEMISTRY SUMMARY  
AFTER 4 WEEKS  
MALES

		GROUP 1 VEHICLE	GROUP 2 CONT T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254
ALAT(GPT) ukat/l	MEAN	0.74	0.76	0.74	0.63	0.71	0.92
	ST.DEV.	0.19	0.14	0.12	0.15	0.11	0.36
	N	14	14	14	13	13	12
ASAT(GOT) ukat/l	MEAN	2.36	2.10	2.14	2.15	2.28	2.52
	ST.DEV.	0.50	0.28	0.39	0.37	0.35	0.49
	N	14	14	14	14	14	14
BILI T. umo/l/l	MEAN	1.8	1.7	1.6	1.7	1.8	1.9
	ST.DEV.	0.4	0.2	0.2	0.3	0.3	0.8
	N	14	14	14	14	14	14
CHOLEST.T. mmo/l/l	MEAN	1.73	1.80	1.31 **	1.84	1.29 **	1.57
	ST.DEV.	0.28	0.36	0.20	0.35	0.34	0.32
	N	14	14	14	14	14	14
TRIGL. mmo/l/l	MEAN	0.66	0.81	0.51	0.46	0.48	0.80
	ST.DEV.	0.24	0.47	0.24	0.16	0.22	0.34
	N	14	14	14	14	14	14
CREATININE umo/l/l	MEAN	40.9	41.0	40.5	39.7	45.7 **	42.9
	ST.DEV.	2.6	3.6	4.0	3.1	3.6	3.4
	N	14	14	14	14	14	14
GLUCOSE mmo/l/l	MEAN	5.86	6.47	5.76	6.04	6.13	7.16 **
	ST.DEV.	0.56	0.55	0.56	0.75	1.06	0.70
	N	14	14	14	14	14	14
UREA mmo/l/l	MEAN	6.0	6.1	6.8	6.4	7.4 **	8.8 **
	ST.DEV.	1.0	0.9	0.5	0.8	1.1	1.5
	N	14	14	14	14	14	14
PROTEIN T. g/l	MEAN	61.5	61.3	59.5	61.7	61.9	60.7
	ST.DEV.	4.1	3.3	2.8	1.9	3.5	4.4
	N	14	14	14	14	14	14
ALBUMIN g/l	MEAN	30.7	30.6	30.6	30.5	33.4 **	34.9 **
	ST.DEV.	1.9	1.6	1.4	0.9	1.6	1.9
	N	14	14	14	14	14	14
GLOBULIN g/l	MEAN	30.8	30.7	29.0	31.3	28.5	25.7 +
	ST.DEV.	2.4	2.0	2.2	1.4	2.3	2.8
	N	14	14	14	14	14	14
A/G RATIO	MEAN	1.0	1.0	1.1	1.0	1.2 +	1.4 +
	ST.DEV.	0.0	0.0	0.1	0.0	0.1	0.1
	N	14	14	14	14	14	14
ALP ukat/l	MEAN	7.61	6.56	7.69	6.93	7.80	10.44 **
	ST.DEV.	1.79	1.36	1.63	1.33	1.78	1.33
	N	14	14	14	14	14	14

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

**CLINICAL BIOCHEMISTRY SUMMARY  
AFTER 4 WEEKS  
MALES**

		GROUP 1 VEHICLE	GROUP 2 CONT T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254
INORG PHOSPH mmo1/1	MEAN	2.51	2.47	2.39	2.43	2.71 *	2.69 *
	ST.DEV.	0.12	0.17	0.18	0.13	0.21	0.20
	N	14	14	14	14	14	14
SODIUM mmo1/1	MEAN	144.3	143.9	144.3	144.7	144.4	143.5
	ST.DEV.	1.2	1.1	1.1	0.9	1.4	1.2
	N	14	14	14	14	14	14
POTASSIUM mmo1/1	MEAN	4.61	4.46	4.44	4.78	4.65	4.83
	ST.DEV.	0.24	0.30	0.38	0.35	0.36	0.47
	N	14	14	14	14	14	14
CALCIUM mmo1/1	MEAN	2.57	2.58	2.52	2.57	2.58	2.54
	ST.DEV.	0.09	0.06	0.05	0.05	0.09	0.09
	N	14	14	14	14	14	14
CHLORIDE mmo1/1	MEAN	97	95	95	95	95	95
	ST.DEV.	2	3	2	3	3	3
	N	14	14	14	14	14	14

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

CLINICAL BIOCHEMISTRY SUMMARY  
AFTER 4 WEEKS  
FEMALES

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
ALAT(GPT) ukat/l	MEAN	0.58	0.58	0.61	0.54	0.62
	ST.DEV.	0.12	0.16	0.11	0.14	0.14
	N	11	13	12	14	14
ASAT(GOT) ukat/l	MEAN	2.14	1.87	1.73 **	1.96	2.00
	ST.DEV.	0.29	0.30	0.31	0.30	0.34
	N	14	14	14	14	14
BILI T. umol/l	MEAN	2.3	2.1	1.9 **	2.2	1.8 **
	ST.DEV.	0.5	0.3	0.3	0.3	0.4
	N	14	14	13	14	14
CHOLEST.T. mmo1/l	MEAN	2.62	2.52	2.90	2.47	2.37
	ST.DEV.	0.42	0.43	0.50	0.33	0.33
	N	14	14	14	14	14
TRIGL. mmo1/l	MEAN	0.43	0.47	0.53	0.45	0.46
	ST.DEV.	0.08	0.09	0.16	0.12	0.17
	N	14	14	14	14	14
CREATININE umol/l	MEAN	49.0	48.9	48.9	47.1	44.1 **
	ST.DEV.	2.8	3.3	4.9	3.3	2.9
	N	14	14	13	14	14
GLUCOSE mmo1/l	MEAN	6.11	6.37	6.32	6.22	5.76
	ST.DEV.	0.66	0.66	0.99	0.71	0.70
	N	14	14	14	14	14
UREA mmo1/l	MEAN	7.3	8.2	8.4	8.2	7.9
	ST.DEV.	0.9	1.7	1.4	1.0	1.0
	N	14	14	14	14	14
PROTEIN T. g/l	MEAN	67.1	64.7	65.9	65.2	66.1
	ST.DEV.	2.9	3.3	2.9	3.2	2.7
	N	14	14	14	14	14
ALBUMIN g/l	MEAN	34.8	33.7	34.0	33.4	34.5
	ST.DEV.	1.5	1.5	1.4	1.5	1.8
	N	14	14	14	14	14
GLOBULIN g/l	MEAN	32.3	31.0	31.9	31.8	31.6
	ST.DEV.	1.9	2.1	2.1	2.0	1.4
	N	14	14	14	14	14
A/G RATIO	MEAN	1.1	1.1	1.1	1.1	1.1
	ST.DEV.	0.1	0.1	0.1	0.1	0.1
	N	14	14	14	14	14
ALP ukat/l	MEAN	4.29	4.02	3.68	4.40	3.74
	ST.DEV.	0.83	0.74	0.54	1.57	0.70
	N	14	14	14	14	14

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

CLINICAL BIOCHEMISTRY SUMMARY  
AFTER 4 WEEKS  
FEMALES

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
INORG PHOSPH mmo1/1	MEAN	2.17	2.21	2.20	2.13	2.16
	ST.DEV.	0.12	0.13	0.15	0.16	0.17
	N	13	14	14	14	14
SODIUM mmo1/1	MEAN	143.2	142.8	143.4	142.8	143.2
	ST.DEV.	1.0	1.1	1.0	1.2	0.6
	N	14	14	14	14	14
POTASSIUM mmo1/1	MEAN	4.34	4.10	4.06	4.47	4.24
	ST.DEV.	0.47	0.33	0.42	0.30	0.29
	N	14	14	14	14	14
CALCIUM mmo1/1	MEAN	2.62	2.60	2.65	2.62	2.62
	ST.DEV.	0.06	0.06	0.07	0.07	0.06
	N	14	14	14	14	14
CHLORIDE mmo1/1	MEAN	97	98	96	97	94 **
	ST.DEV.	1	2	1	2	2
	N	14	14	14	14	14

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

**CLINICAL BIOCHEMISTRY SUMMARY  
AFTER 2 WEEKS RECOVERY  
MALES**

		GROUP 1 VEHICLE	GROUP 2 CONT T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254
ALAT(GPT) ukat/l	MEAN	0.74	0.80	0.89	0.74	0.73	0.59
	ST.DEV.	0.13	0.30	0.05	0.11	0.12	0.04
	N	3	3	3	3	3	3
ASAT(GOT) ukat/l	MEAN	2.07	1.97	1.79	2.29	1.84	1.65
	ST.DEV.	0.35	0.22	0.25	0.23	0.34	0.27
	N	3	3	3	3	3	3
BILI T. umo/l/l	MEAN	1.9	1.9	1.9	1.8	1.2	1.4
	ST.DEV.	0.2	0.1	0.6	0.5	0.3	0.2
	N	3	3	3	3	3	3
CHOLEST.T. mmo/l/l	MEAN	1.73	2.18	1.61	1.97	1.71	1.41
	ST.DEV.	0.23	0.22	0.45	0.22	0.28	0.31
	N	3	3	3	3	3	3
TRIGL. mmo/l/l	MEAN	0.57	0.47	0.76	0.72	0.41	0.39
	ST.DEV.	0.21	0.01	0.16	0.15	0.05	0.03
	N	3	3	3	3	3	3
CREATININE umo/l/l	MEAN	42.0	40.1	40.1	42.3	39.7	41.6
	ST.DEV.	1.7	1.3	2.6	1.7	2.8	3.0
	N	3	3	3	3	3	3
GLUCOSE mmo/l/l	MEAN	7.50	7.69	6.54	6.81	6.22	6.65
	ST.DEV.	1.08	1.11	1.03	0.45	0.08	0.38
	N	3	3	3	3	3	3
UREA mmo/l/l	MEAN	5.2	5.7	6.1	6.4	7.3	6.4
	ST.DEV.	0.3	0.3	0.4	0.9	1.3	1.8
	N	3	3	3	3	3	3
PROTEIN T. g/l	MEAN	60.9	62.7	61.8	63.2	60.1	57.5 *
	ST.DEV.	1.7	0.3	1.2	1.8	0.5	2.0
	N	3	3	3	3	3	3
ALBUMIN g/l	MEAN	30.8	31.3	30.9	32.2 *	31.0	31.9
	ST.DEV.	0.8	0.2	0.1	0.8	0.3	0.6
	N	3	3	3	3	3	3
GLOBULIN g/l	MEAN	30.1	31.4	30.9	31.0	29.1	25.6
	ST.DEV.	1.2	0.3	1.1	1.7	0.5	2.0
	N	3	3	3	3	3	3
A/G RATIO	MEAN	1.0	1.0	1.0	1.0	1.1	1.3
	ST.DEV.	0.0	0.0	0.0	0.1	0.0	0.1
	N	3	3	3	3	3	3
ALP ukat/l	MEAN	5.01	4.22	6.22	5.15	4.66	7.32 **
	ST.DEV.	0.52	0.27	0.09	0.68	1.04	0.95
	N	3	3	3	3	3	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

**CLINICAL BIOCHEMISTRY SUMMARY  
AFTER 2 WEEKS RECOVERY  
MALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254
INORG PHOSPH mmo1/l	MEAN	2.39	2.63	2.45	2.43	2.56	2.55
	ST.DEV.	0.16	0.03	0.16	0.05	0.24	0.21
	N	3	3	3	3	3	3
SODIUM mmo1/l	MEAN	145.1	143.6	145.4	144.2	144.1	144.7
	ST.DEV.	0.9	0.6	0.1	0.8	1.1	3.0
	N	3	3	3	3	3	3
POTASSIUM mmo1/l	MEAN	4.57	4.62	4.11	4.76	4.55	4.97
	ST.DEV.	0.15	0.02	0.29	0.13	0.10	1.03
	N	3	3	3	3	3	3
CALCIUM mmo1/l	MEAN	2.55	2.58	2.52	2.50	2.51	2.52
	ST.DEV.	0.05	0.02	0.08	0.06	0.03	0.10
	N	3	3	3	3	3	3
CHLORIDE mmo1/l	MEAN	96	94	94	93 *	90 **	90 **
	ST.DEV.	1	1	1	2	1	2
	N	3	3	3	3	3	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

**CLINICAL BIOCHEMISTRY SUMMARY  
AFTER 2 WEEKS RECOVERY  
FEMALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
ALAT(GPT) ukat/l	MEAN	0.57	0.70	0.71	0.48	0.52
	ST.DEV.	0.07	0.24	0.06	0.05	0.04
	N	3	3	2	3	3
ASAT(GOT) ukat/l	MEAN	1.47	1.45	1.53	1.42	1.25
	ST.DEV.	0.02	0.46	0.51	0.28	0.15
	N	3	3	2	3	3
BILI T. umo/l/l	MEAN	2.5	2.3	2.6	2.0	1.6 **
	ST.DEV.	0.2	0.3	0.2	0.2	0.2
	N	3	3	2	3	3
CHOLEST.T. mmo/l/l	MEAN	2.81	2.41	3.85	2.53	2.95
	ST.DEV.	0.45	0.41	0.38	0.48	0.20
	N	3	3	2	3	3
TRIGL. mmo/l/l	MEAN	0.44	0.52	0.85 **	0.56	0.40
	ST.DEV.	0.08	0.07	0.09	0.05	0.07
	N	3	3	2	3	3
CREATININE umo/l/l	MEAN	47.5	47.8	48.1	47.5	48.3
	ST.DEV.	4.1	2.7	7.3	2.3	1.3
	N	3	3	2	3	3
GLUCOSE mmo/l/l	MEAN	6.21	6.61	8.06 **	7.64 *	7.41 *
	ST.DEV.	0.66	0.54	0.33	0.37	0.32
	N	3	3	2	3	3
UREA mmo/l/l	MEAN	8.2	7.1	8.0	7.4	7.6
	ST.DEV.	1.0	1.0	1.6	0.5	0.4
	N	3	3	2	3	3
PROTEIN T. g/l	MEAN	67.8	63.7	66.9	64.3	65.7
	ST.DEV.	2.1	3.0	3.5	3.1	3.3
	N	3	3	2	3	3
ALBUMIN g/l	MEAN	34.6	32.9	33.7	33.1	33.5
	ST.DEV.	1.0	1.7	0.1	1.5	2.2
	N	3	3	2	3	3
GLOBULIN g/l	MEAN	33.2	30.8	33.2	31.1	32.2
	ST.DEV.	1.4	2.2	3.7	1.6	1.5
	N	3	3	2	3	3
A/G RATIO	MEAN	1.0	1.1	1.0	1.1	1.0
	ST.DEV.	0.0	0.1	0.1	0.0	0.1
	N	3	3	2	3	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.



**CLINICAL BIOCHEMISTRY SUMMARY  
AFTER 2 WEEKS RECOVERY  
FEMALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
ALP ukat/l	MEAN	3.59	3.24	3.19	4.18	3.26
	ST.DEV.	0.69	0.94	0.35	2.49	0.09
	N	3	3	2	3	3
INORG PHOSPH mmo/l/l	MEAN	2.54	2.25	2.23	1.83 **	1.94 *
	ST.DEV.	0.24	0.22	0.30	0.12	0.12
	N	3	3	2	3	3
SODIUM mmo/l/l	MEAN	143.0	141.8	140.9	142.8	142.2
	ST.DEV.	0.9	0.3	1.4	1.3	0.2
	N	3	3	2	3	3
POTASSIUM mmo/l/l	MEAN	4.46	4.12	4.32	3.77	4.18
	ST.DEV.	0.06	0.26	0.63	0.31	0.33
	N	3	3	2	3	3
CALCIUM mmo/l/l	MEAN	2.67	2.64	2.66	2.59	2.61
	ST.DEV.	0.01	0.05	0.01	0.02	0.05
	N	3	3	2	3	3
CHLORIDE mmo/l/l	MEAN	96	96	96	97	95
	ST.DEV.	1	3	4	2	1
	N	3	3	2	3	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

**CLINICAL BIOCHEMISTRY SUMMARY  
AFTER 4 WEEKS RECOVERY  
MALES**

		GROUP 1 VEHICLE	GROUP 2 CONT T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254
ALAT(GPT) ukat/l	MEAN	0.67	0.63	0.67	0.61	0.84	1.49
	ST.DEV.	0.13	0.16	0.15	0.23	0.16	1.14
	N	3	3	3	3	3	3
ASAT(GOT) ukat/l	MEAN	2.05	1.93	1.78	1.64	1.73	2.17
	ST.DEV.	0.19	0.27	0.29	0.19	0.30	0.89
	N	3	3	3	3	3	3
BILI T. umol/l	MEAN	2.0	2.0	2.0	2.0	1.7	1.2
	ST.DEV.	0.3	0.5	0.3	0.6	0.2	0.3
	N	3	3	3	3	3	3
CHOLEST.T. mmo1/l	MEAN	1.64	1.84	1.33	1.91	1.80	1.49
	ST.DEV.	0.30	0.53	0.14	0.31	0.17	0.40
	N	3	3	3	3	3	3
TRIGL. mmo1/l	MEAN	0.48	0.36	0.43	0.70	0.56	0.61
	ST.DEV.	0.13	0.09	0.01	0.26	0.10	0.23
	N	3	3	3	3	3	3
CREATININE umol/l	MEAN	43.1	42.5	42.5	47.1	49.0	41.9
	ST.DEV.	4.1	6.1	1.4	1.4	3.3	1.4
	N	3	3	3	3	3	3
GLUCOSE mmo1/l	MEAN	6.59	7.00	6.50	7.25	6.69	6.83
	ST.DEV.	0.12	0.62	0.93	0.88	1.48	1.00
	N	3	3	3	3	3	3
UREA mmo1/l	MEAN	5.2	6.3	5.8	6.4	6.7 *	6.5 *
	ST.DEV.	0.4	0.7	0.2	0.5	0.8	0.5
	N	3	3	3	3	3	3
PROTEIN T. g/l	MEAN	61.4	59.5	60.1	62.4	60.1	62.0
	ST.DEV.	4.6	0.8	3.0	2.1	1.8	2.5
	N	3	3	3	3	3	3
ALBUMIN g/l	MEAN	30.5	29.8	29.5	31.3	30.1	31.5
	ST.DEV.	1.5	0.9	0.4	0.9	0.9	0.8
	N	3	3	3	3	3	3
GLOBULIN g/l	MEAN	30.9	29.7	30.6	31.1	30.0	30.6
	ST.DEV.	3.1	0.8	2.7	2.3	1.0	2.0
	N	3	3	3	3	3	3
A/G RATIO	MEAN	1.0	1.0	1.0	1.0	1.0	1.0
	ST.DEV.	0.1	0.0	0.1	0.1	0.0	0.1
	N	3	3	3	3	3	3
ALP ukat/l	MEAN	4.84	4.65	4.48	4.04	4.29	5.15
	ST.DEV.	0.71	0.92	0.63	0.43	1.26	0.42
	N	3	3	3	3	3	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

CLINICAL BIOCHEMISTRY SUMMARY  
AFTER 4 WEEKS RECOVERY  
MALES

		GROUP 1 VEHICLE	GROUP 2 CONT T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254
INORG PHOSPH mmo1/l	MEAN	2.62	2.72	2.59	2.46	2.35	2.19 *
	ST.DEV.	0.18	0.06	0.16	0.19	0.14	0.01
	N	3	3	3	3	3	3
SODIUM mmo1/l	MEAN	145.6	145.6	145.7	143.8	144.2	144.3
	ST.DEV.	1.0	1.1	1.4	1.1	0.2	0.5
	N	3	3	3	3	3	3
POTASSIUM mmo1/l	MEAN	4.78	4.76	4.55	4.73	4.32	4.20
	ST.DEV.	0.14	0.32	0.36	0.37	0.17	0.20
	N	3	3	3	3	3	3
CALCIUM mmo1/l	MEAN	2.53	2.56	2.51	2.56	2.51	2.50
	ST.DEV.	0.06	0.03	0.07	0.06	0.04	0.09
	N	3	3	3	3	3	3
CHLORIDE mmo1/l	MEAN	96	93	94	91	94	91
	ST.DEV.	3	5	2	2	2	4
	N	3	3	3	3	3	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

**CLINICAL BIOCHEMISTRY SUMMARY  
AFTER 4 WEEKS RECOVERY  
FEMALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
ALAT(GPT) ukat/l	MEAN	0.59	0.54	0.49	0.53	0.54
	ST.DEV.	0.13	0.05	0.12	0.14	0.08
	N	3	3	3	3	3
ASAT(GOT) ukat/l	MEAN	2.15	1.75	1.62	1.72	1.53
	ST.DEV.	0.67	0.11	0.22	0.08	0.32
	N	3	3	3	3	3
BILI T. umo/l/l	MEAN	2.5	2.5	2.1	2.1	1.9
	ST.DEV.	0.3	0.5	0.3	0.2	0.1
	N	3	3	3	3	3
CHOLEST.T. mmo/l/l	MEAN	2.73	2.47	2.60	2.53	2.41
	ST.DEV.	0.19	0.47	0.24	0.57	0.44
	N	3	3	3	3	3
TRIGL. mmo/l/l	MEAN	0.47	0.51	0.57	0.76	0.43
	ST.DEV.	0.07	0.09	0.27	0.31	0.06
	N	3	3	3	3	3
CREATININE umo/l/l	MEAN	46.2	51.5	48.1	52.4	50.9
	ST.DEV.	5.1	6.1	6.2	3.3	7.9
	N	3	3	3	3	3
GLUCOSE mmo/l/l	MEAN	6.45	7.57	7.16	7.87	7.05
	ST.DEV.	0.37	0.78	1.18	1.12	0.20
	N	3	3	3	3	3
UREA mmo/l/l	MEAN	6.9	8.2	8.3	7.6	7.5
	ST.DEV.	1.7	0.7	1.0	0.9	1.6
	N	3	3	3	3	3
PROTEIN T. g/l	MEAN	71.5	66.6	68.3	67.8	66.1
	ST.DEV.	2.1	2.7	2.7	1.7	3.2
	N	3	3	3	3	3
ALBUMIN g/l	MEAN	35.8	35.0	35.3	34.3	33.2
	ST.DEV.	0.9	1.3	2.1	0.6	0.8
	N	3	3	3	3	3
GLOBULIN g/l	MEAN	35.7	31.6	33.0	33.5	32.9
	ST.DEV.	1.8	1.4	0.8	2.3	2.6
	N	3	3	3	3	3
A/G RATIO	MEAN	1.0	1.1	1.1	1.0	1.0
	ST.DEV.	0.1	0.0	0.0	0.1	0.1
	N	3	3	3	3	3
ALP ukat/l	MEAN	2.76	2.20	2.25	2.24	2.67
	ST.DEV.	0.33	0.33	0.43	0.29	0.58
	N	3	3	3	3	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

CLINICAL BIOCHEMISTRY SUMMARY  
AFTER 4 WEEKS RECOVERY  
FEMALES

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
INORG PHOSPH mmo1/l	MEAN	2.28	2.30	2.21	1.97	1.83
	ST.DEV.	0.20	0.31	0.15	0.13	0.17
	N	3	3	3	3	3
SODIUM mmo1/l	MEAN	143.7	143.1	142.4	142.4	142.7
	ST.DEV.	0.7	1.6	1.5	1.5	1.4
	N	3	3	3	3	3
POTASSIUM mmo1/l	MEAN	4.53	4.35	4.23	4.46	4.17
	ST.DEV.	0.34	0.34	0.46	0.14	0.45
	N	3	3	3	3	3
CALCIUM mmo1/l	MEAN	2.68	2.62	2.62	2.62	2.57
	ST.DEV.	0.09	0.04	0.02	0.02	0.03
	N	3	3	3	3	3
CHLORIDE mmo1/l	MEAN	98	94	96	94	92 *
	ST.DEV.	4	1	1	4	1
	N	3	3	3	3	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level.

**MACROSCOPIC FINDINGS SUMMARY**  
**MALES**  
**ALL NECROPSIES**

	GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254	GROUP 7 T-7255
ANIMALS EXAMINED	14	14	14	14	14	14	14
ANIMALS WITHOUT FINDINGS	14	14	13	10	14	6	0
ANIMALS AFFECTED:							
STOMACH.....							
FOCUS/FOCI	0	0	0	0	0	0	7 ##
HEMORRHAGE	0	0	0	0	0	0	1
THICKENED	0	0	0	0	0	0	7 ##
DUODENUM.....							
DISCOLOURATION	0	0	0	0	0	0	1
LIVER.....							
ACCENTUATED LOBULAR PATTERN	0	0	0	0	0	1	12 ##
DISCOLOURATION	0	0	0	0	0	8 ##	13 ##
ENLARGED	0	0	0	0	0	8 ##	3
IRREGULAR SURFACE	0	0	0	0	0	0	1
PANCREAS.....							
DISCOLOURATION	0	0	0	0	0	0	1
KIDNEYS.....							
PELVIC DILATION	0	0	1	2	0	0	0
EPIDIDYMIDES.....							
NODULE(S)	0	0	0	1	0	0	0
REDUCED IN SIZE	0	0	0	0	0	0	6 ##
PROSTATE.....							
REDUCED IN SIZE	0	0	0	0	0	0	8 ##
SEMINAL VESICLES.....							
REDUCED IN SIZE	0	0	0	0	0	0	12 ##
SPLEEN.....							
REDUCED IN SIZE	0	0	0	0	0	0	10 ##
THYMUS.....							
DISCOLOURATION	0	0	0	0	0	0	1
REDUCED IN SIZE	0	0	0	0	0	0	12 ##
SKIN.....							
ALOPECIA	0	0	0	1	0	0	3
SCAB FORMATION	0	0	0	1	0	0	0

# / ## : Fisher's Exact Test based on counts significant at 5% (#) or 1% (##) level

**MACROSCOPIC FINDINGS SUMMARY  
FEMALES  
ALL NECROPSIES**

	GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
ANIMALS EXAMINED	14	14	14	14	14
ANIMALS WITHOUT FINDINGS	13	14	12	11	12
ANIMALS AFFECTED:					
LIVER.....					
ACCENTUATED LOBULAR PATTERN	0	0	0	0	1
KIDNEYS.....					
PELVIC DILATION	0	0	1	0	0
OVARIES.....					
HEMORRHAGIC CYST	0	0	0	1	0
UTERUS.....					
DISTENSION	0	0	0	1	0
SPLEEN.....					
REDUCED IN SIZE	0	0	0	1	0
THYMUS.....					
FOCUS/FOCI	1	0	0	0	0
SKIN.....					
ALOPECIA	0	0	0	0	1

# / ## : Fisher's Exact Test based on counts significant at 5% (#) or 1% (##) level

**ORGAN WEIGHTS (GRAM) SUMMARY  
AFTER 4 WEEKS  
MALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254	GROUP 7 T-7255
BODY W.	MEAN	350	357	333	360	342	308 *	---
	ST.DEV.	19	36	34	27	23	39	---
	N	8	8	8	8	8	8	0
BRAIN	MEAN	2.06	2.05	2.01	2.06	2.01	2.04	---
	ST.DEV.	0.07	0.15	0.13	0.07	0.09	0.10	---
	N	8	8	8	8	8	8	0
HEART	MEAN	1.220	1.212	1.135	1.239	1.182	1.074	---
	ST.DEV.	0.102	0.111	0.153	0.139	0.151	0.171	---
	N	8	8	8	8	8	8	0
LIVER	MEAN	10.98	12.20	13.26	11.75	15.70 **	20.16 **	---
	ST.DEV.	0.94	1.49	1.49	1.60	1.64	3.17	---
	N	8	8	8	8	8	8	0
KIDNEYS	MEAN	2.43	2.63	2.65	2.65	2.82 *	2.54	---
	ST.DEV.	0.24	0.33	0.32	0.30	0.32	0.28	---
	N	8	8	8	8	8	8	0
ADRENALS	MEAN	0.063	0.066	0.055	0.061	0.060	0.050	---
	ST.DEV.	0.011	0.015	0.016	0.018	0.014	0.007	---
	N	8	8	8	8	8	8	0
SPLEEN	MEAN	0.671	0.693	0.665	0.691	0.675	0.599	---
	ST.DEV.	0.103	0.099	0.055	0.090	0.100	0.131	---
	N	8	8	8	8	8	8	0
TESTES	MEAN	3.22	3.23	3.10	3.30	3.53	3.15	---
	ST.DEV.	0.21	0.29	0.24	0.55	0.60	0.21	---
	N	8	8	8	8	8	8	0

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level.



**ORGAN/BODY WEIGHT RATIOS SUMMARY  
AFTER 4 WEEKS  
MALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254	GROUP 7 T-7255
BODY W. (GRAM)	MEAN	350	357	333	360	342	308 *	---
	ST.DEV.	19	36	34	27	23	39	---
	N	8	8	8	8	8	8	0
BRAIN (%)	MEAN	0.59	0.58	0.61	0.57	0.59	0.67 *	---
	ST.DEV.	0.03	0.06	0.05	0.04	0.06	0.07	---
	N	8	8	8	8	8	8	0
HEART (%)	MEAN	0.349	0.341	0.341	0.344	0.345	0.349	---
	ST.DEV.	0.036	0.038	0.029	0.017	0.031	0.025	---
	N	8	8	8	8	8	8	0
LIVER (%)	MEAN	3.14	3.41	3.98 **	3.26	4.60 **	6.54 **	---
	ST.DEV.	0.23	0.20	0.21	0.24	0.45	0.37	---
	N	8	8	8	8	8	8	0
KIDNEYS (%)	MEAN	0.69	0.74	0.80 **	0.74	0.82 **	0.83 **	---
	ST.DEV.	0.07	0.05	0.06	0.04	0.07	0.06	---
	N	8	8	8	8	8	8	0
ADRENALS (%)	MEAN	0.018	0.018	0.016	0.017	0.017	0.016	---
	ST.DEV.	0.002	0.002	0.004	0.005	0.003	0.001	---
	N	8	8	8	8	8	8	0
SPLEEN (%)	MEAN	0.191	0.194	0.201	0.192	0.198	0.194	---
	ST.DEV.	0.025	0.025	0.025	0.020	0.030	0.031	---
	N	8	8	8	8	8	8	0
TESTES (%)	MEAN	0.92	0.91	0.94	0.92	1.03	1.04	---
	ST.DEV.	0.07	0.09	0.08	0.15	0.15	0.15	---
	N	8	8	8	8	8	8	0

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level.

**ORGAN WEIGHTS (GRAM) SUMMARY  
AFTER 4 WEEKS  
FEMALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
BODY W.	MEAN	226	229	226	222	214
	ST.DEV.	17	23	17	25	9
	N	8	8	8	8	8
BRAIN	MEAN	1.89	1.96	1.90	1.97	1.88
	ST.DEV.	0.07	0.06	0.14	0.06	0.09
	N	8	8	8	8	7
HEART	MEAN	0.855	0.913	0.865	0.844	0.841
	ST.DEV.	0.134	0.090	0.104	0.083	0.075
	N	8	8	8	8	7
LIVER	MEAN	7.29	7.64	8.01	7.51	7.62
	ST.DEV.	0.73	0.72	0.96	1.14	0.54
	N	8	8	8	8	7
KIDNEYS	MEAN	1.62	1.75	1.71	1.60	1.73
	ST.DEV.	0.15	0.22	0.23	0.20	0.20
	N	8	8	8	8	7
ADRENALS	MEAN	0.068	0.072	0.073	0.069	0.078
	ST.DEV.	0.014	0.011	0.008	0.014	0.016
	N	8	8	8	8	7
SPLEEN	MEAN	0.504	0.506	0.553	0.517	0.567
	ST.DEV.	0.038	0.067	0.068	0.091	0.085
	N	8	8	8	8	7
OVARIES	MEAN	0.140	0.151	0.142	0.144	0.156
	ST.DEV.	0.016	0.022	0.011	0.037	0.034
	N	8	8	8	8	7

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level.

ORGAN/BODY WEIGHT RATIOS SUMMARY  
AFTER 4 WEEKS  
FEMALES

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
BODY W. (GRAM)	MEAN	226	229	226	222	214
	ST. DEV.	17	23	17	25	9
	N	8	8	8	8	8
BRAIN (%)	MEAN	0.84	0.86	0.84	0.89	0.88
	ST. DEV.	0.05	0.08	0.04	0.10	0.06
	N	8	8	8	8	7
HEART (%)	MEAN	0.377	0.398	0.385	0.380	0.393
	ST. DEV.	0.043	0.019	0.052	0.013	0.030
	N	8	8	8	8	7
LIVER (%)	MEAN	3.22	3.34	3.55 *	3.37	3.56 *
	ST. DEV.	0.16	0.22	0.27	0.27	0.16
	N	8	8	8	8	7
KIDNEYS (%)	MEAN	0.71	0.76	0.75	0.72	0.81 **
	ST. DEV.	0.04	0.06	0.05	0.05	0.08
	N	8	8	8	8	7
ADRENALS (%)	MEAN	0.030	0.031	0.032	0.031	0.037
	ST. DEV.	0.007	0.004	0.004	0.005	0.007
	N	8	8	8	8	7
SPLEEN (%)	MEAN	0.223	0.220	0.246	0.231	0.265 *
	ST. DEV.	0.022	0.017	0.031	0.023	0.040
	N	8	8	8	8	7
OVARIES (%)	MEAN	0.062	0.066	0.063	0.065	0.073
	ST. DEV.	0.010	0.010	0.006	0.014	0.015
	N	8	8	8	8	7

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level.

**ORGAN WEIGHTS (GRAM) SUMMARY  
AFTER 2 WEEKS RECOVERY  
MALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254	GROUP 7 T-7255
BODY W.	MEAN	396	376	380	362	376	283 *	---
	ST.DEV.	53	18	43	36	60	21	---
	N	3	3	3	3	3	3	0
BRAIN	MEAN	2.05	1.94	2.05	2.01	2.10	2.03	---
	ST.DEV.	0.17	0.06	0.13	0.04	0.12	0.09	---
	N	3	3	3	3	3	3	0
HEART	MEAN	1.329	1.297	1.285	1.184	1.339	1.045	---
	ST.DEV.	0.172	0.068	0.176	0.114	0.131	0.069	---
	N	3	3	3	3	3	3	0
LIVER	MEAN	11.97	11.60	12.24	10.87	11.56	10.72	---
	ST.DEV.	2.27	0.75	1.60	1.65	1.98	1.31	---
	N	3	3	3	3	3	3	0
KIDNEYS	MEAN	2.84	2.55	2.84	2.56	2.83	2.16	---
	ST.DEV.	0.32	0.13	0.44	0.29	0.51	0.29	---
	N	3	3	3	3	3	3	0
ADRENALS	MEAN	0.068	0.049	0.059	0.062	0.055	0.040 **	---
	ST.DEV.	0.009	0.005	0.010	0.010	0.011	0.006	---
	N	3	3	3	3	3	3	0
SPLEEN	MEAN	0.590	0.719	0.745	0.710	0.672	0.615	---
	ST.DEV.	0.060	0.116	0.094	0.218	0.185	0.139	---
	N	3	3	3	3	3	3	0
TESTES	MEAN	3.17	3.16	3.00	3.12	3.31	3.26	---
	ST.DEV.	0.46	0.26	0.27	0.13	0.45	0.18	---
	N	3	3	3	3	3	3	0

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level.

**ORGAN/BODY WEIGHT RATIOS SUMMARY  
AFTER 2 WEEKS RECOVERY  
MALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254	GROUP 7 T-7255
BODY W. (GRAM)	MEAN	396	376	380	362	376	283 *	---
	ST.DEV.	53	18	43	36	60	21	---
	N	3	3	3	3	3	3	0
BRAIN (%)	MEAN	0.52	0.52	0.54	0.56	0.57	0.72 **	---
	ST.DEV.	0.03	0.03	0.03	0.05	0.08	0.02	---
	N	3	3	3	3	3	3	0
HEART (%)	MEAN	0.336	0.345	0.338	0.327	0.360	0.370	---
	ST.DEV.	0.016	0.019	0.023	0.007	0.041	0.008	---
	N	3	3	3	3	3	3	0
LIVER (%)	MEAN	3.01	3.08	3.21	2.99	3.08	3.79 **	---
	ST.DEV.	0.20	0.05	0.06	0.17	0.20	0.33	---
	N	3	3	3	3	3	3	0
KIDNEYS (%)	MEAN	0.72	0.68	0.74	0.71	0.75	0.76	---
	ST.DEV.	0.08	0.04	0.03	0.02	0.03	0.04	---
	N	3	3	3	3	3	3	0
ADRENALS (%)	MEAN	0.017	0.013 *	0.016	0.017	0.015	0.014	---
	ST.DEV.	0.002	0.001	0.003	0.002	0.001	0.002	---
	N	3	3	3	3	3	3	0
SPLEEN (%)	MEAN	0.150	0.191	0.196	0.193	0.177	0.217	---
	ST.DEV.	0.005	0.029	0.012	0.042	0.023	0.047	---
	N	3	3	3	3	3	3	0
TESTES (%)	MEAN	0.80	0.84	0.79	0.87	0.88	1.16 **	---
	ST.DEV.	0.01	0.05	0.08	0.08	0.02	0.11	---
	N	3	3	3	3	3	3	0

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level.

**ORGAN WEIGHTS (GRAM) SUMMARY  
AFTER 2 WEEKS RECOVERY  
FEMALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
BODY W.	MEAN	255	234	274	265	252
	ST.DEV.	10	12	3	31	10
	N	3	2	2	3	3
BRAIN	MEAN	1.97	1.86	2.00	1.91	1.96
	ST.DEV.	0.09	0.14	0.13	0.08	0.09
	N	3	3	2	3	3
HEART	MEAN	0.927	0.931	1.024	0.954	0.931
	ST.DEV.	0.041	0.070	0.042	0.094	0.021
	N	3	3	2	3	3
LIVER	MEAN	7.91	7.57	9.59	8.44	7.66
	ST.DEV.	0.62	0.69	0.01	0.84	0.92
	N	3	3	2	3	3
KIDNEYS	MEAN	1.70	1.57	1.80	1.79	1.71
	ST.DEV.	0.11	0.19	0.04	0.15	0.17
	N	3	3	2	3	3
ADRENALS	MEAN	0.082	0.075	0.066	0.080	0.077
	ST.DEV.	0.010	0.011	0.007	0.010	0.012
	N	3	3	2	3	3
SPLEEN	MEAN	0.455	0.554	0.515	0.563	0.455
	ST.DEV.	0.049	0.078	0.056	0.161	0.087
	N	3	3	2	3	3
OVARIES	MEAN	0.143	0.170	0.161	0.178	0.175
	ST.DEV.	0.017	0.028	0.021	0.018	0.069
	N	3	3	2	3	3

\*/\*: Dunnett-test based on pooled variance sig. at 5% or 1% level.

ORGAN/BODY WEIGHT RATIOS SUMMARY  
AFTER 2 WEEKS RECOVERY  
FEMALES

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
BODY W. (GRAM)	MEAN	255	234	274	265	252
	ST.DEV.	10	12	3	31	10
	N	3	2	2	3	3
BRAIN (%)	MEAN	0.77	0.77	0.73	0.73	0.78
	ST.DEV.	0.07	0.02	0.04	0.09	0.07
	N	3	2	2	3	3
HEART (%)	MEAN	0.363	0.416 **	0.373	0.361	0.370
	ST.DEV.	0.017	0.010	0.011	0.010	0.008
	N	3	2	2	3	3
LIVER (%)	MEAN	3.10	3.08	3.50	3.19	3.05
	ST.DEV.	0.14	0.22	0.03	0.21	0.44
	N	3	2	2	3	3
KIDNEYS (%)	MEAN	0.67	0.63	0.66	0.68	0.68
	ST.DEV.	0.06	0.02	0.01	0.03	0.09
	N	3	2	2	3	3
ADRENALS (%)	MEAN	0.032	0.031	0.024	0.031	0.031
	ST.DEV.	0.005	0.006	0.002	0.008	0.006
	N	3	2	2	3	3
SPLEEN (%)	MEAN	0.178	0.219	0.188	0.210	0.181
	ST.DEV.	0.014	0.003	0.018	0.040	0.039
	N	3	2	2	3	3
OVARIES (%)	MEAN	0.056	0.067	0.059	0.068	0.069
	ST.DEV.	0.005	0.010	0.008	0.009	0.025
	N	3	2	2	3	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level.

**ORGAN WEIGHTS (GRAM) SUMMARY  
AFTER 4 WEEKS RECOVERY  
MALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254	GROUP 7 T-7255
BODY W.	MEAN	398	406	379	477	421	364	---
	ST.DEV.	38	32	19	60	44	57	---
	N	3	3	3	3	3	3	0
BRAIN	MEAN	2.04	2.15	2.04	2.06	2.10	2.01	---
	ST.DEV.	0.13	0.15	0.10	0.06	0.15	0.15	---
	N	3	3	3	3	3	3	0
HEART	MEAN	1.274	1.304	1.191	1.368	1.410	1.260	---
	ST.DEV.	0.041	0.033	0.066	0.200	0.120	0.161	---
	N	3	3	3	3	3	3	0
LIVER	MEAN	10.50	11.46	10.64	12.68	12.11	12.50	---
	ST.DEV.	1.35	1.86	1.64	2.00	2.58	2.52	---
	N	3	3	3	3	3	3	0
KIDNEYS	MEAN	2.50	2.73	2.57	3.00	2.74	2.49	---
	ST.DEV.	0.18	0.32	0.09	0.13	0.18	0.23	---
	N	3	3	3	3	3	3	0
ADRENALS	MEAN	0.052	0.053	0.065	0.066	0.050	0.043	---
	ST.DEV.	0.013	0.005	0.011	0.009	0.008	0.005	---
	N	3	3	3	3	3	3	0
SPLEEN	MEAN	0.663	0.624	0.592	0.711	0.715	0.645	---
	ST.DEV.	0.095	0.123	0.060	0.038	0.159	0.187	---
	N	3	3	3	3	3	3	0
TESTES	MEAN	3.42	3.44	3.08	3.70	3.58	3.14	---
	ST.DEV.	0.19	0.13	0.14	0.38	0.10	0.26	---
	N	3	3	3	3	3	3	0

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level.



**ORGAN/BODY WEIGHT RATIOS SUMMARY  
AFTER 4 WEEKS RECOVERY  
MALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253	GROUP 6 T-7254	GROUP 7 T-7255
BODY W. (GRAM)	MEAN	398	406	379	477	421	364	---
	ST.DEV.	38	32	19	60	44	57	---
	N	3	3	3	3	3	3	0
BRAIN (%)	MEAN	0.52	0.53	0.54	0.44	0.50	0.56	---
	ST.DEV.	0.04	0.02	0.04	0.04	0.02	0.09	---
	N	3	3	3	3	3	3	0
HEART (%)	MEAN	0.322	0.322	0.315	0.287	0.336	0.348	---
	ST.DEV.	0.020	0.024	0.025	0.022	0.015	0.032	---
	N	3	3	3	3	3	3	0
LIVER (%)	MEAN	2.64	2.81	2.81	2.65	2.86	3.42	---
	ST.DEV.	0.11	0.25	0.38	0.12	0.31	0.27	---
	N	3	3	3	3	3	3	0
KIDNEYS (%)	MEAN	0.63	0.67	0.68	0.63	0.65	0.69	---
	ST.DEV.	0.02	0.05	0.05	0.06	0.02	0.05	---
	N	3	3	3	3	3	3	0
ADRENALS (%)	MEAN	0.013	0.013	0.017	0.014	0.012	0.012	---
	ST.DEV.	0.003	0.002	0.004	0.000	0.002	0.002	---
	N	3	3	3	3	3	3	0
SPLEEN (%)	MEAN	0.167	0.154	0.156	0.151	0.169	0.176	---
	ST.DEV.	0.014	0.026	0.010	0.025	0.023	0.035	---
	N	3	3	3	3	3	3	0
TESTES (%)	MEAN	0.87	0.85	0.81	0.79	0.86	0.88	---
	ST.DEV.	0.09	0.09	0.03	0.16	0.11	0.21	---
	N	3	3	3	3	3	3	0

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level.

ORGAN WEIGHTS (GRAM) SUMMARY  
AFTER 4 WEEKS RECOVERY  
FEMALES

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
BODY W.	MEAN	255	257	267	293	265
	ST. DEV.	20	18	16	54	31
	N	3	3	3	3	3
BRAIN	MEAN	2.05	1.86	1.97	2.01	1.96
	ST. DEV.	0.11	0.09	0.10	0.05	0.04
	N	3	3	3	3	3
HEART	MEAN	0.926	0.910	0.965	1.017	0.998
	ST. DEV.	0.028	0.065	0.034	0.129	0.168
	N	3	3	3	3	3
LIVER	MEAN	7.87	8.27	8.19	9.01	8.23
	ST. DEV.	0.80	0.66	0.43	1.89	0.51
	N	3	3	3	3	3
KIDNEYS	MEAN	1.66	1.76	1.93	1.83	1.93
	ST. DEV.	0.15	0.19	0.15	0.30	0.10
	N	3	3	3	3	3
ADRENALS	MEAN	0.068	0.074	0.071	0.080	0.083
	ST. DEV.	0.004	0.013	0.014	0.013	0.008
	N	3	3	3	3	3
SPLEEN	MEAN	0.420	0.506	0.539	0.522	0.561
	ST. DEV.	0.039	0.049	0.023	0.130	0.050
	N	3	3	3	3	3
OVARIES	MEAN	0.152	0.135	0.158	0.171	0.168
	ST. DEV.	0.034	0.020	0.008	0.033	0.025
	N	3	3	3	3	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level.

**ORGAN/BODY WEIGHT RATIOS SUMMARY  
AFTER 4 WEEKS RECOVERY  
FEMALES**

		GROUP 1 VEHICLE CONT	GROUP 2 T-7250	GROUP 3 T-7251	GROUP 4 T-7252	GROUP 5 T-7253
BODY W. (GRAM)	MEAN	255	257	267	293	265
	ST.DEV.	20	18	16	54	31
	N	3	3	3	3	3
BRAIN (%)	MEAN	0.81	0.73	0.74	0.70	0.75
	ST.DEV.	0.04	0.03	0.01	0.14	0.09
	N	3	3	3	3	3
HEART (%)	MEAN	0.364	0.354	0.361	0.350	0.376
	ST.DEV.	0.023	0.002	0.015	0.023	0.045
	N	3	3	3	3	3
LIVER (%)	MEAN	3.08	3.23	3.07	3.06	3.12
	ST.DEV.	0.11	0.31	0.06	0.09	0.26
	N	3	3	3	3	3
KIDNEYS (%)	MEAN	0.65	0.69	0.72	0.62	0.73
	ST.DEV.	0.04	0.08	0.06	0.01	0.06
	N	3	3	3	3	3
ADRENALS (%)	MEAN	0.027	0.029	0.027	0.027	0.032
	ST.DEV.	0.001	0.007	0.004	0.003	0.007
	N	3	3	3	3	3
SPLEEN (%)	MEAN	0.165	0.198	0.202	0.178	0.212
	ST.DEV.	0.010	0.030	0.007	0.033	0.014
	N	3	3	3	3	3
OVARIES (%)	MEAN	0.060	0.053	0.059	0.059	0.063
	ST.DEV.	0.011	0.010	0.005	0.012	0.004
	N	3	3	3	3	3

\*/\*\*: Dunnett-test based on pooled variance sig. at 5% or 1% level.

HISTORICAL DATA HAEMATOLOGY <sup>1</sup>  
 ANIMALS OF 10-12 WEEKS OF AGE  
 MALES AND FEMALES

PARAMETER	SEX	N	MEAN	ST. DEV.	MIN.	MAX.
RBC	M	30	7.28	0.31	6.80	7.98
T/l	F	31	6.78	0.23	6.38	7.49
HB	M	30	9.4	0.4	8.6	10.1
mmol/l	F	31	9.2	0.4	8.5	10.1
HCT	M	30	0.42	0.018	0.389	0.453
l/l	F	31	0.39	0.016	0.356	0.428
MCV	M	30	57.7	1.4	54.9	60.9
f1	F	31	57.6	2.1	53.5	61.9
MCH	M	30	1.295	0.038	1.216	1.357
fmo1	F	31	1.356	0.054	1.254	1.473
MCHC	M	30	22.4	0.5	21.4	23.3
mmol/l	F	31	23.6	0.7	22.1	24.7
RDW	M	30	12.8	1	11.2	15.9
%	F	31	12	1.5	10.5	15.8
PLATELETS	M	30	1172	111	960	1379
G/l	F	31	1156	109	935	1410
WBC	M	30	10.9	3	5.3	17.6
G/l	F	31	7.4	2	4.9	13
SEG	M	30	0.093	0.038	0.035	0.19
1	F	31	0.062	0.028	0.01	0.13
EO	M	30	0.006	0.005	0	0.015
1	F	31	0.008	0.007	0	0.03
BASO	M	30	0	0	0	0
1	F	31	0	0	0	0
MONO	M	30	0.015	0.011	0	0.03
1	F	31	0.014	0.013	0	0.045
LYMPH	M	30	0.886	0.047	0.785	0.95
1	F	31	0.916	0.039	0.805	0.985
PT	M	30	13.3	1.6	10.8	16.2
sec	F	31	13.6	2.1	10.2	17.3
PTT	M	33	16.3	0.8	14.8	18.2
sec	F	33	15.9	1.4	13.9	18.9

<sup>1</sup> Data are from comparable studies using Sprague Dawley control rats. Due to the limited availability of data no confidence intervals were calculated.

**HISTORICAL DATA HAEMATOLOGY <sup>1</sup>**  
**ANIMALS OF 13-18 WEEKS OF AGE**  
**MALES AND FEMALES**

PARAMETER	SEX	N	MEAN	ST. DEV.	MIN.	MAX.
RBC	M	6	7.61	0.45	6.79	8.14
T/l	F	6	6.97	0.25	6.76	7.40
HB	M	6	9.4	0.5	8.7	9.8
mmo1/l	F	6	9.3	0.3	8.9	9.7
HCT	M	6	0.409	0.024	0.373	0.435
l/l	F	6	0.397	0.019	0.379	0.423
MCV	M	6	53.7	1.5	51.7	55.3
f1	F	6	57	1.5	55.3	59.7
MCH	M	6	1.234	0.043	1.184	1.281
fmo1	F	6	1.338	0.03	1.299	1.369
MCHC	M	6	23	0.3	22.5	23.3
mmo1/l	F	6	23.5	0.8	22.2	24.2
RDW	M	6	14.4	0.5	13.7	15.1
%	F	6	12.9	0.6	12.2	13.7
PLATELETS	M	6	1078	101	952	1204
G/l	F	6	1010	64	911	1084
WBC	M	6	11.4	3.7	5	16.2
G/l	F	6	6.1	0.7	5.3	7
SEG	M	6	0.104	0.039	0.055	0.16
1	F	6	0.061	0.026	0.02	0.085
EO	M	6	0.004	0.005	0	0.01
1	F	6	0.008	0.008	0	0.02
BASO	M	6	0	0	0	0
1	F	6	0	0	0	0
MONO	M	6	0.03	0.029	0	0.075
1	F	6	0.009	0.007	0	0.02
LYMPH	M	6	0.862	0.047	0.775	0.915
1	F	6	0.922	0.025	0.9	0.96
PT	M	5	12.9	1.1	11.5	14.5
sec	F	6	12.2	0.5	11.6	13
PTT	M	5	17.4	1.4	15.9	18.9
sec	F	6	16.1	0.9	14.6	16.9

<sup>1</sup> Data are from comparable studies using Sprague Dawley control rats. Due to the limited availability of data no confidence intervals were calculated.

**HISTORICAL DATA CLINICAL BIOCHEMISTRY <sup>1</sup>**  
**ANIMALS OF 10-12 WEEKS OF AGE**  
**MALES AND FEMALES**

PARAMETER	SEX	N	MEAN	ST. DEV.	MIN.	MAX.
ALAT/GPT μkat/l	M	13	0.61	0.11	0.44	0.78
	F	14	0.51	0.12	0.24	0.69
ASAT/GOT μkat/l	M	14	2.45	0.46	1.50	3.27
	F	14	2.32	0.48	1.67	3.26
BILI T. μmol/l	M	14	1.9	0.3	1.4	2.6
	F	14	2.4	0.5	1.7	3.5
CHOLEST. T. mmol/l	M	14	1.89	0.21	1.51	2.30
	F	14	2.34	0.41	1.82	3.16
TRIGL. mmol/l	M	14	0.78	0.44	0.26	1.78
	F	14	0.47	0.16	0.31	0.97
CREATININE μmol/l	M	14	41.5	2.8	36.9	47.3
	F	14	47.4	2.8	41.9	51.1
GLUCOSE mmol/l	M	14	6.46	1.03	5.14	7.97
	F	14	6.28	0.63	5.19	7.58
UREA mmol/l	M	14	6.0	1.3	4.1	9.0
	F	14	7.0	1.1	5.8	9.3
PROTEIN T. g/l	M	14	60.1	2.1	57.3	64.4
	F	14	65.5	2.9	60.7	71.5
ALBUMIN g/l	M	14	31.2	1.3	29.5	34.3
	F	14	33.9	1.5	31.8	37.1
GLOBULIN g/l	M	14	29.0	1.1	27.8	34.1
	F	14	31.6	1.6	28.9	34.4
A/G RATIO 1	M	14	1.1	0.0	1.0	1.2
	F	14	1.1	0.0	1.0	1.1
ALP μkat/l	M	14	7.15	1.10	6.25	9.56
	F	14	3.73	0.89	2.18	5.43
SODIUM mmol/l	M	34	143.6	1.4	139.8	146.8
	F	34	142.8	1.4	139.8	146.1
POTASSIUM mmol/l	M	34	4.70	0.31	4.01	5.56
	F	34	4.30	0.37	3.41	4.9
CHLORIDE mmol/l	M	14	96	2	94	101
	F	14	97	2	93	100
CALCIUM mmol/l	M	34	2.52	0.07	2.38	2.68
	F	34	2.59	0.08	2.37	2.79
INORG. PHOSPH. mmol/l	M	14	2.44	0.19	1.95	2.78
	F	14	2.18	0.11	2.04	2.43

<sup>1</sup> Data are from comparable studies using Sprague Dawley control rats. Due to the limited availability of data no confidence intervals were calculated.

**HISTORICAL DATA CLINICAL BIOCHEMISTRY <sup>1</sup>**  
**ANIMALS OF 13-18 WEEKS OF AGE**  
**MALES AND FEMALES**

PARAMETER	SEX	N	MEAN	ST. DEV.	MIN.	MAX.
ALAT/GPT μkat/l	M	3	0.71	0.17	0.53	0.85
	F	3	0.47	0.03	0.44	0.50
ASAT/GOT μkat/l	M	3	2.85	0.24	2.58	3.05
	F	3	2.05	0.22	1.80	2.23
BILI T. μmol/l	M	3	2.4	0.6	1.9	3.1
	F	3	2.3	0.5	1.9	2.8
CHOLEST. T. mmol/l	M	3	1.90	0.23	1.65	2.11
	F	3	2.37	0.62	1.66	2.80
TRIGL. mmol/l	M	3	1.15	0.58	0.49	1.61
	F	3	0.62	0.08	0.54	0.69
CREATININE μmol/l	M	3	43.8	1.1	42.7	44.9
	F	3	46.4	1.7	44.9	48.3
GLUCOSE mmol/l	M	3	6.45	1.22	5.12	7.52
	F	3	6.76	0.72	6.30	7.59
UREA mmol/l	M	3	6.5	1.1	5.7	7.8
	F	3	7.1	0.8	6.7	8.0
PROTEIN T. g/l	M	3	63.1	2.3	61.1	65.6
	F	3	69.2	2.7	66.1	71.4
ALBUMIN g/l	M	3	32.4	2.4	30.2	34.9
	F	3	35.8	1.4	34.8	37.4
GLOBULIN g/l	M	3	30.7	3.0	27.6	33.6
	F	3	33.4	1.8	31.3	34.8
A/G RATIO 1	M	3	1.1	0.2	1.0	1.3
	F	3	1.1	0.1	1.0	1.1
ALP μkat/l	M	3	5.40	1.16	4.65	6.74
	F	3	2.04	0.38	1.68	2.43
SODIUM mmol/l	M	6	142.8	1.5	140.8	145.1
	F	6	143.0	1.3	140.5	144
POTASSIUM mmol/l	M	6	4.91	0.54	4.06	5.56
	F	6	4.06	0.28	3.71	4.5
CHLORIDE mmol/l	M	3	97	1	96	98
	F	3	96	4	94	101
CALCIUM mmol/l	M	6	2.52	0.08	2.4	2.6
	F	6	2.53	0.04	2.47	2.58
INORG. PHOSPH. mmol/l	M	3	2.27	0.28	1.95	2.48
	F	3	1.80	0.23	1.62	2.06

<sup>1</sup> Data are from comparable studies using Sprague Dawley control rats. Due to the limited availability of data no confidence intervals were calculated.

**TABLES - INDIVIDUAL DATA**



MORTALITY DATA  
MALES  
GROUP 1 (VEHICLE CONTROL)

ANIMAL	SCHEDULED NECROPSY	KILLED IN EXTREMIS	OTHER	TREATMENT FROM	TO
1	21-SEP-99			24-AUG-99	20-SEP-99
2	21-SEP-99			24-AUG-99	20-SEP-99
3	21-SEP-99			24-AUG-99	20-SEP-99
4	21-SEP-99			24-AUG-99	20-SEP-99
5	22-SEP-99			24-AUG-99	21-SEP-99
6	22-SEP-99			24-AUG-99	21-SEP-99
7	22-SEP-99			24-AUG-99	21-SEP-99
8	22-SEP-99			24-AUG-99	21-SEP-99
9	06-OCT-99			24-AUG-99	21-SEP-99
10	06-OCT-99			24-AUG-99	21-SEP-99
11	06-OCT-99			24-AUG-99	21-SEP-99
13	20-OCT-99			24-AUG-99	21-SEP-99
14	20-OCT-99			24-AUG-99	21-SEP-99
15	20-OCT-99			24-AUG-99	21-SEP-99

MORTALITY DATA  
MALES  
GROUP 2 (T-7250)

ANIMAL	SCHEDULED NECROPSY	KILLED IN EXTREMIS	OTHER	TREATMENT FROM	TO
17	21-SEP-99			24-AUG-99	20-SEP-99
18	21-SEP-99			24-AUG-99	20-SEP-99
19	21-SEP-99			24-AUG-99	20-SEP-99
20	21-SEP-99			24-AUG-99	20-SEP-99
21	22-SEP-99			24-AUG-99	21-SEP-99
22	22-SEP-99			24-AUG-99	21-SEP-99
23	22-SEP-99			24-AUG-99	21-SEP-99
24	22-SEP-99			24-AUG-99	21-SEP-99
25	06-OCT-99			24-AUG-99	21-SEP-99
26	06-OCT-99			24-AUG-99	21-SEP-99
27	06-OCT-99			24-AUG-99	21-SEP-99
29	20-OCT-99			24-AUG-99	21-SEP-99
30	20-OCT-99			24-AUG-99	21-SEP-99
31	20-OCT-99			24-AUG-99	21-SEP-99

MORTALITY DATA  
 MALES  
 GROUP 3 (T-7251)

ANIMAL	SCHEDULED NECROPSY	KILLED IN EXTREMIS	OTHER	TREATMENT FROM	TO
33	21-SEP-99			24-AUG-99	20-SEP-99
34	21-SEP-99			24-AUG-99	20-SEP-99
35	21-SEP-99			24-AUG-99	20-SEP-99
36	21-SEP-99			24-AUG-99	20-SEP-99
37	22-SEP-99			24-AUG-99	21-SEP-99
38	22-SEP-99			24-AUG-99	21-SEP-99
39	22-SEP-99			24-AUG-99	21-SEP-99
40	22-SEP-99			24-AUG-99	21-SEP-99
41	06-OCT-99			24-AUG-99	21-SEP-99
42	06-OCT-99			24-AUG-99	21-SEP-99
43	06-OCT-99			24-AUG-99	21-SEP-99
45	20-OCT-99			24-AUG-99	21-SEP-99
46	20-OCT-99			24-AUG-99	21-SEP-99
47	20-OCT-99			24-AUG-99	21-SEP-99

MORTALITY DATA  
MALES  
GROUP 4 (T-7252)

ANIMAL	SCHEDULED NECROPSY	KILLED IN EXTREMIS	OTHER	TREATMENT FROM	TO
49	21-SEP-99				
50	21-SEP-99			24-AUG-99	20-SEP-99
51	21-SEP-99			24-AUG-99	20-SEP-99
52	21-SEP-99			24-AUG-99	20-SEP-99
53	22-SEP-99			24-AUG-99	20-SEP-99
54	22-SEP-99			24-AUG-99	21-SEP-99
55	22-SEP-99			24-AUG-99	21-SEP-99
56	22-SEP-99			24-AUG-99	21-SEP-99
57	06-OCT-99			24-AUG-99	21-SEP-99
58	06-OCT-99			24-AUG-99	21-SEP-99
59	06-OCT-99			24-AUG-99	21-SEP-99
61	20-OCT-99			24-AUG-99	21-SEP-99
62	20-OCT-99			24-AUG-99	21-SEP-99
63	20-OCT-99			24-AUG-99	21-SEP-99

**MORTALITY DATA  
MALES  
GROUP 5 (T-7253)**

ANIMAL	SCHEDULED NECROPSY	KILLED IN EXTREMIS	OTHER	TREATMENT FROM	TO
65	21-SEP-99			24-AUG-99	20-SEP-99
66	21-SEP-99			24-AUG-99	20-SEP-99
67	21-SEP-99			24-AUG-99	20-SEP-99
68	21-SEP-99			24-AUG-99	20-SEP-99
69	22-SEP-99			24-AUG-99	21-SEP-99
70	22-SEP-99			24-AUG-99	21-SEP-99
71	22-SEP-99			24-AUG-99	21-SEP-99
72	22-SEP-99			24-AUG-99	21-SEP-99
73	06-OCT-99			24-AUG-99	21-SEP-99
74	06-OCT-99			24-AUG-99	21-SEP-99
75	06-OCT-99			24-AUG-99	21-SEP-99
77	20-OCT-99			24-AUG-99	21-SEP-99
78	20-OCT-99			24-AUG-99	21-SEP-99
79	20-OCT-99			24-AUG-99	21-SEP-99

MORTALITY DATA  
MALES  
GROUP 6 (T-7254)

ANIMAL	SCHEDULED NECROPSY	KILLED IN EXTREMIS	OTHER	TREATMENT FROM	TO
81	21-SEP-99			24-AUG-99	20-SEP-99
82	21-SEP-99			24-AUG-99	20-SEP-99
83	21-SEP-99			24-AUG-99	20-SEP-99
84	21-SEP-99			24-AUG-99	20-SEP-99
85	22-SEP-99			24-AUG-99	20-SEP-99
86	22-SEP-99			24-AUG-99	21-SEP-99
87	22-SEP-99			24-AUG-99	21-SEP-99
88	22-SEP-99			24-AUG-99	21-SEP-99
89	06-OCT-99			24-AUG-99	21-SEP-99
90	06-OCT-99			24-AUG-99	21-SEP-99
91	06-OCT-99			24-AUG-99	21-SEP-99
93	20-OCT-99			24-AUG-99	21-SEP-99
94	20-OCT-99			24-AUG-99	21-SEP-99
95	20-OCT-99			24-AUG-99	21-SEP-99

MORTALITY DATA  
MALES  
GROUP 7 (T-7255)

ANIMAL	SCHEDULED NECROPSY	KILLED IN EXTREMIS	OTHER	TREATMENT FROM	TO
97		06-SEP-99		24-AUG-99	02-SEP-99
98		03-SEP-99		24-AUG-99	02-SEP-99
99		06-SEP-99		24-AUG-99	02-SEP-99
100		06-SEP-99		24-AUG-99	02-SEP-99
101		06-SEP-99		24-AUG-99	02-SEP-99
102		02-SEP-99		24-AUG-99	02-SEP-99
103		06-SEP-99		24-AUG-99	02-SEP-99
104		06-SEP-99		24-AUG-99	02-SEP-99
105		06-SEP-99		24-AUG-99	02-SEP-99
106		06-SEP-99		24-AUG-99	02-SEP-99
107		03-SEP-99		24-AUG-99	02-SEP-99
109		06-SEP-99		24-AUG-99	02-SEP-99
110		06-SEP-99		24-AUG-99	02-SEP-99
111		03-SEP-99		24-AUG-99	02-SEP-99

**MORTALITY DATA  
FEMALES  
GROUP 1 (VEHICLE CONTROL)**

ANIMAL	SCHEDULED NECROPSY	KILLED IN EXTREMIS	OTHER	TREATMENT FROM	TO
113	23-SEP-99			26-AUG-99	22-SEP-99
114	23-SEP-99			26-AUG-99	22-SEP-99
115	23-SEP-99			26-AUG-99	22-SEP-99
116	23-SEP-99			26-AUG-99	22-SEP-99
117	24-SEP-99			26-AUG-99	23-SEP-99
118	24-SEP-99			26-AUG-99	23-SEP-99
119	24-SEP-99			26-AUG-99	23-SEP-99
120	24-SEP-99			26-AUG-99	23-SEP-99
121	08-OCT-99			26-AUG-99	23-SEP-99
122	08-OCT-99			26-AUG-99	23-SEP-99
123	08-OCT-99			26-AUG-99	23-SEP-99
125	22-OCT-99			26-AUG-99	23-SEP-99
126	22-OCT-99			26-AUG-99	23-SEP-99
127	22-OCT-99			26-AUG-99	23-SEP-99



**MORTALITY DATA  
FEMALES  
GROUP 2 (T-7250)**

ANIMAL	SCHEDULED NECROPSY	KILLED IN EXTREMIS	OTHER	TREATMENT FROM	TO
129	23-SEP-99			26-AUG-99	22-SEP-99
130	23-SEP-99			26-AUG-99	22-SEP-99
131	23-SEP-99			26-AUG-99	22-SEP-99
132	23-SEP-99			26-AUG-99	22-SEP-99
133	24-SEP-99			26-AUG-99	23-SEP-99
134	24-SEP-99			26-AUG-99	23-SEP-99
135	24-SEP-99			26-AUG-99	23-SEP-99
136	24-SEP-99			26-AUG-99	23-SEP-99
137	08-OCT-99			26-AUG-99	23-SEP-99
138	08-OCT-99			26-AUG-99	23-SEP-99
139	08-OCT-99			26-AUG-99	23-SEP-99
141	22-OCT-99			26-AUG-99	23-SEP-99
142	22-OCT-99			26-AUG-99	23-SEP-99
143	22-OCT-99			26-AUG-99	23-SEP-99

MORTALITY DATA  
FEMALES  
GROUP 3 (T-7251)

ANIMAL	SCHEDULED NECROPSY	KILLED IN EXTREMIS	OTHER	TREATMENT FROM	TO
145	23-SEP-99				
146	23-SEP-99			26-AUG-99	22-SEP-99
147	23-SEP-99			26-AUG-99	22-SEP-99
148	23-SEP-99			26-AUG-99	22-SEP-99
149	24-SEP-99			26-AUG-99	23-SEP-99
150	24-SEP-99			26-AUG-99	23-SEP-99
151	24-SEP-99			26-AUG-99	23-SEP-99
152	24-SEP-99			26-AUG-99	23-SEP-99
153				26-AUG-99	23-SEP-99
154	08-OCT-99		24-SEP-99	26-AUG-99	23-SEP-99
155	08-OCT-99			26-AUG-99	23-SEP-99
157	22-OCT-99			26-AUG-99	23-SEP-99
158	22-OCT-99			26-AUG-99	23-SEP-99
159	22-OCT-99			26-AUG-99	23-SEP-99

MORTALITY DATA  
FEMALES  
GROUP 4 (T-7252)

ANIMAL	SCHEDULED NECROPSY	KILLED IN EXTREMIS	OTHER	TREATMENT FROM	TO
161	23-SEP-99			26-AUG-99	22-SEP-99
162	23-SEP-99			26-AUG-99	22-SEP-99
163	23-SEP-99			26-AUG-99	22-SEP-99
164	23-SEP-99			26-AUG-99	22-SEP-99
165	24-SEP-99			26-AUG-99	23-SEP-99
166	24-SEP-99			26-AUG-99	23-SEP-99
167	24-SEP-99			26-AUG-99	23-SEP-99
168	24-SEP-99			26-AUG-99	23-SEP-99
169	08-OCT-99			26-AUG-99	23-SEP-99
170	08-OCT-99			26-AUG-99	23-SEP-99
171	08-OCT-99			26-AUG-99	23-SEP-99
173	22-OCT-99			26-AUG-99	23-SEP-99
174	22-OCT-99			26-AUG-99	23-SEP-99
175	22-OCT-99			26-AUG-99	23-SEP-99

MORTALITY DATA  
FEMALES  
GROUP 5 (T-7253)

ANIMAL	SCHEDULED NECROPSY	KILLED IN EXTREMIS	OTHER	TREATMENT FROM	TO
177	23-SEP-99				
178	23-SEP-99			26-AUG-99	22-SEP-99
179	23-SEP-99			26-AUG-99	22-SEP-99
180	23-SEP-99			26-AUG-99	22-SEP-99
181				26-AUG-99	22-SEP-99
182	24-SEP-99		24-SEP-99	26-AUG-99	23-SEP-99
183	24-SEP-99			26-AUG-99	23-SEP-99
184	24-SEP-99			26-AUG-99	23-SEP-99
185	08-OCT-99			26-AUG-99	23-SEP-99
186	08-OCT-99			26-AUG-99	23-SEP-99
187	08-OCT-99			26-AUG-99	23-SEP-99
189	22-OCT-99			26-AUG-99	23-SEP-99
190	22-OCT-99			26-AUG-99	23-SEP-99
191	22-OCT-99			26-AUG-99	23-SEP-99

**CLINICAL SIGNS  
MALES  
GROUP 1 (VEHICLE CONTROL)**

SIGN (MAX.GRADE)	TREATMENT
	WEEKS: 1.....2.....3.....4.....5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB
ANIMAL 1	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 2	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 3	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 4	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 5	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 6	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 7	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 8	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 9	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 10	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 11	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 12	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 13	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 14	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 15	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 16	
-----	
NO CLINICAL SIGNS NOTED	

**CLINICAL SIGNS, DAILY  
MALES  
GROUP 1 (VEHICLE CONTROL)**

SIGN (MAX.GRADE) (LOCATION)	RECOVERY WEEKS: 1.....2.....3.....4.....5.
ANIMAL 5 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 6 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 7 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 8 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 9 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 10 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 11 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 13 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 14 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 15 ----- NO CLINICAL SIGNS NOTED	

**CLINICAL SIGNS  
MALES  
GROUP 2 (T-7250)**

	TREATMENT
WEEKS:	1.....2.....3.....4.....5.
DAYS:	1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.
TIME:	ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB

ANIMAL 17  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 18  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 19  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 20  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 21  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 22  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 23  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 24  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 25  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 26  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 27  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 28  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 29  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 30  
-----  
SKIN / FUR / PLUMAGE  
RED STAINING (3)  
(HEAD) G: .....

ANIMAL 31  
-----  
SKIN / FUR / PLUMAGE  
RED STAINING (3)  
(NECK) G: .....11.....

ANIMAL 32  
-----  
NO CLINICAL SIGNS NOTED

G: Highest grades  
Time after treatment (H.Mi) A: 0.00 B: 4.00

**CLINICAL SIGNS, DAILY  
MALES  
GROUP 2 (T-7250)**

SIGN (MAX.GRADE)	RECOVERY
(LOCATION)	WEEKS: 1.....2.....3.....4.....5.

---

ANIMAL 21

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 22

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 23

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 24

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 25

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 26

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 27

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 29

-----  
SKIN / FUR / PLUMAGE  
RED STAINING (3)  
(HEAD)

G: .....111111.....

ANIMAL 30

-----  
SKIN / FUR / PLUMAGE  
RED STAINING (3)  
(HEAD)

G: ...11111111.....

ANIMAL 31

-----  
SKIN / FUR / PLUMAGE  
RED STAINING (3)  
(HEAD)

G: .....111111.....

---

G: Highest daily grades



**CLINICAL SIGNS  
MALES  
GROUP 3 (T-7251)**

TREATMENT  
 WEEKS: 1.....2.....3.....4.....5.  
 DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.  
 TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB

SIGN (MAX.GRADE)	
ANIMAL 33	
-----	
SKIN / FUR / PLUMAGE	
ALOPECIA (3)	G: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : .
(CHEEK LEFT)	G: .....111111..
ALOPECIA (3)	G: : : : : : : : : : : : : : : : : : : : : : : : : : : .
(CHEEK RIGHT)	G: .....111111..
ANIMAL 34	
-----	
SKIN / FUR / PLUMAGE	
ALOPECIA (3)	G: : : : : : : : : : : : : : : : : : : : : : : : : : : .
(NECK)	G: .....1111111111..
ANIMAL 35	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 36	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 37	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 38	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 39	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 40	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 41	
-----	
SKIN / FUR / PLUMAGE	
SWELLING (3)	G: : : : : : : : : : : : : : : : : : : : : .
(PERIORBITAL REGION RIGHT)	G: .....1111111111..
VARIOUS	
EYE RIGHT, INJURED (1)	G: .....1111111111..
DARK (3)	G: : : : : : : : : : .
(EYE RIGHT)	G: .....1111111111..
ANIMAL 42	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 43	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 44	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 45	
-----	
NO CLINICAL SIGNS NOTED	

G: Highest grades  
 Time after treatment (H.Mi) A: 0.00 B: 4.00



**CLINICAL SIGNS, DAILY  
MALES  
GROUP 3 (T-7251)**

SIGN (MAX.GRADE)		RECOVERY					
(LOCATION)		WEEKS:	1.....	2.....	3.....	4.....	5.

---

ANIMAL 37

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 38

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 39

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 40

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 41

-----  
SKIN / FUR / PLUMAGE  
SWELLING (3) G: 11.....  
(PERIORBITAL REGION RIGHT)  
VARIOUS  
EYE RIGHT, INJURED (1) G: 111111111...11.  
DULL (3) G: .....11111.  
(EYE RIGHT)  
DARK (3) G: 11.....  
(EYE RIGHT)

ANIMAL 42

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 43

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 45

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 46

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 47

-----  
NO CLINICAL SIGNS NOTED

---

G: Highest daily grades



**CLINICAL SIGNS, DAILY  
MALES  
GROUP 4 (T-7252)**

SIGN (MAX.GRADE) RECOVERY  
(LOCATION) WEEKS: 1.....2.....3.....4.....5.

---

ANIMAL 53  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 54  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 55  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 56  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 57  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 58  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 59  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 61  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 62  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 63  
-----  
NO CLINICAL SIGNS NOTED



**CLINICAL SIGNS  
MALES  
GROUP 5 (T-7253)**

SIGN (MAX.GRADE)	TREATMENT																																				
	WEEKS:	1.	2.	3.	4.	5.	1.	2.	3.	4.	5.	6.	7.	1.	2.	3.	4.	5.	6.	7.	1.	2.	3.	4.	5.	6.	7.	1.	2.	3.	4.	5.	6.	7.	1.		
	TIME:	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B

---

ANIMAL 79  
-----  
NO CLINICAL SIGNS NOTED

ANIMAL 80  
-----  
NO CLINICAL SIGNS NOTED

**CLINICAL SIGNS, DAILY  
MALES  
GROUP 5 (T-7253)**

SIGN (MAX.GRADE)	RECOVERY
(LOCATION)	WEEKS: 1.....2.....3.....4.....5.

---

ANIMAL 69

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 70

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 71

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 72

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 73

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 74

-----  
SKIN / FUR / PLUMAGE

SCABS (3) G: 1111111111111111.

(NECK)  
WOUND (3) G: .....111...

(NECK)  
RED STAINING (3) G: 11.....  
(NECK)

ANIMAL 75

-----  
SKIN / FUR / PLUMAGE

RED STAINING (3) G: 111.....  
(NECK)

ANIMAL 77

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 78

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 79

-----  
NO CLINICAL SIGNS NOTED

---

G: Highest daily grades







**CLINICAL SIGNS, DAILY  
MALES  
GROUP 6 (T-7254)**

SIGN (MAX.GRADE) (LOCATION)	RECOVERY WEEKS: 1.....2.....3.....4.....5.
--------------------------------	-----------------------------------------------

---

ANIMAL 85

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 86

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 87

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 88

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 89

-----  
POSTURE

HUNCHED POSTURE (1)	G: ...111.....
SKIN / FUR / PLUMAGE	
RED STAINING (3)	G: 111111111111111.
(NECK)	

ANIMAL 90

-----  
POSTURE

HUNCHED POSTURE (1)	G: ...11.....
SKIN / FUR / PLUMAGE	
RED STAINING (3)	G: 111111111111111.
(NECK)	

ANIMAL 91

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 93

-----  
SKIN / FUR / PLUMAGE

PILOERECTOR (1)	G: 11111.....
RED STAINING (3)	G: 111111111.....
(BACK)	
RED STAINING (3)	G: 111111111111111.....
(NECK)	

ANIMAL 94

-----  
SKIN / FUR / PLUMAGE

RED STAINING (3)	G: ..1111111.....
(BACK)	

ANIMAL 95

-----  
SKIN / FUR / PLUMAGE

RED STAINING (3)	G: 111111111.....
(BACK)	
RED STAINING (3)	G: .....1111.....
(FLANK RIGHT)	

G: Highest daily grades













**CLINICAL SIGNS, DAILY  
FEMALES  
GROUP 1 (VEHICLE CONTROL)**

SIGN (MAX.GRADE) (LOCATION)	RECOVERY WEEKS: 1.....2.....3.....4.....5.
--------------------------------	-----------------------------------------------

---

ANIMAL 117

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 118

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 119

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 120

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 121

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 122

-----  
SKIN / FUR / PLUMAGE  
SWELLING (3) G: .111.....  
(PERIORBITAL REGION RIGHT)  
VARIOUS  
BULGING EYE (1) G: 111.....  
(EYE RIGHT)

ANIMAL 123

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 125

-----  
NO CLINICAL SIGNS NOTED

ANIMAL 126

-----  
SKIN / FUR / PLUMAGE  
ALOPECIA (3) G: 1111111.....  
(ABDOMEN)

ANIMAL 127

-----  
NO CLINICAL SIGNS NOTED

G: Highest daily grades





**CLINICAL SIGNS, DAILY  
FEMALES  
GROUP 2 (T-7250)**

SIGN (MAX.GRADE) (LOCATION)	RECOVERY				
	WEEKS: 1.....	2.....	3.....	4.....	5.....
<hr/>					
ANIMAL 133					
-----					
NO CLINICAL SIGNS NOTED					
ANIMAL 134					
-----					
NO CLINICAL SIGNS NOTED					
ANIMAL 135					
-----					
NO CLINICAL SIGNS NOTED					
ANIMAL 136					
-----					
NO CLINICAL SIGNS NOTED					
ANIMAL 137					
-----					
POSTURE					
HUNCHED POSTURE (1)	G: .11.....				
ANIMAL 138					
-----					
POSTURE					
HUNCHED POSTURE (1)	G: .11.....				
SKIN / FUR / PLUMAGE					
RED STAINING (3)	G: .....111.....				
(HEAD)					
RED STAINING (3)	G: 1111111...1111.				
(NECK)					
ANIMAL 139					
-----					
SKIN / FUR / PLUMAGE					
RED STAINING (3)	G: 1111111111.....				
(HEAD)					
RED STAINING (3)	G: 111.....				
(NECK)					
ANIMAL 141					
-----					
SKIN / FUR / PLUMAGE					
SWELLING (3)	G: .111.....				
(PERIORBITAL REGION RIGHT)					
VARIOUS					
BULGING EYE (1)	G: 111.....				
(EYE RIGHT)					
ANIMAL 142					
-----					
NO CLINICAL SIGNS NOTED					
ANIMAL 143					
-----					
NO CLINICAL SIGNS NOTED					

G: Highest daily grades





**CLINICAL SIGNS, DAILY  
FEMALES  
GROUP 3 (T-7251)**

SIGN (MAX.GRADE) (LOCATION)	RECOVERY WEEKS: 1.....2.....3.....4.....5.
ANIMAL 149	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 150	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 151	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 152	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 153	
-----	
NO CLINICAL SIGNS NOTED	
ANIMAL 154	
-----	
SKIN / FUR / PLUMAGE	
RED STAINING (3) (HEAD)	G: .111111111111111.
RED STAINING (3) (NECK)	G: 111111111111111.
ANIMAL 155	
-----	
SKIN / FUR / PLUMAGE	
RED STAINING (3) (HEAD)	G: 111111111111111.
RED STAINING (3) (NECK)	G: 111111111111111.
ANIMAL 157	
-----	
SKIN / FUR / PLUMAGE	
ALOPECIA (3) (HEAD)	G: 1111111.....
RED STAINING (3) (NECK)	G: ....111111111111111.....
ANIMAL 158	
-----	
SKIN / FUR / PLUMAGE	
RED STAINING (3) (HEAD)	G: .11111111111111111111.....
ANIMAL 159	
-----	
SKIN / FUR / PLUMAGE	
RED STAINING (3) (HEAD)	G: .11111111111111111111.....
RED STAINING (3) (NECK)	G: 11111111111111111111.....

G: Highest daily grades







**CLINICAL SIGNS, DAILY  
FEMALES  
GROUP 4 (T-7252)**

SIGN (MAX.GRADE) (LOCATION)	RECOVERY WEEKS: 1.....2.....3.....4.....5.
ANIMAL 165 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 166 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 167 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 168 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 169 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 170 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 171 ----- SKIN / FUR / PLUMAGE ALOPECIA (3)                   G: .....1111111. (NECK) ALOPECIA (3)                   G: 1111111..... (SHOULDER RIGHT)	
ANIMAL 173 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 174 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 175 ----- NO CLINICAL SIGNS NOTED	

G: Highest daily grades





**CLINICAL SIGNS, DAILY  
FEMALES  
GROUP 5 (T-7253)**

SIGN (MAX.GRADE) (LOCATION)	RECOVERY WEEKS: 1.....2.....3.....4.....5.
ANIMAL 181 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 182 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 183 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 184 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 185 ----- SKIN / FUR / PLUMAGE RED STAINING (3) G: .1111111111111. (HEAD) RED STAINING (3) G: 1111111111111. (NECK)	
ANIMAL 186 ----- SKIN / FUR / PLUMAGE RED STAINING (3) G: 1111111..... (NECK)	
ANIMAL 187 ----- SKIN / FUR / PLUMAGE RED STAINING (3) G: 1111111111111. (HEAD) RED STAINING (3) G: 1111111111111. (NECK)	
ANIMAL 189 ----- SKIN / FUR / PLUMAGE ALOPECIA (3) G: 11111111111111111111111111111111 (FLANK LEFT)	
ANIMAL 190 ----- NO CLINICAL SIGNS NOTED	
ANIMAL 191 ----- NO CLINICAL SIGNS NOTED	

G: Highest daily grades

**BODY WEIGHTS (GRAM)**  
**MALES**

**GROUP 1 (VEHICLE CONTROL)**

		TREATMENT									
DAYS		1	5	8	12	15	19	22	25	28	
WEEKS		1	1	2	2	3	3	4	4	4	
ANIMAL											
1		231	254	277	304	331	348	364	370	375	
2		229	254	278	298	324	336	351	365	372	
3		231	261	283	309	336	364	384	397	409	
4		225	249	268	291	310	330	348	364	370	
5		227	253	286	314	344	358	379	390	404	
6		232	260	272	297	305	318	337	346	352	
7		231	257	276	294	320	338	355	364	369	
8		227	252	279	308	331	354	375	381	392	
9		218	250	261	302	305	346	371	383	394	
10		203	225	230	260	261	293	315	325	332	
11		229	260	274	312	323	359	387	405	414	
12		---	---	---	---	---	---	---	---	---	
13		211	240	252	282	283	311	328	342	353	
14		219	245	260	293	306	336	360	371	384	
15		214	243	255	294	289	320	336	350	356	
16		---	---	---	---	---	---	---	---	---	

		RECOVERY									
DAYS		1	5	8	12	14	19	22	25	28	
WEEKS		1	1	2	2	2	3	4	4	4	
ANIMAL											
1		---	---	---	---	---	---	---	---	---	
2		---	---	---	---	---	---	---	---	---	
3		---	---	---	---	---	---	---	---	---	
4		---	---	---	---	---	---	---	---	---	
5		---	---	---	---	---	---	---	---	---	
6		---	---	---	---	---	---	---	---	---	
7		---	---	---	---	---	---	---	---	---	
8		---	---	---	---	---	---	---	---	---	
9		369	408	427	441	435	---	---	---	---	
10		308	342	359	364	366	---	---	---	---	
11		391	438	465	479	479	---	---	---	---	
12		---	---	---	---	---	---	---	---	---	
13		329	357	375	382	389	---	---	---	---	
14		360	401	415	429	427	390	396	403	401	
15		334	367	377	383	380	438	455	463	461	
16		---	---	---	---	---	387	395	397	396	
		---	---	---	---	---	---	---	---	---	

**BODY WEIGHTS (GRAM)  
MALES**

**GROUP 2 (T-7250)**

		TREATMENT								
DAYS		1	5	8	12	15	19	22	25	28
WEEKS		1	1	2	2	3	3	4	4	4
ANIMAL		1	1	2	2	3	3	4	4	4
17		227	261	284	316	336	346	364	376	384
18		222	247	266	295	312	328	343	360	362
19		212	241	259	284	298	322	331	343	353
20		218	250	269	294	319	340	354	367	376
21		218	248	272	303	322	346	363	381	388
22		239	264	291	324	355	379	404	413	421
23		233	267	297	335	370	403	429	446	462
24		214	239	262	292	307	335	348	361	367
25		204	238	249	274	277	298	315	334	342
26		220	253	260	299	297	333	351	374	379
27		222	253	263	297	292	326	345	363	370
28		---	---	---	---	---	---	---	---	---
29		223	255	261	302	294	328	336	354	362
30		220	257	262	300	301	337	353	374	382
31		209	238	247	279	277	310	321	344	348
32		---	---	---	---	---	---	---	---	---

		RECOVERY								
DAYS		1	5	8	12	14	19	22	25	28
WEEKS		1	1	2	2	2	3	4	4	4
ANIMAL		1	1	2	2	2	3	4	4	4
17		---	---	---	---	---	---	---	---	---
18		---	---	---	---	---	---	---	---	---
19		---	---	---	---	---	---	---	---	---
20		---	---	---	---	---	---	---	---	---
21		---	---	---	---	---	---	---	---	---
22		---	---	---	---	---	---	---	---	---
23		---	---	---	---	---	---	---	---	---
24		---	---	---	---	---	---	---	---	---
25		319	354	366	380	388	---	---	---	---
26		353	395	409	421	429	---	---	---	---
27		347	383	405	411	411	---	---	---	---
28		---	---	---	---	---	---	---	---	---
29		333	358	375	379	382	393	395	405	401
30		356	399	414	431	432	451	453	463	463
31		323	365	374	392	389	412	423	432	439
32		---	---	---	---	---	---	---	---	---

**BODY WEIGHTS (GRAM)  
MALES**

**GROUP 3 (T-7251)**

		TREATMENT								
DAYS		1	5	8	12	15	19	22	25	28
WEEKS		1	1	2	2	3	3	4	4	4
ANIMAL		1	1	2	2	3	3	4	4	4
33		221	248	272	296	316	331	348	352	366
34		223	251	267	293	317	333	348	359	371
35		247	283	308	340	362	395	424	433	446
36		200	220	231	250	266	280	292	300	306
37		216	241	263	287	306	321	341	349	355
38		211	241	260	286	304	324	341	349	357
39		220	241	259	280	301	318	336	339	345
40		216	241	261	284	302	318	336	346	360
41		203	230	231	271	272	313	326	331	338
42		226	260	274	313	320	361	382	399	410
43		216	245	251	292	285	327	338	350	358
44		---	---	---	---	---	---	---	---	---
45		204	234	237	274	267	298	312	324	332
46		192	223	231	272	265	307	321	336	348
47		212	247	254	291	292	317	333	346	358
48		---	---	---	---	---	---	---	---	---

		RECOVERY								
DAYS		1	5	8	12	14	19	22	25	28
WEEKS		1	1	2	2	2	3	4	4	4
ANIMAL		1	1	2	2	2	3	4	4	4
33		---	---	---	---	---	---	---	---	---
34		---	---	---	---	---	---	---	---	---
35		---	---	---	---	---	---	---	---	---
36		---	---	---	---	---	---	---	---	---
37		---	---	---	---	---	---	---	---	---
38		---	---	---	---	---	---	---	---	---
39		---	---	---	---	---	---	---	---	---
40		---	---	---	---	---	---	---	---	---
41		318	342	357	363	370	---	---	---	---
42		382	427	454	467	462	---	---	---	---
43		336	372	387	401	403	---	---	---	---
44		---	---	---	---	---	---	---	---	---
45		304	336	348	355	359	---	---	---	---
46		318	351	360	376	380	374	385	389	384
47		332	362	374	381	376	397	416	420	422
48		---	---	---	---	---	394	411	408	410
		---	---	---	---	---	---	---	---	---



**BODY WEIGHTS (GRAM)  
MALES**

**GROUP 4 (T-7252)**

DAYS WEEKS ANIMAL	TREATMENT								
	1	5	8	12	15	19	22	25	28
	1	1	2	2	3	3	4	4	4
49	226	254	274	305	331	348	361	374	379
50	227	245	263	302	321	342	358	371	374
51	226	257	282	322	345	365	383	397	410
52	234	252	274	295	325	345	357	364	376
53	243	271	297	321	348	367	397	410	421
54	211	235	250	274	296	307	323	338	343
55	237	270	296	332	360	376	395	411	412
56	236	267	294	320	350	370	385	393	423
57	225	251	259	292	291	327	345	347	366
58	216	249	252	291	292	337	354	362	379
59	212	235	237	263	261	295	308	317	324
60	---	---	---	---	---	---	---	---	---
61	234	269	278	314	312	349	369	382	401
62	226	259	274	303	310	351	370	383	392
63	233	276	299	336	349	393	379	408	423
64	---	---	---	---	---	---	---	---	---

DAYS WEEKS ANIMAL	RECOVERY								
	1	5	8	12	14	19	22	25	28
	1	1	2	2	2	3	4	4	4
49	---	---	---	---	---	---	---	---	---
50	---	---	---	---	---	---	---	---	---
51	---	---	---	---	---	---	---	---	---
52	---	---	---	---	---	---	---	---	---
53	---	---	---	---	---	---	---	---	---
54	---	---	---	---	---	---	---	---	---
55	---	---	---	---	---	---	---	---	---
56	---	---	---	---	---	---	---	---	---
57	340	379	397	403	406	---	---	---	---
58	348	390	418	431	427	---	---	---	---
59	304	334	345	349	349	---	---	---	---
60	---	---	---	---	---	---	---	---	---
61	372	408	426	437	439	---	---	---	---
62	367	409	438	446	435	453	467	469	473
63	397	465	490	516	508	544	478	477	474
64	---	---	---	---	---	---	564	567	568
	---	---	---	---	---	---	---	---	---

**BODY WEIGHTS (GRAM)**  
**MALES**

**GROUP 5 (T-7253)**

DAYS WEEKS ANIMAL	TREATMENT									
	1	5	8	12	15	19	22	25	28	
	1	1	2	2	3	3	4	4	4	4
65	217	237	256	278	298	313	327	331	336	
66	235	261	280	304	323	338	345	351	357	
67	225	258	280	304	320	339	353	363	377	
68	224	256	285	322	356	373	392	404	407	
69	232	258	279	298	323	342	356	365	369	
70	233	259	286	309	335	346	367	374	382	
71	222	253	274	300	325	342	362	371	377	
72	233	261	288	318	348	366	380	392	402	
73	194	221	227	251	252	279	298	301	307	
74	214	247	257	301	308	348	364	387	387	
75	222	254	256	296	300	335	352	370	383	
76	---	---	---	---	---	---	---	---	---	
77	217	249	225	288	289	328	349	361	372	
78	213	235	218	271	275	295	308	318	324	
79	220	250	236	294	298	335	357	367	382	
80	---	---	---	---	---	---	---	---	---	

DAYS WEEKS ANIMAL	RECOVERY									
	1	5	8	12	14	19	22	25	28	
	1	1	2	2	2	3	4	4	4	4
65	---	---	---	---	---	---	---	---	---	
66	---	---	---	---	---	---	---	---	---	
67	---	---	---	---	---	---	---	---	---	
68	---	---	---	---	---	---	---	---	---	
69	---	---	---	---	---	---	---	---	---	
70	---	---	---	---	---	---	---	---	---	
71	---	---	---	---	---	---	---	---	---	
72	---	---	---	---	---	---	---	---	---	
73	287	317	325	334	337	---	---	---	---	
74	358	411	438	454	463	---	---	---	---	
75	352	392	413	429	435	---	---	---	---	
76	---	---	---	---	---	---	---	---	---	
77	348	389	404	418	421	431	443	442	445	
78	301	340	358	372	375	394	406	408	407	
79	358	405	423	440	451	470	480	487	501	
80	---	---	---	---	---	---	---	---	---	

**BODY WEIGHTS (GRAM)  
MALES**

**GROUP 6 (T-7254)**

DAYS WEEKS ANIMAL	TREATMENT								
	1	5	8	12	15	19	22	25	28
	1	1	2	2	3	3	4	4	4
81	225	255	266	285	299	305	311	321	322
82	227	248	262	273	291	286	290	293	289
83	227	259	279	308	328	348	354	360	368
84	215	238	258	277	302	306	317	320	308
85	228	257	286	314	337	352	367	381	382
86	223	257	283	308	333	353	376	385	391
87	212	230	249	265	276	278	280	292	293
88	215	237	257	278	298	305	313	325	333
89	212	229	222	254	251	265	275	277	281
90	209	226	221	245	235	250	256	252	243
91	188	202	197	219	217	241	252	254	252
92	---	---	---	---	---	---	---	---	---
93	213	234	220	255	238	263	270	269	261
94	225	253	266	289	291	306	324	327	335
95	206	240	249	276	280	311	320	325	335
96	---	---	---	---	---	---	---	---	---

DAYS WEEKS ANIMAL	RECOVERY								
	1	5	8	12	14	19	22	25	28
	1	1	2	2	2	3	4	4	4
81	---	---	---	---	---	---	---	---	---
82	---	---	---	---	---	---	---	---	---
83	---	---	---	---	---	---	---	---	---
84	---	---	---	---	---	---	---	---	---
85	---	---	---	---	---	---	---	---	---
86	---	---	---	---	---	---	---	---	---
87	---	---	---	---	---	---	---	---	---
88	---	---	---	---	---	---	---	---	---
89	255	285	305	318	326	---	---	---	---
90	223	252	277	290	295	---	---	---	---
91	234	268	286	294	295	---	---	---	---
92	---	---	---	---	---	---	---	---	---
93	238	278	294	302	299	---	---	---	---
94	310	348	367	372	382	310	319	314	322
95	312	354	371	384	383	404	421	419	425
96	---	---	---	---	---	405	417	417	425

**BODY WEIGHTS (GRAM)**  
**MALES**

**GROUP 7 (T-7255)**

TREATMENT									
DAYS	1	5	8	12	15	19	22	25	28
WEEKS	1	1	2	2	3	3	4	4	4
ANIMAL									
97	221	233	217	156	---	---	---	---	---
98	222	223	198	---	---	---	---	---	---
99	225	236	227	168	---	---	---	---	---
100	232	239	218	159	---	---	---	---	---
101	218	229	208	159	---	---	---	---	---
102	248	244	208	---	---	---	---	---	---
103	232	250	230	191	---	---	---	---	---
104	238	237	226	171	---	---	---	---	---
105	204	215	192	149	---	---	---	---	---
106	215	229	200	154	---	---	---	---	---
107	211	218	187	---	---	---	---	---	---
108	---	---	---	---	---	---	---	---	---
109	216	233	205	164	---	---	---	---	---
110	208	225	195	147	---	---	---	---	---
111	215	227	198	---	---	---	---	---	---
112	---	---	---	---	---	---	---	---	---

RECOVERY									
DAYS	1	5	8	12	14	19	22	25	28
WEEKS	1	1	2	2	2	3	4	4	4
ANIMAL									
97	---	---	---	---	---	---	---	---	---
98	---	---	---	---	---	---	---	---	---
99	---	---	---	---	---	---	---	---	---
100	---	---	---	---	---	---	---	---	---
101	---	---	---	---	---	---	---	---	---
102	---	---	---	---	---	---	---	---	---
103	---	---	---	---	---	---	---	---	---
104	---	---	---	---	---	---	---	---	---
105	---	---	---	---	---	---	---	---	---
106	---	---	---	---	---	---	---	---	---
107	---	---	---	---	---	---	---	---	---
108	---	---	---	---	---	---	---	---	---
109	---	---	---	---	---	---	---	---	---
110	---	---	---	---	---	---	---	---	---
111	---	---	---	---	---	---	---	---	---
112	---	---	---	---	---	---	---	---	---

**BODY WEIGHTS (GRAM)  
FEMALES**

**GROUP 1 (VEHICLE CONTROL)**

DAYS WEEKS ANIMAL	TREATMENT								
	1 1	5 1	8 2	12 2	15 3	19 3	22 4	25 4	28 4
113	184	195	205	224	233	243	248	253	255
114	178	186	193	203	216	220	226	234	239
115	164	176	174	218	223	207	214	217	212
116	187	197	200	218	198	207	214	217	212
117	191	200	213	231	241	236	246	256	258
118	177	184	205	216	241	248	260	256	270
119	187	199	212	226	230	236	250	248	255
120	179	185	187	205	229	239	256	264	266
121	195	197	199	222	201	214	219	232	235
122	193	198	199	227	204	233	233	247	253
					208	243	260	272	263
123	181	194	194	218	203	233	246	258	266
124	---	---	---	---	---	---	---	---	---
125	168	175	172	197	185	208	220	223	229
126	192	201	200	226	208	242	253	263	263
127	171	189	190	212	197	232	239	251	250
128	---	---	---	---	---	---	---	---	---

DAYS WEEKS ANIMAL	RECOVERY								
	1 1	5 1	8 2	12 2	14 2	19 3	22 4	25 4	28 4
113	---	---	---	---	---	---	---	---	---
114	---	---	---	---	---	---	---	---	---
115	---	---	---	---	---	---	---	---	---
116	---	---	---	---	---	---	---	---	---
117	---	---	---	---	---	---	---	---	---
118	---	---	---	---	---	---	---	---	---
119	---	---	---	---	---	---	---	---	---
120	---	---	---	---	---	---	---	---	---
121	228	255	268	269	267	---	---	---	---
122	239	276	283	281	278	---	---	---	---
123	242	274	282	287	286	---	---	---	---
124	---	---	---	---	---	---	---	---	---
125	211	229	237	240	243	249	253	250	253
126	240	274	282	289	284	299	294	297	300
127	229	256	257	266	264	272	270	282	281
128	---	---	---	---	---	---	---	---	---

**BODY WEIGHTS (GRAM)  
FEMALES**

**GROUP 2 (T-7250)**

DAYS WEEKS ANIMAL	TREATMENT									
	1	5	8	12	15	19	22	25	28	
	1	1	2	2	3	3	4	4	4	4
129	188	200	208	224	237	240	245	253	262	
130	158	169	177	188	197	202	209	201	206	
131	178	189	198	212	217	225	228	241	246	
132	192	200	210	219	230	233	251	252	253	
133	189	198	204	226	242	252	268	268	268	
134	191	200	206	228	245	249	268	275	285	
135	189	198	207	228	235	247	267	271	272	
136	184	188	194	208	220	222	236	242	229	
137	170	182	188	215	196	232	233	243	250	
138	173	182	186	207	189	220	220	228	235	
139	188	202	205	227	216	249	266	268	271	
140	---	---	---	---	---	---	---	---	---	
141	193	201	199	222	202	233	252	258	262	
142	172	177	177	200	186	210	217	223	225	
143	187	196	196	221	204	237	249	247	255	
144	---	---	---	---	---	---	---	---	---	

DAYS WEEKS ANIMAL	RECOVERY									
	1	5	8	12	14	19	22	25	28	
	1	1	2	2	2	3	4	4	4	4
129	---	---	---	---	---	---	---	---	---	
130	---	---	---	---	---	---	---	---	---	
131	---	---	---	---	---	---	---	---	---	
132	---	---	---	---	---	---	---	---	---	
133	---	---	---	---	---	---	---	---	---	
134	---	---	---	---	---	---	---	---	---	
135	---	---	---	---	---	---	---	---	---	
136	---	---	---	---	---	---	---	---	---	
137	223	256	262	263	266	---	---	---	---	
138	212	234	237	245	246	---	---	---	---	
139	248	278	283	282	279	---	---	---	---	
140	---	---	---	---	---	---	---	---	---	
141	242	270	274	281	277	291	289	297	297	
142	208	231	238	243	248	254	263	264	262	
143	232	260	260	262	268	276	288	280	272	
144	---	---	---	---	---	---	---	---	---	

**BODY WEIGHTS (GRAM)  
FEMALES**

**GROUP 3 (T-7251)**

DAYS WEEKS ANIMAL	TREATMENT								
	1	5	8	12	15	19	22	25	28
	1	1	2	2	3	3	4	4	4
145	178	185	195	209	212	219	217	228	233
146	187	199	208	227	223	239	252	261	263
147	182	191	202	215	222	228	231	241	247
148	181	188	191	202	202	214	223	235	237
149	191	204	212	235	237	252	263	276	280
150	178	185	195	209	216	222	224	229	235
151	195	198	218	234	244	260	271	265	275
152	173	185	198	211	214	218	219	232	237
153	163	171	172	200	181	211	212	224	231
154	201	208	212	236	218	253	255	274	279
155	192	206	213	236	212	247	260	272	280
156	---	---	---	---	---	---	---	---	---
157	182	190	194	215	201	220	233	240	242
158	192	203	208	235	215	251	250	268	269
159	176	188	188	211	195	229	242	245	246
160	---	---	---	---	---	---	---	---	---

DAYS WEEKS ANIMAL	RECOVERY								
	1	5	8	12	14	19	22	25	28
	1	1	2	2	2	3	4	4	4
145	---	---	---	---	---	---	---	---	---
146	---	---	---	---	---	---	---	---	---
147	---	---	---	---	---	---	---	---	---
148	---	---	---	---	---	---	---	---	---
149	---	---	---	---	---	---	---	---	---
150	---	---	---	---	---	---	---	---	---
151	---	---	---	---	---	---	---	---	---
152	---	---	---	---	---	---	---	---	---
153	---	---	---	---	---	---	---	---	---
154	253	277	293	297	295	---	---	---	---
155	257	287	289	302	301	---	---	---	---
156	---	---	---	---	---	---	---	---	---
157	227	257	258	261	259	272	271	275	275
158	245	279	283	287	296	306	304	306	317
159	223	259	261	269	269	283	286	289	286
160	---	---	---	---	---	---	---	---	---

**BODY WEIGHTS (GRAM)  
FEMALES**

**GROUP 4 (T-7252)**

DAYS WEEKS ANIMAL	TREATMENT								
	1	5	8	12	15	19	22	25	28
	1	1	2	2	3	3	4	4	4
161	192	202	209	230	232	237	243	249	256
162	176	189	199	211	219	221	230	226	235
163	194	198	207	221	230	236	238	252	254
164	164	168	176	186	186	194	209	213	210
165	193	207	222	235	236	246	265	268	270
166	177	186	203	215	224	230	239	249	250
167	196	207	217	237	251	262	276	275	287
168	167	173	182	190	195	199	212	217	216
169	178	193	192	212	195	223	226	224	235
170	198	218	219	250	226	268	283	281	292
171	197	211	211	230	221	252	272	273	274
172	---	---	---	---	---	---	---	---	---
173	173	179	173	196	177	203	213	220	228
174	204	217	208	243	231	268	287	296	295
175	189	203	199	236	219	253	267	273	276
176	---	---	---	---	---	---	---	---	---

DAYS WEEKS ANIMAL	RECOVERY								
	1	5	8	12	14	19	22	25	28
	1	1	2	2	2	3	4	4	4
161	---	---	---	---	---	---	---	---	---
162	---	---	---	---	---	---	---	---	---
163	---	---	---	---	---	---	---	---	---
164	---	---	---	---	---	---	---	---	---
165	---	---	---	---	---	---	---	---	---
166	---	---	---	---	---	---	---	---	---
167	---	---	---	---	---	---	---	---	---
168	---	---	---	---	---	---	---	---	---
169	218	246	247	251	257	---	---	---	---
170	264	305	311	315	316	---	---	---	---
171	258	291	292	301	305	---	---	---	---
172	---	---	---	---	---	---	---	---	---
173	207	237	237	244	240	255	254	254	259
174	279	315	321	334	336	347	363	367	373
175	255	292	299	303	299	316	314	329	319
176	---	---	---	---	---	---	---	---	---



**BODY WEIGHTS (GRAM)  
FEMALES**

**GROUP 5 (T-7253)**

DAYS WEEKS ANIMAL	TREATMENT								
	1	5	8	12	15	19	22	25	28
	1	1	2	2	3	3	4	4	4
177	174	181	190	204	212	213	230	237	237
178	179	189	199	214	226	233	246	239	251
179	174	182	191	206	209	220	231	233	237
180	182	188	198	212	214	224	236	244	247
181	175	182	193	207	216	228	232	228	233
182	182	187	193	206	208	213	221	230	234
183	170	183	194	207	217	225	232	239	245
184	163	173	178	187	198	204	214	210	210
185	188	197	205	225	208	241	241	260	264
186	186	195	196	211	199	222	236	243	241
187	189	202	201	222	206	240	238	246	254
188	---	---	---	---	---	---	---	---	---
189	177	188	184	202	184	209	216	221	222
190	189	197	209	227	212	247	260	259	266
191	194	205	211	237	220	255	266	270	274
192	---	---	---	---	---	---	---	---	---

DAYS WEEKS ANIMAL	RECOVERY								
	1	5	8	12	14	19	22	25	28
	1	1	2	2	2	3	4	4	4
177	---	---	---	---	---	---	---	---	---
178	---	---	---	---	---	---	---	---	---
179	---	---	---	---	---	---	---	---	---
180	---	---	---	---	---	---	---	---	---
181	---	---	---	---	---	---	---	---	---
182	---	---	---	---	---	---	---	---	---
183	---	---	---	---	---	---	---	---	---
184	---	---	---	---	---	---	---	---	---
185	239	262	277	288	285	---	---	---	---
186	221	258	259	267	265	---	---	---	---
187	230	255	271	276	273	---	---	---	---
188	---	---	---	---	---	---	---	---	---
189	203	230	230	233	236	241	242	250	254
190	240	279	285	287	285	303	302	301	305
191	255	287	289	295	298	308	303	311	311
192	---	---	---	---	---	---	---	---	---

**BODY WEIGHT GAIN (%)**  
**MALES**

**GROUP 1 (VEHICLE CONTROL)**

DAYS WEEKS ANIMAL	TREATMENT									
	1	5	8	12	15	19	22	25	28	
	1	1	2	2	3	3	4	4	4	4
1	0	10	20	32	43	51	58	60	62	
2	0	11	21	30	41	47	53	59	62	
3	0	13	23	34	45	58	66	72	77	
4	0	11	19	29	38	47	55	62	64	
5	0	11	26	38	52	58	67	72	78	
6	0	12	17	28	31	37	45	49	52	
7	0	11	19	27	39	46	54	58	60	
8	0	11	23	36	46	56	65	68	73	
9	0	15	20	39	40	59	70	76	81	
10	0	11	13	28	29	44	55	60	64	
11	0	14	20	36	41	57	69	77	81	
12	---	---	---	---	---	---	---	---	---	
13	0	14	19	34	34	47	55	62	67	
14	0	12	19	34	40	53	64	69	75	
15	0	14	19	37	35	50	57	64	66	
16	---	---	---	---	---	---	---	---	---	

DAYS WEEKS ANIMAL	RECOVERY									
	1	5	8	12	14	19	22	25	28	
	1	1	2	2	2	3	4	4	4	4
1	---	---	---	---	---	---	---	---	---	---
2	---	---	---	---	---	---	---	---	---	---
3	---	---	---	---	---	---	---	---	---	---
4	---	---	---	---	---	---	---	---	---	---
5	---	---	---	---	---	---	---	---	---	---
6	---	---	---	---	---	---	---	---	---	---
7	---	---	---	---	---	---	---	---	---	---
8	---	---	---	---	---	---	---	---	---	---
9	69	87	96	102	100	---	---	---	---	---
10	52	68	77	79	80	---	---	---	---	---
11	71	91	103	109	109	---	---	---	---	---
12	---	---	---	---	---	---	---	---	---	---
13	56	69	78	81	84	85	88	91	90	---
14	64	83	89	96	95	100	108	111	111	---
15	56	71	76	79	78	81	85	86	85	---
16	---	---	---	---	---	---	---	---	---	---

**BODY WEIGHT GAIN (%)**  
**MALES**

**GROUP 2 (T-7250)**

DAYS WEEKS ANIMAL	TREATMENT								
	1	5	8	12	15	19	22	25	28
	1	1	2	2	3	3	4	4	4
17	0	15	25	39	48	52	60	66	69
18	0	11	20	33	41	48	55	62	67
19	0	14	22	34	41	52	56	62	63
20	0	15	23	35	46	56	62	68	72
21	0	14	25	39	48	59	67	75	78
22	0	10	22	36	49	59	69	73	76
23	0	15	27	44	59	73	84	91	98
24	0	12	22	36	43	57	63	69	71
25	0	17	22	34	36	46	54	64	68
26	0	15	18	36	35	51	60	70	72
27	0	14	18	34	32	47	55	64	67
28	---	---	---	---	---	---	---	---	---
29	0	14	17	35	32	47	51	59	62
30	0	17	19	36	37	53	60	70	74
31	0	14	18	33	33	48	54	65	67
32	---	---	---	---	---	---	---	---	---

DAYS WEEKS ANIMAL	RECOVERY								
	1	5	8	12	14	19	22	25	28
	1	1	2	2	2	3	4	4	4
17	---	---	---	---	---	---	---	---	---
18	---	---	---	---	---	---	---	---	---
19	---	---	---	---	---	---	---	---	---
20	---	---	---	---	---	---	---	---	---
21	---	---	---	---	---	---	---	---	---
22	---	---	---	---	---	---	---	---	---
23	---	---	---	---	---	---	---	---	---
24	---	---	---	---	---	---	---	---	---
25	56	74	79	86	90	---	---	---	---
26	60	80	86	91	95	---	---	---	---
27	56	73	82	85	85	---	---	---	---
28	---	---	---	---	---	---	---	---	---
29	49	61	68	70	71	76	77	82	80
30	62	81	88	96	96	105	106	110	110
31	55	75	79	88	86	97	102	107	110
32	---	---	---	---	---	---	---	---	---

**BODY WEIGHT GAIN (%)**  
**MALES**

**GROUP 3 (T-7251)**

DAYS WEEKS ANIMAL	TREATMENT								
	1	5	8	12	15	19	22	25	28
	1	1	2	2	3	3	4	4	4
33	0	12	23	34	43	50	57	59	66
34	0	13	20	31	42	49	56	61	66
35	0	15	25	38	47	60	72	75	81
36	0	10	16	25	33	40	46	50	53
37	0	12	22	33	42	49	58	62	64
38	0	14	23	36	44	54	62	65	69
39	0	10	18	27	37	45	53	54	57
40	0	12	21	31	40	47	56	60	67
41	0	13	14	33	34	54	61	63	67
42	0	15	21	38	42	60	69	77	81
43	0	13	16	35	32	51	56	62	66
44	---	---	---	---	---	---	---	---	---
45	0	15	16	34	31	46	53	59	63
46	0	16	20	42	38	60	67	75	81
47	0	17	20	37	38	50	57	63	69
48	---	---	---	---	---	---	---	---	---

DAYS WEEKS ANIMAL	RECOVERY								
	1	5	8	12	14	19	22	25	28
	1	1	2	2	2	3	4	4	4
33	---	---	---	---	---	---	---	---	---
34	---	---	---	---	---	---	---	---	---
35	---	---	---	---	---	---	---	---	---
36	---	---	---	---	---	---	---	---	---
37	---	---	---	---	---	---	---	---	---
38	---	---	---	---	---	---	---	---	---
39	---	---	---	---	---	---	---	---	---
40	---	---	---	---	---	---	---	---	---
41	57	68	76	79	82	---	---	---	---
42	69	89	101	107	104	---	---	---	---
43	56	72	79	86	87	---	---	---	---
44	---	---	---	---	---	---	---	---	---
45	49	65	71	74	76	83	89	91	88
46	66	83	88	96	98	107	117	119	120
47	57	71	76	80	77	86	94	92	93
48	---	---	---	---	---	---	---	---	---

**BODY WEIGHT GAIN (%)**  
**MALES**

**GROUP 4 (T-7252)**

DAYS WEEKS ANIMAL	TREATMENT									
	1	5	8	12	15	19	22	25	28	
	1	1	2	2	3	3	4	4	4	
49	0	12	21	35	46	54	60	65	68	
50	0	8	16	33	41	51	58	63	65	
51	0	14	25	42	53	62	69	76	81	
52	0	8	17	26	39	47	53	56	61	
53	0	12	22	32	43	51	63	69	73	
54	0	11	18	30	40	45	53	60	63	
55	0	14	25	40	52	59	67	73	74	
56	0	13	25	36	48	57	63	67	79	
57	0	12	15	30	29	45	53	54	63	
58	0	15	17	35	35	56	64	68	75	
59	0	11	12	24	23	39	45	50	53	
60	---	---	---	---	---	---	---	---	---	
61	0	15	19	34	33	49	58	63	71	
62	0	15	21	34	37	55	64	69	73	
63	0	18	28	44	50	69	63	75	82	
64	---	---	---	---	---	---	---	---	---	

DAYS WEEKS ANIMAL	RECOVERY									
	1	5	8	12	14	19	22	25	28	
	1	1	2	2	2	3	4	4	4	
49	---	---	---	---	---	---	---	---	---	
50	---	---	---	---	---	---	---	---	---	
51	---	---	---	---	---	---	---	---	---	
52	---	---	---	---	---	---	---	---	---	
53	---	---	---	---	---	---	---	---	---	
54	---	---	---	---	---	---	---	---	---	
55	---	---	---	---	---	---	---	---	---	
56	---	---	---	---	---	---	---	---	---	
57	51	68	76	79	80	---	---	---	---	
58	61	81	94	100	98	---	---	---	---	
59	43	58	63	65	65	---	---	---	---	
60	---	---	---	---	---	---	---	---	---	
61	59	74	82	87	88	---	---	---	---	
62	62	81	94	97	92	104	100	100	102	
63	70	100	110	121	118	133	142	143	144	
64	---	---	---	---	---	---	---	---	---	

**BODY WEIGHT GAIN (%)**  
**MALES**

**GROUP 5 (T-7253)**

DAYS WEEKS ANIMAL	TREATMENT								
	1 1	5 1	8 2	12 2	15 3	19 3	22 4	25 4	28 4
65	0	9	18	28	37	44	51	53	55
66	0	11	19	29	37	44	47	49	52
67	0	15	24	35	42	51	57	61	68
68	0	14	27	44	59	67	75	80	82
69	0	11	20	28	39	47	53	57	59
70	0	11	23	33	44	48	58	61	64
71	0	14	23	35	46	54	63	67	70
72	0	12	24	36	49	57	63	68	73
73	0	14	17	29	30	44	54	55	58
74	0	15	20	41	44	63	70	81	81
75	0	14	15	33	35	51	59	67	73
76	---	---	---	---	---	---	---	---	---
77	0	15	4	33	33	51	---	---	---
78	0	10	2	27	29	38	61	66	71
79	0	14	7	34	35	52	45	49	52
80	---	---	---	---	---	---	62	67	74

DAYS WEEKS ANIMAL	RECOVERY								
	1 1	5 1	8 2	12 2	14 2	19 3	22 4	25 4	28 4
65	---	---	---	---	---	---	---	---	---
66	---	---	---	---	---	---	---	---	---
67	---	---	---	---	---	---	---	---	---
68	---	---	---	---	---	---	---	---	---
69	---	---	---	---	---	---	---	---	---
70	---	---	---	---	---	---	---	---	---
71	---	---	---	---	---	---	---	---	---
72	---	---	---	---	---	---	---	---	---
73	---	---	---	---	---	---	---	---	---
74	48	63	68	72	74	---	---	---	---
	67	92	105	112	116	---	---	---	---
75	59	77	86	93	96	---	---	---	---
76	---	---	---	---	---	---	---	---	---
77	60	79	86	93	94	---	---	---	---
78	41	60	68	75	76	99	104	104	105
79	63	84	92	100	105	85	91	92	91
80	---	---	---	---	---	114	118	121	128

**BODY WEIGHT GAIN (%)**  
**MALES**

**GROUP 7 (T-7255)**

DAYS WEEKS ANIMAL	TREATMENT									
	1	5	8	12	15	19	22	25	28	
	1	1	2	2	3	3	4	4	4	
97	0	5	-2	-29	---	---	---	---	---	---
98	0	0	-11	---	---	---	---	---	---	---
99	0	5	1	-25	---	---	---	---	---	---
100	0	3	-6	-31	---	---	---	---	---	---
101	0	5	-5	-27	---	---	---	---	---	---
102	0	-2	-16	---	---	---	---	---	---	---
103	0	8	-1	-18	---	---	---	---	---	---
104	0	0	-5	-28	---	---	---	---	---	---
105	0	5	-6	-27	---	---	---	---	---	---
106	0	7	-7	-28	---	---	---	---	---	---
107	0	3	-11	---	---	---	---	---	---	---
108	---	---	---	---	---	---	---	---	---	---
109	0	8	-5	-24	---	---	---	---	---	---
110	0	8	-6	-29	---	---	---	---	---	---
111	0	6	-8	---	---	---	---	---	---	---
112	---	---	---	---	---	---	---	---	---	---

DAYS WEEKS ANIMAL	RECOVERY									
	1	5	8	12	14	19	22	25	28	
	1	1	2	2	2	3	4	4	4	
97	---	---	---	---	---	---	---	---	---	---
98	---	---	---	---	---	---	---	---	---	---
99	---	---	---	---	---	---	---	---	---	---
100	---	---	---	---	---	---	---	---	---	---
101	---	---	---	---	---	---	---	---	---	---
102	---	---	---	---	---	---	---	---	---	---
103	---	---	---	---	---	---	---	---	---	---
104	---	---	---	---	---	---	---	---	---	---
105	---	---	---	---	---	---	---	---	---	---
106	---	---	---	---	---	---	---	---	---	---
107	---	---	---	---	---	---	---	---	---	---
108	---	---	---	---	---	---	---	---	---	---
109	---	---	---	---	---	---	---	---	---	---
110	---	---	---	---	---	---	---	---	---	---
111	---	---	---	---	---	---	---	---	---	---
112	---	---	---	---	---	---	---	---	---	---

**BODY WEIGHT GAIN (%)  
FEMALES**

**GROUP 1 (VEHICLE CONTROL)**

DAYS WEEKS ANIMAL	TREATMENT									
	1	5	8	12	15	19	22	25	28	
	1	1	2	2	3	3	4	4	4	4
113	0	6	11	22	27	32	35	38	39	
114	0	4	8	14	21	24	27	31	34	
115	0	7	6	15	21	26	30	32	29	
116	0	5	7	17	19	26	32	37	38	
117	0	5	12	21	26	30	36	34	41	
118	0	4	16	22	30	33	41	40	44	
119	0	6	13	21	22	28	37	41	42	
120	0	3	4	15	12	20	22	30	31	
121	0	1	2	14	5	19	19	27	30	
122	0	3	3	18	8	26	35	41	36	
123	0	7	7	20	12	29	36	43	47	
124	---	---	---	---	---	---	---	---	---	
125	0	4	2	17	10	24	31	33	36	
126	0	5	4	18	8	26	32	37	37	
127	0	11	11	24	15	36	40	47	46	
128	---	---	---	---	---	---	---	---	---	

DAYS WEEKS ANIMAL	RECOVERY									
	1	5	8	12	14	19	22	25	28	
	1	1	2	2	2	3	4	4	4	4
113	---	---	---	---	---	---	---	---	---	
114	---	---	---	---	---	---	---	---	---	
115	---	---	---	---	---	---	---	---	---	
116	---	---	---	---	---	---	---	---	---	
117	---	---	---	---	---	---	---	---	---	
118	---	---	---	---	---	---	---	---	---	
119	---	---	---	---	---	---	---	---	---	
120	---	---	---	---	---	---	---	---	---	
121	17	31	37	38	37	---	---	---	---	
122	24	43	47	46	44	---	---	---	---	
123	34	51	56	59	58	---	---	---	---	
124	---	---	---	---	---	---	---	---	---	
125	26	36	41	43	45	48	51	49	51	
126	25	43	47	51	48	56	53	55	56	
127	34	50	50	56	54	59	58	65	64	
128	---	---	---	---	---	---	---	---	---	



**BODY WEIGHT GAIN (%)  
FEMALES**

**GROUP 2 (T-7250)**

DAYS WEEKS ANIMAL	TREATMENT									
	1	5	8	12	15	19	22	25	28	
	1	1	2	2	3	3	4	4	4	
129	0	6	11	19	26	28	30	35	39	
130	0	7	12	19	25	28	32	27	30	
131	0	6	11	19	22	26	28	35	38	
132	0	4	9	14	20	21	31	31	32	
133	0	5	8	20	28	33	42	42	42	
134	0	5	8	19	28	30	40	44	49	
135	0	5	10	21	24	31	41	43	44	
136	0	2	5	13	20	21	28	32	24	
137	0	7	11	26	15	36	37	43	47	
138	0	5	8	20	9	27	27	32	36	
139	0	7	9	21	15	32	41	43	44	
140	---	---	---	---	---	---	---	---	---	
141	0	4	3	15	5	21	31	34	36	
142	0	3	3	16	8	22	26	30	31	
143	0	5	5	18	9	27	33	32	36	
144	---	---	---	---	---	---	---	---	---	

DAYS WEEKS ANIMAL	RECOVERY									
	1	5	8	12	14	19	22	25	28	
	1	1	2	2	2	3	4	4	4	
129	---	---	---	---	---	---	---	---	---	
130	---	---	---	---	---	---	---	---	---	
131	---	---	---	---	---	---	---	---	---	
132	---	---	---	---	---	---	---	---	---	
133	---	---	---	---	---	---	---	---	---	
134	---	---	---	---	---	---	---	---	---	
135	---	---	---	---	---	---	---	---	---	
136	---	---	---	---	---	---	---	---	---	
137	31	51	54	55	56	---	---	---	---	
138	23	35	37	42	42	---	---	---	---	
139	32	48	51	50	48	---	---	---	---	
140	---	---	---	---	---	---	---	---	---	
141	25	40	42	46	44	---	---	---	---	
142	21	34	38	41	44	51	50	54	54	
143	24	39	39	40	43	48	53	53	52	
144	---	---	---	---	---	---	---	---	---	

**BODY WEIGHT GAIN (%)  
FEMALES**

**GROUP 3 (T-7251)**

DAYS WEEKS ANIMAL	TREATMENT									
	1	5	8	12	15	19	22	25	28	
	1	1	2	2	3	3	4	4	4	
145	0	4	10	17	19	23	22	28	31	
146	0	6	11	21	19	28	35	40	41	
147	0	5	11	18	22	25	27	32	36	
148	0	4	6	12	12	18	23	30	31	
149	0	7	11	23	24	32	38	45	47	
150	0	4	10	17	21	25	26	29	32	
151	0	2	12	20	25	33	39	36	41	
152	0	7	14	22	24	26	27	34	37	
153	0	5	6	23	11	29	30	37	42	
154	0	3	5	17	8	26	27	36	39	
155	0	7	11	23	10	29	35	42	46	
156	---	---	---	---	---	---	---	---	---	
157	0	4	7	18	10	21	28	32	33	
158	0	6	8	22	12	31	30	40	40	
159	0	7	7	20	11	30	38	39	40	
160	---	---	---	---	---	---	---	---	---	

DAYS WEEKS ANIMAL	RECOVERY									
	1	5	8	12	14	19	22	25	28	
	1	1	2	2	2	3	4	4	4	
145	---	---	---	---	---	---	---	---	---	
146	---	---	---	---	---	---	---	---	---	
147	---	---	---	---	---	---	---	---	---	
148	---	---	---	---	---	---	---	---	---	
149	---	---	---	---	---	---	---	---	---	
150	---	---	---	---	---	---	---	---	---	
151	---	---	---	---	---	---	---	---	---	
152	---	---	---	---	---	---	---	---	---	
153	---	---	---	---	---	---	---	---	---	
154	26	38	46	48	47	---	---	---	---	
155	34	49	51	57	57	---	---	---	---	
156	---	---	---	---	---	---	---	---	---	
157	25	41	42	43	42	49	49	51	51	
158	28	45	47	49	54	59	58	59	65	
159	27	47	48	53	53	61	63	64	63	
160	---	---	---	---	---	---	---	---	---	

**BODY WEIGHT GAIN (%)  
FEMALES**

**GROUP 4 (T-7252)**

DAYS WEEKS ANIMAL	TREATMENT									
	1	5	8	12	15	19	22	25	28	
	1	1	2	2	3	3	4	4	4	4
161	0	5	9	20	21	23	27	30	33	
162	0	7	13	20	24	26	31	28	34	
163	0	2	7	14	19	22	23	30	31	
164	0	2	7	13	13	18	27	30	28	
165	0	7	15	22	22	27	37	39	40	
166	0	5	15	21	27	30	35	41	41	
167	0	6	11	21	28	34	41	40	46	
168	0	4	9	14	17	19	27	30	29	
169	0	8	8	19	10	25	27	26	32	
170	0	10	11	26	14	35	43	42	47	
171	0	7	7	17	12	28	38	39	39	
172	---	---	---	---	---	---	---	---	---	
173	0	3	0	13	2	17	23	27	32	
174	0	6	2	19	13	31	41	45	45	
175	0	7	5	25	16	34	41	44	46	
176	---	---	---	---	---	---	---	---	---	

DAYS WEEKS ANIMAL	RECOVERY									
	1	5	8	12	14	19	22	25	28	
	1	1	2	2	2	3	4	4	4	4
161	---	---	---	---	---	---	---	---	---	
162	---	---	---	---	---	---	---	---	---	
163	---	---	---	---	---	---	---	---	---	
164	---	---	---	---	---	---	---	---	---	
165	---	---	---	---	---	---	---	---	---	
166	---	---	---	---	---	---	---	---	---	
167	---	---	---	---	---	---	---	---	---	
168	---	---	---	---	---	---	---	---	---	
169	22	38	39	41	44	---	---	---	---	
170	33	54	57	59	60	---	---	---	---	
171	31	48	48	53	55	---	---	---	---	
172	---	---	---	---	---	---	---	---	---	
173	20	37	37	41	39	47	47	47	50	
174	37	54	57	64	65	70	78	80	83	
175	35	54	58	60	58	67	66	74	69	
176	---	---	---	---	---	---	---	---	---	

**BODY WEIGHT GAIN (%)  
FEMALES**

**GROUP 5 (T-7253)**

DAYS WEEKS ANIMAL	TREATMENT									
	1	5	8	12	15	19	22	25	28	
	1	1	2	2	3	3	4	4	4	
177	0	4	9	17	22	22	32	36	36	
178	0	6	11	20	26	30	37	34	40	
179	0	5	10	18	20	26	33	34	36	
180	0	3	9	16	18	23	30	34	36	
181	0	4	10	18	23	30	33	30	33	
182	0	3	6	13	14	17	21	26	29	
183	0	8	14	22	28	32	36	41	44	
184	0	6	9	15	21	25	31	29	29	
185	0	5	9	20	11	28	28	38	40	
186	0	5	5	13	7	19	27	31	30	
187	0	7	6	17	9	27	26	30	34	
188	---	---	---	---	---	---	---	---	---	
189	0	6	4	14	4	18	22	25	25	
190	0	4	11	20	12	31	38	37	41	
191	0	6	9	22	13	31	37	39	41	
192	---	---	---	---	---	---	---	---	---	

DAYS WEEKS ANIMAL	RECOVERY									
	1	5	8	12	14	19	22	25	28	
	1	1	2	2	2	3	4	4	4	
177	---	---	---	---	---	---	---	---	---	
178	---	---	---	---	---	---	---	---	---	
179	---	---	---	---	---	---	---	---	---	
180	---	---	---	---	---	---	---	---	---	
181	---	---	---	---	---	---	---	---	---	
182	---	---	---	---	---	---	---	---	---	
183	---	---	---	---	---	---	---	---	---	
184	---	---	---	---	---	---	---	---	---	
185	27	39	47	53	52	---	---	---	---	
186	19	39	39	44	42	---	---	---	---	
187	22	35	43	46	44	---	---	---	---	
188	---	---	---	---	---	---	---	---	---	
189	15	30	30	32	33	---	---	---	---	
190	27	48	51	52	51	36	37	41	44	
191	31	48	49	52	54	60	60	59	61	
192	---	---	---	---	---	59	56	60	60	

**FOOD CONSUMPTION (G/ANIMAL/DAY)  
MALES**

DAYS WEEKS CAGE	TREATMENT				RECOVERY			
	1-8 1/2	8-15 2/3	15-22 3/4	22-28 4	1-8 1/2	8-14 2	14-22 2/4	22-28 4
GROUP 1 (VEHICLE CONTROL)								
1	28	30	29	29	---	---	---	---
2	27	30	27	29	---	---	---	---
3	26	30	32	34	37	35	---	---
4	27	31	31	32	32	32	30	32
GROUP 2 (T-7250)								
5	28	30	30	30	---	---	---	---
6	31	34	34	34	---	---	---	---
7	27	31	32	35	---	---	---	---
8	28	31	32	33	37	36	---	---
GROUP 3 (T-7251)								
9	29	30	29	30	---	---	---	---
10	27	28	28	29	---	---	---	---
11	28	32	33	34	34	34	---	---
12	25	30	31	33	32	33	31	32
GROUP 4 (T-7252)								
13	29	32	31	32	---	---	---	---
14	29	31	30	31	---	---	---	---
15	27	29	31	32	---	---	---	---
16	30	34	32	37	34	32	---	---
GROUP 5 (T-7253)								
17	30	32	30	30	---	---	---	---
18	30	32	30	31	---	---	---	---
19	26	30	31	33	---	---	---	---
20	23	30	30	30	36	37	---	---
GROUP 6 (T-7254)								
21	30	34	31	31	---	---	---	---
22	28	30	30	32	---	---	---	---
23	22	26	28	26	---	---	---	---
24	27	31	32	31	29	28	---	---
GROUP 7 (T-7255)								
25	22	2	---	---	---	---	---	---
26	22	5	---	---	---	---	---	---
27	19	4	---	---	---	---	---	---
28	22	3	---	---	---	---	---	---

**RELATIVE FOOD CONSUMPTION  
(G/KG BODY WEIGHT/DAY)  
MALES**

DAYS WEEKS CAGE	TREATMENT				RECOVERY			
	1-8 1/2	8-15 2/3	15-22 3/4	22-28 4	1-8 1/2	8-14 2	14-22 2/4	22-28 4
GROUP 1 (VEHICLE CONTROL)								
1	109	99	84	79	---	---	---	---
2	107	98	80	79	---	---	---	---
3	108	105	97	91	92	82	---	---
4	110	106	96	89	86	79	73	75
GROUP 2 (T-7250)								
5	112	102	88	84	---	---	---	---
6	120	108	92	86	---	---	---	---
7	109	106	99	99	97	90	---	---
8	112	104	99	92	91	85	78	81
GROUP 3 (T-7251)								
9	116	102	87	84	---	---	---	---
10	110	100	87	83	---	---	---	---
11	113	109	98	95	89	83	---	---
12	108	106	102	98	92	88	80	79
GROUP 4 (T-7252)								
13	114	106	88	86	---	---	---	---
14	112	99	84	81	---	---	---	---
15	110	103	97	94	92	82	---	---
16	113	107	87	94	92	78	76	75
GROUP 5 (T-7253)								
17	118	107	87	82	---	---	---	---
18	115	103	86	81	---	---	---	---
19	108	105	97	92	97	90	---	---
20	95	105	92	87	86	82	74	77
GROUP 6 (T-7254)								
21	121	119	98	95	---	---	---	---
22	116	104	93	93	---	---	---	---
23	99	111	110	101	110	93	---	---
24	110	112	111	100	99	87	80	80
GROUP 7 (T-7255)								
25	95	14	---	---	---	---	---	---
26	91	26	---	---	---	---	---	---
27	88	29	---	---	---	---	---	---
28	97	19	---	---	---	---	---	---

**RELATIVE FOOD CONSUMPTION  
(G/KG BODY WEIGHT/DAY)  
FEMALES**

DAYS WEEKS CAGE	TREATMENT				RECOVERY			
	1-8 1/2	8-15 2/3	15-22 3/4	22-28 4	1-8 1/2	8-14 2	14-22 2/4	22-28 4
GROUP 1 (VEHICLE CONTROL)								
29	105	98	94	94	---	---	---	---
30	113	98	98	97	---	---	---	---
31	107	99	112	105	109	97	---	---
32	101	95	110	104	104	91	85	92
GROUP 2 (T-7250)								
33	108	97	96	97	---	---	---	---
34	108	100	97	94	---	---	---	---
35	108	97	110	107	106	93	---	---
36	110	98	115	106	104	99	88	95
GROUP 3 (T-7251)								
37	107	91	94	93	---	---	---	---
38	110	93	94	95	---	---	---	---
39	106	95	112	110	98	96	---	---
40	109	95	113	103	109	101	87	97
GROUP 4 (T-7252)								
41	108	93	98	97	---	---	---	---
42	110	95	97	94	---	---	---	---
43	110	96	111	106	108	98	---	---
44	97	88	104	97	99	93	83	86
GROUP 5 (T-7253)								
45	111	99	101	96	---	---	---	---
46	114	97	99	101	---	---	---	---
47	107	96	111	105	111	96	---	---
48	105	94	109	103	108	96	89	97

KEY TO MISSING VALUES AND REMARKS HAEMATOLOGY / CLINICAL BIOCHEMISTRY

AFTER 4 WEEKS

Animal 67

--- = sample partly clotted

Animal 141

--- = PTT in plasma not reproducible

Animal 5, 6, 7, 10, 18, 22, 26, 27,  
33, 34, 36, 37, 38, 41, 42, 47, 49,  
52, 53, 54, 55, 56, 58, 63, 65, 66,  
67, 68, 69, 70, 71, 73, 74, 78, 81,  
82, 83, 84, 85, 86, 87, 88, 89, 91,  
93, 94, 114, 122, 129, 135, 139,  
147, 150, 161, 162, 166, 170, 189

haemolytic serum sample

Animal 52, 78, 86, 88, 113, 118,  
122, 139, 145, 146

--- = ALAT in serum not reproducible

Animal 150

--- = CREAT in serum not reproducible

Animal 153

--- = BILI T. in serum not reproducible

Animal 113

--- = inadvertently not repeated

AFTER 2 WEEKS RECOVERY

Animal 10

--- = PTT in plasma not reproducible

Animal 9, 10, 25, 26, 27, 41, 122  
170, 187

haemolytic serum sample

AFTER 4 WEEKS RECOVERY

Animal 173

--- = citrate sample partly clotted

Animal 13, 14, 15, 31, 63

haemolytic serum sample



INCIDENCE OF HAEMOLYTIC SERUM SAMPLES

The incidence of haemolytic serum samples during treatment and recovery was as follows:

Group	substance		incidence	
			males	females
1	vehicle	after treatment	4/14	2/14
		after 2 weeks recovery	2/3	1/3
		after 4 weeks recovery	3/3	0/3
2	T-7250	after treatment	4/14	3/14
		after 2 weeks recovery	3/3	0/3
		after 4 weeks recovery	1/3	0/3
3	T-7251	after treatment	8/14	2/14
		after 2 weeks recovery	1/3	0/3
		after 4 weeks recovery	0/3	0/3
4	T-7252	after treatment	8/14	4/14
		after 2 weeks recovery	0/3	1/3
		after 4 weeks recovery	1/3	0/3
5	T-7253	after treatment	10/14	1/14
		after 2 weeks recovery	0/3	1/3
		after 4 weeks recovery	0/3	0/3
6	T-7254	after treatment	12/14	-
		after 2 weeks recovery	0/3	-
		after 4 weeks recovery	0/3	-
7	T-7255	no samples taken		

**HAEMATOTOLOGY**  
**AFTER 4 WEEKS**  
**MALES**  
**GROUP 1 (VEHICLE CONTROL)**

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
1	7.19	9.8	0.416	57.9	1.363	23.6	12.0	1354
2	7.35	9.8	0.416	56.6	1.333	23.6	11.7	1235
3	6.82	9.6	0.410	60.1	1.408	23.4	12.1	1163
4	7.30	10.0	0.428	58.6	1.370	23.4	11.4	1501
5	6.80	9.5	0.415	61.0	1.397	22.9	11.3	1039
6	7.42	9.6	0.414	55.8	1.294	23.2	12.2	1210
7	7.43	9.5	0.399	53.7	1.279	23.8	13.2	1349
8	7.20	9.9	0.424	58.9	1.375	23.3	11.5	1257
9	6.66	9.3	0.403	60.5	1.396	23.1	12.4	924
10	6.77	9.5	0.401	59.2	1.403	23.7	12.6	1085
11	6.36	8.8	0.377	59.3	1.384	23.3	12.4	1122
13	6.65	8.7	0.384	57.7	1.308	22.7	12.0	1228
14	6.34	8.7	0.370	58.4	1.372	23.5	12.6	1278
15	6.87	9.8	0.423	61.6	1.426	23.2	11.2	1002

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
1	16.2	0.070	0.000	0.000	0.015	0.915	12.2	18.4
2	12.4	0.085	0.010	0.000	0.010	0.895	11.6	17.9
3	12.6	0.095	0.005	0.000	0.025	0.875	11.6	15.4
4	15.8	0.090	0.015	0.000	0.015	0.880	12.2	17.1
5	11.6	0.070	0.005	0.000	0.010	0.915	12.5	17.7
6	9.4	0.065	0.000	0.000	0.020	0.915	12.6	17.3
7	9.9	0.125	0.005	0.000	0.030	0.840	11.9	16.0
8	12.3	0.060	0.000	0.000	0.020	0.920	12.1	16.7
9	8.9	0.080	0.000	0.000	0.005	0.915	12.2	17.9
10	11.4	0.060	0.005	0.000	0.030	0.905	12.2	15.5
11	8.7	0.080	0.020	0.000	0.005	0.895	12.6	17.9
13	11.3	0.060	0.010	0.000	0.015	0.915	12.5	16.8
14	9.5	0.110	0.015	0.000	0.005	0.870	11.9	17.7
15	10.5	0.090	0.000	0.000	0.015	0.895	13.9	16.5

**HAEMATOTOLOGY  
AFTER 4 WEEKS  
MALES  
GROUP 2 (T-7250)**

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
17	7.40	9.7	0.416	56.2	1.311	23.3	12.1	884
18	7.22	10.0	0.423	58.6	1.385	23.6	11.7	1140
19	7.21	9.7	0.420	58.3	1.345	23.1	12.2	1144
20	7.32	9.8	0.428	58.5	1.339	22.9	13.0	1259
21	7.27	9.5	0.422	58.0	1.307	22.5	12.6	1322
22	6.95	9.8	0.411	59.1	1.410	23.8	12.8	1207
23	6.83	8.9	0.395	57.8	1.303	22.5	12.3	1374
24	7.68	9.9	0.426	55.5	1.289	23.2	12.5	1059
25	6.38	8.6	0.367	57.5	1.348	23.4	12.5	1116
26	6.59	8.8	0.372	56.4	1.335	23.7	11.8	1174
27	6.50	8.8	0.386	59.4	1.354	22.8	12.8	1131
29	6.55	9.2	0.398	60.8	1.405	23.1	12.0	927
30	6.80	8.9	0.384	56.5	1.309	23.2	12.7	1119
31	7.11	9.3	0.405	57.0	1.308	23.0	12.0	1051

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
17	18.0	0.110	0.005	0.000	0.020	0.865	12.6	17.8
18	12.8	0.110	0.005	0.000	0.025	0.860	11.4	16.4
19	10.9	0.055	0.005	0.000	0.025	0.915	10.8	17.5
20	13.8	0.065	0.010	0.000	0.020	0.905	11.5	17.7
21	13.0	0.145	0.010	0.000	0.020	0.825	11.7	18.3
22	9.6	0.115	0.010	0.000	0.005	0.870	12.2	20.1
23	12.4	0.145	0.025	0.000	0.010	0.820	12.6	19.0
24	9.2	0.065	0.015	0.000	0.025	0.895	11.5	18.8
25	12.6	0.080	0.005	0.000	0.030	0.885	11.9	15.8
26	9.9	0.120	0.005	0.000	0.015	0.860	12.3	16.0
27	13.1	0.125	0.000	0.000	0.015	0.860	12.8	15.3
29	7.7	0.150	0.005	0.000	0.025	0.820	12.3	19.4
30	10.6	0.070	0.010	0.000	0.020	0.900	13.5	16.9
31	12.9	0.055	0.010	0.000	0.015	0.920	13.2	17.0

**HAEMATOLOGY  
AFTER 4 WEEKS  
MALES  
GROUP 3 (T-7251)**

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
33	6.77	8.9	0.385	56.9	1.315	23.1	11.8	1261
34	6.97	9.8	0.417	59.8	1.406	23.5	12.4	992
35	6.64	9.6	0.409	61.6	1.446	23.5	11.7	1123
36	6.82	9.1	0.379	55.6	1.334	24.0	11.7	1095
37	6.87	8.9	0.386	56.2	1.295	23.1	12.4	1049
38	6.71	9.2	0.395	58.9	1.371	23.3	12.1	1075
39	6.88	9.4	0.395	57.4	1.366	23.8	11.6	1171
40	6.49	8.9	0.385	59.3	1.371	23.1	12.7	997
41	6.68	9.2	0.411	61.5	1.377	22.4	11.0	801
42	6.63	8.9	0.387	58.4	1.342	23.0	12.6	1249
43	6.83	8.9	0.382	55.9	1.303	23.3	12.0	971
45	6.61	8.9	0.382	57.8	1.346	23.3	12.0	1185
46	6.63	8.8	0.381	57.5	1.327	23.1	12.0	1234
47	6.82	9.3	0.400	58.7	1.364	23.2	12.5	1178

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
33	16.1	0.070	0.000	0.000	0.015	0.915	11.7	15.7
34	10.2	0.120	0.005	0.000	0.025	0.850	12.0	16.8
35	9.2	0.090	0.010	0.000	0.030	0.870	12.8	18.3
36	10.8	0.080	0.000	0.000	0.025	0.895	11.5	15.7
37	11.9	0.075	0.015	0.000	0.015	0.895	11.5	16.8
38	13.2	0.090	0.000	0.000	0.015	0.895	11.6	19.2
39	8.8	0.130	0.000	0.000	0.015	0.895	11.6	19.2
40	12.7	0.050	0.005	0.000	0.020	0.850	12.1	16.0
41	12.0	0.095	0.000	0.000	0.010	0.935	11.7	19.1
42	14.6	0.060	0.000	0.000	0.025	0.880	12.5	16.5
43	10.0	0.060	0.005	0.000	0.025	0.915	12.8	18.4
45	7.2	0.150	0.000	0.000	0.020	0.915	12.2	17.9
46	8.7	0.145	0.000	0.000	0.025	0.825	11.2	18.1
47	11.2	0.080	0.015	0.000	0.020	0.835	12.7	16.5
					0.010	0.895	12.9	19.1

**HAEMATOLOGY  
AFTER 4 WEEKS  
MALES  
GROUP 4 (T-7252)**

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
49	7.06	9.8	0.415	58.8	1.388	23.6	12.9	1281
50	7.14	10.0	0.431	60.4	1.401	23.2	12.0	1158
51	6.52	9.2	0.393	60.3	1.411	23.4	13.3	1070
52	7.14	10.0	0.422	59.1	1.401	23.7	12.4	1173
53	6.68	9.2	0.394	59.0	1.377	23.4	12.2	1318
54	6.75	9.3	0.398	59.0	1.378	23.4	13.2	1088
55	6.97	9.5	0.417	59.8	1.363	22.8	12.0	1283
56	7.27	10.0	0.420	57.8	1.376	23.8	11.3	1331
57	6.90	9.2	0.392	56.8	1.333	23.5	12.0	1122
58	6.69	8.6	0.373	55.8	1.286	23.1	12.8	1077
59	7.01	8.8	0.380	54.2	1.255	23.2	13.8	1355
61	7.07	9.1	0.385	54.5	1.287	23.6	12.7	1155
62	6.48	8.9	0.395	61.0	1.373	22.5	11.4	1051
63	6.45	8.8	0.381	59.1	1.364	23.1	13.5	1249

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
49	13.1	0.100	0.005	0.000	0.030	0.865	11.9	17.2
50	7.1	0.055	0.005	0.000	0.015	0.925	11.9	19.0
51	13.9	0.075	0.000	0.000	0.020	0.905	12.4	17.1
52	14.7	0.135	0.000	0.000	0.020	0.845	12.0	16.8
53	13.5	0.130	0.005	0.000	0.005	0.860	12.7	17.2
54	8.5	0.105	0.000	0.000	0.020	0.875	13.0	16.9
55	9.1	0.110	0.010	0.000	0.040	0.840	12.7	17.7
56	12.2	0.075	0.005	0.000	0.020	0.900	11.6	18.7
57	9.4	0.210	0.015	0.000	0.010	0.765	11.9	17.2
58	9.1	0.125	0.005	0.000	0.000	0.870	12.0	18.6
59	10.3	0.090	0.020	0.000	0.010	0.880	11.8	18.6
61	9.3	0.110	0.005	0.000	0.010	0.875	11.2	18.8
62	11.8	0.155	0.000	0.000	0.015	0.830	12.1	16.0
63	10.5	0.120	0.000	0.000	0.010	0.870	12.7	19.2

**HAEMATOTOLOGY  
AFTER 4 WEEKS  
MALES  
GROUP 5 (T-7253)**

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
65	7.16	10.0	0.422	58.9	1.397	23.7	12.1	1156
66	6.57	9.3	0.403	61.3	1.416	23.1	11.2	928
67	---	---	---	---	---	---	---	---
68	7.08	9.6	0.416	58.8	1.356	23.1	11.9	1094
69	7.26	10.0	0.454	62.5	1.377	22.0	11.9	1294
70	6.92	9.2	0.395	57.1	1.329	23.3	12.4	1161
71	6.92	9.3	0.403	58.2	1.344	23.1	12.4	1232
72	6.57	9.3	0.401	61.0	1.416	23.2	11.9	1036
73	6.28	8.7	0.367	58.4	1.385	23.7	13.3	1519
74	6.09	8.6	0.367	60.3	1.412	23.4	12.0	1014
75	6.42	8.7	0.370	57.6	1.355	23.5	13.1	1098
77	6.34	8.9	0.393	62.0	1.404	22.6	11.8	821
78	6.51	8.4	0.365	56.1	1.290	23.0	13.0	1258
79	6.33	8.6	0.367	58.0	1.359	23.4	12.5	1054

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
65	14.8	0.070	0.005	0.000	0.025	0.900	11.4	14.7
66	16.5	0.055	0.005	0.000	0.025	0.915	12.5	16.5
67	---	---	---	---	---	---	---	---
68	10.3	0.125	0.005	0.000	0.010	0.860	12.8	18.2
69	13.0	0.085	0.000	0.000	0.040	0.875	11.9	14.5
70	16.0	0.110	0.005	0.000	0.010	0.875	12.2	14.5
71	11.7	0.065	0.000	0.000	0.015	0.920	12.7	17.1
72	8.8	0.150	0.015	0.000	0.025	0.810	12.1	15.9
73	9.8	0.120	0.005	0.000	0.005	0.870	12.5	15.2
74	11.4	0.165	0.015	0.000	0.020	0.800	11.7	16.9
75	8.5	0.085	0.000	0.000	0.005	0.910	12.5	13.5
77	10.2	0.130	0.000	0.000	0.025	0.845	12.8	14.6
78	7.7	0.100	0.000	0.000	0.015	0.885	11.7	14.2
79	9.8	0.105	0.005	0.000	0.030	0.860	11.4	13.0

**HAEMATOTOLOGY  
AFTER 4 WEEKS  
MALES  
GROUP 6 (T-7254)**

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
81	6.75	8.8	0.393	58.2	1.304	22.4	11.5	998
82	7.34	9.5	0.406	55.3	1.294	23.4	12.1	1159
83	6.34	8.4	0.359	56.6	1.325	23.4	12.3	1072
84	6.71	8.9	0.391	58.3	1.326	22.8	13.0	1287
85	6.45	8.8	0.386	59.8	1.364	22.8	12.9	1072
86	5.87	8.7	0.377	64.2	1.482	23.1	13.5	1364
87	6.14	8.3	0.360	58.6	1.352	23.1	14.3	1321
88	6.13	8.6	0.371	60.5	1.403	23.2	12.9	1296
89	6.56	8.3	0.351	53.5	1.265	23.6	13.3	1326
90	7.22	8.8	0.381	52.8	1.219	23.1	13.4	1387
91	6.82	8.9	0.395	57.9	1.305	22.5	12.8	805
93	7.06	8.4	0.369	52.3	1.190	22.8	14.1	1111
94	6.44	8.6	0.374	58.1	1.335	23.0	11.8	911
95	6.72	8.9	0.390	58.0	1.324	22.8	11.9	1029

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
81	11.1	0.120	0.000	0.000	0.010	0.870	12.1	16.6
82	16.3	0.115	0.005	0.000	0.020	0.860	12.9	16.9
83	12.8	0.095	0.010	0.000	0.010	0.885	11.8	17.2
84	19.3	0.135	0.005	0.000	0.015	0.845	11.9	17.5
85	12.0	0.105	0.000	0.000	0.015	0.880	11.5	18.1
86	15.2	0.120	0.000	0.000	0.010	0.870	11.8	18.6
87	18.8	0.055	0.015	0.000	0.010	0.920	12.9	21.6
88	17.9	0.120	0.005	0.000	0.020	0.855	11.3	19.6
89	13.2	0.175	0.005	0.000	0.010	0.810	12.7	14.9
90	13.0	0.080	0.015	0.000	0.015	0.890	13.9	16.2
91	9.6	0.090	0.005	0.000	0.010	0.895	13.1	18.1
93	9.5	0.095	0.005	0.000	0.010	0.890	12.1	18.5
94	10.0	0.170	0.000	0.000	0.005	0.825	11.3	15.3
95	10.4	0.090	0.005	0.000	0.025	0.880	10.5	17.4

**HAEMATOLOGY  
AFTER 4 WEEKS  
FEMALES  
GROUP 1 (VEHICLE CONTROL)**

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
113	7.04	9.4	0.391	55.5	1.335	24.0	11.2	1316
114	7.13	9.6	0.399	56.0	1.346	24.1	11.0	1199
115	6.66	9.3	0.388	58.3	1.396	24.0	11.1	1158
116	6.79	9.5	0.382	56.3	1.399	24.9	10.5	1248
117	6.70	9.2	0.382	57.0	1.373	24.1	10.7	1129
118	6.61	9.5	0.388	58.7	1.437	24.5	10.9	1138
119	6.48	9.1	0.369	56.9	1.404	24.7	10.8	1278
120	6.93	9.2	0.389	56.1	1.328	23.7	11.3	1305
121	6.50	9.3	0.376	57.8	1.431	24.7	10.7	1235
122	5.95	8.4	0.347	58.3	1.412	24.2	11.3	1217
123	6.37	8.8	0.357	56.0	1.381	24.6	10.8	1188
125	6.38	8.7	0.353	55.3	1.364	24.6	11.3	1237
126	6.43	8.7	0.358	55.7	1.353	24.3	11.7	1180
127	6.69	9.3	0.375	56.1	1.390	24.8	11.2	1155

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PIT SEC
113	9.2	0.115	0.015	0.000	0.015	0.855	11.8	14.9
114	8.5	0.095	0.000	0.000	0.015	0.890	12.0	14.9
115	9.2	0.030	0.005	0.000	0.015	0.950	12.5	14.6
116	9.4	0.035	0.005	0.000	0.010	0.950	12.3	16.2
117	5.3	0.125	0.015	0.000	0.005	0.855	10.8	17.0
118	7.5	0.085	0.005	0.000	0.025	0.885	11.9	14.1
119	11.9	0.055	0.005	0.000	0.010	0.930	11.3	15.4
120	7.7	0.080	0.000	0.000	0.015	0.905	10.8	17.3
121	5.0	0.115	0.005	0.000	0.025	0.855	11.8	16.5
122	6.3	0.130	0.005	0.000	0.005	0.860	12.1	15.3
123	5.3	0.055	0.020	0.000	0.000	0.925	11.5	14.7
125	6.4	0.055	0.000	0.000	0.020	0.925	11.4	15.9
126	5.3	0.050	0.005	0.000	0.005	0.940	12.2	15.4
127	8.9	0.115	0.010	0.000	0.005	0.870	10.5	27.4



**HAEMATOTOLOGY  
AFTER 4 WEEKS  
FEMALES  
GROUP 2 (T-7250)**

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
129	6.57	9.2	0.373	56.8	1.400	24.7	11.2	1276
130	6.50	9.1	0.380	58.5	1.400	23.9	11.0	1112
131	6.15	8.6	0.348	56.6	1.398	24.7	10.8	1268
132	6.91	9.5	0.399	57.7	1.375	23.8	11.2	1262
133	6.97	9.9	0.396	56.8	1.420	25.0	10.7	1118
134	6.50	9.2	0.366	56.3	1.415	25.1	11.3	1308
135	6.93	9.9	0.405	58.4	1.429	24.4	11.2	1103
136	6.87	9.5	0.385	56.0	1.383	24.7	10.8	974
137	6.79	9.3	0.399	58.8	1.370	23.3	11.4	1236
138	6.43	9.2	0.386	60.0	1.431	23.8	11.9	863
139	6.79	9.2	0.386	56.8	1.355	23.8	11.1	1131
141	6.90	8.6	0.379	54.9	1.246	22.7	12.7	1095
142	6.22	8.7	0.362	58.2	1.399	24.0	11.2	1158
143	6.82	8.8	0.379	55.6	1.290	23.2	11.4	1062

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PYT SEC
129	6.6	0.040	0.000	0.000	0.015	0.945	11.5	13.7
130	8.4	0.050	0.000	0.000	0.020	0.930	11.4	16.5
131	6.3	0.060	0.005	0.000	0.015	0.920	12.4	16.3
132	8.2	0.095	0.000	0.000	0.015	0.890	10.9	16.3
133	9.1	0.060	0.005	0.000	0.005	0.930	11.6	15.7
134	11.0	0.045	0.005	0.000	0.005	0.945	11.6	14.6
135	9.0	0.070	0.005	0.000	0.005	0.920	12.2	15.8
136	13.1	0.155	0.005	0.000	0.035	0.805	11.7	15.8
137	9.3	0.150	0.005	0.000	0.030	0.815	10.7	16.6
138	8.6	0.070	0.000	0.000	0.020	0.910	10.5	16.7
139	7.5	0.115	0.005	0.000	0.015	0.865	11.4	15.8
141	6.5	0.110	0.030	0.000	0.005	0.855	12.3	---
142	10.7	0.110	0.005	0.000	0.015	0.870	10.9	14.6
143	8.8	0.065	0.005	0.000	0.015	0.915	11.6	16.5

**HAEMATOTOLOGY  
AFTER 4 WEEKS  
FEMALES  
GROUP 3 (T-7251)**

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
145	6.43	9.5	0.388	60.3	1.477	24.5	11.1	1369
146	6.59	9.3	0.382	58.0	1.411	24.3	10.8	1236
147	6.78	9.2	0.380	56.0	1.357	24.2	10.9	1130
148	6.41	8.6	0.359	56.0	1.342	24.0	11.5	1239
149	6.25	8.9	0.367	58.7	1.424	24.3	11.2	1210
150	6.18	8.9	0.367	59.4	1.440	24.3	11.7	1150
151	6.49	9.3	0.377	58.1	1.433	24.7	10.3	1263
152	5.83	8.3	0.335	57.5	1.424	24.8	11.1	1454
153	6.51	8.8	0.372	57.1	1.352	23.7	11.0	964
154	6.29	8.6	0.367	58.3	1.367	23.4	11.4	1107
155	5.81	8.6	0.357	61.4	1.480	24.1	10.4	1095
157	6.25	8.4	0.351	56.2	1.344	23.9	11.8	1201
158	6.01	8.3	0.344	57.2	1.381	24.1	11.2	1138
159	6.22	8.4	0.351	56.4	1.350	23.9	11.7	1193

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
145	11.4	0.040	0.005	0.000	0.015	0.940	11.4	14.9
146	7.9	0.105	0.010	0.000	0.015	0.870	12.6	16.0
147	6.7	0.075	0.010	0.000	0.020	0.895	11.7	15.1
148	7.5	0.075	0.015	0.000	0.005	0.905	12.7	14.3
149	6.7	0.045	0.005	0.000	0.005	0.945	11.8	17.8
150	7.7	0.050	0.010	0.000	0.010	0.930	11.3	15.9
151	8.8	0.075	0.005	0.000	0.010	0.910	12.0	16.6
152	10.1	0.150	0.005	0.000	0.010	0.835	12.0	16.0
153	9.2	0.055	0.000	0.000	0.020	0.925	11.5	17.8
154	7.2	0.120	0.010	0.000	0.005	0.865	11.4	16.5
155	6.5	0.140	0.020	0.000	0.010	0.830	12.1	16.7
157	7.2	0.065	0.015	0.000	0.010	0.910	11.4	16.2
158	5.7	0.125	0.005	0.000	0.025	0.845	10.3	17.1
159	7.3	0.160	0.025	0.000	0.020	0.795	11.3	15.0

**HAEMATOTOLOGY  
AFTER 4 WEEKS  
FEMALES  
GROUP 4 (T-7252)**

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
161	5.81	8.4	0.345	59.4	1.446	24.3	11.5	1151
162	6.36	8.7	0.355	55.8	1.368	24.5	10.7	1165
163	6.72	9.5	0.399	59.4	1.414	23.8	11.5	1194
164	6.72	9.5	0.393	58.5	1.414	24.2	11.9	1288
165	6.44	9.2	0.373	57.9	1.429	24.7	10.9	1453
166	6.01	8.8	0.365	60.7	1.464	24.1	11.5	1172
167	5.97	8.7	0.362	60.6	1.457	24.0	10.9	1356
168	6.63	8.9	0.371	56.0	1.342	24.0	11.1	1204
169	6.50	8.7	0.365	56.2	1.338	23.8	11.1	1153
170	6.65	9.5	0.389	58.5	1.429	24.4	10.8	1171
171	7.01	9.5	0.393	56.1	1.355	24.2	11.1	1101
173	6.35	8.6	0.361	56.9	1.354	23.8	11.5	1171
174	6.20	8.8	0.370	59.7	1.419	23.8	11.5	1111
175	6.08	8.4	0.349	57.4	1.382	24.1	10.9	1387

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
161	6.9	0.115	0.000	0.000	0.020	0.865	11.8	16.2
162	8.2	0.100	0.000	0.000	0.025	0.875	12.1	16.1
163	6.7	0.145	0.000	0.000	0.015	0.840	10.8	18.5
164	8.4	0.040	0.005	0.000	0.015	0.940	12.7	16.5
165	8.5	0.090	0.005	0.000	0.020	0.885	11.9	17.3
166	6.5	0.205	0.000	0.000	0.010	0.785	12.5	16.4
167	6.4	0.070	0.005	0.000	0.010	0.915	12.0	16.4
168	5.6	0.075	0.000	0.000	0.005	0.920	12.2	16.2
169	4.1	0.085	0.015	0.000	0.005	0.895	12.1	18.2
170	9.5	0.090	0.020	0.000	0.020	0.870	12.0	17.1
171	10.7	0.050	0.015	0.000	0.020	0.915	12.6	17.3
173	6.5	0.105	0.025	0.000	0.005	0.865	12.3	17.5
174	6.9	0.145	0.005	0.000	0.035	0.815	12.0	17.2
175	11.8	0.115	0.010	0.000	0.010	0.865	11.5	16.9

**HAEMATOTOLOGY  
AFTER 4 WEEKS  
FEMALES  
GROUP 5 (T-7253)**

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
177	6.56	8.7	0.356	54.3	1.326	24.4	11.4	1438
178	6.29	8.5	0.353	56.1	1.351	24.1	11.4	1365
179	6.33	8.8	0.365	57.7	1.390	24.1	11.1	1258
180	6.04	8.7	0.357	59.1	1.440	24.4	11.3	1219
181	6.20	8.8	0.373	60.2	1.419	23.6	11.4	1345
182	6.45	8.9	0.379	58.8	1.380	23.5	11.7	1211
183	6.63	8.9	0.368	55.5	1.342	24.2	11.0	1237
184	5.72	8.3	0.345	60.3	1.451	24.1	11.4	1100
185	6.16	8.7	0.360	58.4	1.412	24.2	11.0	1150
186	6.34	8.6	0.361	56.9	1.356	23.8	10.8	1147
187	6.23	8.9	0.370	59.4	1.429	24.1	11.5	1216
189	6.08	8.5	0.350	57.6	1.398	24.3	10.9	1173
190	6.33	8.8	0.366	57.8	1.390	24.0	10.6	1123
191	6.25	8.7	0.364	58.2	1.392	23.9	11.0	1169

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
177	5.8	0.150	0.010	0.000	0.010	0.830	11.9	16.3
178	7.0	0.100	0.000	0.000	0.020	0.880	10.6	18.2
179	10.7	0.095	0.010	0.000	0.015	0.880	11.6	16.1
180	6.3	0.150	0.010	0.000	0.010	0.830	12.1	15.2
181	6.4	0.050	0.000	0.000	0.015	0.935	12.0	16.5
182	10.4	0.095	0.010	0.000	0.015	0.880	11.8	17.3
183	7.9	0.105	0.005	0.000	0.015	0.875	11.7	16.1
184	7.8	0.075	0.000	0.000	0.010	0.915	12.3	18.4
185	5.1	0.120	0.005	0.000	0.010	0.865	11.8	18.1
186	8.2	0.090	0.015	0.000	0.000	0.895	11.9	18.2
187	5.8	0.080	0.020	0.000	0.015	0.885	12.1	17.2
189	3.5	0.060	0.010	0.000	0.010	0.920	12.1	18.3
190	7.4	0.060	0.015	0.000	0.020	0.905	11.6	16.9
191	10.9	0.020	0.005	0.000	0.025	0.950	12.2	16.9

**HAEMATOLOGY**  
**AFTER 2 WEEKS RECOVERY**  
**MALES**  
**GROUP 1 (VEHICLE CONTROL)**

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
9	7.68	10.0	0.437	56.9	1.302	22.9	13.5	943
10	7.54	10.0	0.419	55.6	1.326	23.9	13.9	1186
11	6.83	8.9	0.372	54.5	1.303	23.9	13.7	1266

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PIT SEC
9	9.9	0.055	0.005	0.000	0.025	0.915	11.3	20.0
10	12.2	0.075	0.005	0.000	0.020	0.900	10.9	---
11	10.9	0.085	0.010	0.000	0.025	0.880	12.4	17.2

**HAEMATOLOGY**  
**AFTER 2 WEEKS RECOVERY**  
**MALES**  
**GROUP 2 (T-7250)**

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
25	7.07	9.3	0.380	53.7	1.315	24.5	14.3	1211
26	7.32	9.3	0.386	52.7	1.270	24.1	13.2	1249
27	7.18	9.3	0.400	55.7	1.295	23.2	13.5	1194

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
25	16.0	0.080	0.020	0.000	0.020	0.880	12.1	16.9
26	11.6	0.145	0.005	0.000	0.015	0.835	11.4	18.1
27	18.0	0.085	0.010	0.000	0.005	0.900	11.8	17.1

**HAEMATOTOLOGY**  
**AFTER 2 WEEKS RECOVERY**  
**MALES**  
**GROUP 3 (T-7251)**

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
41	7.06	9.4	0.410	58.1	1.331	22.9	12.5	869
42	7.13	9.2	0.376	52.7	1.290	24.5	13.4	1020
43	7.21	9.5	0.387	53.7	1.318	24.5	13.3	1220

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
41	11.3	0.105	0.000	0.000	0.025	0.870	13.0	16.6
42	12.1	0.075	0.010	0.000	0.010	0.905	12.2	17.6
43	16.0	0.085	0.000	0.000	0.025	0.890	12.8	17.6

**HAEMATOTOLOGY**  
**AFTER 2 WEEKS RECOVERY**  
**MALES**  
**GROUP 4 (T-7252)**

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
57	7.76	9.7	0.411	53.0	1.250	23.6	13.6	1177
58	7.26	9.1	0.378	52.1	1.253	24.1	14.1	1176
59	7.55	9.1	0.384	50.9	1.205	23.7	14.5	1380

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
57	12.1	0.150	0.020	0.000	0.015	0.815	11.5	17.4
58	10.1	0.125	0.010	0.000	0.030	0.835	11.3	16.6
59	11.0	0.090	0.020	0.000	0.040	0.850	11.5	18.7



**HAEMATOLOGY  
AFTER 2 WEEKS RECOVERY  
MALES  
GROUP 5 (T-7253)**

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
73	6.42	8.4	0.348	54.2	1.308	24.1	15.2	1591
74	6.45	8.9	0.369	57.2	1.380	24.1	13.7	1083
75	6.90	9.2	0.380	55.1	1.333	24.2	14.7	1188

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
73	8.9	0.085	0.010	0.000	0.010	0.895	11.9	16.6
74	12.3	0.140	0.005	0.000	0.025	0.830	11.8	18.3
75	9.0	0.075	0.000	0.000	0.030	0.895	11.7	16.9

**HAEMATOTOLOGY**  
**AFTER 2 WEEKS RECOVERY**  
**MALES**  
**GROUP 6 (T-7254)**

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
89	6.65	8.1	0.352	52.9	1.218	23.0	16.5	1476
90	7.54	8.7	0.394	52.3	1.154	22.1	17.7	1404
91	6.65	8.6	0.382	57.4	1.293	22.5	17.1	1060

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PIT SEC
89	13.1	0.185	0.005	0.000	0.035	0.775	11.9	14.5
90	13.4	0.135	0.005	0.000	0.025	0.835	13.0	16.9
91	9.5	0.130	0.005	0.000	0.015	0.850	12.2	17.3

**HAEMATOLOGY  
AFTER 2 WEEKS RECOVERY  
FEMALES  
GROUP 1 (VEHICLE CONTROL)**

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
121	6.93	9.8	0.397	57.3	1.414	24.7	14.3	1361
122	6.14	8.9	0.360	58.6	1.450	24.7	14.7	1236
123	6.51	8.9	0.355	54.5	1.367	25.1	13.8	1209

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. l	EO. l	BASO. l	MONO. l	LYMPH. l	PT SEC	PTT SEC
121	5.7	0.060	0.005	0.000	0.015	0.920	11.7	18.4
122	7.3	0.035	0.000	0.000	0.030	0.935	11.9	18.4
123	6.7	0.035	0.005	0.000	0.020	0.940	12.1	18.7

**HAEMATOLOGY  
AFTER 2 WEEKS RECOVERY  
FEMALES  
GROUP 2 (T-7250)**

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
137	6.86	9.5	0.392	57.1	1.385	24.2	13.0	1254
138	6.45	9.3	0.378	58.6	1.442	24.6	13.0	1022
139	6.79	9.3	0.373	54.9	1.370	24.9	14.1	1117

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
137	8.2	0.130	0.015	0.000	0.035	0.820	12.0	17.3
138	9.3	0.045	0.005	0.000	0.010	0.940	10.7	17.3
139	9.4	0.090	0.000	0.000	0.010	0.900	11.4	16.7

**HAEMATOLOGY  
AFTER 2 WEEKS RECOVERY  
FEMALES  
GROUP 3 (T-7251)**

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
153	---	---	---	---	---	---	---	---
154	6.32	8.9	0.356	56.3	1.408	25.0	12.8	1166
155	5.71	8.8	0.346	60.6	1.541	25.4	13.9	1113

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
153	---	---	---	---	---	---	---	---
154	8.2	0.215	0.005	0.000	0.030	0.750	11.0	15.9
155	8.3	0.105	0.010	0.000	0.010	0.875	11.2	19.2

**HAEMATOTOLOGY  
AFTER 2 WEEKS RECOVERY  
FEMALES  
GROUP 4 (T-7252)**

ANIMAL NUMBER	HAEMATOTOLOGY PARAMETERS							
	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
169	6.38	8.8	0.358	56.1	1.379	24.6	14.9	1192
170	6.76	9.7	0.387	57.2	1.435	25.1	13.5	1199
171	6.68	9.3	0.364	54.5	1.392	25.5	13.5	1227

ANIMAL NUMBER	HAEMATOTOLOGY PARAMETERS							
	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
169	4.0	0.095	0.020	0.000	0.000	0.885	10.9	19.1
170	10.3	0.105	0.005	0.000	0.015	0.875	11.7	16.9
171	11.1	0.095	0.005	0.000	0.010	0.890	11.8	17.4

**HAEMATOLOGY**  
**AFTER 4 WEEKS RECOVERY**  
**MALES**  
**GROUP 1 (VEHICLE CONTROL)**

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
13	7.94	9.6	0.410	51.6	1.209	23.4	13.3	1309
14	7.47	9.5	0.395	52.9	1.272	24.1	14.4	1289
15	7.84	10.3	0.438	55.9	1.314	23.5	12.6	969

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
13	11.7	0.060	0.000	0.000	0.025	0.915	11.6	17.7
14	12.9	0.120	0.005	0.000	0.025	0.850	11.9	18.1
15	14.3	0.115	0.010	0.000	0.040	0.835	11.7	15.6

**HAEMATOLOGY**  
**AFTER 4 WEEKS RECOVERY**  
**MALES**  
**GROUP 2 (T-7250)**

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
29	7.59	9.7	0.411	54.2	1.278	23.6	14.2	1004
30	7.56	9.3	0.384	50.8	1.230	24.2	14.5	1099
31	7.89	9.7	0.413	52.3	1.229	23.5	14.0	1027

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
29	7.9	0.125	0.015	0.000	0.050	0.810	10.6	17.2
30	12.4	0.145	0.015	0.000	0.035	0.805	12.6	16.8
31	14.6	0.115	0.015	0.000	0.020	0.850	11.5	17.3



**HAEMATOLOGY  
AFTER 4 WEEKS RECOVERY  
MALES  
GROUP 3 (T-7251)**

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
45	7.43	9.3	0.390	52.5	1.252	23.8	13.2	1152
46	7.50	9.3	0.389	51.9	1.240	23.9	13.2	1232
47	7.33	9.3	0.394	53.8	1.269	23.6	13.8	1118

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
45	8.9	0.135	0.000	0.000	0.020	0.845	11.3	17.3
46	9.8	0.140	0.005	0.000	0.040	0.815	11.9	16.5
47	11.7	0.120	0.015	0.000	0.040	0.825	12.5	18.4

**HAEMATOLOGY**  
**AFTER 4 WEEKS RECOVERY**  
**MALES**  
**GROUP 4 (T-7252)**

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
61	7.65	8.9	0.373	48.8	1.163	23.9	14.3	1167
62	7.27	9.3	0.393	54.1	1.279	23.7	12.8	1010
63	7.18	9.2	0.386	53.8	1.281	23.8	13.6	1210

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
61	9.1	0.140	0.005	0.000	0.025	0.830	10.4	16.2
62	12.4	0.155	0.010	0.000	0.030	0.805	12.0	15.8
63	11.6	0.130	0.015	0.000	0.040	0.815	11.2	15.8

**HAEMATOLOGY  
AFTER 4 WEEKS RECOVERY  
MALES  
GROUP 5 (T-7253)**

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
77	7.44	9.5	0.414	55.6	1.277	22.9	12.6	938
78	7.21	8.9	0.381	52.8	1.234	23.4	13.5	1274
79	7.35	9.3	0.387	52.7	1.265	24.0	13.0	1015

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PTT SEC
77	10.4	0.090	0.010	0.000	0.020	0.880	11.6	16.0
78	9.6	0.075	0.005	0.000	0.015	0.905	10.8	15.0
79	10.5	0.125	0.000	0.000	0.025	0.850	12.2	15.4

**HAEMATOTOLOGY**  
**AFTER 4 WEEKS RECOVERY**  
**MALES**  
**GROUP 6 (T-7254)**

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
93	7.39	8.6	0.376	50.9	1.164	22.9	16.8	1022
94	7.50	9.3	0.404	53.9	1.240	23.0	15.0	908
95	7.61	9.3	0.393	51.6	1.222	23.7	13.6	1103

HAEMATOTOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PIT SEC
93	7.7	0.145	0.015	0.000	0.025	0.815	12.0	14.5
94	7.7	0.165	0.020	0.000	0.030	0.785	11.6	14.1
95	10.6	0.140	0.015	0.000	0.015	0.830	10.8	14.5

**HAEMATOLOGY  
AFTER 4 WEEKS RECOVERY  
FEMALES  
GROUP 2 (T-7250)**

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
141	7.21	8.8	0.376	52.1	1.221	23.4	13.6	1199
142	6.34	8.7	0.361	56.9	1.372	24.1	13.0	1111
143	7.49	9.4	0.399	53.3	1.255	23.6	13.5	1039

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. 1	EO. 1	BASO. 1	MONO. 1	LYMPH. 1	PT SEC	PIT SEC
141	5.7	0.135	0.015	0.000	0.025	0.825	11.1	15.8
142	9.5	0.115	0.000	0.000	0.030	0.855	11.1	16.8
143	9.3	0.060	0.015	0.000	0.015	0.910	11.5	16.8

**HAEMATOLOGY**  
**AFTER 4 WEEKS RECOVERY**  
**FEMALES**  
**GROUP 4 (T-7252)**

ANIMAL NUMBER	HAEMATOLOGY PARAMETERS							
	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
173	6.93	9.1	0.380	54.8	1.313	23.9	14.2	875
174	6.61	8.9	0.376	56.9	1.346	23.7	12.2	989
175	6.44	8.8	0.356	55.3	1.366	24.7	12.9	1268

ANIMAL NUMBER	HAEMATOLOGY PARAMETERS							
	WBC G/l	SEG. l	EO. l	BASO. l	MONO. l	LYMPH. l	PT SEC	PTT SEC
173	7.8	0.065	0.025	0.000	0.010	0.900	---	---
174	5.6	0.105	0.010	0.000	0.015	0.870	11.4	15.8
175	10.7	0.120	0.010	0.000	0.030	0.840	11.1	16.2

**HAEMATOLOGY  
AFTER 4 WEEKS RECOVERY  
FEMALES  
GROUP 5 (T-7253)**

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	RBC T/l	HB mmol/l	HCT l/l	MCV fl	MCH fmol	MCHC mmol/l	RDW %	PLATELETS G/l
189	6.75	9.3	0.381	56.4	1.378	24.4	12.2	1069
190	6.93	9.2	0.379	54.7	1.328	24.3	12.8	1075
191	6.68	8.9	0.370	55.4	1.332	24.1	12.9	1158

HAEMATOLOGY PARAMETERS								
ANIMAL NUMBER	WBC G/l	SEG. l	EO. l	BASO. l	MONO. l	LYMPH. l	PT SEC	PIT SEC
189	3.8	0.075	0.010	0.000	0.010	0.905	10.6	18.1
190	7.7	0.105	0.005	0.000	0.020	0.870	11.8	16.1
191	8.4	0.060	0.000	0.000	0.015	0.925	10.7	14.8

**CLINICAL BIOCHEMISTRY  
AFTER 4 WEEKS  
MALES  
GROUP 1 (VEHICLE CONTROL)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
1	0.63	1.95	1.9	1.53	0.74	41.1	5.62	4.9
2	0.62	2.04	2.4	2.12	0.60	45.8	5.71	5.5
3	0.67	1.91	2.2	2.26	1.18	43.4	6.16	5.2
4	0.72	2.16	2.2	1.83	0.47	41.1	6.56	5.4
5	0.62	2.32	1.3	1.54	1.14	39.8	5.19	7.1
6	0.95	3.41	1.4	1.25	0.61	36.2	6.85	5.3
7	1.17	3.12	1.7	1.63	0.60	37.4	5.75	6.1
8	0.73	2.58	1.8	1.55	0.62	44.6	5.76	8.1
9	0.62	1.74	1.2	1.69	0.35	38.6	5.43	6.5
10	0.65	2.56	2.2	1.68	0.62	42.2	6.35	5.2
11	0.77	2.48	1.6	2.15	0.40	39.8	5.57	6.6
13	0.50	1.64	1.8	1.78	0.54	42.2	6.59	5.6
14	0.66	2.38	1.6	1.76	0.77	39.8	5.58	5.2
15	1.06	2.68	1.8	1.49	0.63	41.0	4.93	7.1

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
1	62.5	31.0	31.5	1.0	7.71	2.60	144.6	4.45
2	66.5	33.2	33.3	1.0	6.99	2.62	144.5	4.40
3	66.6	32.4	34.2	0.9	6.12	2.33	143.1	4.42
4	65.7	33.1	32.6	1.0	9.18	2.66	143.4	4.49
5	59.3	29.1	30.2	1.0	6.14	2.63	146.5	4.54
6	67.6	32.8	34.8	0.9	11.31	2.60	146.1	4.73
7	58.9	31.2	27.7	1.1	7.82	2.57	142.8	5.25
8	64.3	32.2	32.1	1.0	10.14	2.46	144.3	4.57
9	58.5	28.7	29.8	1.0	5.85	2.30	143.9	4.33
10	59.2	30.5	28.7	1.1	6.53	2.40	144.8	4.73
11	60.0	29.5	30.5	1.0	6.43	2.64	144.1	4.54
13	55.4	27.6	27.8	1.0	5.83	2.48	145.3	4.59
14	60.5	30.0	30.5	1.0	6.69	2.39	142.5	4.54
15	55.6	28.2	27.4	1.0	9.78	2.51	144.0	4.93

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
1	2.59	96
2	2.67	99
3	2.71	96
4	2.63	96
5	2.57	98
6	2.61	98
7	2.58	99
8	2.65	96
9	2.53	97
10	2.45	96
11	2.58	100
13	2.47	98
14	2.46	94
15	2.42	95



**CLINICAL BIOCHEMISTRY**  
**AFTER 4 WEEKS**  
**MALES**  
**GROUP 2 (T-7250)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST. T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
17	0.66	2.13	1.7	1.64	1.39	44.6	6.20	5.6
18	0.86	2.62	1.7	2.18	0.48	47.3	7.04	7.3
19	0.75	2.17	1.7	1.67	0.50	46.9	5.80	6.3
20	0.76	2.61	2.1	1.37	0.94	42.2	6.48	4.4
21	0.76	1.87	1.7	1.88	1.54	42.2	6.69	6.2
22	0.90	1.87	1.7	1.47	0.60	39.8	6.17	5.6
23	0.64	1.84	1.6	1.61	1.63	42.2	6.78	6.0
24	0.69	1.99	1.7	1.58	1.35	39.8	7.83	4.6
25	0.73	2.10	1.7	2.05	0.33	39.8	5.83	6.5
26	0.65	2.24	1.9	2.51	0.66	37.4	6.48	6.0
27	1.13	2.03	1.5	1.92	0.56	37.4	5.97	5.6
29	0.67	1.85	1.4	1.18	0.31	42.2	6.88	8.1
30	0.83	1.69	1.7	2.00	0.56	36.2	6.38	6.2
31	0.61	2.37	1.6	2.10	0.43	36.2	6.00	6.4

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
17	61.6	32.1	29.5	1.1	6.16	2.63	144.4	3.82
18	64.5	32.4	32.1	1.0	7.75	2.48	143.8	4.42
19	65.3	32.8	32.5	1.0	9.09	2.72	144.2	4.60
20	64.5	32.6	31.9	1.0	5.59	2.44	143.3	4.94
21	65.6	31.1	34.5	0.9	4.84	2.55	145.3	4.55
22	58.6	28.6	30.0	1.0	6.69	2.71	143.3	4.15
23	61.3	29.6	31.7	0.9	6.95	2.66	144.4	4.70
24	64.6	32.0	32.6	1.0	7.85	2.20	144.1	4.29
25	58.9	29.4	29.5	1.0	5.28	2.29	143.7	4.11
26	60.2	30.6	29.6	1.0	4.69	2.27	141.5	4.48
27	61.6	30.8	30.8	1.0	5.71	2.31	143.2	4.33
29	57.0	28.8	28.2	1.0	6.74	2.34	146.2	4.63
30	58.6	28.9	29.7	1.0	5.92	2.53	143.9	4.69
31	55.3	28.1	27.2	1.0	8.58	2.48	143.5	4.75

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
17	2.61	96
18	2.61	100
19	2.61	99
20	2.59	91
21	2.69	95
22	2.57	93
23	2.69	94
24	2.57	95
25	2.55	94
26	2.50	96
27	2.55	94
29	2.51	99
30	2.59	93
31	2.52	96

**CLINICAL BIOCHEMISTRY  
AFTER 4 WEEKS  
MALES  
GROUP 4 (T-7252)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
49	0.90	2.69	1.6	1.91	0.38	39.9	4.95	5.3
50	0.61	1.75	2.1	1.62	0.44	39.9	7.55	6.0
51	0.75	1.66	1.7	1.83	0.68	39.9	7.39	5.6
52	---	2.40	2.3	1.80	0.68	46.9	5.39	8.2
53	0.44	2.78	1.4	1.22	0.37	35.0	6.09	5.9
54	0.80	2.09	1.6	1.55	0.22	37.4	5.59	6.8
55	0.46	2.07	1.5	1.11	0.56	42.2	5.35	7.6
56	0.58	1.88	1.3	2.08	0.64	39.8	6.79	6.6
57	0.65	2.16	1.8	2.12	0.23	38.6	6.17	6.8
58	0.66	1.94	1.4	2.23	0.51	36.2	6.10	6.0
59	0.75	2.71	1.8	2.07	0.41	42.2	5.89	7.4
61	0.44	1.93	1.3	2.28	0.39	36.2	5.73	6.0
62	0.50	1.80	1.5	2.00	0.28	39.8	5.49	6.0
63	0.71	2.23	2.1	1.89	0.59	42.2	6.14	5.7

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
49	63.3	31.1	32.2	1.0	6.44	2.56	144.3	5.02
50	63.5	31.8	31.7	1.0	5.70	2.45	145.6	4.59
51	60.2	30.0	30.2	1.0	8.43	2.36	143.6	4.47
52	62.9	31.8	31.1	1.0	5.15	2.32	144.2	4.34
53	61.1	29.8	31.3	1.0	6.30	2.66	145.3	5.34
54	60.1	30.1	30.0	1.0	8.87	2.33	144.6	4.87
55	62.5	31.5	31.0	1.0	8.38	2.67	145.2	5.46
56	62.8	30.1	32.7	0.9	8.06	2.43	144.7	4.62
57	59.7	29.6	30.1	1.0	5.38	2.34	146.0	4.56
58	62.0	30.0	32.0	0.9	6.81	2.35	143.9	4.82
59	61.5	30.7	30.8	1.0	8.17	2.22	144.8	5.00
61	57.3	28.9	28.4	1.0	7.77	2.38	144.5	4.64
62	62.8	30.9	31.9	1.0	5.06	2.39	146.0	4.24
63	64.5	30.2	34.3	0.9	6.55	2.50	142.8	4.93

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
49	2.61	96
50	2.66	97
51	2.54	99
52	2.58	97
53	2.54	93
54	2.53	91
55	2.64	92
56	2.60	93
57	2.49	93
58	2.58	94
59	2.52	96
61	2.54	93
62	2.62	98
63	2.57	92

**CLINICAL BIOCHEMISTRY**  
**AFTER 4 WEEKS**  
**MALES**  
**GROUP 5 (T-7253)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
65	0.82	1.77	1.7	1.18	0.59	44.6	7.79	6.7
66	0.69	2.09	1.5	1.08	0.37	42.2	6.08	6.5
67	0.88	2.33	1.9	1.53	0.38	46.9	6.81	8.4
68	0.68	2.09	1.6	0.81	1.14	43.4	8.24	6.1
69	0.75	2.04	1.9	0.88	0.42	47.9	6.19	8.1
70	0.81	3.01	2.4	1.83	0.60	39.7	5.60	7.7
71	0.78	2.18	1.7	1.15	0.37	42.0	4.98	7.7
72	0.51	2.54	1.5	0.79	0.33	45.6	4.70	5.5
73	0.59	1.83	2.3	1.66	0.35	50.3	5.43	9.5
74	0.61	2.54	1.8	1.23	0.34	45.6	5.45	8.5
75	0.74	2.31	1.6	1.32	0.32	44.4	5.13	6.5
77	0.60	2.26	1.6	1.57	0.56	47.9	6.08	7.5
78	---	2.80	2.2	1.27	0.31	53.8	7.28	8.4
79	0.83	2.07	1.8	1.75	0.64	45.6	6.04	6.3

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
65	66.2	34.7	31.5	1.1	7.58	3.10	146.5	5.44
66	60.8	33.0	27.8	1.2	10.60	2.60	145.6	4.50
67	66.4	34.3	32.1	1.1	8.76	2.59	143.9	5.14
68	64.2	32.9	31.3	1.1	5.99	2.77	143.4	4.38
69	63.8	34.4	29.4	1.2	7.13	2.83	146.8	5.06
70	68.5	36.4	32.1	1.1	9.17	2.81	145.1	4.77
71	60.9	33.5	27.4	1.2	7.80	2.81	145.4	4.86
72	59.0	31.9	27.1	1.2	7.90	2.44	144.9	4.67
73	59.7	33.8	25.9	1.3	9.08	3.11	142.8	4.49
74	58.5	32.4	26.1	1.2	6.13	2.72	142.1	4.42
75	56.8	31.1	25.7	1.2	4.86	2.50	143.0	4.27
77	57.8	30.2	27.6	1.1	5.07	2.56	143.9	4.37
78	61.3	34.2	27.1	1.3	9.91	2.59	144.4	4.61
79	62.7	35.0	27.7	1.3	9.15	2.50	143.1	4.16

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
65	2.77	99
66	2.67	94
67	2.59	96
68	2.63	92
69	2.59	99
70	2.65	95
71	2.63	98
72	2.54	96
73	2.49	91
74	2.50	93
75	2.44	94
77	2.52	95
78	2.50	93
79	2.55	92

**CLINICAL BIOCHEMISTRY  
AFTER 4 WEEKS  
FEMALES  
GROUP 1 (VEHICLE CONTROL)**

ANIMAL NUMBER	ALAT (GPT) ukat/l	ASAT (GOT) ukat/l	BILI T. umol/l	CHOLEST. T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
113	---	1.93	3.2	3.04	0.45	44.4	5.36	7.3
114	0.39	2.45	1.8	2.38	0.41	46.8	6.50	6.9
115	0.65	2.11	2.2	2.22	0.37	49.1	5.21	8.2
116	0.46	1.59	1.9	2.06	0.55	45.6	5.83	6.4
117	0.66	2.07	2.8	3.04	0.34	49.3	5.79	8.6
118	---	2.23	2.1	2.38	0.39	51.7	5.52	6.8
119	0.60	1.88	3.2	3.23	0.35	48.1	5.96	6.8
120	0.73	2.09	2.6	2.01	0.41	45.8	6.56	6.5
121	0.38	2.38	1.9	2.40	0.39	51.7	5.71	5.9
122	---	2.25	1.8	2.26	0.33	46.9	7.69	7.4
123	0.57	2.10	2.3	3.06	0.56	52.9	5.70	8.3
125	0.56	2.21	2.1	2.72	0.52	49.3	6.63	7.8
126	0.69	2.77	2.2	2.96	0.50	52.9	6.54	8.8
127	0.64	1.85	2.5	2.94	0.40	51.7	6.48	6.7

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
113	66.5	33.6	32.9	1.0	4.37	---	144.6	3.98
114	69.2	36.0	33.2	1.1	4.00	2.02	144.0	4.34
115	66.6	33.6	33.0	1.0	5.01	2.17	144.7	3.97
116	67.1	36.1	31.0	1.2	4.25	2.19	143.4	3.71
117	67.5	35.9	31.6	1.1	5.01	2.26	141.9	4.11
118	64.0	34.2	29.8	1.1	3.34	2.28	143.7	3.63
119	70.6	34.7	35.9	1.0	4.91	2.23	142.1	4.59
120	71.8	38.0	33.8	1.1	2.29	1.90	143.0	4.47
121	67.1	34.4	32.7	1.1	3.67	2.08	144.0	4.08
122	60.2	31.8	28.4	1.1	3.83	2.18	143.1	4.94
123	65.3	34.3	31.0	1.1	5.21	2.19	143.8	4.39
125	65.9	33.7	32.2	1.0	4.44	2.38	141.7	5.04
126	66.6	34.6	32.0	1.1	5.34	2.20	142.7	5.13
127	70.3	36.3	34.0	1.1	4.34	2.17	142.0	4.44

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
113	2.69	96
114	2.66	99
115	2.59	97
116	2.65	98
117	2.63	98
118	2.60	97
119	2.68	97
120	2.63	95
121	2.52	95
122	2.54	97
123	2.56	98
125	2.54	97
126	2.64	97
127	2.70	97

**CLINICAL BIOCHEMISTRY  
AFTER 4 WEEKS  
FEMALES  
GROUP 2 (T-7250)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST. T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
129	0.74	1.65	1.9	2.11	0.52	45.6	5.86	8.0
130	0.68	2.13	2.6	2.99	0.34	46.8	6.38	7.7
131	0.57	2.17	2.3	2.26	0.41	45.6	7.09	8.8
132	0.78	1.77	2.1	2.78	0.47	43.2	6.00	8.8
133	0.72	1.77	2.1	2.28	0.45	49.3	5.54	7.6
134	0.70	1.72	2.6	2.19	0.32	50.9	5.37	12.5
135	0.69	2.56	2.2	3.33	0.50	47.0	6.59	7.1
136	0.59	1.82	2.1	2.74	0.61	47.0	5.95	7.6
137	0.33	2.16	2.0	2.68	0.41	54.4	6.21	6.5
138	0.51	1.55	2.1	2.74	0.38	48.6	6.80	8.8
139	---	1.64	1.8	1.91	0.59	50.5	6.92	6.1
141	0.29	1.99	2.1	1.89	0.58	49.3	5.75	7.5
142	0.37	1.46	2.4	2.90	0.50	53.2	7.44	7.0
143	0.53	1.78	1.7	2.42	0.44	52.9	7.23	10.4

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
129	62.2	33.1	29.1	1.1	3.41	2.26	142.7	3.99
130	70.5	35.4	35.1	1.0	4.31	2.05	143.9	3.83
131	68.4	36.1	32.3	1.1	2.83	2.10	143.0	4.39
132	69.9	35.9	34.0	1.1	4.69	2.35	142.6	4.05
133	62.8	32.7	30.1	1.1	4.63	2.28	144.3	3.91
134	66.3	33.4	32.9	1.0	5.06	2.44	143.0	4.24
135	63.4	33.3	30.1	1.1	3.36	2.22	144.1	4.75
136	64.3	32.2	32.1	1.0	4.62	2.17	143.4	3.77
137	63.7	32.4	31.3	1.0	5.20	2.36	142.5	4.30
138	64.7	34.3	30.4	1.1	3.69	1.93	141.3	3.81
139	58.5	30.9	27.6	1.1	3.55	2.13	143.1	4.02
141	65.9	35.1	30.8	1.1	3.27	2.17	143.6	4.54
142	60.9	32.9	28.0	1.2	3.55	2.26	140.8	3.55
143	63.9	34.0	29.9	1.1	4.13	2.18	140.7	4.28

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
129	2.55	95
130	2.65	100
131	2.65	98
132	2.74	101
133	2.59	97
134	2.65	95
135	2.55	97
136	2.67	99
137	2.58	99
138	2.58	97
139	2.53	97
141	2.61	96
142	2.52	96
143	2.57	98

**CLINICAL BIOCHEMISTRY  
AFTER 4 WEEKS  
FEMALES  
GROUP 3 (T-7251)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST. T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
145	---	1.91	2.3	3.63	0.55	43.2	4.94	6.2
146	---	1.55	2.5	2.82	0.47	50.3	5.43	8.6
147	0.64	2.18	2.0	2.36	0.86	49.1	7.36	8.0
148	0.57	1.61	1.9	2.74	0.55	50.3	5.64	8.9
149	0.53	1.63	2.1	2.97	0.56	48.0	6.97	9.8
150	0.52	2.28	1.9	2.55	0.46	---	5.13	7.3
151	0.83	1.47	1.8	3.23	0.74	44.6	5.56	6.8
152	0.75	2.00	1.9	2.57	0.35	46.9	6.30	7.7
153	0.58	1.42	---	2.69	0.68	50.3	7.44	9.3
154	0.59	2.12	1.5	3.44	0.38	44.6	8.50	8.5
155	0.71	1.68	1.4	3.73	0.68	46.9	6.33	7.9
157	0.53	1.41	1.4	2.24	0.41	49.2	6.21	7.9
158	0.44	1.58	1.8	2.29	0.30	49.2	6.21	8.2
159	0.58	1.36	1.8	3.36	0.41	63.0	6.44	12.2

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
145	65.6	34.1	31.5	1.1	3.28	2.15	144.4	4.30
146	65.6	33.9	31.7	1.1	3.81	2.11	142.6	3.96
147	60.9	31.9	29.0	1.1	3.38	2.15	144.6	4.22
148	64.7	33.7	31.0	1.1	3.52	2.24	143.4	4.07
149	70.2	36.6	33.6	1.1	3.54	2.04	144.1	3.83
150	68.3	35.2	33.1	1.1	3.50	2.09	143.3	3.94
151	70.1	36.5	33.6	1.1	3.65	2.30	144.2	4.08
152	67.3	34.0	33.3	1.0	4.54	2.25	143.2	3.93
153	60.3	32.6	27.7	1.2	3.81	2.60	144.1	5.28
154	64.4	33.4	31.0	1.1	5.07	2.23	143.2	3.70
155	68.1	32.3	35.8	0.9	3.22	2.29	141.2	3.85
157	65.6	34.6	31.0	1.1	2.99	2.09	144.7	3.89
158	65.0	34.4	30.6	1.1	3.55	2.23	142.3	3.45
159	66.1	33.1	33.0	1.0	3.67	2.02	142.6	4.33

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
145	2.67	96
146	2.69	94
147	2.68	96
148	2.69	99
149	2.66	96
150	2.56	96
151	2.75	98
152	2.57	95
153	2.67	98
154	2.56	96
155	2.65	96
157	2.62	97
158	2.58	94
159	2.76	96

**CLINICAL BIOCHEMISTRY  
AFTER 4 WEEKS  
FEMALES  
GROUP 4 (T-7252)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
161	0.50	2.31	2.5	2.46	0.43	47.9	5.92	8.3
162	0.56	2.56	2.1	2.35	0.37	45.6	5.65	9.1
163	0.58	2.07	2.8	2.77	0.49	43.2	6.36	6.0
164	0.70	2.06	2.1	2.15	0.40	43.2	5.61	10.6
165	0.42	2.16	2.1	2.38	0.37	52.7	5.68	8.0
166	0.39	1.91	2.1	2.34	0.71	44.6	5.75	8.0
167	0.60	1.42	2.8	2.48	0.44	42.3	5.41	7.6
168	0.55	1.96	1.9	3.03	0.50	43.4	6.66	7.8
169	0.59	1.76	2.5	2.16	0.37	50.4	5.50	8.7
170	0.33	1.63	1.7	2.37	0.36	49.2	7.28	8.0
171	0.72	1.91	2.0	2.81	0.53	49.2	6.24	7.8
173	0.62	2.19	2.1	2.21	0.26	49.2	7.73	9.0
174	0.68	1.82	1.8	3.08	0.61	48.0	6.68	8.4
175	0.29	1.68	1.9	2.01	0.51	50.4	6.63	7.8

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
161	64.8	34.0	30.8	1.1	5.31	1.98	143.6	5.03
162	64.4	32.4	32.0	1.0	4.22	2.10	143.3	4.42
163	72.0	35.9	36.1	1.0	4.66	2.11	142.5	3.97
164	61.4	32.6	28.8	1.1	5.23	2.28	144.6	4.47
165	65.3	33.2	32.1	1.0	4.95	2.34	144.0	4.31
166	61.6	32.0	29.6	1.1	2.91	2.15	144.0	4.47
167	68.9	35.1	33.8	1.0	2.64	2.25	142.2	4.53
168	68.9	36.9	32.0	1.2	3.82	1.81	143.4	4.37
169	66.2	33.6	32.6	1.0	3.39	2.00	143.8	4.16
170	62.1	32.2	29.9	1.1	8.85	2.28	141.9	4.26
171	62.4	31.9	30.5	1.0	3.47	2.23	141.1	4.36
173	65.0	33.2	31.8	1.0	5.17	1.88	141.8	5.05
174	62.7	32.5	30.2	1.1	2.92	2.27	140.3	4.74
175	67.0	32.5	34.5	0.9	4.11	2.17	143.1	4.45

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
161	2.64	96
162	2.52	97
163	2.67	98
164	2.53	100
165	2.65	96
166	2.56	95
167	2.76	96
168	2.69	101
169	2.66	98
170	2.60	99
171	2.60	96
173	2.57	100
174	2.59	95
175	2.67	94

**CLINICAL BIOCHEMISTRY  
AFTER 4 WEEKS  
FEMALES  
GROUP 5 (T-7253)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
177	0.76	1.99	2.1	1.79	0.50	42.0	5.23	8.5
178	0.45	2.61	1.7	2.03	0.38	43.2	5.77	6.4
179	0.63	1.56	2.2	2.62	0.50	47.9	5.85	7.6
180	0.57	1.80	2.3	2.04	0.34	47.9	5.47	9.7
181	0.69	1.98	2.4	2.33	0.40	43.4	4.88	7.8
182	0.87	2.10	2.0	2.37	0.77	43.4	4.73	8.0
183	0.72	1.76	1.5	2.48	0.86	38.8	5.26	7.7
184	0.82	1.69	2.2	2.40	0.55	42.3	5.46	9.1
185	0.42	1.71	1.6	2.64	0.34	45.7	6.69	7.5
186	0.62	1.64	1.7	2.61	0.41	44.6	7.06	8.8
187	0.40	2.68	1.4	2.85	0.39	49.2	5.48	7.5
189	0.61	2.22	1.8	1.85	0.40	41.1	6.29	6.0
190	0.54	2.02	1.5	2.61	0.29	42.3	6.68	7.2
191	0.58	2.20	1.4	2.60	0.33	45.8	5.73	8.3

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
177	63.8	34.4	29.4	1.2	3.45	2.24	143.2	4.29
178	66.9	34.9	32.0	1.1	5.60	2.02	143.3	4.64
179	69.0	36.1	32.9	1.1	3.77	2.04	143.5	4.12
180	64.8	35.1	29.7	1.2	3.32	2.33	143.6	4.16
181	70.1	37.7	32.4	1.2	2.93	2.31	142.4	4.20
182	68.5	35.2	33.3	1.1	3.38	2.29	144.5	4.18
183	65.4	33.5	31.9	1.1	2.96	2.27	143.2	3.87
184	66.5	36.0	30.5	1.2	3.35	2.20	143.2	4.31
185	68.9	35.8	33.1	1.1	3.89	1.91	143.0	3.73
186	63.1	32.3	30.8	1.0	3.98	2.33	143.2	4.10
187	65.3	32.6	32.7	1.0	3.77	2.11	143.9	4.01
189	66.9	33.8	33.1	1.0	3.58	1.79	142.7	4.27
190	60.2	30.9	29.3	1.1	4.74	2.22	142.8	4.69
191	65.6	34.3	31.3	1.1	3.61	2.23	142.0	4.73

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
177	2.62	91
178	2.62	96
179	2.69	97
180	2.65	94
181	2.72	94
182	2.65	95
183	2.68	95
184	2.68	93
185	2.53	94
186	2.61	91
187	2.51	93
189	2.60	92
190	2.54	92
191	2.58	92



**CLINICAL BIOCHEMISTRY  
AFTER 2 WEEKS RECOVERY  
MALES  
GROUP 1 (VEHICLE CONTROL)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
9	0.62	1.74	1.8	1.72	0.41	40.5	6.68	5.5
10	0.87	2.03	1.8	1.51	0.81	41.6	7.09	5.0
11	0.74	2.44	2.2	1.96	0.49	43.8	8.72	5.2

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
9	62.0	30.8	31.2	1.0	4.42	2.33	145.4	4.45
10	61.7	31.6	30.1	1.0	5.36	2.26	145.9	4.52
11	59.0	30.1	28.9	1.0	5.26	2.57	144.1	4.73

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
9	2.61	97
10	2.53	95
11	2.51	96

**CLINICAL BIOCHEMISTRY  
AFTER 2 WEEKS RECOVERY  
MALES  
GROUP 2 (T-7250)**

ANIMAL NUMBER	ALAT (GPT) ukat/l	ASAT (GOT) ukat/l	BILI T. umol/l	CHOLEST. T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
25	0.66	2.22	1.8	2.13	0.48	41.6	6.41	5.9
26	0.60	1.83	2.0	2.42	0.47	39.3	8.32	5.8
27	1.14	1.85	1.8	2.00	0.47	39.3	8.35	5.3

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
25	62.4	31.3	31.1	1.0	4.23	2.64	143.0	4.64
26	63.0	31.5	31.5	1.0	3.95	2.65	144.2	4.62
27	62.8	31.1	31.7	1.0	4.49	2.59	143.7	4.60

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
25	2.60	94
26	2.57	94
27	2.58	93

**CLINICAL BIOCHEMISTRY  
AFTER 2 WEEKS RECOVERY  
MALES  
GROUP 3 (T-7251)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
41	0.90	1.94	1.4	1.56	0.57	41.6	5.82	6.0
42	0.84	1.50	1.7	1.18	0.87	41.6	7.72	5.8
43	0.93	1.94	2.5	2.08	0.83	37.1	6.08	6.5

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
41	60.5	30.9	29.6	1.0	6.30	2.32	145.5	3.89
42	62.4	31.0	31.4	1.0	6.13	2.40	145.5	4.01
43	62.6	30.9	31.7	1.0	6.23	2.62	145.3	4.44

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
41	2.44	93
42	2.52	94
43	2.60	94

**CLINICAL BIOCHEMISTRY  
AFTER 2 WEEKS RECOVERY  
MALES  
GROUP 4 (T-7252)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
57	0.62	2.56	2.3	2.21	0.89	43.8	6.31	6.2
58	0.78	2.13	1.3	1.93	0.67	40.5	6.97	5.7
59	0.83	2.19	1.8	1.78	0.60	42.7	7.16	7.4

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
57	64.1	33.1	31.0	1.1	4.50	2.47	145.0	4.61
58	64.3	31.6	32.7	1.0	5.10	2.43	144.2	4.82
59	61.1	31.8	29.3	1.1	5.86	2.38	143.5	4.85

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
57	2.48	94
58	2.56	91
59	2.45	94

**CLINICAL BIOCHEMISTRY  
AFTER 2 WEEKS RECOVERY  
MALES  
GROUP 5 (T-7253)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
73	0.59	1.51	1.1	1.90	0.45	37.1	6.13	8.5
74	0.79	1.84	1.6	1.83	0.43	42.7	6.26	7.5
75	0.81	2.18	1.0	1.39	0.36	39.3	6.26	5.9

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
73	60.6	31.0	29.6	1.0	5.27	2.80	145.4	4.48
74	59.9	31.2	28.7	1.1	5.25	2.55	143.3	4.66
75	59.7	30.7	29.0	1.1	3.46	2.32	143.6	4.51

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
73	2.52	90
74	2.53	90
75	2.47	91

**CLINICAL BIOCHEMISTRY  
AFTER 2 WEEKS RECOVERY  
MALES  
GROUP 6 (T-7254)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
89	0.63	1.51	1.7	1.36	0.41	38.2	6.74	5.3
90	0.58	1.96	1.3	1.74	0.40	43.8	6.24	8.5
91	0.56	1.48	1.3	1.12	0.36	42.7	6.98	5.3

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
89	59.4	32.4	27.0	1.2	8.18	2.61	141.4	5.09
90	55.4	32.1	23.3	1.4	6.30	2.73	145.3	5.93
91	57.8	31.3	26.5	1.2	7.47	2.32	147.4	3.88

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
89	2.53	88
90	2.62	91
91	2.42	92

**CLINICAL BIOCHEMISTRY  
AFTER 2 WEEKS RECOVERY  
FEMALES  
GROUP 1 (VEHICLE CONTROL)**

ANIMAL NUMBER	ALAT (GPT) ukat/l	ASAT (GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
121	0.64	1.49	2.6	2.50	0.35	42.9	5.57	8.0
122	0.50	1.46	2.7	2.61	0.45	50.9	6.89	7.4
123	0.58	1.46	2.3	3.33	0.51	48.6	6.16	9.3

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
121	69.0	34.5	34.5	1.0	2.79	2.39	143.9	4.49
122	65.4	33.7	31.7	1.1	3.99	2.82	142.8	4.51
123	69.1	35.6	33.5	1.1	3.99	2.41	142.2	4.39

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
121	2.67	97
122	2.67	95
123	2.66	95

**CLINICAL BIOCHEMISTRY  
AFTER 2 WEEKS RECOVERY  
FEMALES  
GROUP 3 (T-7251)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
153	---	---	---	---	---	---	---	---
154	0.66	1.89	2.7	3.58	0.78	53.2	8.29	9.1
155	0.75	1.17	2.4	4.12	0.91	42.9	7.82	6.8

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
153	---	---	---	---	---	---	---	---
154	64.4	33.8	30.6	1.1	3.44	2.44	141.9	4.76
155	69.4	33.6	35.8	0.9	2.94	2.02	139.9	3.87

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
153	---	---
154	2.65	98
155	2.67	93



**CLINICAL BIOCHEMISTRY  
AFTER 2 WEEKS RECOVERY  
FEMALES  
GROUP 4 (T-7252)**

ANIMAL NUMBER	ALAT (GPT) ukat/l	ASAT (GOT) ukat/l	BILI T. umol/l	CHOLEST. T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
169	0.47	1.70	2.2	2.21	0.53	47.4	7.27	7.9
170	0.43	1.42	2.1	2.30	0.53	45.2	8.01	7.2
171	0.53	1.15	1.8	3.09	0.61	49.8	7.64	7.0

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
169	67.8	34.9	32.9	1.1	3.08	1.70	144.3	3.91
170	62.7	32.2	30.5	1.1	7.03	1.94	142.3	3.98
171	62.3	32.3	30.0	1.1	2.42	1.84	141.8	3.42

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
169	2.61	99
170	2.58	97
171	2.58	95

**CLINICAL BIOCHEMISTRY  
AFTER 2 WEEKS RECOVERY  
FEMALES  
GROUP 5 (T-7253)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
185	0.56	1.08	1.5	2.76	0.41	49.8	7.34	7.4
186	0.48	1.36	1.5	3.15	0.46	47.5	7.76	7.3
187	0.52	1.32	1.8	2.94	0.33	47.5	7.13	8.1

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
185	69.5	36.0	33.5	1.1	3.21	1.81	142.0	3.81
186	63.4	32.8	30.6	1.1	3.37	1.98	142.3	4.26
187	64.3	31.8	32.5	1.0	3.21	2.04	142.2	4.46

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
185	2.67	95
186	2.57	95
187	2.59	96

**CLINICAL BIOCHEMISTRY  
AFTER 4 WEEKS RECOVERY  
MALES  
GROUP 1 (VEHICLE CONTROL)**

ANIMAL NUMBER	ALAT (GPT) ukat/l	ASAT (GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
13	0.52	1.83	2.0	1.90	0.44	40.3	6.46	4.8
14	0.78	2.15	1.7	1.71	0.62	47.8	6.70	5.1
15	0.71	2.16	2.3	1.32	0.37	41.3	6.62	5.6

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
13	62.5	30.9	31.6	1.0	4.29	2.55	146.6	4.77
14	65.3	31.7	33.6	0.9	4.58	2.48	144.6	4.92
15	56.3	28.8	27.5	1.0	5.64	2.82	145.5	4.65

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
13	2.55	98
14	2.58	97
15	2.46	92

**CLINICAL BIOCHEMISTRY  
AFTER 4 WEEKS RECOVERY  
MALES  
GROUP 2 (T-7250)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
29	0.62	1.98	1.6	1.24	0.26	36.6	6.72	6.1
30	0.80	1.63	2.6	2.06	0.42	48.7	7.71	7.0
31	0.48	2.17	1.8	2.22	0.41	42.2	6.57	5.7

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
29	59.9	30.8	29.1	1.1	4.50	2.67	146.8	4.97
30	60.1	29.5	30.6	1.0	3.81	2.78	145.2	4.39
31	58.6	29.1	29.5	1.0	5.63	2.72	144.7	4.91

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
29	2.53	97
30	2.59	88
31	2.55	93

**CLINICAL BIOCHEMISTRY  
AFTER 4 WEEKS RECOVERY  
MALES  
GROUP 3 (T-7251)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
45	0.54	1.67	1.7	1.39	0.43	42.2	6.00	5.8
46	0.65	1.55	2.1	1.42	0.44	41.3	7.58	5.6
47	0.83	2.11	2.2	1.17	0.43	44.0	5.93	6.0

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
45	63.6	29.9	33.7	0.9	4.02	2.42	144.5	4.32
46	58.6	29.4	29.2	1.0	5.20	2.62	145.4	4.97
47	58.1	29.1	29.0	1.0	4.22	2.74	147.2	4.36

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
45	2.58	96
46	2.51	93
47	2.45	92

**CLINICAL BIOCHEMISTRY  
AFTER 4 WEEKS RECOVERY  
MALES  
GROUP 4 (T-7252)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
61	0.36	1.65	1.4	2.26	0.61	45.9	6.24	6.1
62	0.81	1.45	2.4	1.65	0.49	46.8	7.87	6.9
63	0.66	1.83	2.3	1.83	0.99	48.7	7.63	6.1

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
61	60.1	31.0	29.1	1.1	4.46	2.30	144.0	4.70
62	63.0	32.4	30.6	1.1	3.61	2.41	144.8	4.37
63	64.2	30.6	33.6	0.9	4.04	2.67	142.7	5.11

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
61	2.51	93
62	2.62	90
63	2.54	89

**CLINICAL BIOCHEMISTRY  
AFTER 4 WEEKS RECOVERY  
MALES  
GROUP 5 (T-7253)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
77	0.70	1.91	1.5	1.71	0.58	45.9	5.84	7.2
78	1.02	1.89	1.8	1.69	0.45	52.4	5.82	7.2
79	0.80	1.38	1.7	1.99	0.64	48.7	8.40	5.8

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
77	58.4	29.0	29.4	1.0	2.84	2.24	144.0	4.25
78	62.0	30.8	31.2	1.0	5.16	2.30	144.3	4.51
79	59.8	30.4	29.4	1.0	4.87	2.51	144.3	4.20

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
77	2.48	92
78	2.49	96
79	2.56	93

**CLINICAL BIOCHEMISTRY  
AFTER 4 WEEKS RECOVERY  
MALES  
GROUP 6 (T-7254)**

ANIMAL NUMBER	ALAT (GPT) ukat/l	ASAT (GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
93	2.77	3.19	1.1	1.04	0.35	40.3	5.71	7.1
94	1.09	1.60	1.6	1.82	0.66	43.1	7.14	6.1
95	0.60	1.72	1.0	1.60	0.81	42.2	7.64	6.4

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
93	59.3	31.0	28.3	1.1	5.33	2.19	144.5	4.34
94	62.6	31.0	31.6	1.0	4.67	2.20	144.7	3.97
95	64.2	32.4	31.8	1.0	5.44	2.18	143.8	4.28

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
93	2.40	90
94	2.53	95
95	2.58	87



**CLINICAL BIOCHEMISTRY  
AFTER 4 WEEKS RECOVERY  
FEMALES  
GROUP 1 (VEHICLE CONTROL)**

ANIMAL NUMBER	ALAT (GPT) ukat/1	ASAT (GOT) ukat/1	BILI T. umol/1	CHOLEST.T. mmol/1	TRIGL. mmol/1	CREATININE umol/1	GLUCOSE mmol/1	UREA mmol/1
125	0.46	2.05	2.2	2.75	0.46	45.9	6.29	5.5
126	0.72	2.87	2.4	2.90	0.55	51.5	6.18	8.8
127	0.59	1.54	2.8	2.53	0.41	41.3	6.87	6.4

ANIMAL NUMBER	PROTEIN T. g/1	ALBUMIN g/1	GLOBULIN g/1	A/G RATIO	ALP ukat/1	INORG PHOS mmol/1	SODIUM mmol/1	POTASSIUM mmol/1
125	70.4	34.7	35.7	1.0	2.80	2.16	144.3	4.22
126	73.9	36.4	37.5	1.0	3.07	2.51	143.8	4.89
127	70.1	36.2	33.9	1.1	2.41	2.18	143.0	4.48

ANIMAL NUMBER	CALCIUM mmol/1	CHLORIDE mmol/1
125	2.58	98
126	2.76	95
127	2.71	102

**CLINICAL BIOCHEMISTRY  
AFTER 4 WEEKS RECOVERY  
FEMALES  
GROUP 2 (T-7250)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
141	0.48	1.71	2.3	2.06	0.56	45.9	6.68	7.5
142	0.56	1.66	3.0	2.99	0.57	58.0	7.86	8.8
143	0.57	1.87	2.1	2.36	0.41	50.6	8.16	8.3

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
141	68.5	35.9	32.6	1.1	1.83	2.21	143.6	4.70
142	63.5	33.5	30.0	1.1	2.45	2.65	144.4	4.03
143	67.8	35.5	32.3	1.1	2.31	2.05	141.3	4.32

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
141	2.67	93
142	2.59	93
143	2.60	95

**CLINICAL BIOCHEMISTRY  
AFTER 4 WEEKS RECOVERY  
FEMALES  
GROUP 3 (T-7251)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
157	0.60	1.86	2.0	2.62	0.86	41.3	7.80	9.2
158	0.37	1.55	2.5	2.35	0.34	49.6	5.80	8.5
159	0.50	1.44	1.9	2.83	0.51	53.4	7.87	7.3

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
157	70.9	37.0	33.9	1.1	2.11	2.17	143.7	4.76
158	65.5	33.0	32.5	1.0	2.73	2.38	140.7	4.00
159	68.4	35.9	32.5	1.1	1.90	2.08	142.7	3.94

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
157	2.62	97
158	2.60	96
159	2.64	96

**CLINICAL BIOCHEMISTRY  
AFTER 4 WEEKS RECOVERY  
FEMALES  
GROUP 4 (T-7252)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
173	0.54	1.77	2.0	2.24	0.60	51.5	7.60	6.6
174	0.67	1.77	2.3	3.19	1.12	49.6	9.10	8.4
175	0.39	1.63	2.0	2.16	0.57	56.1	6.91	7.7

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
173	67.4	34.7	32.7	1.1	2.57	1.83	143.7	4.61
174	66.3	34.5	31.8	1.1	2.03	2.06	140.8	4.45
175	69.7	33.6	36.1	0.9	2.11	2.03	142.6	4.33

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
173	2.61	97
174	2.60	90
175	2.64	94

**CLINICAL BIOCHEMISTRY  
AFTER 4 WEEKS RECOVERY  
FEMALES  
GROUP 5 (T-7253)**

ANIMAL NUMBER	ALAT(GPT) ukat/l	ASAT(GOT) ukat/l	BILI T. umol/l	CHOLEST.T. mmol/l	TRIGL. mmol/l	CREATININE umol/l	GLUCOSE mmol/l	UREA mmol/l
189	0.61	1.90	1.9	2.07	0.39	47.8	7.21	6.3
190	0.45	1.30	2.0	2.25	0.39	45.0	7.10	6.9
191	0.57	1.39	1.9	2.91	0.50	59.9	6.83	9.4

ANIMAL NUMBER	PROTEIN T. g/l	ALBUMIN g/l	GLOBULIN g/l	A/G RATIO	ALP ukat/l	INORG PHOS mmol/l	SODIUM mmol/l	POTASSIUM mmol/l
189	68.2	34.0	34.2	1.0	2.59	1.73	141.2	4.35
190	62.4	32.5	29.9	1.1	3.29	1.73	143.8	3.66
191	67.8	33.2	34.6	1.0	2.13	2.03	143.2	4.51

ANIMAL NUMBER	CALCIUM mmol/l	CHLORIDE mmol/l
189	2.61	91
190	2.55	93
191	2.56	92

MACROSCOPIC FINDINGS  
MALES  
GROUP 1 (VEHICLE CONTROL)

ANIMAL 1 (SCHEDULED NECROPSY, 21-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 2 (SCHEDULED NECROPSY, 21-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 3 (SCHEDULED NECROPSY, 21-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 4 (SCHEDULED NECROPSY, 21-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 5 (SCHEDULED NECROPSY, 22-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 6 (SCHEDULED NECROPSY, 22-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 7 (SCHEDULED NECROPSY, 22-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 8 (SCHEDULED NECROPSY, 22-SEP-99)

---

NO FINDINGS NOTED

MACROSCOPIC FINDINGS  
MALES  
GROUP 1 (VEHICLE CONTROL)

ANIMAL 9 (SCHEDULED NECROPSY, 06-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 10 (SCHEDULED NECROPSY, 06-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 11 (SCHEDULED NECROPSY, 06-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 13 (SCHEDULED NECROPSY, 20-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 14 (SCHEDULED NECROPSY, 20-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 15 (SCHEDULED NECROPSY, 20-OCT-99)

---

NO FINDINGS NOTED

**MACROSCOPIC FINDINGS**  
**MALES**  
**GROUP 2 (T-7250)**

ANIMAL 17	(SCHEDULED NECROPSY, 21-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 18	(SCHEDULED NECROPSY, 21-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 19	(SCHEDULED NECROPSY, 21-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 20	(SCHEDULED NECROPSY, 21-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 21	(SCHEDULED NECROPSY, 22-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 22	(SCHEDULED NECROPSY, 22-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 23	(SCHEDULED NECROPSY, 22-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 24	(SCHEDULED NECROPSY, 22-SEP-99)
<hr/>	
NO FINDINGS NOTED	



MACROSCOPIC FINDINGS  
MALES  
GROUP 2 (T-7250)

ANIMAL 25

(SCHEDULED NECROPSY, 06-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 26

(SCHEDULED NECROPSY, 06-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 27

(SCHEDULED NECROPSY, 06-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 29

(SCHEDULED NECROPSY, 20-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 30

(SCHEDULED NECROPSY, 20-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 31

(SCHEDULED NECROPSY, 20-OCT-99)

---

NO FINDINGS NOTED

MACROSCOPIC FINDINGS  
MALES  
GROUP 3 (T-7251)

ANIMAL 33  
\_\_\_\_\_  
(SCHEDULED NECROPSY, 21-SEP-99)  
NO FINDINGS NOTED

ANIMAL 34  
\_\_\_\_\_  
(SCHEDULED NECROPSY, 21-SEP-99)  
NO FINDINGS NOTED

ANIMAL 35  
\_\_\_\_\_  
(SCHEDULED NECROPSY, 21-SEP-99)  
KIDNEYS..... BOTH SIDES: PELVIC DILATION.

ANIMAL 36  
\_\_\_\_\_  
(SCHEDULED NECROPSY, 21-SEP-99)  
NO FINDINGS NOTED

ANIMAL 37  
\_\_\_\_\_  
(SCHEDULED NECROPSY, 22-SEP-99)  
NO FINDINGS NOTED

ANIMAL 38  
\_\_\_\_\_  
(SCHEDULED NECROPSY, 22-SEP-99)  
NO FINDINGS NOTED

ANIMAL 39  
\_\_\_\_\_  
(SCHEDULED NECROPSY, 22-SEP-99)  
NO FINDINGS NOTED

ANIMAL 40  
\_\_\_\_\_  
(SCHEDULED NECROPSY, 22-SEP-99)  
NO FINDINGS NOTED

**MACROSCOPIC FINDINGS  
MALES  
GROUP 3 (T-7251)**

ANIMAL 41	(SCHEDULED NECROPSY, 06-OCT-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 42	(SCHEDULED NECROPSY, 06-OCT-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 43	(SCHEDULED NECROPSY, 06-OCT-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 45	(SCHEDULED NECROPSY, 20-OCT-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 46	(SCHEDULED NECROPSY, 20-OCT-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 47	(SCHEDULED NECROPSY, 20-OCT-99)
<hr/>	
NO FINDINGS NOTED	

MACROSCOPIC FINDINGS  
MALES  
GROUP 4 (T-7252)

ANIMAL 49 (SCHEDULED NECROPSY, 21-SEP-99)  
SKIN..... BACK OF THE NECK: ALOPECIA.  
BACK OF THE NECK: SCAB FORMATION.

ANIMAL 50 (SCHEDULED NECROPSY, 21-SEP-99)  
NO FINDINGS NOTED

ANIMAL 51 (SCHEDULED NECROPSY, 21-SEP-99)  
NO FINDINGS NOTED

ANIMAL 52 (SCHEDULED NECROPSY, 21-SEP-99)  
KIDNEYS..... PELVIC DILATION.

ANIMAL 53 (SCHEDULED NECROPSY, 22-SEP-99)  
NO FINDINGS NOTED

ANIMAL 54 (SCHEDULED NECROPSY, 22-SEP-99)  
EPIDIDYIMIDES..... RIGHT SIDE, HEAD: NODULE(S), D=6X4 MM, YELLOWISH.

ANIMAL 55 (SCHEDULED NECROPSY, 22-SEP-99)  
NO FINDINGS NOTED

ANIMAL 56 (SCHEDULED NECROPSY, 22-SEP-99)  
NO FINDINGS NOTED

MACROSCOPIC FINDINGS  
MALES  
GROUP 4 (T-7252)

ANIMAL 57

(SCHEDULED NECROPSY, 06-OCT-99)

NO FINDINGS NOTED

ANIMAL 58

(SCHEDULED NECROPSY, 06-OCT-99)

NO FINDINGS NOTED

ANIMAL 59

(SCHEDULED NECROPSY, 06-OCT-99)

NO FINDINGS NOTED

ANIMAL 61

(SCHEDULED NECROPSY, 20-OCT-99)

NO FINDINGS NOTED

ANIMAL 62

(SCHEDULED NECROPSY, 20-OCT-99)

NO FINDINGS NOTED

ANIMAL 63

(SCHEDULED NECROPSY, 20-OCT-99)

KIDNEYS..... RIGHT SIDE: PELVIC DILATION.

**MACROSCOPIC FINDINGS  
MALES  
GROUP 5 (T-7253)**

ANIMAL 65 (SCHEDULED NECROPSY, 21-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 66 (SCHEDULED NECROPSY, 21-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 67 (SCHEDULED NECROPSY, 21-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 68 (SCHEDULED NECROPSY, 21-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 69 (SCHEDULED NECROPSY, 22-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 70 (SCHEDULED NECROPSY, 22-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 71 (SCHEDULED NECROPSY, 22-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 72 (SCHEDULED NECROPSY, 22-SEP-99)

---

NO FINDINGS NOTED

**MACROSCOPIC FINDINGS  
MALES  
GROUP 5 (T-7253)**

ANIMAL 73

(SCHEDULED NECROPSY, 06-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 74

(SCHEDULED NECROPSY, 06-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 75

(SCHEDULED NECROPSY, 06-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 77

(SCHEDULED NECROPSY, 20-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 78

(SCHEDULED NECROPSY, 20-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 79

(SCHEDULED NECROPSY, 20-OCT-99)

---

NO FINDINGS NOTED

**MACROSCOPIC FINDINGS**  
**MALES**  
**GROUP 6 (T-7254)**

ANIMAL 81	(SCHEDULED NECROPSY, 21-SEP-99)
LIVER.....	ENLARGED. DISCOLOURATION, DARK BROWN
ANIMAL 82	(SCHEDULED NECROPSY, 21-SEP-99)
LIVER.....	ENLARGED. DISCOLOURATION, DARK BROWN
ANIMAL 83	(SCHEDULED NECROPSY, 21-SEP-99)
LIVER.....	ACCENTUATED LOBULAR PATTERN. ENLARGED. DISCOLOURATION, DARK BROWN
ANIMAL 84	(SCHEDULED NECROPSY, 21-SEP-99)
LIVER.....	ENLARGED. DISCOLOURATION, DARK BROWN
ANIMAL 85	(SCHEDULED NECROPSY, 22-SEP-99)
LIVER.....	ENLARGED. DISCOLOURATION, DARK BROWN.
ANIMAL 86	(SCHEDULED NECROPSY, 22-SEP-99)
LIVER.....	ENLARGED. DISCOLOURATION, DARK BROWN.
ANIMAL 87	(SCHEDULED NECROPSY, 22-SEP-99)
LIVER.....	ENLARGED. DISCOLOURATION, DARK BROWN.



MACROSCOPIC FINDINGS  
MALES  
GROUP 6 (T-7254)

ANIMAL 88 (SCHEDULED NECROPSY, 22-SEP-99)

---

LIVER..... ENLARGED.  
DISCOLOURATION, DARK BROWN.

ANIMAL 89 (SCHEDULED NECROPSY, 06-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 90 (SCHEDULED NECROPSY, 06-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 91 (SCHEDULED NECROPSY, 06-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 93 (SCHEDULED NECROPSY, 20-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 94 (SCHEDULED NECROPSY, 20-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 95 (SCHEDULED NECROPSY, 20-OCT-99)

---

NO FINDINGS NOTED

**MACROSCOPIC FINDINGS**  
**MALES**  
**GROUP 7 (T-7255)**

## ANIMAL 97

(KILLED IN EXTREMIS, 06-SEP-99)

---

LIVER.....	ACCENTUATED LOBULAR PATTERN. DISCOLOURATION, PALE.
EPIDIDYMIDES.....	REDUCED IN SIZE.
PROSTATE.....	REDUCED IN SIZE.
SPLEEN.....	REDUCED IN SIZE.
THYMUS.....	REDUCED IN SIZE.

## ANIMAL 98

(KILLED IN EXTREMIS, 03-SEP-99)

---

STOMACH.....	GLANDULAR MUCOSA: THICKENED. LIMITING RIDGE: THICKENED.
LIVER.....	DISCOLOURATION, PALE.
EPIDIDYMIDES.....	RIGHT SIDE: REDUCED IN SIZE.
SEMINAL VESICLES....	REDUCED IN SIZE.
SPLEEN.....	REDUCED IN SIZE.

## ANIMAL 99

(KILLED IN EXTREMIS, 06-SEP-99)

---

LIVER.....	ACCENTUATED LOBULAR PATTERN. DISCOLOURATION, PALE.
EPIDIDYMIDES.....	REDUCED IN SIZE.
SEMINAL VESICLES....	REDUCED IN SIZE.
THYMUS.....	REDUCED IN SIZE.

## ANIMAL 100

(KILLED IN EXTREMIS, 06-SEP-99)

---

STOMACH.....	GLANDULAR MUCOSA: FOCUS/FOCI, RED-BROWN.
LIVER.....	ACCENTUATED LOBULAR PATTERN. DISCOLOURATION, PALE.
EPIDIDYMIDES.....	REDUCED IN SIZE.
PROSTATE.....	REDUCED IN SIZE.
SEMINAL VESICLES....	REDUCED IN SIZE.

**MACROSCOPIC FINDINGS**  
**MALES**  
**GROUP 7 (T-7255)**

ANIMAL 100 (cont.)

(KILLED IN EXTREMIS, 06-SEP-99)

---

SPLEEN..... REDUCED IN SIZE.  
 THYMUS..... REDUCED IN SIZE.  
 SKIN..... HEAD, BACK OF THE NECK: ALOPECIA.

ANIMAL 101

(KILLED IN EXTREMIS, 06-SEP-99)

---

STOMACH..... GLANDULAR MUCOSA: FOCUS/FOCI, RED-BROWN.  
 GLANDULAR MUCOSA: THICKENED.  
 LIVER..... ACCENTUATED LOBULAR PATTERN.  
 ENLARGED.  
 DISCOLOURATION, PALE.  
 EPIDIDYMIDES..... REDUCED IN SIZE.  
 PROSTATE..... REDUCED IN SIZE.  
 SEMINAL VESICLES.... REDUCED IN SIZE.  
 SPLEEN..... REDUCED IN SIZE.  
 THYMUS..... REDUCED IN SIZE.

ANIMAL 102

(KILLED IN EXTREMIS, 02-SEP-99)

---

STOMACH..... HEMORRHAGE.  
 LIVER..... ACCENTUATED LOBULAR PATTERN.  
 ENLARGED.  
 DISCOLOURATION, PALE.

ANIMAL 103

(KILLED IN EXTREMIS, 06-SEP-99)

---

STOMACH..... GLANDULAR MUCOSA: FOCUS/FOCI, RED-BROWN.  
 GLANDULAR MUCOSA: THICKENED.  
 LIVER..... ACCENTUATED LOBULAR PATTERN.  
 DISCOLOURATION, PALE.  
 PROSTATE..... REDUCED IN SIZE.  
 SEMINAL VESICLES.... REDUCED IN SIZE.  
 THYMUS..... REDUCED IN SIZE.

MACROSCOPIC FINDINGS  
MALES  
GROUP 7 (T-7255)

ANIMAL 103 (cont.)

(KILLED IN EXTREMIS, 06-SEP-99)

SKIN..... RIGHT SIDE, FLANK: ALOPECIA.

ANIMAL 104

(KILLED IN EXTREMIS, 06-SEP-99)

STOMACH..... GLANDULAR MUCOSA: FOCUS/FOCI, RED-BROWN.

LIVER..... ACCENTUATED LOBULAR PATTERN.  
DISCOLOURATION, PALE.

PROSTATE..... REDUCED IN SIZE.

SEMINAL VESICLES.... REDUCED IN SIZE.

SPLEEN..... REDUCED IN SIZE.

THYMUS..... REDUCED IN SIZE.

ANIMAL 105

(KILLED IN EXTREMIS, 06-SEP-99)

STOMACH..... GLANDULAR MUCOSA: FOCUS/FOCI, RED-BROWN.  
GLANDULAR MUCOSA: THICKENED.

LIVER..... ACCENTUATED LOBULAR PATTERN.  
LEF LATERAL LOBE: IRREGULAR SURFACE, GRAY-WHITE, D=1X20 MM.  
DISCOLOURATION, PALE.

PANCREAS..... DISCOLOURATION, PALE.

SEMINAL VESICLES.... REDUCED IN SIZE.

SPLEEN..... REDUCED IN SIZE.

THYMUS..... REDUCED IN SIZE.

SKIN..... ABDOMINAL REGION: ALOPECIA.

ANIMAL 106

(KILLED IN EXTREMIS, 06-SEP-99)

STOMACH..... GLANDULAR MUCOSA: THICKENED.

LIVER..... ACCENTUATED LOBULAR PATTERN.  
DISCOLOURATION, PALE.

PROSTATE..... REDUCED IN SIZE.

SEMINAL VESICLES.... REDUCED IN SIZE.

**MACROSCOPIC FINDINGS**  
**MALES**  
**GROUP 7 (T-7255)**

ANIMAL 106 (cont.)

(KILLED IN EXTREMIS, 06-SEP-99)

---

SPLEEN.....	REDUCED IN SIZE.
THYMUS.....	REDUCED IN SIZE.

ANIMAL 107

(KILLED IN EXTREMIS, 03-SEP-99)

---

STOMACH.....	GLANDULAR MUCOSA: THICKENED. LIMITING RIDGE: THICKENED.
LIVER.....	ACCENTUATED LOBULAR PATTERN. ENLARGED. DISCOLOURATION, PALE.
SEMINAL VESICLES....	REDUCED IN SIZE.
SPLEEN.....	REDUCED IN SIZE.
THYMUS.....	REDUCED IN SIZE.

ANIMAL 109

(KILLED IN EXTREMIS, 06-SEP-99)

---

STOMACH.....	GLANDULAR MUCOSA: FOCUS/FOCI, RED-BROWN. GLANDULAR MUCOSA: THICKENED.
LIVER.....	ACCENTUATED LOBULAR PATTERN. DISCOLOURATION, PALE.
PROSTATE.....	REDUCED IN SIZE.
SEMINAL VESICLES....	REDUCED IN SIZE.
SPLEEN.....	REDUCED IN SIZE.
THYMUS.....	REDUCED IN SIZE.

ANIMAL 110

(KILLED IN EXTREMIS, 06-SEP-99)

---

STOMACH.....	GLANDULAR MUCOSA: FOCUS/FOCI, RED-BROWN.
DUODENUM.....	DISCOLOURATION, DARK RED.
EPIDIDYMIDES.....	REDUCED IN SIZE.
PROSTATE.....	REDUCED IN SIZE.
SEMINAL VESICLES....	REDUCED IN SIZE.

MACROSCOPIC FINDINGS  
MALES  
GROUP 7 (T-7255)

ANIMAL 110 (cont.)

(KILLED IN EXTREMIS, 06-SEP-99)

---

THYMUS..... REDUCED IN SIZE.  
DISCOLOURATION, DARK RED.

ANIMAL 111

(KILLED IN EXTREMIS, 03-SEP-99)

---

LIVER..... ACCENTUATED LOBULAR PATTERN.  
DISCOLOURATION, PALE.  
SEMINAL VESICLES.... REDUCED IN SIZE.  
SPLEEN..... REDUCED IN SIZE.  
THYMUS..... REDUCED IN SIZE.

MACROSCOPIC FINDINGS  
FEMALES  
GROUP 1 (VEHICLE CONTROL)

ANIMAL 113 (SCHEDULED NECROPSY, 23-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 114 (SCHEDULED NECROPSY, 23-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 115 (SCHEDULED NECROPSY, 23-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 116 (SCHEDULED NECROPSY, 23-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 117 (SCHEDULED NECROPSY, 24-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 118 (SCHEDULED NECROPSY, 24-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 119 (SCHEDULED NECROPSY, 24-SEP-99)

---

THYMUS..... FOCUS/FOCI, ISOLATED , LIGHT RED.

ANIMAL 120 (SCHEDULED NECROPSY, 24-SEP-99)

---

NO FINDINGS NOTED

MACROSCOPIC FINDINGS  
FEMALES  
GROUP 1 (VEHICLE CONTROL)

ANIMAL 121 (SCHEDULED NECROPSY, 08-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 122 (SCHEDULED NECROPSY, 08-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 123 (SCHEDULED NECROPSY, 08-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 125 (SCHEDULED NECROPSY, 22-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 126 (SCHEDULED NECROPSY, 22-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 127 (SCHEDULED NECROPSY, 22-OCT-99)

---

NO FINDINGS NOTED



MACROSCOPIC FINDINGS  
FEMALES  
GROUP 2 (T-7250)

ANIMAL 129	(SCHEDULED NECROPSY, 23-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 130	(SCHEDULED NECROPSY, 23-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 131	(SCHEDULED NECROPSY, 23-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 132	(SCHEDULED NECROPSY, 23-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 133	(SCHEDULED NECROPSY, 24-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 134	(SCHEDULED NECROPSY, 24-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 135	(SCHEDULED NECROPSY, 24-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 136	(SCHEDULED NECROPSY, 24-SEP-99)
<hr/>	
NO FINDINGS NOTED	

**MACROSCOPIC FINDINGS  
FEMALES  
GROUP 2 (T-7250)**

ANIMAL 137

(SCHEDULED NECROPSY, 08-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 138

(SCHEDULED NECROPSY, 08-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 139

(SCHEDULED NECROPSY, 08-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 141

(SCHEDULED NECROPSY, 22-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 142

(SCHEDULED NECROPSY, 22-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 143

(SCHEDULED NECROPSY, 22-OCT-99)

---

NO FINDINGS NOTED

**MACROSCOPIC FINDINGS  
FEMALES  
GROUP 3 (T-7251)**

ANIMAL 145	(SCHEDULED NECROPSY, 23-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 146	(SCHEDULED NECROPSY, 23-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 147	(SCHEDULED NECROPSY, 23-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 148	(SCHEDULED NECROPSY, 23-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 149	(SCHEDULED NECROPSY, 24-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 150	(SCHEDULED NECROPSY, 24-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 151	(SCHEDULED NECROPSY, 24-SEP-99)
<hr/>	
NO FINDINGS NOTED	
ANIMAL 152	(SCHEDULED NECROPSY, 24-SEP-99)
<hr/>	
NO FINDINGS NOTED	

**MACROSCOPIC FINDINGS  
FEMALES  
GROUP 3 (T-7251)**

ANIMAL 153

(OTHER, 24-SEP-99)

---

GENERAL OBSERVATIONS      DIED AFTER BLOOD SAMPLING.

ANIMAL 154

(SCHEDULED NECROPSY, 08-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 155

(SCHEDULED NECROPSY, 08-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 157

(SCHEDULED NECROPSY, 22-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 158

(SCHEDULED NECROPSY, 22-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 159

(SCHEDULED NECROPSY, 22-OCT-99)

---

KIDNEYS.....      BOTH SIDES: PELVIC DILATION.

**MACROSCOPIC FINDINGS  
FEMALES  
GROUP 4 (T-7252)**

ANIMAL 161 (SCHEDULED NECROPSY, 23-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 162 (SCHEDULED NECROPSY, 23-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 163 (SCHEDULED NECROPSY, 23-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 164 (SCHEDULED NECROPSY, 23-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 165 (SCHEDULED NECROPSY, 24-SEP-99)

---

UTERUS..... DISTENSION.

ANIMAL 166 (SCHEDULED NECROPSY, 24-SEP-99)

---

OVARIES..... LEFT SIDE: HEMORRHAGIC CYST.

ANIMAL 167 (SCHEDULED NECROPSY, 24-SEP-99)

---

NO FINDINGS NOTED

ANIMAL 168 (SCHEDULED NECROPSY, 24-SEP-99)

---

NO FINDINGS NOTED

**MACROSCOPIC FINDINGS  
FEMALES  
GROUP 4 (T-7252)**

ANIMAL 169 (SCHEDULED NECROPSY, 08-OCT-99)

---

SPLEEN..... REDUCED IN SIZE.

ANIMAL 170 (SCHEDULED NECROPSY, 08-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 171 (SCHEDULED NECROPSY, 08-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 173 (SCHEDULED NECROPSY, 22-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 174 (SCHEDULED NECROPSY, 22-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 175 (SCHEDULED NECROPSY, 22-OCT-99)

---

NO FINDINGS NOTED

MACROSCOPIC FINDINGS  
FEMALES  
GROUP 5 (T-7253)

ANIMAL 177

(SCHEDULED NECROPSY, 23-SEP-99)

NO FINDINGS NOTED

ANIMAL 178

(SCHEDULED NECROPSY, 23-SEP-99)

NO FINDINGS NOTED

ANIMAL 179

(SCHEDULED NECROPSY, 23-SEP-99)

NO FINDINGS NOTED

ANIMAL 180

(SCHEDULED NECROPSY, 23-SEP-99)

NO FINDINGS NOTED

ANIMAL 181

(OTHER, 24-SEP-99)

GENERAL OBSERVATIONS      DIED AFTER BLOOD SAMPLING

ANIMAL 182

(SCHEDULED NECROPSY, 24-SEP-99)

NO FINDINGS NOTED

ANIMAL 183

(SCHEDULED NECROPSY, 24-SEP-99)

LIVER.....      ACCENTUATED LOBULAR PATTERN.  
SKIN.....      FLANK, LEFT SIDE: ALOPECIA.  
                    HEAD: ALOPECIA.

ANIMAL 184

(SCHEDULED NECROPSY, 24-SEP-99)

NO FINDINGS NOTED

**MACROSCOPIC FINDINGS  
FEMALES  
GROUP 5 (T-7253)**

ANIMAL 185

(SCHEDULED NECROPSY, 08-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 186

(SCHEDULED NECROPSY, 08-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 187

(SCHEDULED NECROPSY, 08-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 189

(SCHEDULED NECROPSY, 22-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 190

(SCHEDULED NECROPSY, 22-OCT-99)

---

NO FINDINGS NOTED

ANIMAL 191

(SCHEDULED NECROPSY, 22-OCT-99)

---

NO FINDINGS NOTED



**ORGAN WEIGHTS (GRAM)  
AFTER 4 WEEKS  
MALES****GROUP 1 (VEHICLE CONTROL)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
1	347	2.11	1.328	10.43	2.41	0.056	0.848	3.50
2	338	2.01	1.102	9.73	2.19	0.064	0.583	3.11
3	371	2.05	1.294	11.70	2.23	0.066	0.642	3.08
4	340	1.98	1.070	10.10	2.44	0.049	0.587	3.39
5	375	2.00	1.217	11.32	2.43	0.083	0.760	3.44
6	322	2.09	1.346	11.28	2.62	0.063	0.570	3.00
7	341	2.06	1.236	10.70	2.21	0.054	0.621	3.23
8	365	2.18	1.163	12.62	2.89	0.069	0.753	2.98

**GROUP 2 (T-7250)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
17	349	2.30	1.129	11.42	2.63	0.069	0.801	3.16
18	333	2.10	1.112	10.44	2.29	0.055	0.719	3.30
19	323	1.89	1.121	10.88	2.32	0.052	0.693	3.32
20	342	1.93	1.144	11.90	2.64	0.057	0.550	2.66
21	354	1.94	1.199	13.57	2.46	0.056	0.660	3.24
22	393	2.26	1.334	13.30	3.24	0.079	0.808	3.68
23	430	1.97	1.243	14.71	2.98	0.097	0.751	3.37
24	334	2.03	1.415	11.41	2.48	0.061	0.559	3.11

**GROUP 3 (T-7251)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
33	330	2.06	0.984	13.56	2.36	0.050	0.655	3.00
34	336	2.22	1.161	13.53	2.54	0.049	0.656	3.17
35	405	2.09	1.372	15.96	3.25	0.082	0.736	3.22
36	282	1.84	0.916	11.08	2.38	0.035	0.727	2.71
37	331	1.93	1.288	12.79	3.02	0.055	0.657	3.04
38	330	2.06	1.196	11.90	2.61	0.061	0.649	2.93
39	318	1.87	1.120	12.90	2.55	0.071	0.559	3.27
40	331	2.01	1.039	14.36	2.51	0.038	0.683	3.49

**GROUP 4 (T-7252)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
49	347	2.00	1.152	10.94	2.54	0.046	0.690	2.86
50	340	2.05	1.208	10.94	2.63	0.101	0.548	2.97
51	372	2.05	1.227	11.58	2.84	0.052	0.635	4.55
52	343	2.09	1.165	9.85	2.34	0.051	0.645	3.51
53	388	2.05	1.346	13.36	3.03	0.054	0.790	2.89
54	316	2.04	1.007	10.08	2.20	0.049	0.668	3.04
55	388	2.21	1.432	14.16	3.03	0.072	0.713	3.25
56	383	1.97	1.377	13.07	2.60	0.061	0.835	3.31

**ORGAN WEIGHTS (GRAM)  
AFTER 4 WEEKS  
MALES****GROUP 5 (T-7253)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
65	303	2.07	0.978	13.92	2.54	0.050	0.633	2.38
66	325	2.12	1.088	15.86	2.57	0.040	0.752	3.28
67	341	1.97	1.031	13.69	2.55	0.048	0.556	3.63
68	374	1.87	1.234	15.49	2.96	0.074	0.588	3.30
69	330	1.92	1.099	14.64	2.47	0.051	0.576	3.52
70	350	2.07	1.340	17.76	3.04	0.063	0.834	3.78
71	344	1.98	1.351	18.15	3.30	0.077	0.722	4.49
72	370	2.10	1.336	16.10	3.13	0.074	0.735	3.85

**GROUP 6 (T-7254)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
81	293	1.93	0.943	17.95	2.52	0.049	0.436	3.04
82	261	2.00	0.946	17.64	2.45	0.045	0.618	3.40
83	333	2.06	1.138	23.01	2.61	0.058	0.649	3.27
84	278	2.08	1.011	17.96	2.11	0.046	0.429	3.38
85	353	2.05	1.273	25.12	2.97	0.055	0.697	3.13
86	364	2.24	1.379	22.92	2.86	0.058	0.789	3.24
87	270	1.91	0.966	16.42	2.39	0.042	0.498	2.79
88	310	2.06	0.939	20.26	2.38	0.043	0.678	2.96

**GROUP 7 (T-7255)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
97	---	---	---	---	---	---	---	---
98	---	---	---	---	---	---	---	---
99	---	---	---	---	---	---	---	---
100	---	---	---	---	---	---	---	---
101	---	---	---	---	---	---	---	---
102	---	---	---	---	---	---	---	---
103	---	---	---	---	---	---	---	---
104	---	---	---	---	---	---	---	---

**ORGAN/BODY WEIGHT RATIOS (%)  
AFTER 4 WEEKS  
MALES****GROUP 1 (VEHICLE CONTROL)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
1	347	0.61	0.383	3.00	0.69	0.016	0.244	1.01
2	338	0.60	0.326	2.88	0.65	0.019	0.172	0.92
3	371	0.55	0.349	3.15	0.60	0.018	0.173	0.83
4	340	0.58	0.315	2.97	0.72	0.014	0.173	1.00
5	375	0.53	0.325	3.02	0.65	0.022	0.203	0.92
6	322	0.65	0.418	3.50	0.81	0.020	0.177	0.93
7	341	0.60	0.362	3.14	0.65	0.016	0.182	0.95
8	365	0.60	0.319	3.46	0.79	0.019	0.206	0.82

**GROUP 2 (T-7250)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
17	349	0.66	0.323	3.27	0.75	0.020	0.230	0.91
18	333	0.63	0.334	3.14	0.69	0.017	0.216	0.99
19	323	0.59	0.347	3.37	0.72	0.016	0.215	1.03
20	342	0.56	0.335	3.48	0.77	0.017	0.161	0.78
21	354	0.55	0.339	3.83	0.70	0.016	0.186	0.92
22	393	0.57	0.339	3.38	0.83	0.020	0.206	0.94
23	430	0.46	0.289	3.42	0.69	0.023	0.175	0.78
24	334	0.61	0.424	3.42	0.74	0.018	0.167	0.93

**GROUP 3 (T-7251)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
33	330	0.62	0.298	4.11	0.72	0.015	0.198	0.91
34	336	0.66	0.346	4.03	0.75	0.015	0.195	0.94
35	405	0.52	0.339	3.94	0.80	0.020	0.182	0.79
36	282	0.65	0.325	3.93	0.85	0.012	0.258	0.96
37	331	0.58	0.389	3.86	0.91	0.017	0.198	0.92
38	330	0.62	0.362	3.61	0.79	0.018	0.197	0.89
39	318	0.59	0.352	4.06	0.80	0.022	0.176	1.03
40	331	0.61	0.314	4.34	0.76	0.011	0.206	1.05

**GROUP 4 (T-7252)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
49	347	0.58	0.332	3.15	0.73	0.013	0.199	0.82
50	340	0.60	0.355	3.22	0.77	0.030	0.161	0.87
51	372	0.55	0.330	3.11	0.76	0.014	0.171	1.22
52	343	0.61	0.340	2.87	0.68	0.015	0.188	1.02
53	388	0.53	0.347	3.44	0.78	0.014	0.204	0.75
54	316	0.65	0.319	3.19	0.70	0.016	0.211	0.96
55	388	0.57	0.369	3.65	0.78	0.019	0.184	0.84
56	383	0.52	0.360	3.41	0.68	0.016	0.218	0.86

**ORGAN/BODY WEIGHT RATIOS (%)  
AFTER 4 WEEKS  
MALES****GROUP 5 (T-7253)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
65	303	0.68	0.323	4.60	0.84	0.017	0.209	0.79
66	325	0.65	0.335	4.88	0.79	0.012	0.231	1.01
67	341	0.58	0.302	4.01	0.75	0.014	0.163	1.07
68	374	0.50	0.330	4.14	0.79	0.020	0.157	0.88
69	330	0.58	0.333	4.43	0.75	0.015	0.175	1.07
70	350	0.59	0.383	5.07	0.87	0.018	0.238	1.08
71	344	0.58	0.393	5.28	0.96	0.022	0.210	1.31
72	370	0.57	0.361	4.35	0.85	0.020	0.199	1.04

**GROUP 6 (T-7254)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
81	293	0.66	0.322	6.13	0.86	0.017	0.149	1.04
82	261	0.77	0.362	6.76	0.94	0.017	0.237	1.30
83	333	0.62	0.342	6.91	0.78	0.017	0.195	0.98
84	278	0.75	0.364	6.46	0.76	0.017	0.154	1.22
85	353	0.58	0.361	7.12	0.84	0.016	0.197	0.89
86	364	0.62	0.379	6.30	0.79	0.016	0.217	0.89
87	270	0.71	0.358	6.08	0.89	0.016	0.184	1.03
88	310	0.67	0.303	6.54	0.77	0.014	0.219	0.96

**GROUP 7 (T-7255)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
97	---	---	---	---	---	---	---	---
98	---	---	---	---	---	---	---	---
99	---	---	---	---	---	---	---	---
100	---	---	---	---	---	---	---	---
101	---	---	---	---	---	---	---	---
102	---	---	---	---	---	---	---	---
103	---	---	---	---	---	---	---	---
104	---	---	---	---	---	---	---	---

**ORGAN WEIGHTS (GRAM)  
AFTER 4 WEEKS  
FEMALES****GROUP 1 (VEHICLE CONTROL)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
113	231	1.82	0.749	7.86	1.64	0.069	0.575	0.151
114	211	1.89	0.780	6.58	1.48	0.063	0.482	0.129
115	198	1.84	0.689	6.38	1.34	0.086	0.494	0.136
116	234	1.96	0.888	7.31	1.65	0.058	0.543	0.151
117	246	1.96	0.906	7.91	1.68	0.059	0.455	0.129
118	235	1.88	1.108	8.21	1.84	0.088	0.484	0.143
119	243	1.98	0.940	7.65	1.72	0.073	0.504	0.114
120	213	1.80	0.780	6.41	1.59	0.048	0.491	0.166

**GROUP 2 (T-7250)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
129	234	1.97	0.909	8.02	1.94	0.080	0.555	0.137
130	187	1.87	0.751	6.23	1.24	0.057	0.390	0.122
131	219	1.92	0.831	8.37	1.76	0.078	0.466	0.191
132	230	2.03	0.943	7.69	1.72	0.055	0.480	0.135
133	244	1.99	0.914	7.71	1.83	0.073	0.585	0.166
134	259	1.87	1.002	7.99	1.85	0.086	0.499	0.149
135	249	2.01	1.033	8.18	1.89	0.072	0.586	0.163
136	213	2.00	0.917	6.91	1.75	0.074	0.485	0.148

**GROUP 3 (T-7251)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
145	210	1.86	0.845	7.32	1.60	0.068	0.544	0.127
146	236	2.06	0.875	7.72	1.74	0.078	0.623	0.156
147	221	1.94	0.862	8.58	1.68	0.085	0.537	0.138
148	210	1.87	0.738	6.40	1.45	0.067	0.437	0.157
149	249	2.06	0.839	9.31	2.16	0.083	0.616	0.144
150	214	1.70	1.076	7.89	1.52	0.065	0.523	0.130
151	251	1.95	0.926	9.08	1.93	0.064	0.507	0.145
152	213	1.73	0.762	7.75	1.60	0.070	0.637	0.139

**GROUP 4 (T-7252)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
161	228	2.02	0.860	7.51	1.70	0.091	0.559	0.198
162	210	2.00	0.840	7.63	1.45	0.070	0.508	0.154
163	228	1.96	0.832	7.59	1.62	0.055	0.464	0.119
164	187	1.94	0.725	5.91	1.31	0.055	0.428	0.116
165	241	1.85	0.868	7.40	1.57	0.068	0.640	0.119
166	226	1.96	0.870	8.67	1.83	0.078	0.541	0.181
167	264	2.02	0.999	9.30	1.89	0.079	0.617	0.170
168	195	1.99	0.754	6.10	1.42	0.053	0.377	0.096

**ORGAN WEIGHTS (GRAM)  
AFTER 4 WEEKS  
FEMALES****GROUP 5 (T-7253)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
177	213	2.01	0.834	7.97	1.72	0.084	0.479	0.129
178	225	1.86	0.855	7.95	1.81	0.100	0.592	0.193
179	211	1.96	0.780	7.71	1.92	0.056	0.638	0.134
180	222	1.75	0.833	7.54	1.64	0.079	0.463	0.143
181	214	---	---	---	---	---	---	---
182	211	1.96	0.955	7.81	1.96	0.093	0.670	0.215
183	221	1.86	0.902	7.92	1.71	0.076	0.629	0.149
184	195	1.80	0.726	6.45	1.37	0.061	0.498	0.127

**ORGAN/BODY WEIGHT RATIOS (%)  
AFTER 4 WEEKS  
FEMALES****GROUP 1 (VEHICLE CONTROL)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
113	231	0.79	0.324	3.40	0.71	0.030	0.249	
114	211	0.90	0.370	3.12	0.70	0.030	0.228	0.065
115	198	0.93	0.348	3.22	0.68	0.043	0.249	0.061
116	234	0.84	0.379	3.12	0.70	0.025	0.232	0.069
117	246	0.80	0.368	3.22	0.68	0.024	0.185	0.065
118	235	0.80	0.471	3.49	0.78	0.037	0.206	0.052
119	243	0.81	0.387	3.15	0.71	0.030	0.207	0.061
120	213	0.84	0.366	3.01	0.75	0.023	0.231	0.047
								0.078

**GROUP 2 (T-7250)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
129	234	0.84	0.388	3.43	0.83	0.034	0.237	
130	187	1.00	0.402	3.33	0.66	0.030	0.209	0.059
131	219	0.87	0.379	3.82	0.80	0.036	0.213	0.065
132	230	0.88	0.410	3.34	0.75	0.024	0.209	0.087
133	244	0.81	0.375	3.16	0.75	0.030	0.240	0.059
134	259	0.72	0.387	3.08	0.72	0.033	0.193	0.068
135	249	0.81	0.415	3.28	0.76	0.029	0.235	0.058
136	213	0.94	0.431	3.24	0.82	0.035	0.228	0.065
								0.069

**GROUP 3 (T-7251)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
145	210	0.89	0.402	3.49	0.76	0.032		
146	236	0.87	0.371	3.27	0.74	0.033	0.259	0.060
147	221	0.88	0.390	3.88	0.76	0.038	0.264	0.066
148	210	0.89	0.351	3.05	0.69	0.032	0.243	0.062
149	249	0.83	0.337	3.74	0.87	0.033	0.208	0.075
150	214	0.79	0.503	3.69	0.71	0.030	0.247	0.058
151	251	0.78	0.369	3.62	0.77	0.025	0.244	0.061
152	213	0.81	0.358	3.64	0.75	0.033	0.202	0.058
							0.299	0.065

**GROUP 4 (T-7252)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
161	228	0.88	0.377	3.29	0.74	0.040		
162	210	0.95	0.400	3.64	0.69	0.033	0.245	0.087
163	228	0.86	0.365	3.33	0.71	0.024	0.242	0.073
164	187	1.04	0.388	3.16	0.70	0.029	0.204	0.052
165	241	0.77	0.360	3.07	0.65	0.028	0.229	0.062
166	226	0.87	0.385	3.84	0.81	0.035	0.266	0.049
167	264	0.77	0.378	3.52	0.72	0.030	0.239	0.080
168	195	1.02	0.387	3.13	0.73	0.027	0.234	0.064
							0.193	0.049

**ORGAN/BODY WEIGHT RATIOS (%)**  
**AFTER 4 WEEKS**  
**FEMALES**

**GROUP 5 (T-7253)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
177	213	0.94	0.392	3.74	0.81	0.039	0.225	0.061
178	225	0.83	0.380	3.53	0.81	0.044	0.263	0.086
179	211	0.93	0.370	3.65	0.91	0.027	0.302	0.064
180	222	0.79	0.375	3.40	0.74	0.036	0.209	0.064
181	214	---	---	---	---	---	---	---
182	211	0.93	0.453	3.70	0.93	0.044	0.318	0.102
183	221	0.84	0.408	3.58	0.77	0.034	0.285	0.067
184	195	0.92	0.372	3.31	0.70	0.031	0.255	0.065



**ORGAN WEIGHTS (GRAM)  
AFTER 2 WEEKS RECOVERY  
MALES****GROUP 1 (VEHICLE CONTROL)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
9	405	2.14	1.290	11.70	2.60	0.077	0.605	3.20
10	339	1.85	1.179	9.85	2.73	0.060	0.524	2.70
11	443	2.15	1.517	14.36	3.20	0.066	0.642	3.63

**GROUP 2 (T-7250)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
25	358	1.93	1.235	10.89	2.45	0.044	0.619	2.88
26	394	1.88	1.287	12.38	2.50	0.053	0.691	3.24
27	376	2.00	1.369	11.53	2.69	0.051	0.846	3.37

**GROUP 3 (T-7251)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
41	340	1.91	1.202	10.85	2.43	0.051	0.700	2.71
42	426	2.18	1.487	13.99	3.30	0.057	0.853	3.05
43	375	2.07	1.166	11.88	2.79	0.070	0.683	3.25

**GROUP 4 (T-7252)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
57	372	2.06	1.188	10.92	2.56	0.070	0.690	3.27
58	392	2.01	1.296	12.49	2.85	0.065	0.937	3.07
59	322	1.97	1.069	9.19	2.28	0.051	0.502	3.01

**GROUP 5 (T-7253)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
73	308	2.02	1.246	9.72	2.24	0.043	0.490	2.80
74	423	2.23	1.488	13.65	3.17	0.064	0.860	3.65
75	397	2.04	1.282	11.31	3.09	0.058	0.666	3.48

**ORGAN WEIGHTS (GRAM)  
AFTER 2 WEEKS RECOVERY  
MALES****GROUP 6 (T-7254)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
89	307	2.13	1.123	11.77	2.49	0.044	0.669	3.20
90	272	1.98	0.992	11.14	2.03	0.043	0.719	3.45
91	269	1.97	1.019	9.26	1.97	0.034	0.457	3.11

**GROUP 7 (T-7255)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
105	---	---	---	---	---	---	---	---
106	---	---	---	---	---	---	---	---
107	---	---	---	---	---	---	---	---

**ORGAN/BODY WEIGHT RATIOS (%)  
AFTER 2 WEEKS RECOVERY  
MALES****GROUP 1 (VEHICLE CONTROL)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
9	405	0.53	0.319	2.89	0.64	0.019	0.149	0.79
10	339	0.55	0.348	2.90	0.81	0.018	0.155	0.80
11	443	0.49	0.342	3.24	0.72	0.015	0.145	0.82

**GROUP 2 (T-7250)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
25	358	0.54	0.345	3.04	0.68	0.012	0.173	0.80
26	394	0.48	0.327	3.14	0.63	0.013	0.175	0.82
27	376	0.53	0.364	3.07	0.72	0.014	0.225	0.90

**GROUP 3 (T-7251)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
41	340	0.56	0.354	3.19	0.71	0.015	0.206	0.80
42	426	0.51	0.349	3.28	0.78	0.013	0.200	0.72
43	375	0.55	0.311	3.17	0.74	0.019	0.182	0.87

**GROUP 4 (T-7252)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
57	372	0.55	0.319	2.93	0.69	0.019	0.185	0.88
58	392	0.51	0.331	3.19	0.73	0.017	0.239	0.78
59	322	0.61	0.332	2.86	0.71	0.016	0.156	0.94

**GROUP 5 (T-7253)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
73	308	0.66	0.405	3.16	0.73	0.014	0.159	0.91
74	423	0.53	0.352	3.23	0.75	0.015	0.203	0.86
75	397	0.51	0.323	2.85	0.78	0.015	0.168	0.88

**ORGAN/BODY WEIGHT RATIOS (%)  
AFTER 2 WEEKS RECOVERY  
MALES****GROUP 6 (T-7254)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
89	307	0.69	0.366	3.83	0.81	0.014	0.218	1.04
90	272	0.73	0.365	4.09	0.75	0.016	0.264	1.27
91	269	0.73	0.379	3.44	0.73	0.013	0.170	1.16

**GROUP 7 (T-7255)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
105	---	---	---	---	---	---	---	---
106	---	---	---	---	---	---	---	---
107	---	---	---	---	---	---	---	---

**ORGAN WEIGHTS (GRAM)  
AFTER 2 WEEKS RECOVERY  
FEMALES****GROUP 1 (VEHICLE CONTROL)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
121	244	2.08	0.921	7.42	1.77	0.093	0.421	0.126
122	258	1.92	0.890	7.72	1.58	0.076	0.433	0.159
123	264	1.91	0.971	8.60	1.75	0.076	0.511	0.143

**GROUP 2 (T-7250)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
137	242	1.91	0.988	7.08	1.56	0.063	0.534	0.144
138	225	1.71	0.952	7.27	1.39	0.079	0.487	0.167
139	---	1.96	0.852	8.36	1.76	0.084	0.640	0.200

**GROUP 3 (T-7251)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
153	---	---	---	---	---	---	---	---
154	272	1.91	0.994	9.58	1.77	0.061	0.475	0.176
155	276	2.09	1.053	9.60	1.83	0.071	0.554	0.146

**GROUP 4 (T-7252)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
169	230	1.92	0.854	7.55	1.62	0.091	0.377	0.177
170	289	1.99	1.040	8.55	1.89	0.078	0.652	0.196
171	276	1.84	0.968	9.21	1.86	0.072	0.661	0.161

**GROUP 5 (T-7253)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
185	262	1.86	0.955	7.66	1.71	0.064	0.455	0.252
186	242	2.05	0.917	8.58	1.88	0.088	0.542	0.156
187	251	1.98	0.920	6.75	1.55	0.078	0.368	0.117

**ORGAN/BODY WEIGHT RATIOS (%)  
AFTER 2 WEEKS RECOVERY  
FEMALES****GROUP 1 (VEHICLE CONTROL)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
121	244	0.85	0.377	3.04	0.73	0.038	0.173	0.052
122	258	0.74	0.345	2.99	0.61	0.029	0.168	0.062
123	264	0.72	0.368	3.26	0.66	0.029	0.194	0.054

**GROUP 2 (T-7250)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
137	242	0.79	0.408	2.92	0.65	0.026	0.221	0.060
138	225	0.76	0.423	3.23	0.62	0.035	0.216	0.074
139	---	---	---	---	---	---	---	---

**GROUP 3 (T-7251)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
153	---	---	---	---	---	---	---	---
154	272	0.70	0.365	3.52	0.65	0.022	0.175	0.065
155	276	0.76	0.382	3.48	0.66	0.026	0.201	0.053

**GROUP 4 (T-7252)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
169	230	0.83	0.371	3.28	0.70	0.040	0.164	0.077
170	289	0.69	0.360	2.96	0.65	0.027	0.226	0.068
171	276	0.67	0.351	3.34	0.67	0.026	0.239	0.058

**GROUP 5 (T-7253)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
185	262	0.71	0.365	2.93	0.65	0.024	0.174	0.096
186	242	0.85	0.379	3.54	0.78	0.036	0.224	0.064
187	251	0.79	0.367	2.69	0.62	0.031	0.147	0.047

**ORGAN WEIGHTS (GRAM)  
AFTER 4 WEEKS RECOVERY  
MALES****GROUP 1 (VEHICLE CONTROL)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
13	377	1.89	1.263	10.08	2.38	0.056	0.569	3.61
14	442	2.13	1.320	12.01	2.71	0.063	0.759	3.42
15	374	2.11	1.240	9.42	2.41	0.038	0.662	3.24

**GROUP 2 (T-7250)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
29	372	1.98	1.301	9.75	2.54	0.059	0.605	3.54
30	435	2.21	1.338	13.45	3.10	0.050	0.755	3.49
31	411	2.26	1.272	11.17	2.56	0.050	0.512	3.29

**GROUP 3 (T-7251)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
45	358	2.04	1.188	10.23	2.62	0.077	0.548	2.94
46	394	1.93	1.127	12.44	2.47	0.056	0.660	3.07
47	384	2.14	1.258	9.24	2.62	0.062	0.567	3.23

**GROUP 4 (T-7252)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
61	439	2.08	1.348	11.04	2.85	0.059	0.729	3.67
62	447	2.00	1.179	12.09	3.06	0.063	0.736	4.10
63	546	2.12	1.578	14.90	3.08	0.077	0.667	3.34

**GROUP 5 (T-7253)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
77	416	2.12	1.343	11.62	2.71	0.058	0.754	3.49
78	380	1.94	1.339	9.82	2.58	0.043	0.540	3.69
79	467	2.24	1.548	14.90	2.93	0.050	0.851	3.55

**ORGAN WEIGHTS (GRAM)  
AFTER 4 WEEKS RECOVERY  
MALES**

**GROUP 6 (T-7254)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
93	298	1.96	1.114	9.85	2.22	0.042	0.500	3.33
94	396	2.18	1.235	12.78	2.60	0.048	0.580	3.23
95	398	1.89	1.432	14.86	2.64	0.038	0.856	2.84

**GROUP 7 (T-7255)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
109	---	---	---	---	---	---	---	---
110	---	---	---	---	---	---	---	---
111	---	---	---	---	---	---	---	---



**ORGAN/BODY WEIGHT RATIOS (%)  
AFTER 4 WEEKS RECOVERY  
MALES****GROUP 1 (VEHICLE CONTROL)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
13	377	0.50	0.335	2.67	0.63	0.015	0.151	0.96
14	442	0.48	0.299	2.72	0.61	0.014	0.172	0.77
15	374	0.56	0.332	2.52	0.64	0.010	0.177	0.87

**GROUP 2 (T-7250)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
29	372	0.53	0.350	2.62	0.68	0.016	0.163	0.95
30	435	0.51	0.308	3.09	0.71	0.011	0.174	0.80
31	411	0.55	0.309	2.72	0.62	0.012	0.125	0.80

**GROUP 3 (T-7251)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
45	358	0.57	0.332	2.86	0.73	0.022	0.153	0.82
46	394	0.49	0.286	3.16	0.63	0.014	0.168	0.78
47	384	0.56	0.328	2.41	0.68	0.016	0.148	0.84

**GROUP 4 (T-7252)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
61	439	0.47	0.307	2.51	0.65	0.013	0.166	0.84
62	447	0.45	0.264	2.70	0.68	0.014	0.165	0.92
63	546	0.39	0.289	2.73	0.56	0.014	0.122	0.61

**GROUP 5 (T-7253)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
77	416	0.51	0.323	2.79	0.65	0.014	0.181	0.84
78	380	0.51	0.352	2.58	0.68	0.011	0.142	0.97
79	467	0.48	0.331	3.19	0.63	0.011	0.182	0.76

**ORGAN/BODY WEIGHT RATIOS (%)  
AFTER 4 WEEKS RECOVERY  
MALES****GROUP 6 (T-7254)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
93	298	0.66	0.374	3.31	0.74	0.014	0.168	1.12
94	396	0.55	0.312	3.23	0.66	0.012	0.146	0.82
95	398	0.47	0.360	3.73	0.66	0.010	0.215	0.71

**GROUP 7 (T-7255)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	TESTES
109	---	---	---	---	---	---	---	---
110	---	---	---	---	---	---	---	---
111	---	---	---	---	---	---	---	---

**ORGAN WEIGHTS (GRAM)  
AFTER 4 WEEKS RECOVERY  
FEMALES****GROUP 1 (VEHICLE CONTROL)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
125	233	1.94	0.909	6.95	1.50	0.064	0.378	0.118
126	273	2.07	0.958	8.36	1.68	0.071	0.427	0.153
127	259	2.16	0.910	8.31	1.80	0.070	0.455	0.186

**GROUP 2 (T-7250)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
141	276	1.93	0.981	8.74	1.88	0.073	0.494	0.138
142	240	1.75	0.853	8.57	1.85	0.088	0.559	0.153
143	254	1.90	0.895	7.52	1.54	0.062	0.464	0.113

**GROUP 3 (T-7251)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
157	256	1.92	0.968	7.77	1.76	0.059	0.513	0.165
158	285	2.08	0.997	8.63	1.97	0.087	0.558	0.158
159	261	1.91	0.930	8.18	2.05	0.068	0.547	0.150

**GROUP 4 (T-7252)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
173	236	2.03	0.871	7.13	1.51	0.066	0.387	0.145
174	344	2.05	1.114	10.91	2.12	0.083	0.533	0.160
175	300	1.95	1.067	8.99	1.85	0.091	0.647	0.209

**GROUP 5 (T-7253)**

ANIMAL NUMBER	BODY W.	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
189	230	1.94	0.845	7.73	1.83	0.091	0.509	0.145
190	277	2.01	1.177	8.75	2.03	0.084	0.608	0.165
191	288	1.95	0.971	8.20	1.92	0.075	0.565	0.194

**ORGAN/BODY WEIGHT RATIOS (%)  
AFTER 4 WEEKS RECOVERY  
FEMALES****GROUP 1 (VEHICLE CONTROL)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
125	233	0.83	0.390	2.98	0.64	0.027	0.162	0.051
126	273	0.76	0.351	3.06	0.62	0.026	0.156	0.056
127	259	0.83	0.351	3.21	0.69	0.027	0.176	0.072

**GROUP 2 (T-7250)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
141	276	0.70	0.355	3.17	0.68	0.026	0.179	0.050
142	240	0.73	0.355	3.57	0.77	0.037	0.233	0.064
143	254	0.75	0.352	2.96	0.61	0.024	0.183	0.044

**GROUP 3 (T-7251)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
157	256	0.75	0.378	3.03	0.69	0.023	0.200	0.064
158	285	0.73	0.350	3.03	0.69	0.031	0.196	0.055
159	261	0.73	0.356	3.13	0.79	0.026	0.210	0.057

**GROUP 4 (T-7252)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
173	236	0.86	0.369	3.02	0.64	0.028	0.164	0.061
174	344	0.60	0.324	3.17	0.62	0.024	0.155	0.047
175	300	0.65	0.356	3.00	0.62	0.030	0.216	0.070

**GROUP 5 (T-7253)**

ANIMAL NUMBER	BODY W. (GRAM)	BRAIN	HEART	LIVER	KIDNEYS	ADRENALS	SPLEEN	OVARIES
189	230	0.84	0.367	3.36	0.79	0.040	0.221	0.063
190	277	0.72	0.425	3.16	0.73	0.030	0.219	0.060
191	288	0.68	0.337	2.85	0.67	0.026	0.196	0.067

## APPENDIX 1

ProPath GmbH

### Draft Pathology Report

Exploratory 28-Day Oral Toxicity with  
T-7250, T-7251, T-7252, T-7253, T-7254 and  
T-7255

by Daily Gavage in the Rat

followed by a 14/28-Day Recovery Period

NOTOX Project 264656

NOTOX Substances 91872, 91881, 91899, 91908, 91917 and 91926  
3M Test no. T-7250, T-7251, T-7252, T-7253, T-7254 and T-7255

This report contains 166 pages

Dr. J.Th. Wilson  
Oberemattstr.52a  
Pratteln 4133  
Switzerland

tel: +41 61 823 04 10  
fax: +41 61 823 04 11

**PATHOLOGY REPORT (DRAFT)**

Page 2/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Table of Contents**

Table of contents ..... 2

Authentication ..... 3

Summary ..... 4

Materials and methods ..... 5

Results ..... 7

Conclusions ..... 8

Incidence table - macroscopic findings ..... 9

Incidence table - selected microscopic findings with grades ..... 13

Incidence table - microscopic findings ..... 15

Individual animal microscopic findings ..... 26

Animal data list ..... 49

Individual animal data records ..... 54

**PATHOLOGY REPORT (DRAFT)**

Page 3/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Authentication**

The undersigned hereby declares, that the histopathology data in this report were compiled by him, and that they reflect accurately the primary data records. This report, consisting of 166 pages, was created by the computer system of Propath GmbH.

Jeffrey Th. Wilson, Dr.med.vet, BVSc, MSc, MRCVS  
Toxicologic Pathologist

**Propath GmbH**  
CH-4133 Pratteln, Switzerland

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

### Summary

Pathomorphologic examination was performed on 168 Sprague Dawley rats (98 males, 70 females) which had been subjected to an exploratory 28-day oral (gavage) toxicity study with the test articles **T-7250, T-7251, T-7252, T-7253, T-7254 and T-7255**.

The rats were assigned to seven dose groups, five containing fourteen males and fourteen females (groups 1, 2, 3, 4 and 5) and two consisting of fourteen males only (groups 6 and 7). Test articles were administered once daily by gavage at doses of 30 mg/kg (T-7250, T-7251, T-7252, T-7253) (dose groups 2, 3, 4 and 5) or 15 mg/kg (T-7254 and T-7255) (dose groups 6 and 7 respectively) for 28/29 days. The rats of the control group 1 received the vehicle, 1% aqueous carboxymethyl cellulose, alone. At the end of the treatment period eight animals of each sex from all groups were killed and subjected to complete necropsies (main study). Three males and three females from each dose group were subjected to necropsy following 14-day or 28-day treatment-free periods (recovery allocation 1 and 2).

All rats were necropsied. Histopathologic examination was performed on adrenal glands, kidneys, liver, lymph nodes - mandibular and mesenteric, ovaries, pancreas, spleen, testes, thymus and all organs or tissues with macroscopic findings.

All group 7 (**T-7255**) animals were sacrificed after 9 to 13 test days due to loss of body weight. One female group 3 (**T-7251**) rat and a female group 5 (**T-7253**) rat died at blood sampling at the end of the treatment period. All other rats survived their assigned study periods.

At necropsy enlarged/discolored and/or accentuated lobular patterns were noted in the livers of **male** rats from groups 6 (**T-7254**) and 7 (**T-7255**).

The primary morphologic alteration due to treatment was hepatocellular hypertrophy in the **liver** of **males** only from the **T-7251, T-7253 and T-7254** groups. Group 6, **T-7254** was affected to the greatest degree. Complete reversal of this finding had occurred in all the affected groups by the end of the 28 day recovery period.

Slightly increased severity of hemopoiesis (erythroid) in the **spleen** occurred in the **T-7250, T-7252 and T-7254** group **males** at the end of the **main study**. In the **T-7250** group, severity of this finding was lower following the recovery periods but remained slightly increased in the **T-7252 and 7254** groups.

In the **T-7255** group which was sacrificed after 10 days of treatment due to bodyweight losses, there were secondary effects - primarily atrophy or indications of reduced function, in a range of organs.

There were no treatment related morphological findings recorded in any group (**T-7250, T-7251, T-7252 or T-7253**) of females.



**PATHOLOGY REPORT (DRAFT)**

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Materials and Methods**

*Study Design*

Dose group	Dose mg/kg	Number of rats				Animal numbers					
		males		females		males			females		
		main	rec.1 /2	main	rec.1 /2	main	rec.1	rec.2	main	rec.1	rec.2
1 Vehicle control		8	3/3	8	3/3	1 - 8	9-11	13-15	113-120	121-123	125-127
2 T-7250	30	8	3/3	8	3/3	17-24	25-27	29-31	129-136	137-139	141-143
3 T-7251	30	8	3/3	8	3/3	33-40	41-43	45-47	145-152	153-155	157-159
4 T-7252	30	8	3/3	8	3/3	49-56	57-59	61-63	161-168	169-171	173-175
5 T-7253	30	8	3/3	8	3/3	65-72	73-75	77-79	177-184	185-187	189-191
6 T-7254	15	8	3/3	-	-	81-88	89-91	93-95	-	-	-
7 T-7255	15	8	3/3	-	-	97-104	105-107	109-111	-	-	-

*Administration of the Test Article*

The test article was administered daily by gavage for at least 28 days. The recovery group rats were allowed a 14-day (recovery 1) or 28-day (recovery 2) treatment free period. Rats of the control group 1 received the vehicle, 1% aqueous carboxymethyl cellulose, alone.

*Necropsy and Histopathology*

At the end of the assigned study periods, the rats were killed by exsanguination following anesthesia by ether vapour. Complete necropsies were performed on all rats. Representative tissue samples of the following organs were preserved in 4% phosphate buffered neutral formaldehyde solution (10% formalin).

Adrenal glands, aorta, bone - sternum and femur including joint; brain, clitoral glands, epididymides, esophagus, eyes with optic nerve and Harderian glands; identification marks, heart, kidneys, lacrimal glands - exorbital, large intestine - cecum, colon and rectum; larynx, liver, lungs, lymph nodes - mandibular and mesenteric; female mammary gland area, ovaries, pancreas, pituitary gland, preputial glands, prostate gland, salivary glands - mandibular and sublingual; sciatic nerve, seminal vesicles, skeletal muscle, skin, small intestine - duodenum, jejunum and ileum with Peyer's patches; spinal cord - cervical, midthoracic and lumbar; spleen, stomach, testes, thymus, thyroid glands with parathyroid glands, tongue, trachea, urinary bladder, uterus and all organs or tissues with macroscopic abnormalities.

**PATHOLOGY REPORT (DRAFT)**

Page 6/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Materials and Methods**

Following fixation, the following organs from all animals of the **main study** and all **unscheduled decedents**, were trimmed, processed and embedded in paraffin wax. Sections were cut at a thickness of 2-4 micrometers and stained with hematoxylin and eosin. Numbers of sections made are given in parentheses.

Adrenal glands (2), kidneys (2), liver (2), lymph nodes - mandibular (2) and mesenteric (1), ovaries (2), pancreas (1), spleen (1), testes (2), thymus (1) and all organs or tissues with macroscopic findings.

Following examination of the above tissues, sections of **liver** from groups 3 (T-7251), 5 (T-7253) and 6 (T-7254) and **spleen** from groups 2 (T-7250), 4 and 6 of **recovery allocations 1 and 2** animals, were prepared and examined.

The sections were in evaluated in January and February 2000.

*Data Compilation*

The animal data and macroscopic findings were electronically transferred from the necropsy raw data files of NOTOX into the computer system of Propath GmbH where the microscopic findings were recorded by the undersigned pathologist using on-line input

Macroscopic findings are presented in summary in the table "Incidence of Macroscopic Findings" and in full descriptive terms in the "Individual Animal Data Records". Wherever possible, macroscopic findings were correlated with a microscopic finding.

Microscopic findings are listed for each animal along with severity grades in the table "Individual Microscopic Findings" and summarized in the tables "Incidence of All Microscopic Findings" and "Incidence Table - Selected Microscopic Findings with Grades". They are further given in full descriptive terms in the "Individual Animal Data Records". Histologic changes were described according to their distribution, severity, and morphologic character.

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

## Results

### Mortality

All group 7 (**T-7255**) animals were sacrificed after 9 to 13 test days due to loss of bodyweight. One female group 3 (T-7251) rat (no. 153) and a female group 5 (T-7253) rat (no. 181), died at blood sampling at the end of the treatment period. All other rats survived their assigned study periods.

### Macroscopic Findings

The following macroscopic findings were considered to be primary effects of the test articles:

**Liver** - enlarged/discolored/accentuated lobular pattern were noted in male rats from groups 6 and 7 (T-7255) of the **main study allocation**.

Other macroscopic observations in the treated groups included: reduced size of **prostate, seminal vesicles, spleen and thymus** in group 7 (males).

### Microscopic Findings

Primary treatment related microscopic findings were noted in the **liver** and **spleen**. At the end of the **main study**, midzonal/centrilobular hypertrophy in the **liver** was seen in all group 3 and 6 and in seven group 5 **males** only. Severity of this finding varied between minimal to moderate, the mean grade being greatest in group 6. Focal coagulative necrosis accompanied this alteration in two group 5 and five group 6 rats. Complete reversal of this finding had occurred in all affected groups at the end of the 28 day **recovery 2** period.

In the **spleen** a slight increase in the severity of hemopoiesis - primarily erythropoiesis, was recorded in groups 2, 4 and 6 **males** at the end of the **main study**. Severity grades of this finding were lower in group 2 following the recovery periods, whereas in groups 4 and 6 they remained at levels similar to those at the end of treatment.

A range of findings were recorded in various organs from group 7 (male) rats which can be considered as secondary effects related to the lack of growth in these animals. These included hepatocellular atrophy in the **liver**, reduced zymogen in the **pancreas** and atrophy of the **prostate** and **seminal vesicles**.

The remainder of the microscopic findings recorded at **all necropsies**, were within the range of background pathology encountered in Sprague Dawley rats of this age and strain and occurred at similar incidences and severity in both control and treated rats.

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

### Conclusions

The primary morphologic alteration following the administration of **T-7250, T-7251, T-7252, T-7253 or T-7254** by once daily gavage to Sprague Dawley rats for twenty eight days, was present in the **liver** at the end of the **main study**. This took the form of hepatocellular hypertrophy in males only from the **T-7251, T-7253 and T-7254** groups. **T-7254** treated animals were affected to the greatest degree. Complete reversal of this finding had occurred in all the affected groups by the end of the 28 day recovery period.

Slightly increased severity of hemopoiesis (erythroid) in the **spleen** occurred in the **T-7250, T-7252 and T-7254** group **males** at the end of the **main study**. In the **T-7250** group, severity of this finding was lower following the recovery periods but remained slightly increased in the **T-7252 and 7254** groups.

In the **T-7255** group which was sacrificed after 10 days of treatment due to body weight losses, there were secondary effects - primarily atrophy or indications of reduced function, in a range of organs.

There were no treatment related morphological findings recorded in any group (**T-7250, T-7251, T-7252 or T-7253**) of females.

**PATHOLOGY REPORT (DRAFT)**

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Incidence Table - Macroscopic Findings**

**Main Study**

SEX: DOSE GROUP:	MALE							FEMALE						
	1	2	3	4	5	6	7	1	2	3	4	5	6	7
number of animals	8	8	8	8	8	8	8	8	8	8	8	8	8	8
<u>General observations</u>														
Died after blood sampling	0	0	0	0	0	0	0	0	0	0	0	0	1	
<u>Stomach</u>														
Thickened general	0	0	0	0	0	0	1	0	0	0	0	0	0	
limiting ridge	0	0	0	0	0	0	1	0	0	0	0	0	0	
glandular mucosa	0	0	0	0	0	0	2	0	0	0	0	0	0	
Focus/foci glandular mucosa	0	0	0	0	0	0	4	0	0	0	0	0	0	
Hemorrhage general	0	0	0	0	0	0	1	0	0	0	0	0	0	
<u>Liver</u>														
Enlarged Discolouration	0	0	0	0	0	8	2	0	0	0	0	0	0	
Accentuated lobular pattern	0	0	0	0	0	8	8	0	0	0	0	0	0	
	0	0	0	0	0	0	7	0	0	0	0	0	1	
<u>Kidneys</u>														
Pelvic dilation	0	0	1	1	0	0	0	0	0	0	0	0	0	
<u>Epididymides</u>														
Nodule(s) Reduced in size	0	0	0	1	0	0	0	0	0	0	0	0	0	
	0	0	0	0	0	0	5							
<u>Prostate</u>														
Reduced in size	0	0	0	0	0	0	5							
<u>Seminal vesicles</u>														
Reduced in size	0	0	0	0	0	0	6							



**PATHOLOGY REPORT (DRAFT)**

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no. : 00006  
 Date : 29.Feb.2000

**Incidence Table - Macroscopic Findings**

**Recovery Allocation 1**

SEX: DOSE GROUP:	MALE							FEMALE						
	1	2	3	4	5	6	7	1	2	3	4	5	6	7
number of animals	3	3	3	3	3	3	3	3	3	3	3	3	3	3
<u>General observations</u>														
Died after blood sampling	0	0	0	0	0	0	0	0	0	0	1	0	0	0
<u>Stomach</u>														
Thickened limiting ridge glandular mucosa	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Focus/foci glandular mucosa	0	0	0	0	0	0	3	0	0	0	0	0	0	0
<u>Liver</u>														
Enlarged Discolouration	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Accentuated lobular pattern	0	0	0	0	0	0	3	0	0	0	0	0	0	0
Irregular surface	0	0	0	0	0	0	1	0	0	0	0	0	0	0
<u>Pancreas</u>														
Discolouration	0	0	0	0	0	0	1	0	0	0	0	0	0	0
<u>Prostate</u>														
Reduced in size	0	0	0	0	0	0	1	0	0	0	0	0	0	0
<u>Seminal vesicles</u>														
Reduced in size	0	0	0	0	0	0	3	0	0	0	0	0	0	0
<u>Spleen</u>														
Reduced in size	0	0	0	0	0	0	3	0	0	0	1	0	0	0
<u>Thymus</u>														
Reduced in size	0	0	0	0	0	0	3	0	0	0	0	0	0	0
<u>Skin</u>														
Alopecia abdominal region	0	0	0	0	0	0	1	0	0	0	0	0	0	0

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Incidence Table - Macroscopic Findings**

**Recovery Allocation 2**

DOSE GROUP:	SEX: MALE							SEX: FEMALE						
	1	2	3	4	5	6	7	1	2	3	4	5	6	7
number of animals	3	3	3	3	3	3	3	3	3	3	3	3	3	3
<u>Stomach</u>														
Thickened glandular mucosa	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Focus/foci glandular mucosa	0	0	0	0	0	0	2	0	0	0	0	0	0	0
<u>Duodenum</u>														
Discolouration	0	0	0	0	0	0	1	0	0	0	0	0	0	0
<u>Liver</u>														
Discolouration	0	0	0	0	0	0	2	0	0	0	0	0	0	0
Accentuated lobular pattern	0	0	0	0	0	0	2	0	0	0	0	0	0	0
<u>Kidneys</u>														
Pelvic dilation	0	0	0	1	0	0	0	0	0	1	0	0	0	0
<u>Epididymides</u>														
Reduced in size	0	0	0	0	0	0	1	0	0	0	0	0	0	0
<u>Prostate</u>														
Reduced in size	0	0	0	0	0	0	2	0	0	0	0	0	0	0
<u>Seminal vesicles</u>														
Reduced in size	0	0	0	0	0	0	3	0	0	0	0	0	0	0
<u>Spleen</u>														
Reduced in size	0	0	0	0	0	0	2	0	0	0	0	0	0	0
<u>Thymus</u>														
Reduced in size	0	0	0	0	0	0	3	0	0	0	0	0	0	0
Discolouration	0	0	0	0	0	0	1	0	0	0	0	0	0	0



Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Incidence Table - Selected Microscopic Findings with Grades**

**Main Study**

DOSE GROUP:	SEX: MALE							SEX: FEMALE						
	1	2	3	4	5	6	7	1	2	3	4	5	6	7
number of animals	8	8	8	8	8	8	8	8	8	8	8	8	8	8
<u>Liver</u>														
number examined	8	8	8	8	8	8	8	8	8	8	8	8	8	8
Midzonal/ centrilobular hypertrophy, diffuse (minimal)	0	0	4	0	3	0	0	0	0	0	0	0	0	0
(slight)	0	0	4	0	4	6	0	0	0	0	0	0	0	0
(moderate)	0	0	0	0	0	2	0	0	0	0	0	0	0	0
<b>Total</b>	<b>0</b>	<b>0</b>	<b>8</b>	<b>0</b>	<b>7</b>	<b>8</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<u>Spleen</u>														
number examined	8	8	8	8	8	8	8	8	8	8	8	8	8	8
Hemopoiesis, primarily erythropoiesis (minimal)	5	3	6	2	6	4	0	6	4	3	6	8	8	8
(slight)	3	3	2	5	1	2	0	1	2	2	2	0	0	0
(moderate)	0	2	0	1	0	2	0	0	0	0	0	0	0	0
<b>Total</b>	<b>8</b>	<b>8</b>	<b>8</b>	<b>8</b>	<b>7</b>	<b>8</b>	<b>0</b>	<b>7</b>	<b>6</b>	<b>5</b>	<b>8</b>	<b>8</b>	<b>8</b>	<b>8</b>

**PATHOLOGY REPORT (DRAFT)**

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Incidence Table - Selected Microscopic Findings with Grades**

**Recovery Allocation 1**

SEX: DOSE GROUP:	MALE							FEMALE						
	1	2	3	4	5	6	7	1	2	3	4	5	6	7
number of animals	3	3	3	3	3	3	3	3	3	3	3	3		
<u>Liver</u>														
number examined			3		3	3	3			3		3		
Midzonal/ centrilobular hypertrophy, diffuse (minimal)			0		0	1	2			0		0		
<u>Spleen</u>														
number examined		3		3		3	3		3	1		3		
Hemopoiesis, primarily erythropoiesis (minimal) (slight) (moderate)		3		2		0	0		2	1		1		
		0		1		1	0		1	0		2		
		0		0		2	0		0	0		0		
<b>Total</b>		<b>3</b>		<b>3</b>		<b>3</b>	<b>0</b>		<b>3</b>	<b>1</b>		<b>3</b>		

**Recovery Allocation 2**

SEX: DOSE GROUP:	MALE							FEMALE						
	1	2	3	4	5	6	7	1	2	3	4	5	6	7
number of animals	3	3	3	3	3	3	3	3	3	3	3	3		
<u>Spleen</u>														
number examined		3		3		3	3		3		3			
Hemopoiesis, primarily erythropoiesis (minimal) (slight) (moderate)		3		1		1	0		2		3			
		0		1		2	0		0		0			
		0		1		0	0		0		0			
<b>Total</b>		<b>3</b>		<b>3</b>		<b>3</b>	<b>0</b>		<b>2</b>		<b>3</b>			

**PATHOLOGY REPORT (DRAFT)**

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Incidence Table - Microscopic Findings**

**Main Study**

SEX: DOSE GROUP:	MALE							FEMALE						
	1	2	3	4	5	6	7	1	2	3	4	5	6	7
number of animals	8	8	8	8	8	8	8	8	8	8	8	8	8	8
<u>General Observations</u>														
number examined														
Macro observation confirmed													1	
													1	
<u>Stomach</u>														
number examined							6							
Erosion glandular mucosa							2							
Mineralization, focal in glandular mucosa							1							
Forestomach, inflammation							2							
<u>Liver</u>														
number examined	8	8	8	8	8	8	8	8	8	8	8	8	8	8
Kupffer cell pigment, brown	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Hepatocellular vacuolation	0	0	0	1	1	0	0	0	1	0	0	0	0	0
Lymphocytic cell foci, periportal	6	5	5	6	4	2	2	1	2	2	1	3		
Inflammation - granulohistiocytic	1	0	0	0	0	2	0	0	0	0	0	0	0	0
Inflammatory cell foci/single cell necrosis	8	8	7	8	8	8	1	8	7	8	8	6		
Hepatocellular atrophy, diffuse	0	0	0	0	0	0	8	0	0	0	0	0	0	0
Midzonal/centrilobular hypertrophy, diffuse	0	0	8	0	7	8	0	0	0	0	0	0	0	0
Coagulative necrosis, focal	0	1	0	0	2	5	2	0	1	0	0	0	0	0

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Incidence Table - Microscopic Findings**

SEX: DOSE GROUP:	MALE							FEMALE						
	1	2	3	4	5	6	7	1	2	3	4	5	6	7
number of animals	8	8	8	8	8	8	8	8	8	8	8	8	8	8
<u>Pancreas</u>														
number examined	8	8	8	8	8	8	8	8	8	8	8	8	8	8
Reduced zymogen	0	0	0	0	0	0	5	0	0	0	0	0	0	0
Inflammation, lymphoid	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Apoptosis/single cell necrosis, exocrine	2	1	3	1	3	0	0	0	0	0	0	0	0	0
<u>Kidneys</u>														
number examined	8	8	8	8	8	8	8	8	8	8	8	8	8	8
Pelvic dilation	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Hyaline cast(s)	1	0	1	1	0	1	0	0	0	0	0	0	0	0
Tubular mineralisation	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Cystic tubules	1	1	0	0	1	1	0	0	0	1	0	0	0	0
Interstitial inflammation, lymphocytic	3	3	3	3	3	1	0	1	1	1	0	1	0	1
Atrophy	6	7	8	2	5	2	2	1	2	2	0	3	0	3
Tubular necrosis/ degeneration, outer stripe	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Pelvic inflammation, lymphogranulocytic	0	0	0	0	0	0	0	1	1	0	1	1	0	1
Urothelial proliferation, focal	0	0	1	0	0	0	0	0	0	0	0	0	0	0
<u>Testes</u>														
number examined	8	8	8	8	8	8	8	8	8	8	8	8	8	8
Immature	0	0	0	0	0	0	1	0	0	0	0	0	0	1
Seminiferous cell debris, intratubular	0	0	0	0	0	0	1	0	0	0	0	0	0	1



Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Incidence Table - Microscopic Findings**

SEX: DOSE GROUP:	MALE							FEMALE						
	1	2	3	4	5	6	7	1	2	3	4	5	6	7
number of animals	8	8	8	8	8	8	8	8	8	8	8	8	8	8
<u>Adrenal Glands</u>														
number examined	8	8	8	8	8	8	8	8	8	8	8	8	8	8
Extracapsular nodule	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Cortical hypertrophy, focal	0	0	1	0	0	0	0	0	0	0	0	0	0	0
<u>Spleen</u>														
number examined	8	8	8	8	8	8	8	8	8	8	8	8	8	8
Hemopoiesis, primarily erythropoiesis	8	8	8	8	7	8	0	7	6	5	8	8		
Hemosiderin pigment	5	3	6	4	6	8	4	8	8	8	8	8		
Lymphoid atrophy	0	0	0	0	0	0	5	0	0	0	0	0		
Lymphoid hyperplasia	3	2	0	2	0	0	0	2	2	0	1	2		
<u>Thymus</u>														
number examined	8	8	8	8	8	8	7	8	8	8	8	8		
Congestion	0	0	0	0	0	0	0	1	0	0	0	0		
Lymphoid atrophy - involution	0	1	0	0	0	0	6	2	1	3	1	3		
<u>Mesenteric Lymph Node</u>														
number examined	8	8	8	8	8	8	8	8	8	8	8	8		
Lymphoid atrophy	0	0	0	0	0	0	4	0	0	0	0	0		
<u>Mandibular Lymph Nodes</u>														
number examined	8	8	8	8	8	8	8	8	8	8	8	8		
Lymphoid atrophy	0	0	0	0	0	0	4	0	0	0	0	0		
Plasmacytosis	2	1	0	0	0	3	0	0	1	2	1	1		
Lymphoid hyperplasia	2	1	0	0	3	2	0	3	1	4	3	2		

**PATHOLOGY REPORT (DRAFT)**

Page 19/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Incidence Table - Microscopic Findings**

DOSE GROUP:	SEX: MALE							SEX: FEMALE						
	1	2	3	4	5	6	7	1	2	3	4	5	6	7
number of animals	8	8	8	8	8	8	8	8	8	8	8	8		
<u>Skin</u>														
number examined				1			2					1		
Inflammation, lymphoid				1			0					0		
Epithelial hyperplasia, focal				1			0					0		





**PATHOLOGY REPORT (DRAFT)**

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Incidence Table - Microscopic Findings**

SEX: DOSE GROUP:	MALE							FEMALE						
	1	2	3	4	5	6	7	1	2	3	4	5	6	7
number of animals	3	3	3	3	3	3	3	3	3	3	3	3	3	3
<u>Testes</u>														
Spermatidic giant cell(s)							1							
<u>Prostate Gland</u>														
number examined							1							
Atrophy							1							
<u>Seminal Vesicles</u>														
number examined							3							
Atrophy							3							
<u>Adrenal Glands</u>														
number examined							3			1				
Congestion							0			1				
<u>Spleen</u>														
number examined	3		3		3	3		3	1	3				
Hemopoiesis, primarily erythropoiesis	3		3		3	0		3	1	3				
Hemosiderin pigment	3		3		3	1		3	0	3				
Lymphoid atrophy	0		0		0	3		0	0	0				
<u>Thymus</u>														
number examined							3			1				
Lymphoid atrophy - involution							3			0				
<u>Mesenteric Lymph Node</u>														
number examined							3			1				
Lymphoid atrophy							2			0				

**PATHOLOGY REPORT (DRAFT)**

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Incidence Table - Microscopic Findings**

SEX: DOSE GROUP:	MALE							FEMALE						
	1	2	3	4	5	6	7	1	2	3	4	5	6	7
number of animals	3	3	3	3	3	3	3	3	3	3	3	3	3	3
<u>Mandibular Lymph Nodes</u>														
number examined							3					1		
Lymphoid atrophy							1					0		
<u>Skin</u>														
number examined							1							



**PATHOLOGY REPORT (DRAFT)**

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Incidence Table - Microscopic Findings**

SEX: DOSE GROUP:	MALE							FEMALE						
	1	2	3	4	5	6	7	1	2	3	4	5	6	7
number of animals	3	3	3	3	3	3	3	3	3	3	3	3	3	3
<u>Kidneys</u>														
number examined				1			3				1			
Pelvic dilation				1			0				1			
Interstitial inflammation, lymphocytic				0			0				1			
Atrophy				1			1				1			
Urothelial proliferation, focal				1			0				0			
<u>Testes</u>														
number examined							3							
Immature							1							
<u>Epididymides</u>														
number examined							1							
Seminiferous cell debris							1							
<u>Prostate Gland</u>														
number examined							2							
Atrophy							1							
<u>Seminal Vesicles</u>														
number examined							3							
Atrophy							3							
<u>Adrenal Glands</u>														
number examined							3							

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Incidence Table - Microscopic Findings**

SEX: DOSE GROUP:	MALE							FEMALE						
	1	2	3	4	5	6	7	1	2	3	4	5	6	7
number of animals	3	3	3	3	3	3	3	3	3	3	3	3	3	3
<u>Spleen</u>														
number examined		3		3		3	3		3		3			
Hemopoiesis, primarily erythropoiesis		3		3		3	0		2		3			
Hemosiderin pigment		3		3		3	1		3		3			
Lymphoid atrophy		0		0		0	3		0		0			
<u>Thymus</u>														
number examined							3							
Congestion							1							
Lymphoid atrophy - involution							3							
<u>Mesenteric Lymph Node</u>														
number examined							3							
Lymphoid atrophy							1							
<u>Mandibular Lymph Nodes</u>														
number examined							3							
Lymphoid atrophy							1							

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Microscopic Findings**

Codes and symbols in table heading:

m Males  
f Females

Codes and symbols in animal lines:

p Planned sacrifice (main study)  
r Recovery 1 (planned sacrifice)  
s Recovery 2 (planned sacrifice)  
k Killed moribund  
o Other

Grading system used in finding lines:

0 finding not present  
1 minimal  
2 slight  
3 moderate  
4 severe  
5 very severe  
x present

Only organs/groups with findings are listed in the table

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

**Individual Animal Microscopic Findings**

**Males**

**Dose group 1**

	1	2	3	4	5	6	7	8
	m	m	m	m	m	m	m	m
necropsy status	P	P	P	P	P	P	P	P
<b>Liver</b>								
Lymphocytic cell foci, periportal	2	1	1	0	1	1	0	1
Inflammation - granulohistiocytic	0	0	0	0	1	0	0	0
Inflammatory cell foci/single cell necrosis	2	1	2	2	1	2	2	1
<b>Pancreas</b>								
Apoptosis/single cell necrosis, exocrine	0	0	0	0	0	0	1	1
<b>Kidneys</b>								
Hyaline cast(s)	0	0	1	0	0	0	0	0
Cystic tubules	0	0	0	0	0	0	1	0
Interstitial inflammation, lymphocytic	0	0	1	2	2	0	0	0
Atrophy	1	1	1	1	0	0	1	1
<b>Testes</b>								
Atrophy	0	0	3	0	0	0	0	0
<b>Adrenal Glands</b>								
Extracapsular nodule	0	0	x	0	0	0	0	0
<b>Spleen</b>								
Hemopoiesis, primarily erythropoiesis	1	1	2	1	2	1	2	1
Hemosiderin pigment	1	0	1	1	0	0	2	1
Lymphoid hyperplasia	2	0	0	2	0	2	0	0
<b>Mandibular Lymph Nodes</b>								
Plasmacytosis	2	0	0	0	0	0	2	0
Lymphoid hyperplasia	2	2	0	0	0	0	0	0

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

**Individual Animal Microscopic Findings**

**Males**

**Dose group 2**

	17	18	19	20	21	22	23	24
	m	m	m	m	m	m	m	m
necropsy status	p	p	p	p	p	p	p	p
<b>Liver</b>								
Lymphocytic cell foci, periportal	2	0	1	1	0	1	1	0
Inflammatory cell foci/single cell necrosis	1	2	2	2	1	2	1	2
Coagulative necrosis, focal	0	0	0	0	0	0	0	1
<b>Pancreas</b>								
Apoptosis/single cell necrosis, exocrine	0	0	0	1	0	0	0	0
<b>Kidneys</b>								
Cystic tubules	0	0	0	1	0	0	0	0
Interstitial inflammation, lymphocytic	0	1	2	0	0	0	1	0
Atrophy	1	1	1	1	0	1	1	1
<b>Spleen</b>								
Hemopoiesis, primarily erythropoiesis	1	2	1	2	3	2	3	1
Hemosiderin pigment	0	1	0	1	0	0	0	1
Lymphoid hyperplasia	0	2	0	0	0	0	0	2
<b>Thymus</b>								
Lymphoid atrophy - involution	0	0	0	0	0	0	0	2
<b>Mandibular Lymph Nodes</b>								
Plasmacytosis	0	0	0	0	2	0	0	0
Lymphoid hyperplasia	0	0	2	0	0	0	0	0



**PATHOLOGY REPORT (DRAFT)**

Page 29/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Microscopic Findings**

**Males**

**Dose group 2**

	25	26	27	29	30	31
	m	m	m	m	m	m
necropsy status	r	r	r	s	s	s
Spleen						
Hemopoiesis, primarily erythropoiesis	1	1	1	1	1	1
Hemosiderin pigment	1	1	1	2	1	2

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

**Individual Animal Microscopic Findings**

**Males**

**Dose group 3**

	33	34	35	36	37	38	39	40
	m	m	m	m	m	m	m	m
necropsy status	P	P	P	P	P	P	P	P
<b>Liver</b>								
Lymphocytic cell foci, periportal	0	0	1	1	1	1	1	0
Inflammatory cell foci/single cell necrosis	2	2	1	1	2	0	2	2
Midzonal/centrilobular hypertrophy, diffuse	2	2	1	2	2	1	1	1
<b>Pancreas</b>								
Apoptosis/single cell necrosis, exocrine	1	1	0	0	0	0	0	1
<b>Kidneys</b>								
Pelvic dilation	0	0	x	0	0	0	0	0
Hyaline cast(s)	0	0	0	0	0	0	1	0
Interstitial inflammation, lymphocytic	0	0	1	0	0	2	0	1
Atrophy	1	1	2	1	1	1	1	2
Urothelial proliferation, focal	0	0	0	0	0	0	0	1
<b>Testes</b>								
Spermatidic giant cell(s)	0	0	0	0	0	1	0	0
<b>Adrenal Glands</b>								
Cortical hypertrophy, focal	0	1	0	0	0	0	0	0
<b>Spleen</b>								
Hemopoiesis, primarily erythropoiesis	1	2	1	1	1	1	1	2
Hemosiderin pigment	1	1	2	1	1	0	0	1

**PATHOLOGY REPORT (DRAFT)**

Page 31/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Microscopic Findings**

**Males**

**Dose group 3**

	41	42	43	45	46	47
	m	m	m	m	m	m
necropsy status	r	r	r	s	s	s
Liver						
Hepatocellular vacuolation	0	1	0	0	0	0
Inflammatory cell foci/single cell necrosis	2	1	2	2	2	3

**PATHOLOGY REPORT (DRAFT)**

Page 32/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

**Individual Animal Microscopic Findings****Males****Dose group 4**

	49	50	51	52	53	54	55	56
	m	m	m	m	m	m	m	m
necropsy status	P	P	P	P	P	P	P	P
<b>Liver</b>								
Hepatocellular vacuolation	0	1	0	0	0	0	0	0
Lymphocytic cell foci, periportal	2	2	1	0	1	0	1	1
Inflammatory cell foci/single cell necrosis	2	1	1	3	1	2	2	1
<b>Pancreas</b>								
Apoptosis/single cell necrosis, exocrine	0	0	0	0	0	0	1	0
<b>Kidneys</b>								
Hyaline cast(s)	0	0	0	1	0	0	0	0
Interstitial inflammation, lymphocytic	1	0	1	0	1	0	0	0
Atrophy	0	0	0	1	1	0	0	0
<b>Testes</b>								
Atrophy	0	0	3	0	0	0	0	0
<b>Epididymides</b>								
Sperm granuloma						3		
<b>Spleen</b>								
Hemopoiesis, primarily erythropoiesis	2	2	2	3	2	1	2	1
Hemosiderin pigment	0	0	1	1	0	1	0	1
Lymphoid hyperplasia	2	0	2	0	0	0	0	0
<b>Skin</b>								
Inflammation, lymphoid	2							
Epithelial hyperplasia, focal	2							

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Microscopic Findings**

**Males**

**Dose group 4**

	57	58	59	61	62	63
	m	m	m	m	m	m
necropsy status	r	r	r	s	s	s
<b>Kidneys</b>						
Pelvic dilation						x
Atrophy						1
Urothelial proliferation, focal						1
<b>Spleen</b>						
Hemopoiesis, primarily erythropoiesis	1	2	1	1	2	3
Hemosiderin pigment	2	1	2	2	2	2

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Individual Animal Microscopic Findings**

**Males**

**Dose group 5**

	65	66	67	68	69	70	71	72
	m	m	m	m	m	m	m	m
necropsy status	P	P	P	P	P	P	P	P
<b>Liver</b>								
Hepatocellular vacuolation	0	0	0	1	0	0	0	0
Lymphocytic cell foci, periportal	0	0	1	1	1	0	0	1
Inflammatory cell foci/single cell necrosis	2	2	1	1	1	1	1	1
Midzonal/centrilobular hypertrophy, diffuse	2	2	1	1	0	2	1	2
Coagulative necrosis, focal	0	0	0	0	0	2	0	1
<b>Pancreas</b>								
Apoptosis/single cell necrosis, exocrine	1	0	0	0	0	0	1	1
<b>Kidneys</b>								
Cystic tubules	0	0	0	1	0	0	0	0
Interstitial inflammation, lymphocytic	0	1	0	2	1	0	0	0
Atrophy	1	1	0	1	1	0	0	1
<b>Spleen</b>								
Hemopoiesis, primarily erythropoiesis	1	1	0	1	1	1	1	2
Hemosiderin pigment	1	1	1	1	1	0	1	0
<b>Mandibular Lymph Nodes</b>								
Lymphoid hyperplasia	2	3	0	0	0	0	0	2

**PATHOLOGY REPORT (DRAFT)**

Page 35/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Microscopic Findings**

**Males**

**Dose group 5**

	73	74	75	77	78	79
	m	m	m	m	m	m
necropsy status	r	r	r	s	s	s
<b>Liver</b>						
Hepatocellular vacuolation	0	0	0	0	0	1
Inflammatory cell foci/single cell necrosis	2	3	2	2	1	1

**PATHOLOGY REPORT (DRAFT)**

Page 36/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Individual Animal Microscopic Findings**

**Males**

**Dose group 6**

	81	82	83	84	85	86	87	88
	m	m	m	m	m	m	m	m
necropsy status	P	P	P	P	P	P	P	P
<b>Liver</b>								
Kupffer cell pigment, brown	0	0	0	0	0	0	2	0
Lymphocytic cell foci, periportal	0	0	1	1	0	0	0	0
Inflammation - granulohistiocytic	0	0	0	2	0	0	1	0
Inflammatory cell foci/single cell necrosis	2	1	2	1	2	2	1	1
Midzonal/centrilobular hypertrophy, diffuse	2	2	3	2	2	2	2	3
Coagulative necrosis, focal	2	1	1	0	1	0	1	0
<b>Kidneys</b>								
Hyaline cast(s)	0	0	0	1	0	0	0	0
Cystic tubules	0	0	1	0	0	0	0	0
Interstitial inflammation, lymphocytic	0	0	0	0	1	0	0	0
Atrophy	1	0	0	0	0	0	0	1
<b>Spleen</b>								
Hemopoiesis, primarily erythropoiesis	1	1	1	1	2	3	2	3
Hemosiderin pigment	2	2	1	1	2	2	2	2
<b>Mandibular Lymph Nodes</b>								
Plasmacytosis	0	2	0	0	0	2	2	0
Lymphoid hyperplasia	2	3	0	0	0	0	0	0



**PATHOLOGY REPORT (DRAFT)**

Page 37/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Microscopic Findings**

**Males**

**Dose group 6**

	89	90	91	93	94	95
	m	m	m	m	m	m
necropsy status	r	r	r	s	s	s
Liver						
Lymphocytic cell foci, periportal	0	0	1	0	1	0
Inflammatory cell foci/single cell necrosis	2	1	2	1	2	1
Midzonal/centrilobular hypertrophy, diffuse	1	0	0	0	0	0
Spleen						
Hemopoiesis, primarily erythropoiesis	3	3	2	1	2	2
Hemosiderin pigment	1	1	1	1	2	2

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

**Individual Animal Microscopic Findings****Males****Dose group 7**

	97	98	99	100	101	102	103	104
	m	m	m	m	m	m	m	m
necropsy status	k	k	k	k	k	k	k	k
<b>Stomach</b>								
Erosion glandular mucosa		0		1	0	0	2	0
Mineralization, focal in glandular mucosa		0		0	0	0	0	1
Forestomach, inflammation		0		0	2	0	0	3
<b>Liver</b>								
Lymphocytic cell foci, periportal	0	1	0	0	0	1	0	0
Inflammatory cell foci/single cell necrosis	0	0	0	0	0	2	0	0
Hepatocellular atrophy, diffuse	2	1	3	1	2	1	1	1
Coagulative necrosis, focal	0	0	3	0	3	0	0	0
<b>Pancreas</b>								
Reduced zymogen	2	0	1	3	3	1	0	0
<b>Kidneys</b>								
Atrophy	0	0	0	1	0	1	0	0
Tubular necrosis/degeneration, outer stripe	0	0	0	0	0	0	2	0
<b>Testes</b>								
Immature	0	0	0	0	0	0	0	x
Seminiferous cell debris, intratubular	0	2	0	0	0	0	0	0
Retained residual bodies	0	1	0	0	0	0	0	0
<b>Epididymides</b>								
Seminiferous cell debris	1	1	0	1	1			
<b>Prostate Gland</b>								
Atrophy	3			3	0		1	1
<b>Seminal Vesicles</b>								
Atrophy		3	4	3	3		3	3
<b>Spleen</b>								
Hemosiderin pigment	1	1	1	0	1	0	0	0
Lymphoid atrophy	3	0	2	4	2	0	0	1
<b>Thymus</b>								
Lymphoid atrophy - involution	4	-	4	4	4	0	3	4
<b>Mesenteric Lymph Node</b>								
Lymphoid atrophy	3	0	2	2	1	0	0	0
<b>Mandibular Lymph Nodes</b>								
Lymphoid atrophy	4	0	2	0	2	2	0	0

**PATHOLOGY REPORT (DRAFT)**

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Individual Animal Microscopic Findings**

**Males**

**Dose group 7**

	105	106	107	109	110	111
	m	m	m	m	m	m
necropsy status	k	k	k	k	k	k
<b>Stomach</b>						
Erosion glandular mucosa	2	0	0	1	2	
Forestomach, inflammation	0	0	2	0	0	
<b>Duodenum</b>						
Hemorrhage					3	
<b>Liver</b>						
Bile duct pigment, gold-brown	0	0	0	0	1	2
Inflammation - granulohistiocytic	0	0	0	0	0	1
Hepatocellular atrophy, diffuse	0	0	0	0	2	1
Midzonal/centrilobular hypertrophy, diffuse	1	0	1	0	0	0
Coagulative necrosis, focal	2	0	0	0	0	3
<b>Pancreas</b>						
Reduced zymogen	2	0	0	0	0	0
<b>Kidneys</b>						
Atrophy	1	0	1	0	0	1
<b>Testes</b>						
Immature	x	x	0	x	0	0
Spermatidic giant cell(s)	0	1	0	0	0	0
<b>Epididymides</b>						
Seminiferous cell debris					1	
<b>Prostate Gland</b>						
Atrophy		1		1	0	
<b>Seminal Vesicles</b>						
Atrophy	2	3	3	2	2	2
<b>Spleen</b>						
Hemosiderin pigment	1	0	0	0	2	0
Lymphoid atrophy	2	2	1	2	4	1
<b>Thymus</b>						
Congestion	0	0	0	0	x	0
Lymphoid atrophy - involution	4	4	4	4	4	4
<b>Mesenteric Lymph Node</b>						
Lymphoid atrophy	0	2	2	0	3	0
<b>Mandibular Lymph Nodes</b>						
Lymphoid atrophy	0	2	0	0	3	0

**PATHOLOGY REPORT (DRAFT)**

Page 40/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

**Individual Animal Microscopic Findings**

**Females**

**Dose group 1**

	113 f	114 f	115 f	116 f	117 f	118 f	119 f	120 f
necropsy status	P	P	P	P	P	P	P	P
<b>Liver</b>								
Lymphocytic cell foci, periportal	0	0	0	0	1	0	0	0
Inflammatory cell foci/single cell necrosis	1	2	1	2	1	1	1	2
<b>Pancreas</b>								
Inflammation, lymphoid	0	0	0	0	0	1	0	0
<b>Kidneys</b>								
Interstitial inflammation, lymphocytic	0	0	0	0	0	0	1	0
Atrophy	0	0	0	0	1	0	0	0
Pelvic inflammation, lymphogranulocytic	0	2	0	0	0	0	0	0
<b>Spleen</b>								
Hemopoiesis, primarily erythropoiesis	1	1	1	1	1	2	1	0
Hemosiderin pigment	1	2	2	2	2	2	2	2
Lymphoid hyperplasia	0	2	0	0	0	0	2	0
<b>Thymus</b>								
Congestion	0	0	0	0	0	0		
Lymphoid atrophy - involution	0	0	1	0	0	1	x 0	0 0
<b>Mandibular Lymph Nodes</b>								
Lymphoid hyperplasia	2	0	0	2	0	2	0	0

**PATHOLOGY REPORT (DRAFT)**

Page 41/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Individual Animal Microscopic Findings**

**Females**

**Dose group 2**

	129 f	130 f	131 f	132 f	133 f	134 f	135 f	136 f
necropsy status	P	P	P	P	P	P	P	P
<b>Liver</b>								
Hepatocellular vacuolation	0	0	0	0	0	1	0	0
Lymphocytic cell foci, periportal	0	0	0	1	0	0	0	1
Inflammatory cell foci/single cell necrosis	1	0	1	2	1	1	1	1
Coagulative necrosis, focal	0	0	0	2	0	0	0	0
<b>Kidneys</b>								
Tubular mineralisation	0	0	0	0	0	0	1	0
Interstitial inflammation, lymphocytic	0	0	0	0	0	0	0	1
Atrophy	1	1	0	0	0	0	0	0
Pelvic inflammation, lymphogranulocytic	0	0	0	0	0	0	0	3
<b>Spleen</b>								
Hemopoiesis, primarily erythropoiesis	1	0	0	1	1	2	2	1
Hemosiderin pigment	2	2	3	2	2	2	2	2
Lymphoid hyperplasia	0	0	0	2	0	0	2	0
<b>Thymus</b>								
Lymphoid atrophy - involution	0	0	0	0	0	0	1	0
<b>Mandibular Lymph Nodes</b>								
Plasmacytosis	0	0	0	2	0	0	0	0
Lymphoid hyperplasia	0	2	0	0	0	0	0	0

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Microscopic Findings**

**Females**

**Dose group 2**

	137	138	139	141	142	143
	f	f	f	f	f	f
necropsy status	r	r	r	s	s	s
Spleen						
Hemopoiesis, primarily erythropoiesis	1	2	1	1	1	0
Hemosiderin pigment	3	2	3	3	3	3

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

**Individual Animal Microscopic Findings****Females****Dose group 3**

	145	146	147	148	149	150	151	152
	f	f	f	f	f	f	f	f
necropsy status	P	P	P	P	P	P	P	P
Liver								
Lymphocytic cell foci, periportal	0	0	1	0	1	0	0	0
Inflammatory cell foci/single cell necrosis	1	3	1	1	2	1	2	2
Kidneys								
Cystic tubules	0	0	0	0	2	0	0	0
Interstitial inflammation, lymphocytic	0	0	1	0	0	0	0	0
Atrophy	0	0	1	0	0	0	1	0
Spleen								
Hemopoiesis, primarily erythropoiesis	1	0	1	1	2	0	0	2
Hemosiderin pigment	1	2	1	1	2	1	2	2
Thymus								
Lymphoid atrophy - involution	0	0	1	1	0	2	0	0
Mandibular Lymph Nodes								
Plasmacytosis	0	3	0	0	0	0	2	0
Lymphoid hyperplasia	0	0	2	0	2	2	0	2

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Microscopic Findings**

**Females**

**Dose group 3**

	153	154	155	157	158	159
	f	f	f	f	f	f
necropsy status	o	r	r	s	s	s
<b>Liver</b>						
Lymphocytic cell foci, periportal	0	0	0	0	0	1
Inflammatory cell foci/single cell necrosis	0	1	2	1	1	1
<b>Kidneys</b>						
Pelvic dilation	0					x
Interstitial inflammation, lymphocytic	0					2
Atrophy	0					2
<b>Adrenal Glands</b>						
Congestion	x					
<b>Spleen</b>						
Hemopoiesis, primarily erythropoiesis	1					



Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

**Individual Animal Microscopic Findings**

**Females**

**Dose group 4**

	161 f	162 f	163 f	164 f	165 f	166 f	167 f	168 f
necropsy status	P	P	P	P	P	P	P	P
<b>Liver</b>								
Lymphocytic cell foci, periportal	1	0	0	0	0	0	0	0
Inflammatory cell foci/single cell necrosis	1	1	2	1	1	1	1	1
<b>Kidneys</b>								
Pelvic inflammation, lymphogranulocytic	2	0	0	0	0	0	0	0
<b>Ovaries</b>								
Congestion	0	0	0	0	0	x	0	0
<b>Uterus</b>								
Pro-/Estrus epithelium					x			
<b>Spleen</b>								
Hemopoiesis, primarily erythropoiesis	1	1	2	1	1	2	1	1
Hemosiderin pigment	2	2	1	2	1	2	1	2
Lymphoid hyperplasia	0	0	0	2	0	0	0	0
<b>Thymus</b>								
Lymphoid atrophy - involution	0	0	0	0	0	0	0	1
<b>Mandibular Lymph Nodes</b>								
Plasmacytosis	0	0	0	0	0	2	0	0
Lymphoid hyperplasia	0	0	2	2	3	0	0	0

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Microscopic Findings**

**Females**

**Dose group 4**

	169	170	171	173	174	175
	f	f	f	f	f	f
necropsy status	r	r	r	s	s	s
Spleen						
Hemopoiesis, primarily erythropoiesis	2	2	1	1	1	1
Hemosiderin pigment	1	2	2	3	3	3

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Individual Animal Microscopic Findings**

**Females**

**Dose group 5**

	177	178	179	180	181	182	183	184
	f	f	f	f	f	f	f	f
necropsy status	p	p	p	p	o	p	p	p
<b>General Observations</b>								
Macro observation confirmed					x			
<b>Liver</b>								
Lymphocytic cell foci, periportal	1	1	0	0	0	1	0	0
Inflammatory cell foci/single cell necrosis	1	1	3	2	0	0	2	1
<b>Kidneys</b>								
Interstitial inflammation, lymphocytic	0	0	0	2	0	0	0	0
Atrophy	0	1	0	0	0	0	1	1
Pelvic inflammation, lymphogranulocytic	0	0	0	0	0	2	0	0
<b>Spleen</b>								
Hemopoiesis, primarily erythropoiesis	1	1	1	1	1	1	1	1
Hemosiderin pigment	1	1	1	2	2	2	1	1
Lymphoid hyperplasia	0	2	2	0	0	0	0	0
<b>Thymus</b>								
Lymphoid atrophy - involution	1	0	0	0	0	1	0	2
<b>Mandibular Lymph Nodes</b>								
Plasmacytosis	0	0	0	0	2	0	0	0
Lymphoid hyperplasia	3	0	0	0	0	0	0	3

**PATHOLOGY REPORT (DRAFT)**

Page 48/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Microscopic Findings**

**Females**

**Dose group 5**

	185	186	187	189	190	191
	f	f	f	f	f	f
necropsy status	r	r	r	s	s	s
Liver						
Inflammatory cell foci/single cell necrosis	1	0	1	1	1	1

**PATHOLOGY REPORT (DRAFT)**

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Animal Data List**

**Males**

	ANIMAL NUMBER	SEX M/F	FINAL STATE	TEST DAYS	FIRST DAY	LAST DAY	DATE NECROPSY
DOSE GROUP 1							
	1	m	p	28	24/08/99	20/09/99	21/09/99
	2	m	p	28	24/08/99	20/09/99	21/09/99
	3	m	p	28	24/08/99	20/09/99	21/09/99
	4	m	p	28	24/08/99	20/09/99	21/09/99
	5	m	p	29	24/08/99	21/09/99	22/09/99
	6	m	p	29	24/08/99	21/09/99	22/09/99
	7	m	p	29	24/08/99	21/09/99	22/09/99
	8	m	p	29	24/08/99	21/09/99	22/09/99
	9	m	r	29	24/08/99	21/09/99	06/10/99
	10	m	r	29	24/08/99	21/09/99	06/10/99
	11	m	r	29	24/08/99	21/09/99	06/10/99
	13	m	s	32	24/08/99	21/09/99	20/10/99
	14	m	s	32	24/08/99	21/09/99	20/10/99
	15	m	s	32	24/08/99	21/09/99	20/10/99
DOSE GROUP 2							
	17	m	p	28	24/08/99	20/09/99	21/09/99
	18	m	p	28	24/08/99	20/09/99	21/09/99
	19	m	p	28	24/08/99	20/09/99	21/09/99
	20	m	p	28	24/08/99	20/09/99	21/09/99
	21	m	p	29	24/08/99	21/09/99	22/09/99
	22	m	p	29	24/08/99	21/09/99	22/09/99
	23	m	p	29	24/08/99	21/09/99	22/09/99
	24	m	p	29	24/08/99	21/09/99	22/09/99
	25	m	r	29	24/08/99	21/09/99	06/10/99
	26	m	r	29	24/08/99	21/09/99	06/10/99
	27	m	r	29	24/08/99	21/09/99	06/10/99
	29	m	s	32	24/08/99	21/09/99	20/10/99
	30	m	s	32	24/08/99	21/09/99	20/10/99
	31	m	s	32	24/08/99	21/09/99	20/10/99
DOSE GROUP 3							
	33	m	p	28	24/08/99	20/09/99	21/09/99
	34	m	p	28	24/08/99	20/09/99	21/09/99
	35	m	p	28	24/08/99	20/09/99	21/09/99
	36	m	p	28	24/08/99	20/09/99	21/09/99
	37	m	p	29	24/08/99	21/09/99	22/09/99
	38	m	p	29	24/08/99	21/09/99	22/09/99
	39	m	p	29	24/08/99	21/09/99	22/09/99
	40	m	p	29	24/08/99	21/09/99	22/09/99
	41	m	r	29	24/08/99	21/09/99	06/10/99
	42	m	r	29	24/08/99	21/09/99	06/10/99
	43	m	r	29	24/08/99	21/09/99	06/10/99
	45	m	s	32	24/08/99	21/09/99	20/10/99
	46	m	s	32	24/08/99	21/09/99	20/10/99
	47	m	s	32	24/08/99	21/09/99	20/10/99

**PATHOLOGY REPORT (DRAFT)**

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Animal Data List**

**Males**

	ANIMAL NUMBER	SEX M/F	FINAL STATE	TEST DAYS	FIRST DAY	LAST DAY	DATE NECROPSY
DOSE GROUP 4							
	49	m	p	28	24/08/99	20/09/99	21/09/99
	50	m	p	28	24/08/99	20/09/99	21/09/99
	51	m	p	28	24/08/99	20/09/99	21/09/99
	52	m	p	28	24/08/99	20/09/99	21/09/99
	53	m	p	29	24/08/99	21/09/99	22/09/99
	54	m	p	29	24/08/99	21/09/99	22/09/99
	55	m	p	29	24/08/99	21/09/99	22/09/99
	56	m	p	29	24/08/99	21/09/99	22/09/99
	57	m	r	29	24/08/99	21/09/99	22/09/99
	58	m	r	29	24/08/99	21/09/99	06/10/99
	59	m	r	29	24/08/99	21/09/99	06/10/99
	61	m	s	32	24/08/99	21/09/99	06/10/99
	62	m	s	32	24/08/99	21/09/99	20/10/99
	63	m	s	32	24/08/99	21/09/99	20/10/99
DOSE GROUP 5							
	65	m	p	28	24/08/99	20/09/99	21/09/99
	66	m	p	28	24/08/99	20/09/99	21/09/99
	67	m	p	28	24/08/99	20/09/99	21/09/99
	68	m	p	28	24/08/99	20/09/99	21/09/99
	69	m	p	29	24/08/99	21/09/99	22/09/99
	70	m	p	29	24/08/99	21/09/99	22/09/99
	71	m	p	29	24/08/99	21/09/99	22/09/99
	72	m	p	29	24/08/99	21/09/99	22/09/99
	73	m	r	29	24/08/99	21/09/99	22/09/99
	74	m	r	29	24/08/99	21/09/99	06/10/99
	75	m	r	29	24/08/99	21/09/99	06/10/99
	77	m	s	32	24/08/99	21/09/99	06/10/99
	78	m	s	32	24/08/99	21/09/99	20/10/99
	79	m	s	32	24/08/99	21/09/99	20/10/99
DOSE GROUP 6							
	81	m	p	28	24/08/99	20/09/99	21/09/99
	82	m	p	28	24/08/99	20/09/99	21/09/99
	83	m	p	28	24/08/99	20/09/99	21/09/99
	84	m	p	28	24/08/99	20/09/99	21/09/99
	85	m	p	29	24/08/99	21/09/99	22/09/99
	86	m	p	29	24/08/99	21/09/99	22/09/99
	87	m	p	29	24/08/99	21/09/99	22/09/99
	88	m	p	29	24/08/99	21/09/99	22/09/99
	89	m	r	29	24/08/99	21/09/99	22/09/99
	90	m	r	29	24/08/99	21/09/99	06/10/99
	91	m	r	29	24/08/99	21/09/99	06/10/99
	93	m	s	32	24/08/99	21/09/99	06/10/99
	94	m	s	32	24/08/99	21/09/99	20/10/99
	95	m	s	32	24/08/99	21/09/99	20/10/99

**PATHOLOGY REPORT (DRAFT)**

Page 51/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Animal Data List**

**Males**

ANIMAL NUMBER	SEX M/F	FINAL STATE	TEST DAYS	FIRST DAY	LAST DAY	DATE NECROPSY
DOSE GROUP 7						
97	m	k	10	24/08/99	02/09/99	06/09/99
98	m	k	10	24/08/99	02/09/99	03/09/99
99	m	k	10	24/08/99	02/09/99	06/09/99
100	m	k	10	24/08/99	02/09/99	06/09/99
101	m	k	10	24/08/99	02/09/99	06/09/99
102	m	k	10	24/08/99	02/09/99	06/09/99
103	m	k	10	24/08/99	02/09/99	06/09/99
104	m	k	10	24/08/99	02/09/99	06/09/99
105	m	k	10	24/08/99	02/09/99	06/09/99
106	m	k	10	24/08/99	02/09/99	06/09/99
107	m	k	10	24/08/99	02/09/99	06/09/99
109	m	k	10	24/08/99	02/09/99	03/09/99
110	m	k	10	24/08/99	02/09/99	06/09/99
111	m	k	10	24/08/99	02/09/99	06/09/99

**PATHOLOGY REPORT (DRAFT)**

Page 52/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Animal Data List**

**Females**

ANIMAL NUMBER	SEX M/F	FINAL STATE	TEST DAYS	FIRST DAY	LAST DAY	DATE NECROPSY
DOSE GROUP 1						
113	f	p	28	26/08/99	22/09/99	23/09/99
114	f	p	28	26/08/99	22/09/99	23/09/99
115	f	p	28	26/08/99	22/09/99	23/09/99
116	f	p	28	26/08/99	22/09/99	23/09/99
117	f	p	29	26/08/99	23/09/99	21/09/99
118	f	p	29	26/08/99	23/09/99	21/09/99
119	f	p	29	26/08/99	23/09/99	21/09/99
120	f	p	29	26/08/99	23/09/99	21/09/99
121	f	r	29	26/08/99	23/09/99	21/09/99
122	f	r	29	26/08/99	23/09/99	08/10/99
123	f	r	29	26/08/99	23/09/99	08/10/99
125	f	s	30	26/08/99	23/09/99	22/10/99
126	f	s	30	26/08/99	23/09/99	22/10/99
127	f	s	30	26/08/99	23/09/99	22/10/99
DOSE GROUP 2						
129	f	p	28	26/08/99	22/09/99	23/09/99
130	f	p	28	26/08/99	22/09/99	23/09/99
131	f	p	28	26/08/99	22/09/99	23/09/99
132	f	p	28	26/08/99	22/09/99	23/09/99
133	f	p	29	26/08/99	23/09/99	21/09/99
134	f	p	29	26/08/99	23/09/99	21/09/99
135	f	p	29	26/08/99	23/09/99	21/09/99
136	f	p	29	26/08/99	23/09/99	21/09/99
137	f	r	29	26/08/99	23/09/99	21/09/99
138	f	r	29	26/08/99	23/09/99	08/10/99
139	f	r	29	26/08/99	23/09/99	08/10/99
141	f	s	30	26/08/99	23/09/99	08/10/99
142	f	s	30	26/08/99	23/09/99	22/10/99
143	f	s	30	26/08/99	23/09/99	22/10/99
DOSE GROUP 3						
145	f	p	28	26/08/99	22/09/99	23/09/99
146	f	p	28	26/08/99	22/09/99	23/09/99
147	f	p	28	26/08/99	22/09/99	23/09/99
148	f	p	28	26/08/99	22/09/99	23/09/99
149	f	p	29	26/08/99	23/09/99	21/09/99
150	f	p	29	26/08/99	23/09/99	21/09/99
151	f	p	29	26/08/99	23/09/99	21/09/99
152	f	p	29	26/08/99	23/09/99	21/09/99
153	f	o	29	26/08/99	23/09/99	21/09/99
154	f	r	29	26/08/99	23/09/99	21/09/99
155	f	r	29	26/08/99	23/09/99	08/10/99
157	f	s	30	26/08/99	23/09/99	08/10/99
158	f	s	30	26/08/99	23/09/99	22/10/99
159	f	s	30	26/08/99	23/09/99	22/10/99



**PATHOLOGY REPORT (DRAFT)**

Page 53/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

**Animal Data List**

**Females**

	ANIMAL NUMBER	SEX M/F	FINAL STATE	TEST DAYS	FIRST DAY	LAST DAY	DATE NECROPSY
DOSE GROUP 4							
	161	f	p	28	26/08/99	22/09/99	23/09/99
	162	f	p	28	26/08/99	22/09/99	23/09/99
	163	f	p	28	26/08/99	22/09/99	23/09/99
	164	f	p	28	26/08/99	22/09/99	23/09/99
	165	f	p	29	26/08/99	23/09/99	21/09/99
	166	f	p	29	26/08/99	23/09/99	21/09/99
	167	f	p	29	26/08/99	23/09/99	21/09/99
	168	f	p	29	26/08/99	23/09/99	21/09/99
	169	f	r	29	26/08/99	23/09/99	08/10/99
	170	f	r	29	26/08/99	23/09/99	08/10/99
	171	f	r	29	26/08/99	23/09/99	08/10/99
	173	f	s	30	26/08/99	23/09/99	22/10/99
	174	f	s	30	26/08/99	23/09/99	22/10/99
	175	f	s	30	26/08/99	23/09/99	22/10/99
DOSE GROUP 5							
	177	f	p	28	26/08/99	22/09/99	23/09/99
	178	f	p	28	26/08/99	22/09/99	23/09/99
	179	f	p	28	26/08/99	22/09/99	23/09/99
	180	f	p	28	26/08/99	22/09/99	23/09/99
	181	f	o	29	26/08/99	23/09/99	21/09/99
	182	f	p	29	26/08/99	23/09/99	21/09/99
	183	f	p	29	26/08/99	23/09/99	21/09/99
	184	f	p	29	26/08/99	23/09/99	21/09/99
	185	f	r	29	26/08/99	23/09/99	08/10/99
	186	f	r	29	26/08/99	23/09/99	08/10/99
	187	f	r	29	26/08/99	23/09/99	08/10/99
	189	f	s	30	26/08/99	23/09/99	22/10/99
	190	f	s	30	26/08/99	23/09/99	22/10/99
	191	f	s	30	26/08/99	23/09/99	22/10/99

**PATHOLOGY REPORT (DRAFT)**

Page 54/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 1  
SEX: Male  
DOSE GROUP: Group 1, Vehicle Control

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1	Atrophy (minimal)
Liver	Lymphocytic cell foci, periportal (slight) Inflammatory cell foci/single cell necrosis (slight)
Mandibular Lymph Node/ 1	Plasmacytosis (slight)
Mandibular Lymph Node/ 2	Lymphoid hyperplasia (slight)
Spleen	Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal) Lymphoid hyperplasia (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 2

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

No findings noted

**PATHOLOGY REPORT (DRAFT)**

Page 55/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 2  
SEX: Male  
DOSE GROUP: Group 1, Vehicle Control

**MICROSCOPIC FINDINGS**

Kidney/1	Atrophy (minimal)
Liver	Lymphocytic cell foci, periportal (minimal) Inflammatory cell foci/single cell necrosis (minimal)
Mandibular Lymph Node/ 1	Lymphoid hyperplasia (slight)
Mandibular Lymph Node/ 2	Lymphoid hyperplasia (slight)
Spleen	Hemopoiesis, primarily erythropoiesis (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 3

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Adrenal Gland/1	Extracapsular nodule present
Kidney/1	Interstitial inflammation, lymphocytic (minimal) Atrophy (minimal)
Kidney/2	Hyaline cast(s) (minimal)
Liver	Lymphocytic cell foci, periportal (minimal) Inflammatory cell foci/single cell necrosis (slight)

**PATHOLOGY REPORT (DRAFT)**

Page 56/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 3  
SEX: Male  
DOSE GROUP: Group 1, Vehicle Control

**MICROSCOPIC FINDINGS**  
(continued)

Spleen Hemopoiesis, primarily erythropoiesis (slight)  
Hemosiderin pigment (minimal)

Testes/1 Atrophy (moderate)

No abnormalities found in: Adrenal Gland/2,  
Mandibular Lymph Node/1, Mandibular Lymph Node/2,  
Mesenteric Lymph Node, Pancreas, Testes/2, Thymus.

Animal No: 4

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1 Interstitial inflammation, lymphocytic (slight)  
Atrophy (minimal)

Kidney/2 Atrophy (minimal)

Liver Inflammatory cell foci/single cell necrosis (slight)

Spleen Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)  
Lymphoid hyperplasia (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal  
Gland/2, Mandibular Lymph Node/1, Mandibular Lymph  
Node/2, Mesenteric Lymph Node, Pancreas, Testes/1,  
Testes/2, Thymus.

**PATHOLOGY REPORT (DRAFT)**

Page 57/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 5  
SEX: Male  
DOSE GROUP: Group 1, Vehicle Control

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1 Interstitial inflammation, lymphocytic (slight)  
Kidney/2 Interstitial inflammation, lymphocytic (minimal)

Liver Lymphocytic cell foci, periportal (minimal)  
Inflammation - granulohistiocytic (minimal)  
Inflammatory cell foci/single cell necrosis (minimal)

Spleen Hemopoiesis, primarily erythropoiesis (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 6

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

No findings noted

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 6  
 SEX: Male  
 DOSE GROUP: Group 1, Vehicle Control

**MICROSCOPIC FINDINGS**

Liver Lymphocytic cell foci, periportal (minimal)  
 Inflammatory cell foci/single cell necrosis (slight)

Spleen Hemopoiesis, primarily erythropoiesis (minimal)  
 Lymphoid hyperplasia (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 7

**MACROSCOPIC FINDINGS**

days of treatment : 29  
 sacrifice group : terminal sacrifice  
 necropsy status : planned terminal  
 date of start of treatment: 24/08/99  
 date of end of treatment: 21/09/99  
 date of necropsy : 22/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1 Cystic tubules (minimal)  
 Atrophy (minimal)

Liver Inflammatory cell foci/single cell necrosis (slight)

Mandibular Lymph Node/  
 1 Plasmacytosis (slight)

Pancreas Apoptosis/single cell necrosis, exocrine (minimal)

Spleen Hemopoiesis, primarily erythropoiesis (slight)  
 Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Testes/1, Testes/2, Thymus.

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 8  
 SEX: Male  
 DOSE GROUP: Group 1, Vehicle Control

**MACROSCOPIC FINDINGS**

days of treatment : 29  
 sacrifice group : terminal sacrifice  
 necropsy status : planned terminal  
 date of start of treatment: 24/08/99  
 date of end of treatment: 21/09/99  
 date of necropsy : 22/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1 Atrophy (minimal)  
 Liver Lymphocytic cell foci, periportal (minimal)  
 Inflammatory cell foci/single cell necrosis (minimal)  
 Pancreas Apoptosis/single cell necrosis, exocrine (minimal)  
 Spleen Hemopoiesis, primarily erythropoiesis (minimal)  
 Hemosiderin pigment (minimal)  
 No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Testes/1, Testes/2, Thymus.

Animal No: 9

**MACROSCOPIC FINDINGS**

days of treatment : 29  
 sacrifice group : recovery group 1  
 necropsy status : planned recovery 1  
 date of start of treatment: 24/08/99  
 date of end of treatment: 21/09/99  
 date of necropsy : 06/10/99

No findings noted

**MICROSCOPIC FINDINGS**

No tissues examined

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 10  
SEX: Male  
DOSE GROUP: Group 1, Vehicle Control

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 06/10/99

No findings noted

**MICROSCOPIC FINDINGS**

No tissues examined

Animal No: 11

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 06/10/99

No findings noted

**MICROSCOPIC FINDINGS**

No tissues examined

Animal No: 13

**MACROSCOPIC FINDINGS**

days of treatment : 32  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 24/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 20/10/99

No findings noted



Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 13  
SEX: Male  
DOSE GROUP: Group 1, Vehicle Control

**MICROSCOPIC FINDINGS**

No tissues examined

Animal No: 14

**MACROSCOPIC FINDINGS**

days of treatment : 32  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 24/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 20/10/99

No findings noted

**MICROSCOPIC FINDINGS**

No tissues examined

Animal No: 15

**MACROSCOPIC FINDINGS**

days of treatment : 32  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 24/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 20/10/99

No findings noted

**MICROSCOPIC FINDINGS**

No tissues examined

**PATHOLOGY REPORT (DRAFT)**

Page 62/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 113  
SEX: Female  
DOSE GROUP: Group 1, Vehicle Control

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 22/09/99  
date of necropsy : 23/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis  
(minimal)

Mandibular Lymph Node/  
1

Lymphoid hyperplasia (slight)

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal  
Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/  
2, Mesenteric Lymph Node, Ovary/1, Ovary/2,  
Pancreas, Thymus.

Animal No: 114

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 22/09/99  
date of necropsy : 23/09/99

No findings noted

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 114  
 SEX: Female  
 DOSE GROUP: Group 1, Vehicle Control

**MICROSCOPIC FINDINGS**

Kidney/1 Pelvic inflammation, lymphogranulocytic (slight)  
 Liver Inflammatory cell foci/single cell necrosis (slight)  
 Spleen Hemopoiesis, primarily erythropoiesis (minimal)  
 Hemosiderin pigment (slight)  
 Lymphoid hyperplasia (slight)  
 No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 115

**MACROSCOPIC FINDINGS**

days of treatment : 28  
 sacrifice group : terminal sacrifice  
 necropsy status : planned terminal  
 date of start of treatment: 26/08/99  
 date of end of treatment: 22/09/99  
 date of necropsy : 23/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver Inflammatory cell foci/single cell necrosis (minimal)  
 Spleen Hemopoiesis, primarily erythropoiesis (minimal)  
 Hemosiderin pigment (slight)  
 Thymus Lymphoid atrophy - involution (minimal)  
 No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas.

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 116  
 SEX: Female  
 DOSE GROUP: Group 1, Vehicle Control

**MACROSCOPIC FINDINGS**

days of treatment : 28  
 sacrifice group : terminal sacrifice  
 necropsy status : planned terminal  
 date of start of treatment: 26/08/99  
 date of end of treatment: 22/09/99  
 date of necropsy : 23/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver	Inflammatory cell foci/single cell necrosis (slight)
Mandibular Lymph Node/ 1	Lymphoid hyperplasia (slight)
Mandibular Lymph Node/ 2	Lymphoid hyperplasia (slight)
Spleen	Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 117

**MACROSCOPIC FINDINGS**

days of treatment : 29  
 sacrifice group : terminal sacrifice  
 necropsy status : planned terminal  
 date of start of treatment: 26/08/99  
 date of end of treatment: 23/09/99  
 date of necropsy : 24/09/99

No findings noted

**PATHOLOGY REPORT (DRAFT)**

Page 65/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 117  
SEX: Female  
DOSE GROUP: Group 1, Vehicle Control

**MICROSCOPIC FINDINGS**

Kidney/1	Atrophy (minimal)
Liver	Lymphocytic cell foci, periportal (minimal) Inflammatory cell foci/single cell necrosis (minimal)
Spleen	Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 118

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 24/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver	Inflammatory cell foci/single cell necrosis (minimal)
Mandibular Lymph Node/ 1	Lymphoid hyperplasia (slight)
Pancreas	Inflammation, lymphoid (minimal)
Spleen	Hemopoiesis, primarily erythropoiesis (slight) Hemosiderin pigment (slight)
Thymus	Lymphoid atrophy - involution (minimal)

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 118  
 SEX: Female  
 DOSE GROUP: Group 1, Vehicle Control

**MICROSCOPIC FINDINGS**  
 (continued)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2.

Animal No: 119

**MACROSCOPIC FINDINGS**

days of treatment : 29  
 sacrifice group : terminal sacrifice  
 necropsy status : planned terminal  
 date of start of treatment: 26/08/99  
 date of end of treatment: 23/09/99  
 date of necropsy : 24/09/99

Thymus

Focus ISOLATED, LIGHT RED

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Kidney/1

Interstitial inflammation, lymphocytic (minimal)

Liver

Inflammatory cell foci/single cell necrosis (minimal)

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
 Hemosiderin pigment (slight)  
 Lymphoid hyperplasia (slight)

Thymus

Congestion present (correlates to GROSS finding)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas.

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 120  
SEX: Female  
DOSE GROUP: Group 1, Vehicle Control

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 24/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver Inflammatory cell foci/single cell necrosis (slight)  
Spleen Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 121

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 08/10/99

No findings noted

**MICROSCOPIC FINDINGS**

No tissues examined

**PATHOLOGY REPORT (DRAFT)**

Page 68/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 122  
SEX: Female  
DOSE GROUP: Group 1, Vehicle Control

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 08/10/99

No findings noted

**MICROSCOPIC FINDINGS**

No tissues examined

Animal No: 123

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 08/10/99

No findings noted

**MICROSCOPIC FINDINGS**

No tissues examined

Animal No: 125

**MACROSCOPIC FINDINGS**

days of treatment : 30  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 26/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 22/10/99

No findings noted



Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 125  
SEX: Female  
DOSE GROUP: Group 1, Vehicle Control

**MICROSCOPIC FINDINGS**

No tissues examined

Animal No: 126

**MACROSCOPIC FINDINGS**

days of treatment : 30  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 26/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 22/10/99

No findings noted

**MICROSCOPIC FINDINGS**

No tissues examined

Animal No: 127

**MACROSCOPIC FINDINGS**

days of treatment : 30  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 26/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 22/10/99

No findings noted

**MICROSCOPIC FINDINGS**

No tissues examined

**PATHOLOGY REPORT (DRAFT)**

Page 70/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 17  
SEX: Male  
DOSE GROUP: Group 2, T-7250

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1

Atrophy (minimal)

Liver

Lymphocytic cell foci, periportal (slight)  
Inflammatory cell foci/single cell necrosis  
(minimal)

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal  
Gland/2, Kidney/2, Mandibular Lymph Node/1,  
Mandibular Lymph Node/2, Mesenteric Lymph Node,  
Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 18

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

No findings noted

**PATHOLOGY REPORT (DRAFT)**

Page 71/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 18  
SEX: Male  
DOSE GROUP: Group 2, T-7250

**MICROSCOPIC FINDINGS**

Kidney/1 Interstitial inflammation, lymphocytic (minimal)  
Atrophy (minimal)

Kidney/2 Atrophy (minimal)

Liver Inflammatory cell foci/single cell necrosis (slight)

Spleen Hemopoiesis, primarily erythropoiesis (slight)  
Hemosiderin pigment (minimal)  
Lymphoid hyperplasia (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 19

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1 Interstitial inflammation, lymphocytic (slight)  
Atrophy (minimal)

Liver Lymphocytic cell foci, periportal (minimal)  
Inflammatory cell foci/single cell necrosis (slight)

Mandibular Lymph Node/  
1 Lymphoid hyperplasia (slight)

Spleen Hemopoiesis, primarily erythropoiesis (minimal)

**PATHOLOGY REPORT (DRAFT)**

Page 72/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 19  
SEX: Male  
DOSE GROUP: Group 2, T-7250

**MICROSCOPIC FINDINGS**  
(continued)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 20

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1	Atrophy (minimal)
Kidney/2	Cystic tubules (minimal)
Liver	Lymphocytic cell foci, periportal (minimal) Inflammatory cell foci/single cell necrosis (slight)
Pancreas	Apoptosis/single cell necrosis, exocrine (minimal)
Spleen	Hemopoiesis, primarily erythropoiesis (slight) Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Testes/1, Testes/2, Thymus.

**PATHOLOGY REPORT (DRAFT)**

Page 73/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 21  
SEX: Male  
DOSE GROUP: Group 2, T-7250

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis  
(minimal)

Mandibular Lymph Node/  
1

Plasmacytosis (slight)

Spleen

Hemopoiesis, primarily erythropoiesis (moderate)

No abnormalities found in: Adrenal Gland/1, Adrenal  
Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/  
2, Mesenteric Lymph Node, Pancreas, Testes/1,  
Testes/2, Thymus.

Animal No: 22

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

No findings noted

**PATHOLOGY REPORT (DRAFT)**

Page 74/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 22  
SEX: Male  
DOSE GROUP: Group 2, T-7250

**MICROSCOPIC FINDINGS**

Kidney/1 Atrophy (minimal)  
Liver Lymphocytic cell foci, periportal (minimal)  
Inflammatory cell foci/single cell necrosis (slight)  
Spleen Hemopoiesis, primarily erythropoiesis (slight)  
No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 23

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1 Interstitial inflammation, lymphocytic (minimal)  
Atrophy (minimal)  
Kidney/2 Interstitial inflammation, lymphocytic (minimal)  
Atrophy (minimal)  
Liver Lymphocytic cell foci, periportal (minimal)  
Inflammatory cell foci/single cell necrosis (minimal)  
Spleen Hemopoiesis, primarily erythropoiesis (moderate)  
No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

**PATHOLOGY REPORT (DRAFT)**

Page 75/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 24  
SEX: Male  
DOSE GROUP: Group 2, T-7250

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1	Atrophy (minimal)
Liver	Inflammatory cell foci/single cell necrosis (slight) Coagulative necrosis, focal (minimal)
Spleen	Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal) Lymphoid hyperplasia (slight)
Thymus	Lymphoid atrophy - involution (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2.

Animal No: 25

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 06/10/99

No findings noted

**PATHOLOGY REPORT (DRAFT)**

Page 76/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 25  
SEX: Male  
DOSE GROUP: Group 2, T-7250

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)

Animal No: 26

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 06/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)

Animal No: 27

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 06/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)



**PATHOLOGY REPORT (DRAFT)**

Page 77/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 29  
SEX: Male  
DOSE GROUP: Group 2, T-7250

**MACROSCOPIC FINDINGS**

days of treatment : 32  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 24/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 20/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (slight)

Animal No: 30

**MACROSCOPIC FINDINGS**

days of treatment : 32  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 24/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 20/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)

Animal No: 31

**MACROSCOPIC FINDINGS**

days of treatment : 32  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 24/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 20/10/99

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 31  
SEX: Male  
DOSE GROUP: Group 2, T-7250

**MACROSCOPIC FINDINGS**  
(continued)

No findings noted

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (slight)

Animal No: 129  
SEX: Female

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 22/09/99  
date of necropsy : 23/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1

Atrophy (minimal)

Liver

Inflammatory cell foci/single cell necrosis  
(minimal)

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

**PATHOLOGY REPORT (DRAFT)**

Page 79/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 130  
SEX: Female  
DOSE GROUP: Group 2, T-7250

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 22/09/99  
date of necropsy : 23/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1 Atrophy (minimal)  
Mandibular Lymph Node/2 Lymphoid hyperplasia (slight)  
Spleen Hemosiderin pigment (slight)

Number of Sections less than protocol for Mandibular Lymph Node/1 (0).

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Liver, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 131

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 22/09/99  
date of necropsy : 23/09/99

No findings noted

**PATHOLOGY REPORT (DRAFT)**

Page 80/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 131  
SEX: Female  
DOSE GROUP: Group 2, T-7250

**MICROSCOPIC FINDINGS**

Liver Inflammatory cell foci/single cell necrosis (minimal)

Spleen Hemosiderin pigment (moderate)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 132

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 22/09/99  
date of necropsy : 23/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver Lymphocytic cell foci, periportal (minimal)  
Inflammatory cell foci/single cell necrosis (slight)  
Coagulative necrosis, focal (slight)

Mandibular Lymph Node/  
1 Plasmacytosis (slight)

Spleen Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (slight)  
Lymphoid hyperplasia (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

**PATHOLOGY REPORT (DRAFT)**

Page 81/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 133  
SEX: Female  
DOSE GROUP: Group 2, T-7250

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 24/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis  
(minimal)

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 134

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 24/09/99

No findings noted

**PATHOLOGY REPORT (DRAFT)**

Page 82/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 134  
SEX: Female  
DOSE GROUP: Group 2, T-7250

**MICROSCOPIC FINDINGS**

Liver

Hepatocellular vacuolation (minimal)  
Inflammatory cell foci/single cell necrosis  
(minimal)

Spleen

Hemopoiesis, primarily erythropoiesis (slight)  
Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal  
Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/  
1, Mandibular Lymph Node/2, Mesenteric Lymph Node,  
Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 135

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 24/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1

Tubular mineralisation (minimal)

Liver

Inflammatory cell foci/single cell necrosis  
(minimal)

Spleen

Hemopoiesis, primarily erythropoiesis (slight)  
Hemosiderin pigment (slight)  
Lymphoid hyperplasia (slight)

Thymus

Lymphoid atrophy - involution (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal  
Gland/2, Kidney/2, Mandibular Lymph Node/1,  
Mandibular Lymph Node/2, Mesenteric Lymph Node,  
Ovary/1, Ovary/2, Pancreas.

**PATHOLOGY REPORT (DRAFT)**

Page 83/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 136  
SEX: Female  
DOSE GROUP: Group 2, T-7250

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 24/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1  
Kidney/2  
Liver  
Spleen

Interstitial inflammation, lymphocytic (minimal)  
Pelvic inflammation, lymphogranulocytic (moderate)  
Pelvic inflammation, lymphogranulocytic (slight)  
Lymphocytic cell foci, periportal (minimal)  
Inflammatory cell foci/single cell necrosis (minimal)  
Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 137

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 08/10/99

No findings noted

**PATHOLOGY REPORT (DRAFT)**

Page 84/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 137  
SEX: Female  
DOSE GROUP: Group 2, T-7250

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (moderate)

Animal No: 138

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 08/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (slight)  
Hemosiderin pigment (slight)

Animal No: 139

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 08/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (moderate)



**PATHOLOGY REPORT (DRAFT)**

Page 85/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 141  
SEX: Female  
DOSE GROUP: Group 2, T-7250

**MACROSCOPIC FINDINGS**

days of treatment : 30  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 26/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 22/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (moderate)

Animal No: 142

**MACROSCOPIC FINDINGS**

days of treatment : 30  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 26/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 22/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (moderate)

Animal No: 143

**MACROSCOPIC FINDINGS**

days of treatment : 30  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 26/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 22/10/99

**PATHOLOGY REPORT (DRAFT)**

Page 86/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 143  
SEX: Female  
DOSE GROUP: Group 2, T-7250

**MACROSCOPIC FINDINGS**  
(continued)

No findings noted

**MICROSCOPIC FINDINGS**

Spleen

Hemosiderin pigment (moderate)

Animal No: 33  
SEX: Male  
DOSE GROUP: Group 3, T-7251

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1

Atrophy (minimal)

Liver

Inflammatory cell foci/single cell necrosis (slight)  
Midzonal/centrilobular hypertrophy, diffuse (slight)

Pancreas

Apoptosis/single cell necrosis, exocrine (minimal)

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Testes/1, Testes/2, Thymus.

**PATHOLOGY REPORT (DRAFT)**

Page 87/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 34  
SEX: Male  
DOSE GROUP: Group 3, T-7251

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Adrenal Gland/1  
Kidney/1  
Liver  
Pancreas  
Spleen

Cortical hypertrophy, focal (minimal)  
Atrophy (minimal)  
Inflammatory cell foci/single cell necrosis (slight)  
Midzonal/centrilobular hypertrophy, diffuse (slight)  
Apoptosis/single cell necrosis, exocrine (minimal)  
Hemopoiesis, primarily erythropoiesis (slight)  
Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/2, Kidney/  
2, Mandibular Lymph Node/1, Mandibular Lymph Node/  
2, Mesenteric Lymph Node, Testes/1, Testes/2,  
Thymus.

Animal No: 35

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

Kidneys

both sides Pelvic dilation

No abnormalities were found in any of the other  
tissues examined

**PATHOLOGY REPORT (DRAFT)**

Page 88/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 35  
SEX: Male  
DOSE GROUP: Group 3, T-7251

**MICROSCOPIC FINDINGS**

Kidney/1

Pelvic dilation present (correlates to GROSS finding)  
Interstitial inflammation, lymphocytic (minimal)  
Atrophy (slight)

Liver

Lymphocytic cell foci, periportal (minimal)  
Inflammatory cell foci/single cell necrosis (minimal)  
Midzonal/centrilobular hypertrophy, diffuse (minimal)

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 36

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1

Atrophy (minimal)

Liver

Lymphocytic cell foci, periportal (minimal)  
Inflammatory cell foci/single cell necrosis (minimal)  
Midzonal/centrilobular hypertrophy, diffuse (slight)

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)

**PATHOLOGY REPORT (DRAFT)**

Page 89/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 36  
SEX: Male  
DOSE GROUP: Group 3, T-7251

**MICROSCOPIC FINDINGS**  
(continued)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 37

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1

Atrophy (minimal)

Liver

Lymphocytic cell foci, periportal (minimal)  
Inflammatory cell foci/single cell necrosis (slight)  
Midzonal/centrilobular hypertrophy, diffuse (slight)

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

**PATHOLOGY REPORT (DRAFT)**

Page 90/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 38  
SEX: Male  
DOSE GROUP: Group 3, T-7251

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1 Interstitial inflammation, lymphocytic (slight)  
Atrophy (minimal)

Liver Lymphocytic cell foci, periportal (minimal)  
Midzonal/centrilobular hypertrophy, diffuse  
(minimal)

Spleen Hemopoiesis, primarily erythropoiesis (minimal)

Testes/1 Spermatidic giant cell(s) (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal  
Gland/2, Kidney/2, Mandibular Lymph Node/1,  
Mandibular Lymph Node/2, Mesenteric Lymph Node,  
Pancreas, Testes/2, Thymus.

Animal No: 39

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

No findings noted

**PATHOLOGY REPORT (DRAFT)**

Page 91/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 39  
SEX: Male  
DOSE GROUP: Group 3, T-7251

**MICROSCOPIC FINDINGS**

Kidney/1 Hyaline cast(s) (minimal)  
Atrophy (minimal)

Liver Lymphocytic cell foci, periportal (minimal)  
Inflammatory cell foci/single cell necrosis (slight)  
Midzonal/centrilobular hypertrophy, diffuse (minimal)

Spleen Hemopoiesis, primarily erythropoiesis (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 40

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1 Atrophy (minimal)

Kidney/2 Interstitial inflammation, lymphocytic (minimal)  
Atrophy (slight)  
Urothelial proliferation, focal (minimal)

Liver Inflammatory cell foci/single cell necrosis (slight)  
Midzonal/centrilobular hypertrophy, diffuse (minimal)

Pancreas Apoptosis/single cell necrosis, exocrine (minimal)

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 40  
SEX: Male  
DOSE GROUP: Group 3, T-7251

**MICROSCOPIC FINDINGS**  
(continued)

Spleen Hemopoiesis, primarily erythropoiesis (slight)  
Hemosiderin pigment (minimal)

Number of Sections less than protocol for Adrenal  
Gland/1 (0).

No abnormalities found in: Adrenal Gland/2,  
Mandibular Lymph Node/1, Mandibular Lymph Node/2,  
Mesenteric Lymph Node, Testes/1, Testes/2, Thymus.

Animal No: 41

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 06/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver Inflammatory cell foci/single cell necrosis (slight)

Animal No: 42

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 06/10/99

No findings noted



**PATHOLOGY REPORT (DRAFT)**

Page 93/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 42  
SEX: Male  
DOSE GROUP: Group 3, T-7251

**MICROSCOPIC FINDINGS**

Liver

Hepatocellular vacuolation (minimal)  
Inflammatory cell foci/single cell necrosis  
(minimal)

Animal No: 43

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 06/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis (slight)

Animal No: 45

**MACROSCOPIC FINDINGS**

days of treatment : 32  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 24/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 20/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis (slight)

**PATHOLOGY REPORT (DRAFT)**

Page 94/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 46  
SEX: Male  
DOSE GROUP: Group 3, T-7251

**MACROSCOPIC FINDINGS**

days of treatment : 32  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 24/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 20/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis (slight)

Animal No: 47

**MACROSCOPIC FINDINGS**

days of treatment : 32  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 24/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 20/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis  
(moderate)

Animal No: 145  
SEX: Female

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 22/09/99  
date of necropsy : 23/09/99

**PATHOLOGY REPORT (DRAFT)**

Page 95/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 145  
SEX: Female  
DOSE GROUP: Group 3, T-7251

**MACROSCOPIC FINDINGS**  
(continued)

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis  
(minimal)

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal  
Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/  
1, Mandibular Lymph Node/2, Mesenteric Lymph Node,  
Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 146

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 22/09/99  
date of necropsy : 23/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis  
(moderate)

Mandibular Lymph Node/  
1

Plasmacytosis (moderate)

Spleen

Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal  
Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/  
2, Mesenteric Lymph Node, Ovary/1, Ovary/2,  
Pancreas, Thymus.

**PATHOLOGY REPORT (DRAFT)**

Page 96/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 147  
SEX: Female  
DOSE GROUP: Group 3, T-7251

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 22/09/99  
date of necropsy : 23/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1	Atrophy (minimal)
Kidney/2	Interstitial inflammation, lymphocytic (minimal) Atrophy (minimal)
Liver	Lymphocytic cell foci, periportal (minimal) Inflammatory cell foci/single cell necrosis (minimal)
Mandibular Lymph Node/ 1	Lymphoid hyperplasia (slight)
Spleen	Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal)
Thymus	Lymphoid atrophy - involution (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas.

Animal No: 148

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 22/09/99  
date of necropsy : 23/09/99

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 148  
 SEX: Female  
 DOSE GROUP: Group 3, T-7251

**MACROSCOPIC FINDINGS**  
 (continued)

No findings noted

**MICROSCOPIC FINDINGS**

Liver	Inflammatory cell foci/single cell necrosis (minimal)
Spleen	Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal)
Thymus	Lymphoid atrophy - involution (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas.

Animal No: 149

**MACROSCOPIC FINDINGS**

days of treatment : 29  
 sacrifice group : terminal sacrifice  
 necropsy status : planned terminal  
 date of start of treatment: 26/08/99  
 date of end of treatment: 23/09/99  
 date of necropsy : 24/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1	Cystic tubules (slight) medulla
Liver	Lymphocytic cell foci, periportal (minimal) Inflammatory cell foci/single cell necrosis (slight)
Mandibular Lymph Node/ 1	Lymphoid hyperplasia (slight)
Spleen	Hemopoiesis, primarily erythropoiesis (slight) Hemosiderin pigment (slight)

**PATHOLOGY REPORT (DRAFT)**

Page 98/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 149  
SEX: Female  
DOSE GROUP: Group 3, T-7251

**MICROSCOPIC FINDINGS**  
(continued)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 150

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 24/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver	Inflammatory cell foci/single cell necrosis (minimal)
Mandibular Lymph Node/ 1	Lymphoid hyperplasia (slight)
Spleen	Hemosiderin pigment (minimal)
Thymus	Lymphoid atrophy - involution (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas.

**PATHOLOGY REPORT (DRAFT)**

Page 99/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 151  
SEX: Female  
DOSE GROUP: Group 3, T-7251

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 24/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1	Atrophy (minimal)
Liver	Inflammatory cell foci/single cell necrosis (slight)
Mandibular Lymph Node/ 1	Plasmacytosis (slight)
Spleen	Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 152

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 24/09/99

No findings noted

**PATHOLOGY REPORT (DRAFT)**

Page 100/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 152  
SEX: Female  
DOSE GROUP: Group 3, T-7251

**MICROSCOPIC FINDINGS**

Liver Inflammatory cell foci/single cell necrosis (slight)

Mandibular Lymph Node/  
1 Lymphoid hyperplasia (slight)

Spleen Hemopoiesis, primarily erythropoiesis (slight)  
Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 153

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : other  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 24/09/99

General observations

Died after blood sampling

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Adrenal Gland/1 Congestion present

Adrenal Gland/2 Congestion present

Spleen Hemopoiesis, primarily erythropoiesis (minimal)

No abnormalities found in: Kidney/1, Kidney/2, Liver, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Thymus.



**PATHOLOGY REPORT (DRAFT)**

Page 101/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 154  
SEX: Female  
DOSE GROUP: Group 3, T-7251

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 08/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis  
(minimal)

Animal No: 155

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 08/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis (slight)

Animal No: 157

**MACROSCOPIC FINDINGS**

days of treatment : 30  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 26/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 22/10/99

No findings noted

**PATHOLOGY REPORT (DRAFT)**

Page 102/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 157  
SEX: Female  
DOSE GROUP: Group 3, T-7251

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis  
(minimal)

Animal No: 158

**MACROSCOPIC FINDINGS**

days of treatment : 30  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 26/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 22/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis  
(minimal)

Animal No: 159

**MACROSCOPIC FINDINGS**

days of treatment : 30  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 26/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 22/10/99

Kidneys

both sides Pelvic dilation

No abnormalities were found in any of the other  
tissues examined

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 159  
 SEX: Female  
 DOSE GROUP: Group 3, T-7251

**MICROSCOPIC FINDINGS**

Kidney/1 Pelvic dilation present (correlates to GROSS finding)  
 Interstitial inflammation, lymphocytic (slight)  
 Atrophy (slight)

Kidney/2 Pelvic dilation present (correlates to GROSS finding)  
 Atrophy (slight)

Liver Lymphocytic cell foci, periportal (minimal)  
 Inflammatory cell foci/single cell necrosis (minimal)

Animal No: 49  
 SEX: Male  
 DOSE GROUP: Group 4, T-7252

**MACROSCOPIC FINDINGS**

days of treatment : 28  
 sacrifice group : terminal sacrifice  
 necropsy status : planned terminal  
 date of start of treatment: 24/08/99  
 date of end of treatment: 20/09/99  
 date of necropsy : 21/09/99

Skin back of the neck Alopecia  
 back of the neck Scab formation

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Kidney/1 Interstitial inflammation, lymphocytic (minimal)

Liver Lymphocytic cell foci, periportal (slight)  
 Inflammatory cell foci/single cell necrosis (slight)

Skin Inflammation, lymphoid (slight)  
 Epithelial hyperplasia, focal (slight) (correlates to GROSS finding)  
 None (correlates to GROSS finding)

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 49  
 SEX: Male  
 DOSE GROUP: Group 4, T-7252

**MICROSCOPIC FINDINGS**  
 (continued)

Spleen Hemopoiesis, primarily erythropoiesis (slight)  
 Lymphoid hyperplasia (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 50

**MACROSCOPIC FINDINGS**

days of treatment : 28  
 sacrifice group : terminal sacrifice  
 necropsy status : planned terminal  
 date of start of treatment: 24/08/99  
 date of end of treatment: 20/09/99  
 date of necropsy : 21/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver Hepatocellular vacuolation (minimal)  
 Lymphocytic cell foci, periportal (slight)  
 Inflammatory cell foci/single cell necrosis (minimal)

Spleen Hemopoiesis, primarily erythropoiesis (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255    NOTOX no. :            264656  
Test System : Exploratory 28-Day Gavage Study in Rats    Propath no.:            00006  
Sponsor : 3M Corporate Toxicology                            Date :    29.Feb.2000

---

**Individual Animal Data Records**

Animal No:        51  
SEX:              Male  
DOSE GROUP:      Group 4, T-7252

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1	Interstitial inflammation, lymphocytic (minimal)
Liver	Lymphocytic cell foci, periportal (minimal) Inflammatory cell foci/single cell necrosis (minimal)
Spleen	Hemopoiesis, primarily erythropoiesis (slight) Hemosiderin pigment (minimal) Lymphoid hyperplasia (slight)
Testes/1	Atrophy (moderate)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/2, Thymus.

Animal No:        52

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

Kidneys

Pelvic dilation

No abnormalities were found in any of the other tissues examined

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 52  
 SEX: Male  
 DOSE GROUP: Group 4, T-7252

**MICROSCOPIC FINDINGS**

Kidney/1	Hyaline cast(s) (minimal) Atrophy (minimal) None (correlates to GROSS finding)
Kidney/2	None (correlates to GROSS finding)
Liver	Inflammatory cell foci/single cell necrosis (moderate)
Spleen	Hemopoiesis, primarily erythropoiesis (moderate) Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 53

**MACROSCOPIC FINDINGS**

days of treatment : 29  
 sacrifice group : terminal sacrifice  
 necropsy status : planned terminal  
 date of start of treatment: 24/08/99  
 date of end of treatment: 21/09/99  
 date of necropsy : 22/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1	Interstitial inflammation, lymphocytic (minimal) Atrophy (minimal)
Kidney/2	Interstitial inflammation, lymphocytic (minimal)
Liver	Lymphocytic cell foci, periportal (minimal) Inflammatory cell foci/single cell necrosis (minimal)
Spleen	Hemopoiesis, primarily erythropoiesis (slight)

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 53  
SEX: Male  
DOSE GROUP: Group 4, T-7252

**MICROSCOPIC FINDINGS**  
(continued)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 54

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

Epididymides

right side, head Nodule(s) D=6X4 MM, YELLOWISH

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Epididymis/1

Sperm granuloma (slight) (correlates to GROSS finding)

Epididymis/2

Sperm granuloma (moderate) (correlates to GROSS finding)

Liver

Inflammatory cell foci/single cell necrosis (slight)

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 55  
SEX: Male  
DOSE GROUP: Group 4, T-7252

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver Lymphocytic cell foci, periportal (minimal)  
Inflammatory cell foci/single cell necrosis (slight)

Pancreas Apoptosis/single cell necrosis, exocrine (minimal)

Spleen Hemopoiesis, primarily erythropoiesis (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Testes/1, Testes/2, Thymus.

Animal No: 56

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

No findings noted



**PATHOLOGY REPORT (DRAFT)**

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 56  
SEX: Male  
DOSE GROUP: Group 4, T-7252

**MICROSCOPIC FINDINGS**

Liver Lymphocytic cell foci, periportal (minimal)  
Inflammatory cell foci/single cell necrosis (minimal)

Spleen Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 57

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 06/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Spleen Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (slight)

Animal No: 58

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 06/10/99

No findings noted

**PATHOLOGY REPORT (DRAFT)**

Page 110/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 58  
SEX: Male  
DOSE GROUP: Group 4, T-7252

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (slight)  
Hemosiderin pigment (minimal)

Animal No: 59

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 06/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (slight)

Animal No: 61

**MACROSCOPIC FINDINGS**

days of treatment : 32  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 24/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 20/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (slight)

**PATHOLOGY REPORT (DRAFT)**

Page 111/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 62  
SEX: Male  
DOSE GROUP: Group 4, T-7252

**MACROSCOPIC FINDINGS**

days of treatment : 32  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 24/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 20/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (slight)  
Hemosiderin pigment (slight)

Animal No: 63

**MACROSCOPIC FINDINGS**

days of treatment : 32  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 24/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 20/10/99

Kidneys

right side Pelvic dilation

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Kidney/1

Pelvic dilation present (correlates to GROSS finding)

Atrophy (minimal)

Urothelial proliferation, focal (minimal)

Spleen

Hemopoiesis, primarily erythropoiesis (moderate)  
Hemosiderin pigment (slight)

No abnormalities found in: Kidney/2.

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 161  
SEX: Female  
DOSE GROUP: Group 4, T-7252

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 22/09/99  
date of necropsy : 23/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1	Pelvic inflammation, lymphogranulocytic (slight)
Kidney/2	Pelvic inflammation, lymphogranulocytic (slight)
Liver	Lymphocytic cell foci, periportal (minimal) Inflammatory cell foci/single cell necrosis (minimal)
Spleen	Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 162

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 22/09/99  
date of necropsy : 23/09/99

No findings noted

**PATHOLOGY REPORT (DRAFT)**

Page 113/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 162  
SEX: Female  
DOSE GROUP: Group 4, T-7252

**MICROSCOPIC FINDINGS**

Liver Inflammatory cell foci/single cell necrosis (minimal)

Spleen Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 163

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 22/09/99  
date of necropsy : 23/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver Inflammatory cell foci/single cell necrosis (slight)

Mandibular Lymph Node/1 Lymphoid hyperplasia (slight)

Spleen Hemopoiesis, primarily erythropoiesis (slight)  
Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 164  
 SEX: Female  
 DOSE GROUP: Group 4, T-7252

**MACROSCOPIC FINDINGS**

days of treatment : 28  
 sacrifice group : terminal sacrifice  
 necropsy status : planned terminal  
 date of start of treatment: 26/08/99  
 date of end of treatment: 22/09/99  
 date of necropsy : 23/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver	Inflammatory cell foci/single cell necrosis (minimal)
Mandibular Lymph Node/ 1	Lymphoid hyperplasia (slight)
Spleen	Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) Lymphoid hyperplasia (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 165

**MACROSCOPIC FINDINGS**

days of treatment : 29  
 sacrifice group : terminal sacrifice  
 necropsy status : planned terminal  
 date of start of treatment: 26/08/99  
 date of end of treatment: 23/09/99  
 date of necropsy : 24/09/99

Uterus Distension

No abnormalities were found in any of the other tissues examined

**PATHOLOGY REPORT (DRAFT)**

Page 115/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 165  
SEX: Female  
DOSE GROUP: Group 4, T-7252

**MICROSCOPIC FINDINGS**

Liver	Inflammatory cell foci/single cell necrosis (minimal)
Mandibular Lymph Node/ 1	Lymphoid hyperplasia (moderate)
Spleen	Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal)
Uterus	Pro-/Estrus epithelium present (correlates to GROSS finding)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 166

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 24/09/99

Ovaries

left side Hemorrhagic cyst

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Liver	Inflammatory cell foci/single cell necrosis (minimal)
Mandibular Lymph Node/ 1	Plasmacytosis (slight)
Ovary/1	Congestion present (correlates to GROSS finding)

**PATHOLOGY REPORT (DRAFT)**

Page 116/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 166  
SEX: Female  
DOSE GROUP: Group 4, T-7252

**MICROSCOPIC FINDINGS**  
(continued)

Ovary/2 Congestion present (correlates to GROSS finding)

Spleen Hemopoiesis, primarily erythropoiesis (slight)  
Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Thymus.

Animal No: 167

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 24/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver Inflammatory cell foci/single cell necrosis (minimal)

Spleen Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.



Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 168  
SEX: Female  
DOSE GROUP: Group 4, T-7252

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 24/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver Inflammatory cell foci/single cell necrosis (minimal)  
Spleen Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (slight)  
Thymus Lymphoid atrophy - involution (minimal)  
No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas.

Animal No: 169

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 08/10/99

Spleen Reduced in size

No abnormalities were found in any of the other tissues examined

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 169  
SEX: Female  
DOSE GROUP: Group 4, T-7252

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (slight)  
Hemosiderin pigment (minimal)  
None (correlates to GROSS finding)

Animal No: 170

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 08/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (slight)  
Hemosiderin pigment (slight)

Animal No: 171

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 08/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (slight)

**PATHOLOGY REPORT (DRAFT)**

Page 119/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 173  
SEX: Female  
DOSE GROUP: Group 4, T-7252

**MACROSCOPIC FINDINGS**

days of treatment : 30  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 26/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 22/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (moderate)

Animal No: 174

**MACROSCOPIC FINDINGS**

days of treatment : 30  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 26/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 22/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (moderate)

Animal No: 175

**MACROSCOPIC FINDINGS**

days of treatment : 30  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 26/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 22/10/99

**PATHOLOGY REPORT (DRAFT)**

Page 120/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 175  
SEX: Female  
DOSE GROUP: Group 4, T-7252

**MACROSCOPIC FINDINGS**  
(continued)

No findings noted

**MICROSCOPIC FINDINGS**

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (moderate)

Animal No: 65  
SEX: Male  
DOSE GROUP: Group 5, T-7253

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1

Atrophy (minimal)

Liver

Inflammatory cell foci/single cell necrosis (slight)  
Midzonal/centrilobular hypertrophy, diffuse (slight)

Mandibular Lymph Node/  
1

Lymphoid hyperplasia (slight)

Pancreas

Apoptosis/single cell necrosis, exocrine (minimal)

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Testes/1, Testes/2, Thymus.

**PATHOLOGY REPORT (DRAFT)**

Page 121/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 66  
SEX: Male  
DOSE GROUP: Group 5, T-7253

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1	Interstitial inflammation, lymphocytic (minimal) Atrophy (minimal)
Kidney/2	Interstitial inflammation, lymphocytic (minimal)
Liver	Inflammatory cell foci/single cell necrosis (slight) Midzonal/centrilobular hypertrophy, diffuse (slight)
Mandibular Lymph Node/ 1	Lymphoid hyperplasia (moderate)
Spleen	Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 67

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

No findings noted

**PATHOLOGY REPORT (DRAFT)**

Page 122/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 67  
SEX: Male  
DOSE GROUP: Group 5, T-7253

**MICROSCOPIC FINDINGS**

Liver

Lymphocytic cell foci, periportal (minimal)  
Inflammatory cell foci/single cell necrosis (minimal)  
Midzonal/centrilobular hypertrophy, diffuse (minimal)

Spleen

Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 68

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1

Cystic tubules (minimal)  
Interstitial inflammation, lymphocytic (slight)  
Atrophy (minimal)

Liver

Hepatocellular vacuolation (minimal)  
Lymphocytic cell foci, periportal (minimal)  
Inflammatory cell foci/single cell necrosis (minimal)  
Midzonal/centrilobular hypertrophy, diffuse (minimal)

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255      NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats      Propath no.: 00006  
Sponsor : 3M Corporate Toxicology      Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 68  
SEX: Male  
DOSE GROUP: Group 5, T-7253

**MICROSCOPIC FINDINGS**  
(continued)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 69

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/2	Interstitial inflammation, lymphocytic (minimal) Atrophy (minimal)
Liver	Lymphocytic cell foci, periportal (minimal) Inflammatory cell foci/single cell necrosis (minimal)
Spleen	Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 70  
SEX: Male  
DOSE GROUP: Group 5, T-7253

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis (minimal)  
Midzonal/centrilobular hypertrophy, diffuse (slight)  
Coagulative necrosis, focal (slight)

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 71

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

No findings noted



Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 71  
 SEX: Male  
 DOSE GROUP: Group 5, T-7253

**MICROSCOPIC FINDINGS**

Liver Inflammatory cell foci/single cell necrosis (minimal)  
 Midzonal/centrilobular hypertrophy, diffuse (minimal)

Pancreas Apoptosis/single cell necrosis, exocrine (minimal)

Spleen Hemopoiesis, primarily erythropoiesis (minimal)  
 Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Testes/1, Testes/2, Thymus.

Animal No: 72

**MACROSCOPIC FINDINGS**

days of treatment : 29  
 sacrifice group : terminal sacrifice  
 necropsy status : planned terminal  
 date of start of treatment: 24/08/99  
 date of end of treatment: 21/09/99  
 date of necropsy : 22/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1 Atrophy (minimal)

Liver Lymphocytic cell foci, periportal (minimal)  
 Inflammatory cell foci/single cell necrosis (minimal)  
 Midzonal/centrilobular hypertrophy, diffuse (slight)  
 Coagulative necrosis, focal (minimal)

Mandibular Lymph Node/1 Lymphoid hyperplasia (slight)

Pancreas Apoptosis/single cell necrosis, exocrine (minimal)

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 72  
SEX: Male  
DOSE GROUP: Group 5, T-7253

**MICROSCOPIC FINDINGS**  
(continued)

Spleen

Hemopoiesis, primarily erythropoiesis (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Testes/1, Testes/2, Thymus.

Animal No: 73

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 06/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis (slight)

Animal No: 74

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 06/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis (moderate)

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 75  
SEX: Male  
DOSE GROUP: Group 5, T-7253

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 06/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis (slight)

Animal No: 77

**MACROSCOPIC FINDINGS**

days of treatment : 32  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 24/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 20/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis (slight)

Animal No: 78

**MACROSCOPIC FINDINGS**

days of treatment : 32  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 24/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 20/10/99

No findings noted

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 78  
SEX: Male  
DOSE GROUP: Group 5, T-7253

**MICROSCOPIC FINDINGS**

Liver Inflammatory cell foci/single cell necrosis (minimal)

Animal No: 79

**MACROSCOPIC FINDINGS**

days of treatment : 32  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 24/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 20/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver Hepatocellular vacuolation (minimal)  
Inflammatory cell foci/single cell necrosis (minimal)

Animal No: 177  
SEX: Female

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 22/09/99  
date of necropsy : 23/09/99

No findings noted

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 177  
SEX: Female  
DOSE GROUP: Group 5, T-7253

**MICROSCOPIC FINDINGS**

Liver	Lymphocytic cell foci, periportal (minimal) Inflammatory cell foci/single cell necrosis (minimal)
Mandibular Lymph Node/ 1	Lymphoid hyperplasia (moderate)
Spleen	Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal)
Thymus	Lymphoid atrophy - involution (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas.

Animal No: 178

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 22/09/99  
date of necropsy : 23/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1	Atrophy (minimal)
Kidney/2	Atrophy (minimal)
Liver	Lymphocytic cell foci, periportal (minimal) Inflammatory cell foci/single cell necrosis (minimal)
Spleen	Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal) Lymphoid hyperplasia (slight)

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 178  
SEX: Female  
DOSE GROUP: Group 5, T-7253

**MICROSCOPIC FINDINGS**  
(continued)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 179

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 22/09/99  
date of necropsy : 23/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis (moderate)

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)  
Lymphoid hyperplasia (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 180

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 22/09/99  
date of necropsy : 23/09/99

**PATHOLOGY REPORT (DRAFT)**

Page 131/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 180  
SEX: Female  
DOSE GROUP: Group 5, T-7253

**MACROSCOPIC FINDINGS**  
(continued)

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1

Interstitial inflammation, lymphocytic (slight)  
capsular with fibrosis and retraction

Liver

Inflammatory cell foci/single cell necrosis (slight)

Spleen

Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal  
Gland/2, Kidney/2, Mandibular Lymph Node/1,  
Mandibular Lymph Node/2, Mesenteric Lymph Node,  
Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 181

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : other  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 24/09/99

General observations

Died after blood sampling

No abnormalities were found in any of the other  
tissues examined

**MICROSCOPIC FINDINGS**

General Observations

Macro observation confirmed present (correlates to  
GROSS finding)

Mandibular Lymph Node/  
1

Plasmacytosis (slight)

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 181  
 SEX: Female  
 DOSE GROUP: Group 5, T-7253

**MICROSCOPIC FINDINGS**  
 (continued)

Spleen Hemopoiesis, primarily erythropoiesis (minimal)  
 Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Liver, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 182

**MACROSCOPIC FINDINGS**

days of treatment : 29  
 sacrifice group : terminal sacrifice  
 necropsy status : planned terminal  
 date of start of treatment: 26/08/99  
 date of end of treatment: 23/09/99  
 date of necropsy : 24/09/99

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1 Pelvic inflammation, lymphogranulocytic (slight)

Liver Lymphocytic cell foci, periportal (minimal)

Spleen Hemopoiesis, primarily erythropoiesis (minimal)  
 Hemosiderin pigment (slight)

Thymus Lymphoid atrophy - involution (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas.



Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 183  
SEX: Female  
DOSE GROUP: Group 5, T-7253

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 24/09/99

Liver Accentuated lobular pattern

Skin flank: left side Alopecia  
head Alopecia

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Kidney/1 Atrophy (minimal)  
Liver Inflammatory cell foci/single cell necrosis (slight)  
None (correlates to GROSS finding)  
Skin None (correlates to GROSS finding)  
Spleen Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas, Thymus.

Animal No: 184

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 24/09/99

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 184  
 SEX: Female  
 DOSE GROUP: Group 5, T-7253

**MACROSCOPIC FINDINGS**  
 (continued)

No findings noted

**MICROSCOPIC FINDINGS**

Kidney/1	Atrophy (minimal)
Liver	Inflammatory cell foci/single cell necrosis (minimal)
Mandibular Lymph Node/1	Lymphoid hyperplasia (moderate)
Spleen	Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal)
Thymus	Lymphoid atrophy - involution (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Ovary/1, Ovary/2, Pancreas.

Animal No: 185

**MACROSCOPIC FINDINGS**

days of treatment : 29  
 sacrifice group : recovery group 1  
 necropsy status : planned recovery 1  
 date of start of treatment: 26/08/99  
 date of end of treatment: 23/09/99  
 date of necropsy : 08/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver	Inflammatory cell foci/single cell necrosis (minimal)
-------	-------------------------------------------------------

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 186  
SEX: Female  
DOSE GROUP: Group 5, T-7253

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 08/10/99

No findings noted

**MICROSCOPIC FINDINGS**

No abnormality detected

No abnormalities found in: Liver.

Animal No: 187

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 26/08/99  
date of end of treatment: 23/09/99  
date of necropsy : 08/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis  
(minimal)

Animal No: 189

**MACROSCOPIC FINDINGS**

days of treatment : 30  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 26/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 22/10/99

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 189  
SEX: Female  
DOSE GROUP: Group 5, T-7253

**MACROSCOPIC FINDINGS**  
(continued)

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis  
(minimal)

Animal No: 190

**MACROSCOPIC FINDINGS**

days of treatment : 30  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 26/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 22/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis  
(minimal)

Animal No: 191

**MACROSCOPIC FINDINGS**

days of treatment : 30  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 26/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 22/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver

Inflammatory cell foci/single cell necrosis  
(minimal)

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 81  
SEX: Male  
DOSE GROUP: Group 6, T-7254

**MACROSCOPIC FINDINGS**

Liver  
days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

Enlarged  
Discolouration DARK BROWN

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Kidney/1 Atrophy (minimal)  
Liver Inflammatory cell foci/single cell necrosis (slight)  
Midzonal/centrilobular hypertrophy, diffuse (slight)  
(correlates to GROSS finding)  
Coagulative necrosis, focal (slight)  
Mandibular Lymph Node/1 Lymphoid hyperplasia (slight)  
Spleen Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 82

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

**PATHOLOGY REPORT (DRAFT)**

Page 138/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 82  
SEX: Male  
DOSE GROUP: Group 6, T-7254

**MACROSCOPIC FINDINGS**  
(continued)

Liver  
Enlarged  
Discolouration DARK BROWN

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Liver  
Inflammatory cell foci/single cell necrosis (minimal)  
Midzonal/centrilobular hypertrophy, diffuse (slight) (correlates to GROSS finding)  
Coagulative necrosis, focal (minimal)

Mandibular Lymph Node/  
1  
Lymphoid hyperplasia (moderate)

Mandibular Lymph Node/  
2  
Plasmacytosis (slight)

Spleen  
Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 83

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

Liver  
Enlarged  
Discolouration DARK BROWNACCENTUATED LOBULAR PATTERN

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 83  
SEX: Male  
DOSE GROUP: Group 6, T-7254

**MACROSCOPIC FINDINGS**  
(continued)

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Kidney/1	Cystic tubules (minimal)
Liver	Lymphocytic cell foci, periportal (minimal) Inflammatory cell foci/single cell necrosis (slight) Midzonal/centrilobular hypertrophy, diffuse (moderate) (correlates to GROSS finding) Coagulative necrosis, focal (minimal)
Spleen	Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 84

**MACROSCOPIC FINDINGS**

days of treatment : 28  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 20/09/99  
date of necropsy : 21/09/99

Liver

Enlarged  
Discolouration DARK BROWN

No abnormalities were found in any of the other tissues examined

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 84  
SEX: Male  
DOSE GROUP: Group 6, T-7254

**MICROSCOPIC FINDINGS**

Kidney/1 Hyaline cast(s) (minimal)

Liver Lymphocytic cell foci, periportal (minimal)  
Inflammation - granulohistiocytic (slight)  
Inflammatory cell foci/single cell necrosis (minimal)  
Midzonal/centrilobular hypertrophy, diffuse (slight) (correlates to GROSS finding)

Spleen Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 85

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

Liver Enlarged  
Discolouration DARK BROWN

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Kidney/1 Interstitial inflammation, lymphocytic (minimal)

Liver Inflammatory cell foci/single cell necrosis (slight)  
Midzonal/centrilobular hypertrophy, diffuse (slight) (correlates to GROSS finding)  
Coagulative necrosis, focal (minimal)



Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 87  
SEX: Male  
DOSE GROUP: Group 6, T-7254

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

Liver

Enlarged  
Discolouration DARK BROWN

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Liver

Kupffer cell pigment, brown (slight) (correlates to GROSS finding)  
Inflammation - granulohistiocytic (minimal)  
Inflammatory cell foci/single cell necrosis (minimal)  
Midzonal/centrilobular hypertrophy, diffuse (slight) (correlates to GROSS finding)  
Coagulative necrosis, focal (minimal)

Mandibular Lymph Node/  
1

Plasmacytosis (slight)

Spleen

Hemopoiesis, primarily erythropoiesis (slight)  
Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 88  
SEX: Male  
DOSE GROUP: Group 6, T-7254

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : terminal sacrifice  
necropsy status : planned terminal  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 22/09/99

Liver

Enlarged  
Discolouration DARK BROWN

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Kidney/1

Atrophy (minimal)

Liver

Inflammatory cell foci/single cell necrosis (minimal)  
Midzonal/centrilobular hypertrophy, diffuse (moderate) (correlates to GROSS finding)

Spleen

Hemopoiesis, primarily erythropoiesis (moderate)  
Hemosiderin pigment (slight)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2, Thymus.

Animal No: 89

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 06/10/99

No findings noted

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 89  
SEX: Male  
DOSE GROUP: Group 6, T-7254

**MICROSCOPIC FINDINGS**

Liver Inflammatory cell foci/single cell necrosis (slight)  
Midzonal/centrilobular hypertrophy, diffuse  
(minimal)

Spleen Hemopoiesis, primarily erythropoiesis (moderate)  
Hemosiderin pigment (minimal)

Animal No: 90

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 06/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver Inflammatory cell foci/single cell necrosis  
(minimal)

Spleen Hemopoiesis, primarily erythropoiesis (moderate)  
Hemosiderin pigment (minimal)

Animal No: 91

**MACROSCOPIC FINDINGS**

days of treatment : 29  
sacrifice group : recovery group 1  
necropsy status : planned recovery 1  
date of start of treatment: 24/08/99  
date of end of treatment: 21/09/99  
date of necropsy : 06/10/99

No findings noted

**PATHOLOGY REPORT (DRAFT)**

Page 145/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 91  
SEX: Male  
DOSE GROUP: Group 6, T-7254

**MICROSCOPIC FINDINGS**

Liver Lymphocytic cell foci, periportal (minimal)  
Inflammatory cell foci/single cell necrosis (slight)

Spleen Hemopoiesis, primarily erythropoiesis (slight)  
Hemosiderin pigment (minimal)

Animal No: 93

**MACROSCOPIC FINDINGS**

days of treatment : 32  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 24/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 20/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver Inflammatory cell foci/single cell necrosis  
(minimal)

Spleen Hemopoiesis, primarily erythropoiesis (minimal)  
Hemosiderin pigment (minimal)

Animal No: 94

**MACROSCOPIC FINDINGS**

days of treatment : 32  
sacrifice group : recovery group 2  
necropsy status : planned recovery 2  
date of start of treatment: 24/08/99  
date of end of treatment: 24/09/99  
date of necropsy : 20/10/99

No findings noted

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 94  
 SEX: Male  
 DOSE GROUP: Group 6, T-7254

**MICROSCOPIC FINDINGS**

Liver Lymphocytic cell foci, periportal (minimal)  
 Inflammatory cell foci/single cell necrosis (slight)

Spleen Hemopoiesis, primarily erythropoiesis (slight)  
 Hemosiderin pigment (slight)

Animal No: 95

**MACROSCOPIC FINDINGS**

days of treatment : 32  
 sacrifice group : recovery group 2  
 necropsy status : planned recovery 2  
 date of start of treatment: 24/08/99  
 date of end of treatment: 24/09/99  
 date of necropsy : 20/10/99

No findings noted

**MICROSCOPIC FINDINGS**

Liver Inflammatory cell foci/single cell necrosis  
 (minimal)

Spleen Hemopoiesis, primarily erythropoiesis (slight)  
 Hemosiderin pigment (slight)

Animal No: 97  
 DOSE GROUP: Group 7, T-7255

**MACROSCOPIC FINDINGS**

days of treatment : 10  
 sacrifice group : terminal sacrifice  
 necropsy status : killed moribund  
 date of start of treatment: 24/08/99  
 date of end of treatment: 02/09/99  
 date of necropsy : 06/09/99

Epididymides

Reduced in size

Liver

Accentuated lobular pattern  
 Discolouration PALE

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 97  
SEX: Male  
DOSE GROUP: Group 7, T-7255

**MACROSCOPIC FINDINGS**  
(continued)

Prostate	Reduced in size
Spleen	Reduced in size
Thymus	Reduced in size

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Epididymis/1	Seminiferous cell debris (minimal) Small organ, normal histology (correlates to GROSS finding)
Epididymis/2	Seminiferous cell debris (minimal) Small organ, normal histology (correlates to GROSS finding)
Liver	Hepatocellular atrophy, diffuse (slight) (correlates to GROSS finding)
Mandibular Lymph Node/ 1	Lymphoid atrophy (severe)
Mandibular Lymph Node/ 2	Lymphoid atrophy (moderate)
Mesenteric Lymph Node	Lymphoid atrophy (moderate)
Pancreas	Reduced zymogen (slight)
Prostate Gland	Atrophy (moderate) (correlates to GROSS finding)
Spleen	Hemosiderin pigment (minimal) Lymphoid atrophy (moderate) (correlates to GROSS finding)
Thymus	Lymphoid atrophy - involution (severe) (correlates to GROSS finding)

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255    NOTOX no. :            264656  
Test System : Exploratory 28-Day Gavage Study in Rats    Propath no.:            00006  
Sponsor : 3M Corporate Toxicology                            Date :    29.Feb.2000

---

**Individual Animal Data Records**

Animal No:        97  
SEX:                Male  
DOSE GROUP:        Group 7, T-7255

**MICROSCOPIC FINDINGS**  
(continued)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Testes/1, Testes/2.

Animal No:        98

**MACROSCOPIC FINDINGS**

days of treatment : 10  
sacrifice group : terminal sacrifice  
necropsy status : killed moribund  
date of start of treatment: 24/08/99  
date of end of treatment: 02/09/99  
date of necropsy : 03/09/99

Epididymides	right side Reduced in size
Liver	Discolouration PALE
Seminal vesicles	Reduced in size
Spleen	Reduced in size
Stomach	glandular mucosa Thickened limiting ridge: Thickened

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Epididymis/1	Seminiferous cell debris (minimal) Small organ, normal histology (correlates to GROSS finding)
Epididymis/2	Seminiferous cell debris (minimal) Small organ, normal histology (correlates to GROSS finding)
Liver	Lymphocytic cell foci, periportal (minimal) Hepatocellular atrophy, diffuse (minimal) (correlates to GROSS finding)

**PATHOLOGY REPORT (DRAFT)**

Page 149/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 98  
SEX: Male  
DOSE GROUP: Group 7, T-7255

**MICROSCOPIC FINDINGS**  
(continued)

Seminal Vesicle/1	Atrophy (moderate) (correlates to GROSS finding)
Seminal Vesicle/2	Atrophy (moderate) (correlates to GROSS finding)
Spleen	Hemosiderin pigment (minimal) None (correlates to GROSS finding)
Stomach	None (correlates to GROSS finding)
Testes/1	Seminiferous cell debris, intratubular (slight)
Testes/2	Retained residual bodies (minimal)

Number of Sections less than protocol for Thymus (0).

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas.

Animal No: 99

**MACROSCOPIC FINDINGS**

	days of treatment : 10
	sacrifice group : terminal sacrifice
	necropsy status : killed moribund
	date of start of treatment: 24/08/99
	date of end of treatment: 02/09/99
	date of necropsy : 06/09/99
Epididymides	Reduced in size
Liver	Discolouration PALE Accentuated lobular pattern
Seminal vesicles	Reduced in size
Thymus	Reduced in size



Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 99  
 SEX: Male  
 DOSE GROUP: Group 7, T-7255

**MACROSCOPIC FINDINGS**  
 (continued)

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Epididymis/1	None (correlates to GROSS finding)
Epididymis/2	None (correlates to GROSS finding)
Liver	Hepatocellular atrophy, diffuse (moderate) (correlates to GROSS finding) Coagulative necrosis, focal (moderate) (correlates to GROSS finding)
Mandibular Lymph Node/ 1	Lymphoid atrophy (slight)
Mesenteric Lymph Node	Lymphoid atrophy (slight)
Pancreas	Reduced zymogen (minimal)
Seminal Vesicle/1	Atrophy (severe) (correlates to GROSS finding)
Seminal Vesicle/2	Atrophy (severe) (correlates to GROSS finding)
Spleen	Hemosiderin pigment (minimal) Lymphoid atrophy (slight)
Thymus	Lymphoid atrophy - involution (severe) (correlates to GROSS finding)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/2, Testes/1, Testes/2.

**PATHOLOGY REPORT (DRAFT)**

Page 151/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 100  
SEX: Male  
DOSE GROUP: Group 7, T-7255

**MACROSCOPIC FINDINGS**

days of treatment : 10  
sacrifice group : terminal sacrifice  
necropsy status : killed moribund  
date of start of treatment: 24/08/99  
date of end of treatment: 02/09/99  
date of necropsy : 06/09/99

Epididymides Reduced in size

Liver Accentuated lobular pattern  
Discolouration PALE

Prostate Reduced in size

Seminal vesicles Reduced in size

Skin head, back of the neck Alopecia

Spleen Reduced in size

Stomach glandular mucosa: Focus RED-BROWN

Thymus Reduced in size

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Epididymis/1 Seminiferous cell debris (minimal)  
Small organ, normal histology (correlates to GROSS finding)

Epididymis/2 Seminiferous cell debris (minimal)  
Small organ, normal histology (correlates to GROSS finding)

Kidney/1 Atrophy (minimal)

Liver Hepatocellular atrophy, diffuse (minimal)  
(correlates to GROSS finding)

Mesenteric Lymph Node Lymphoid atrophy (slight)

**PATHOLOGY REPORT (DRAFT)**

Page 152/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 100  
SEX: Male  
DOSE GROUP: Group 7, T-7255

**MICROSCOPIC FINDINGS**  
(continued)

Pancreas	Reduced zymogen (moderate)
Prostate Gland	Atrophy (moderate) (correlates to GROSS finding)
Seminal Vesicle/1	Atrophy (moderate) (correlates to GROSS finding)
Seminal Vesicle/2	Atrophy (moderate) (correlates to GROSS finding)
Skin	None (correlates to GROSS finding)
Spleen	Lymphoid atrophy (severe) (correlates to GROSS finding)
Stomach	Erosion glandular mucosa (minimal) (correlates to GROSS finding)
Thymus	Lymphoid atrophy - involution (severe) (correlates to GROSS finding)

Number of Sections less than protocol for Mandibular Lymph Node/1 (0).

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/2, Testes/1, Testes/2.

Animal No: 101

**MACROSCOPIC FINDINGS**

	days of treatment : 10
	sacrifice group : terminal sacrifice
	necropsy status : killed moribund
	date of start of treatment: 24/08/99
	date of end of treatment: 02/09/99
	date of necropsy : 06/09/99
Epididymides	Reduced in size
Liver	Discolouration PALE Enlarged Accentuated lobular pattern

**PATHOLOGY REPORT (DRAFT)**

Page 153/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 101  
SEX: Male  
DOSE GROUP: Group 7, T-7255

**MACROSCOPIC FINDINGS**  
(continued)

Prostate	Reduced in size
Seminal vesicles	Reduced in size
Spleen	Reduced in size
Stomach	glandular mucosa: Thickened glandular mucosa: Focus RED-BROWN
Thymus	Reduced in size

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Epididymis/1	Seminiferous cell debris (minimal) Small organ, normal histology (correlates to GROSS finding)
Epididymis/2	Small organ, normal histology (correlates to GROSS finding)
Liver	Hepatocellular atrophy, diffuse (slight) (correlates to GROSS finding) Coagulative necrosis, focal (moderate) None (correlates to GROSS finding)
Mandibular Lymph Node/ 1	Lymphoid atrophy (slight)
Mandibular Lymph Node/ 2	Lymphoid atrophy (slight)
Mesenteric Lymph Node	Lymphoid atrophy (minimal)
Pancreas	Reduced zymogen (moderate)
Prostate Gland	None (correlates to GROSS finding)
Seminal Vesicle/1	Atrophy (moderate) (correlates to GROSS finding)

**PATHOLOGY REPORT (DRAFT)**

Page 154/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 101  
SEX: Male  
DOSE GROUP: Group 7, T-7255

**MICROSCOPIC FINDINGS**  
(continued)

Seminal Vesicle/2	Atrophy (moderate) (correlates to GROSS finding)
Spleen	Hemosiderin pigment (minimal) Lymphoid atrophy (slight) (correlates to GROSS finding)
Stomach	Forestomach, inflammation (slight) None (correlates to GROSS finding)
Thymus	Lymphoid atrophy - involution (severe) (correlates to GROSS finding)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Testes/1, Testes/2.

Animal No: 102

**MACROSCOPIC FINDINGS**

	days of treatment : 10
	sacrifice group : terminal sacrifice
	necropsy status : killed moribund
	date of start of treatment: 24/08/99
	date of end of treatment: 02/09/99
	date of necropsy : 02/09/99
Liver	Accentuated lobular pattern Enlarged Discolouration PALE
Stomach	Hemorrhage

No abnormalities were found in any of the other tissues examined

**PATHOLOGY REPORT (DRAFT)**

Page 155/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 102  
SEX: Male  
DOSE GROUP: Group 7, T-7255

**MICROSCOPIC FINDINGS**

Kidney/1	Atrophy (minimal)
Liver	Lymphocytic cell foci, periportal (minimal) Inflammatory cell foci/single cell necrosis (slight) Hepatocellular atrophy, diffuse (minimal) (correlates to GROSS finding) None (correlates to GROSS finding)
Mandibular Lymph Node/ 1	Lymphoid atrophy (slight)
Mandibular Lymph Node/ 2	Lymphoid atrophy (slight)
Pancreas	Reduced zymogen (minimal)
Stomach	None (correlates to GROSS finding)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mesenteric Lymph Node, Spleen, Testes/1, Testes/2, Thymus.

Animal No: 103

**MACROSCOPIC FINDINGS**

	days of treatment : 10
	sacrifice group : terminal sacrifice
	necropsy status : killed moribund
	date of start of treatment: 24/08/99
	date of end of treatment: 02/09/99
	date of necropsy : 06/09/99
Liver	Accentuated lobular pattern Discolouration PALE
Prostate	Reduced in size
Seminal vesicles	Reduced in size
Skin	flank: right side Alopecia

**PATHOLOGY REPORT (DRAFT)**

Page 156/166

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
Test System : Exploratory 28-Day Gavage Study in Rats  
Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
Propath no.: 00006  
Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 103  
SEX: Male  
DOSE GROUP: Group 7, T-7255

**MACROSCOPIC FINDINGS**  
(continued)

Stomach glandular mucosa: Focus RED-BROWN  
glandular mucosa: Thickened

Thymus Reduced in size

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Kidney/1 Tubular necrosis/degeneration, outer stripe (slight)

Liver Hepatocellular atrophy, diffuse (minimal)  
(correlates to GROSS finding)

Prostate Gland Atrophy (minimal) (correlates to GROSS finding)

Seminal Vesicle/1 Atrophy (moderate) (correlates to GROSS finding)

Seminal Vesicle/2 Atrophy (moderate) (correlates to GROSS finding)

Skin None (correlates to GROSS finding)

Stomach Erosion glandular mucosa (slight) (correlates to GROSS finding)  
None (correlates to GROSS finding)

Thymus Lymphoid atrophy - involution (moderate) (correlates to GROSS finding)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Spleen, Testes/1, Testes/2.

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 104  
 SEX: Male  
 DOSE GROUP: Group 7, T-7255

**MACROSCOPIC FINDINGS**

days of treatment : 10  
 sacrifice group : terminal sacrifice  
 necropsy status : killed moribund  
 date of start of treatment: 24/08/99  
 date of end of treatment: 02/09/99  
 date of necropsy : 06/09/99

Liver	Discolouration PALE Accentuated lobular pattern
Prostate	Reduced in size
Seminal vesicles	Reduced in size
Spleen	Reduced in size
Stomach	glandular mucosa: Focus RED-BROWN
Thymus	Reduced in size
	No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Liver	Hepatocellular atrophy, diffuse (minimal) (correlates to GROSS finding)
Prostate Gland	Atrophy (minimal) (correlates to GROSS finding)
Seminal Vesicle/1	Atrophy (moderate) (correlates to GROSS finding)
Seminal Vesicle/2	Atrophy (moderate) (correlates to GROSS finding)
Spleen	Lymphoid atrophy (minimal) (correlates to GROSS finding)
Stomach	Mineralization, focal in glandular mucosa (minimal) Forestomach, inflammation (moderate) None (correlates to GROSS finding)
Testes/1	Immature present



Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 104  
 SEX: Male  
 DOSE GROUP: Group 7, T-7255

**MICROSCOPIC FINDINGS**  
 (continued)

Testes/2	Immature present
Thymus	Lymphoid atrophy - involution (severe) (correlates to GROSS finding)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas.

Animal No: 105

**MACROSCOPIC FINDINGS**

	days of treatment : 10
	sacrifice group : recovery group 1
	necropsy status : killed moribund
	date of start of treatment: 24/08/99
	date of end of treatment: 02/09/99
	date of necropsy : 06/09/99
Liver	Discolouration PALE left lateral lobe Irregular surface GRAY-WHITE, D=1X20 MM Accentuated lobular pattern
Pancreas	Discolouration PALE
Seminal vesicles	Reduced in size
Skin	abdominal region: Alopecia
Spleen	Reduced in size
Stomach	glandular mucosa: Thickened glandular mucosa: Focus RED-BROWN
Thymus	Reduced in size

No abnormalities were found in any of the other tissues examined

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 105  
 SEX: Male  
 DOSE GROUP: Group 7, T-7255

**MICROSCOPIC FINDINGS**

Kidney/1	Atrophy (minimal)
Liver	Midzonal/centrilobular hypertrophy, diffuse (minimal) (correlates to GROSS finding) Coagulative necrosis, focal (slight) (correlates to GROSS finding)
Pancreas	Reduced zymogen (slight) (correlates to GROSS finding)
Seminal Vesicle/1	Atrophy (slight) (correlates to GROSS finding)
Seminal Vesicle/2	Atrophy (slight) (correlates to GROSS finding)
Skin	None (correlates to GROSS finding)
Spleen	Hemosiderin pigment (minimal) Lymphoid atrophy (slight) (correlates to GROSS finding)
Stomach	Erosion glandular mucosa (slight) (correlates to GROSS finding) None (correlates to GROSS finding)
Testes/1	Immature present
Testes/2	Immature present
Thymus	Lymphoid atrophy - involution (severe) (correlates to GROSS finding)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node.

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 106  
 SEX: Male  
 DOSE GROUP: Group 7, T-7255

**MACROSCOPIC FINDINGS**

days of treatment : 10  
 sacrifice group : recovery group 1  
 necropsy status : killed moribund  
 date of start of treatment: 24/08/99  
 date of end of treatment: 02/09/99  
 date of necropsy : 06/09/99

Liver	Discolouration PALE Accentuated lobular pattern
Prostate	Reduced in size
Seminal vesicles	Reduced in size
Spleen	Reduced in size
Stomach	glandular mucosa: Thickened
Thymus	Reduced in size

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Liver	None (correlates to GROSS finding)
Mandibular Lymph Node/ 1	Lymphoid atrophy (slight)
Mandibular Lymph Node/ 2	Lymphoid atrophy (slight)
Mesenteric Lymph Node	Lymphoid atrophy (slight)
Prostate Gland	Atrophy (minimal) (correlates to GROSS finding)
Seminal Vesicle/1	Atrophy (moderate) (correlates to GROSS finding)
Seminal Vesicle/2	Atrophy (moderate) (correlates to GROSS finding)
Spleen	Lymphoid atrophy (slight) (correlates to GROSS finding)

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 106  
 SEX: Male  
 DOSE GROUP: Group 7, T-7255

**MICROSCOPIC FINDINGS**  
 (continued)

Stomach	None (correlates to GROSS finding)
Testes/1	Immature present Spermatidic giant cell(s) (minimal)
Testes/2	Immature present
Thymus	Lymphoid atrophy - involution (severe) (correlates to GROSS finding)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Pancreas.

Animal No: 107

**MACROSCOPIC FINDINGS**

	days of treatment : 10
	sacrifice group : recovery group 1
	necropsy status : killed moribund
	date of start of treatment: 24/08/99
	date of end of treatment: 02/09/99
	date of necropsy : 03/09/99
Liver	Enlarged Discolouration PALE Accentuated lobular pattern
Seminal vesicles	Reduced in size
Spleen	Reduced in size
Stomach	glandular mucosa: Thickened limiting ridge: Thickened
Thymus	Reduced in size

No abnormalities were found in any of the other tissues examined

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 107  
 SEX: Male  
 DOSE GROUP: Group 7, T-7255

**MICROSCOPIC FINDINGS**

Kidney/1	Atrophy (minimal)
Liver	Midzonal/centrilobular hypertrophy, diffuse (minimal) (correlates to GROSS finding)
Mesenteric Lymph Node	Lymphoid atrophy (slight)
Seminal Vesicle/1	Atrophy (moderate) (correlates to GROSS finding)
Seminal Vesicle/2	Atrophy (moderate) (correlates to GROSS finding)
Spleen	Lymphoid atrophy (minimal) (correlates to GROSS finding)
Stomach	Forestomach, inflammation (slight) (correlates to GROSS finding) None (correlates to GROSS finding)
Thymus	Lymphoid atrophy - involution (severe) (correlates to GROSS finding)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Pancreas, Testes/1, Testes/2.

Animal No: 109

**MACROSCOPIC FINDINGS**

	days of treatment : 10
	sacrifice group : recovery group 2
	necropsy status : killed moribund
	date of start of treatment: 24/08/99
	date of end of treatment: 02/09/99
	date of necropsy : 06/09/99
Liver	Accentuated lobular pattern Discolouration PALE
Prostate	Reduced in size
Seminal vesicles	Reduced in size

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 109  
SEX: Male  
DOSE GROUP: Group 7, T-7255

**MACROSCOPIC FINDINGS**  
(continued)

Spleen	Reduced in size
Stomach	glandular mucosa: Focus RED-BROWN glandular mucosa: Thickened
Thymus	Reduced in size

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Liver	None (correlates to GROSS finding)
Prostate Gland	Atrophy (minimal) (correlates to GROSS finding)
Seminal Vesicle/1	Atrophy (slight) (correlates to GROSS finding)
Seminal Vesicle/2	Atrophy (slight) (correlates to GROSS finding)
Spleen	Lymphoid atrophy (slight) (correlates to GROSS finding)
Stomach	Erosion glandular mucosa (minimal) (correlates to GROSS finding) None (correlates to GROSS finding)
Testes/1	Immature present
Thymus	Lymphoid atrophy - involution (severe) (correlates to GROSS finding)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/2.

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 110  
 SEX: Male  
 DOSE GROUP: Group 7, T-7255

**MACROSCOPIC FINDINGS**

	days of treatment : 10
	sacrifice group : recovery group 2
	necropsy status : killed moribund
	date of start of treatment: 24/08/99
	date of end of treatment: 02/09/99
	date of necropsy : 06/09/99
Duodenum	Discolouration DARK RED
Epididymides	Reduced in size
Prostate	Reduced in size
Seminal vesicles	Reduced in size
Stomach	glandular mucosa: Focus RED-BROWN
Thymus	Reduced in size Discolouration DARK RED
	No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Duodenum	Hemorrhage (moderate) (correlates to GROSS finding)
Epididymis/1	Seminiferous cell debris (minimal) Small organ, normal histology (correlates to GROSS finding)
Epididymis/2	Seminiferous cell debris (minimal) Small organ, normal histology (correlates to GROSS finding)
Liver	Bile duct pigment, gold-brown (minimal) Hepatocellular atrophy, diffuse (slight)
Mandibular Lymph Node/ 1	Lymphoid atrophy (slight)
Mandibular Lymph Node/ 2	Lymphoid atrophy (moderate)

Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255 NOTOX no. : 264656  
 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 00006  
 Sponsor : 3M Corporate Toxicology Date : 29.Feb.2000

**Individual Animal Data Records**

Animal No: 110  
 SEX: Male  
 DOSE GROUP: Group 7, T-7255

**MICROSCOPIC FINDINGS**  
 (continued)

Mesenteric Lymph Node	Lymphoid atrophy (moderate)
Prostate Gland	None (correlates to GROSS finding)
Seminal Vesicle/1	Atrophy (slight) (correlates to GROSS finding)
Seminal Vesicle/2	Atrophy (slight) (correlates to GROSS finding)
Spleen	Hemosiderin pigment (slight) Lymphoid atrophy (severe)
Stomach	Erosion glandular mucosa (slight) (correlates to GROSS finding)
Thymus	Congestion present (correlates to GROSS finding) Lymphoid atrophy - involution (severe) (correlates to GROSS finding)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/1, Kidney/2, Pancreas, Testes/1, Testes/2.

Animal No: 111

**MACROSCOPIC FINDINGS**

	days of treatment : 10
	sacrifice group : recovery group 2
	necropsy status : killed moribund
	date of start of treatment: 24/08/99
	date of end of treatment: 02/09/99
	date of necropsy : 03/09/99
Liver	Discolouration PALE Accentuated lobular pattern
Seminal vesicles	Reduced in size
Spleen	Reduced in size
Thymus	Reduced in size



Test Article: T-7250, T-7251, T-7252, T-7253, T-7254 AND T-7255  
 Test System : Exploratory 28-Day Gavage Study in Rats  
 Sponsor : 3M Corporate Toxicology

NOTOX no. : 264656  
 Propath no.: 00006  
 Date : 29.Feb.2000

---

**Individual Animal Data Records**

Animal No: 111  
 SEX: Male  
 DOSE GROUP: Group 7, T-7255

**MACROSCOPIC FINDINGS**  
 (continued)

No abnormalities were found in any of the other tissues examined

**MICROSCOPIC FINDINGS**

Kidney/1	Atrophy (minimal)
Liver	Bile duct pigment, gold-brown (slight) Inflammation - granulohistiocytic (minimal) Hepatocellular atrophy, diffuse (minimal) (correlates to GROSS finding) Coagulative necrosis, focal (moderate) (correlates to GROSS finding)
Seminal Vesicle/1	Atrophy (slight) (correlates to GROSS finding)
Seminal Vesicle/2	Atrophy (slight) (correlates to GROSS finding)
Spleen	Lymphoid atrophy (minimal) (correlates to GROSS finding)
Thymus	Lymphoid atrophy - involution (severe) (correlates to GROSS finding)

No abnormalities found in: Adrenal Gland/1, Adrenal Gland/2, Kidney/2, Mandibular Lymph Node/1, Mandibular Lymph Node/2, Mesenteric Lymph Node, Pancreas, Testes/1, Testes/2.